Nothing Special   »   [go: up one dir, main page]

EP1311505A2 - Quinuclidine-substituted heteroaryl moieties for treatment of disease ( nicotinic acetylcholine receptor ligands ) - Google Patents

Quinuclidine-substituted heteroaryl moieties for treatment of disease ( nicotinic acetylcholine receptor ligands )

Info

Publication number
EP1311505A2
EP1311505A2 EP01961664A EP01961664A EP1311505A2 EP 1311505 A2 EP1311505 A2 EP 1311505A2 EP 01961664 A EP01961664 A EP 01961664A EP 01961664 A EP01961664 A EP 01961664A EP 1311505 A2 EP1311505 A2 EP 1311505A2
Authority
EP
European Patent Office
Prior art keywords
azabicyclo
oct
carboxamide
methyl
thiophene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01961664A
Other languages
German (de)
French (fr)
Inventor
Jason K. Myers
Bruce N. Rogers
Vincent E. Groppi, Jr.
David W. Piotrowski
Alice L. Bodnar
Eric Jon Jacobsen
Jeffrey W. Corbett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co LLC
Original Assignee
Pharmacia and Upjohn Co
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn Co, Upjohn Co filed Critical Pharmacia and Upjohn Co
Publication of EP1311505A2 publication Critical patent/EP1311505A2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • Nicotinic acetylcholine receptors play a large role in central nervous system (CNS) activity. Particularly, they are known to be involved in cognition, learning, mood, emotion, and neuroprotection. There are several types of nicotinic acetylcholine receptors, and each one appears to have a different role in regulating CNS function. Nicotine affects all such receptors, and has a variety of activities. Unfortunately, not all of the activities are desirable. In fact, one of the least desirable properties of nicotine is its addictive nature and the low ratio between efficacy and safety.
  • the present invention relates to molecules that have a greater effect upon the al nAChRs as compared to other closely related members of this large ligand-gated receptor family. Thus, the invention provides compounds that are active drug molecules with fewer side effects.
  • US Patent 5,977,144 discloses compositions for benzylidene- and cinnamylidene-anabaseines and methods for using these compositions for treating conditions associated with defects or malfunctioning of nicotinic subtypes brain receptors. These compositions target the al receptor subtype with little or no activation of the 4 ⁇ 2 or other receptor subtypes.
  • US Patent 5,837,489 discloses human neuronal nicotinic acetylcholine receptor and cells transformed with same DNA and mRNA encoding subunits.
  • US Patent 5,712,270 discloses a group of 2-aroylaminothiazole derivatives which bind to and stimulate central muscarinic acetylcholine receptors and are useful agents for treating symptoms of cognitive disorders, specifically the impaired memory associated with a decrease in the neurotransmitter, acetylcholine. Some of the compounds of this invention also bind to 5HT ⁇ A receptors and dopamine D 2 receptors, making them useful as antipsychotic agents.
  • US Patent 5,624,941 discloses pyrazole derivatives useful in pharmaceuticals in which cannabis is known to be involved.
  • US Patent 5,561,149 discloses the use of a mono or bicyclic carbocyclic, or heterocyclic carboxylic, acid ester or amide or an imidazolyl carbazol in the manufacture of a medicament suitable for the treatment of stress-related psychiatric disorders, for increasing vigilance, for the treatment of rhinitis or serotonin-induced disorders and/or coadministralion with another active agent to increase the bioavailability thereof, or for nasal administration.
  • US Patent 5,510,478 discloses a group of 2-aroylaminothiazole derivatives which bind to and stimulate central muscarinic acetylcholine receptors and are useful agents for treating symptoms of cognitive disorders, specifically the impaired memory associated with a decrease in the neurotransmitter, acetylcholine. Some of the compounds of this invention also bind to 5HT IA receptors and dopamine D 2 receptors, making them useful as antipsychotic agents.
  • US Patent 5,364,863 discloses bicyclic carboxylic esters and amides, their pharmaceutical formulations, and a method for their use in treating migraine, emesis, gastrointestinal disorders, schizophrenia, or anxiety in mammals.
  • US Patent 5,342,845 discloses indole derivatives and drugs effective as gastrointestinal motor activity regulator, antimigraine, antipsychotic or anti anxiety drugs.
  • US Patent 5,273,972 discloses novel 2-substituted-3-quinuclidinyl arylcarboxamides and arylthiocarboxamides and corresponding arylcarboxylates which have utility as therapeutic agents which exhibit gastric prokinetic, antiemetic, anxiolytic and 5-HT (serotonin) antagonist effects in warm blooded animals.
  • US Patent 5,246,942 discloses certain dibenzofurancarboxamides and their use as 5-HT 3 antagonists having unique CNS, anti-emetic and gastric prokinetic activity void of any significant D 2 receptor binding properties.
  • US Patent 5,237,066 discloses enantiomers of absolute configuration S of amide derivatives of 3-aminoquinuclidine, the process for preparing them and their use as medicinal products having activity in respect of gastric movements and antiemetic activity.
  • US Patent 5,236,931 discloses novel 3-quinuclidinyl benzamides and benzoates which have utility as therapeutical agents which exhibit anxiolytic, antipsychotic, cognition improvement, antiemetic and gastric prokinetic effects in warm blooded animals.
  • US Patent 5,217,975 discloses azabicyclic compounds for treating dementia.
  • US Patent 5,206,246 discloses anxiolytic-R-N-(l-azabicyclo[2.2.2]oct-3-yl) benzamides and thiobenzamides, their N-oxides and pharmaceutically acceptable salts thereof.
  • a preferred compound is R-(+)-4-amino-N-(l-azabicyclo[2.2.2]oct-3-yl)-5- chloro-2-methoxybenzamide.
  • US Patent 5,183,822 discloses new heterocyclic compounds (3,4-annelated benzimidazole-2(lH)-ones) having an antagonistic activity on 5-hydroxytryptamine (5-HT) receptors.
  • US Patent 5,175,173 discloses carboxamides useful as antiemetic or antipsychotic agents.
  • US Patent 5,070,095 discloses novel l-(azabicyclo[2.2.2]oct-3- or -4- yl)benzamides substituted on the benzene ring with the basic substituted aminomethyleneamino group which have been found to be useful in treating emesis, including emesis due to chemical and radiation anticancer therapy, anxiety, and impaired gastric emptying.
  • US Patent 5,057,519 discloses 5-HT 3 antagonists as being useful in reducing opiate tolerance.
  • US Patent 5,039,680 discloses 5-HT antagonists in preventing or reducing dependency on dependency-inducing agents.
  • US Patent 5,025,022 discloses a method of treating or preventing schizophrenia and/or psychosis using S-N-(l-azabicyclo[2.2.2]oct-3-yl)benzamides and thiobenzamides, their N-oxides and pharmaceutically acceptable salts thereof.
  • a preferred compound is S(-)-4-amino-N-( 1 -azabicyclo[2.2.2]oct-3-yl)-5-chloro-2- methoxybenzamide.
  • US Patent 5,017,580 discloses memory enhancing R-N-(l- azabicyclo[2.2.2.]oct-3-yl)benzamides and thiobenzamides, their N-oxides and pharmaceutically acceptable salts thereof.
  • a preferred compound is R-(+)-4-amino- N-( 1 -azabicyclo[2.2.2]oct-3-yl)-5-chloro-2-methoxybenzamide.
  • US Patent 4,988,691 discloses isoxazole-containing compounds exhibiting anti-serotonin activity.
  • US Patent 4,921,982 discloses 5-halo-2,3-dihydro-2,2-dimethylbenzofuran-7- carboxylic acids which are useful as intermediates for 5-HT 3 antagonists.
  • US Patent 4,835,162 discloses agonists and antagonists to nicotine as smoking deterrents.
  • US Patent 4,822,795 discloses pharmaceutically useful esters and amides having 5-HT antagonist activity.
  • US Patent 4,803,199 discloses pharmaceutically useful heterocyclic acid esters and amides or alkylene bridged peperidines as serotonin M antagonists.
  • US Patent 4,798,829 discloses l-azabicyclo[3.2.2]nonane derivatives having gastric motility enhancing activity and/or anti -emetic activity and/or 5-HT receptor antagonist activity.
  • US Patent 4,789,673 discloses dicarboxylic, heterocyclic and substituted benzoic acid alkylene-bridged piperidyl amides and esters as being serotonin M antagonists.
  • US Patent 4,721,720 discloses a method of treating emesis, anxiety and/or irritable bowel syndrome.
  • US Patent 4,657,911 discloses 3-amino quinuclidine derivatives and the application thereof as accelerators of gastro-intestinal motor function and as medicament potentiators.
  • US Patent 4,605,652 discloses a method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes, and the pharmaceutically acceptable acid addition salts, hydrates and alcoholates thereof.
  • US Patent 3,702,324 discloses 3,4,5-trimethoxybenzamides of substituted anilines and of alkylpiperidines which exert a specific effect on the central nervous system and a somewhat lesser effect on muscle function, and thus have utility as tranquilizers.
  • WO 01/36417 Al discloses novel N-azabicyclo-amide derivatives and use in therapy, especially in the treatment of prophylaxis of psychotic disorders and intellectual impairment disorders.
  • WO 00/73431 A2 discloses two binding assays to directly measure the affinity and selectivity of compounds at the al nAChR and the 5-HT 3 R. The combined use of these functional and binding assays may be used to identify compounds that are selective agonists of the al nAChR.
  • WO 92/15579 discloses multicyclic tertiary a ine polyaromatic squalene synthase inhibitors and method of treatment for lowering serum cholesterol levels using the compounds.
  • WO 92/11259 discloses azabicyclic amides or esters of halogenated benzoic acids having 5-HT receptor antagonist activity.
  • WO 90/14347 A as abstracted in chemical abstract 1991 : 143,158 discloses N- quinuclidinyl-indolecarboxamide derivatives as being antiemetics.
  • EP 512 350 A2 discloses 3-(indolyl-2-carboxamido) quinuclidines useful for treating diseases characterized by an excess or enhanced sensitivity to serotonin, e.g., psychosis, nausea, vomiting, dementia or other cognitive diseases, migraine, diabetes.
  • the compound may be used to control anxiety, aggression, depression, and pain.
  • the compounds are disclosed as serotonin 5-HT antagonists.
  • DE 3810552 Al discloses esters and amides of indolyl-, benzo[b]thiophenyl-, benzo[b]furancarboxylic acids or 4-amino-2 methoxy-benzoic acids with N- heterocyclic or N-heterobicyclic alcohols or amines.
  • the compounds disclosed have activity against pain especially migraine, as an anti-a ⁇ hythmic for gastrointestinal disturbances, stomach disturbances, gastritis ulcer, gall bladder, spastic colon, Crohn's disease, ulcerative colitis, carcinoid syndrome, diarrhea of various types.
  • the compounds are also disclosed as speeding stomach emptying, controlling gastro duodenal and gastro esophageal reflux, disturbances of esophageal motility, hiatal hernia, cardiac insufficiency, hypotonic stomach, paralytic ileus, manic depressive psychosis and other psychoses.
  • the compounds are also disclosed as useful for stress related diseases, senility, and enhancement of nasal absorption of other agents, e.g., in the treatment of emesis.
  • FR 2 625 678 discloses N-(quinuclidin-3-yl)-benzamides and thiobenzamides useful as diet-control agents.
  • Ri is selected from -H, alkyl, cycloalkyl, halogenated alkyl, or aryl;
  • Alkyl is both straight and branched-chain moieties having from 1-6 carbon atoms;
  • Halogenated alkyl is an alkyl moiety having from 1-6 carbon atoms and having 1 to (2n+l) substituent(s) independently selected from -F, -CI, -Br, or -I where n is the maximum number of carbon atoms in the moiety;
  • Cycloalkyl is a cyclic alkyl moiety having from 3-6 carbon atoms;
  • Aryl is phenyl, substituted phenyl, naphthyl, or substituted naphthyl;
  • Substituted phenyl is a phenyl either having 1-4 substituents independently selected from -F, -CI, -Br, or -I, or having 1 substituent selected from -R ⁇ 2 and 0-3 substituents independently selected from -F, -CI, -Br, or -I;
  • Substituted naphthyl is a naphthalene moiety either having 1-4 substituents independently selected from -F, -CI, -Br, or -I, or having 1 substituent selected from -Ri 2 and 0-3 substituents independently selected from -F, -CI, -Br, or -I, where the substitution can be independently on either the same ring or different rings of said naphthalene moiety;
  • R 2 is -H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, benzyl, substituted benzyl, or aryl;
  • Substituted alkyl is an alkyl moiety having from 1-6 carbon atoms and having 0-3 substituents independently selected from -F, -CI, -Br, or -I, and further having 1 substituent selected from -R 7 , -R 9 , -ORio, -SRio, -NRioRio, -C(O)R 10 , -NO 2 , -C(O)NR 10 R.o, -CN, -NR 10 C(O)R 10 , -S(O) 2 NR ⁇ 0 R ⁇ o, -NR 10 S(O) 2 R 10 , phenyl, or substituted phenyl;
  • Substituted benzyl is a benzyl either having 1-4 substituents independently selected from -F, -CI, -Br, or -I, or having 1 substituent selected from -R ⁇ 2 and 0-3 substituents independently selected from -F, -CI, -Br, or -I, provided that all substitution is on the phenyl ring of the benzyl;
  • X is O or S
  • W is a cyclic heteroaromatic moiety where the heteroatoms can be from 1-3 atoms selected from oxygen, sulfur, or nitrogen of the following structures:
  • Limited substituted alkyl is a substituted alkyl having from 1-6 carbon atoms and having 0-3 substituents independently selected from -F, -CI, -Br, or -I, and further having 1 substituent on either only the ⁇ carbon and selected from -ORn, -SRn, -NR supplementR ⁇ , -C(O)R n , -NO 2 , -C(O)NR ⁇ R graffiti, -CN, -NR ⁇ 0 C(O)R H , -S(O) 2 NR i0 R ⁇ o, or -NRioS(O) 2 Rio, or on any carbon with sufficient valency but not on the ⁇ carbon and selected from -R 7 , -R 9 , -ORjo, -SR 10 , -NR 10 R ⁇ o, -C(O)R ]0 , -NO 2 , -C(O)NR !0 R, 0 , -CN, -NRi 0
  • Alkenyl is straight and branched-chain moieties having from 2-6 carbon atoms and having at least one carbon-carbon double bond;
  • Halogenated alkenyl is an unsaturated alkenyl moiety having from 2-6 carbon atoms and having 1 to (2n-l) substituent(s) independently selected from -F, -CI, -Br, or -I where n is the maximum number of carbon atoms in the moiety;
  • Substituted alkenyl is an unsaturated alkenyl moiety having from 2-6 carbon atoms and having 0-3 substituents independently selected from -F, or -CI, and further having 1 substituent selected from -R 7 , -R 9 , -OR 10 , -SR !0 , -NRioRio, -C(O)R, 0 , -C(O)NR 10 R 10 , -CN, -NRioC(O)R, 0 , -S(O) 2 NR 10 R ⁇ o, -NR lQ S(O) 2 R 10 , phenyl, or substituted phenyl;
  • Alkynyl is straight and branched-chain moieties having from 2-6 carbon atoms and having at least one carbon-carbon triple bond;
  • Halogenated alkynyl is an unsaturated alkynyl moiety having from 3-6 carbon atoms and having 1 to (2n-3) substituent(s) independently selected from -F, -CI, -Br, or -I where n is the maximum number of carbon atoms in the moiety;
  • Substituted alkynyl is an unsaturated alkynyl moiety having from 3-6 carbon atoms and having 0-3 substituents independently selected from -F, or -CI, and further having 1 substituent selected from -R 7 , -R 9 , -OR ⁇ 0 , -SRio, -NRioRio, -C(O)R ⁇ 0 , -CN, -C(O)NR,oR.o, -NRi 0 C(O)R,o, -S(O) 2 NR ⁇ 0 R ⁇ o, -NR 10 S(O) 2 R ⁇ o, phenyl, or substituted phenyl;
  • Halogenated cycloalkyl is a cyclic moiety having from 3-6 carbon atoms and having 1-4 substituents independently selected from -F, or -CI;
  • Substituted cycloalkyl is a cyclic moiety having from 3-6 carbon atoms and having 0-3 substituents independently selected from -F, or -CI, and further having 1 substituent selected from -ORio, -SRio, -NR, 0 R ⁇ o, -C(O)R ⁇ 0 , -C(O)NR ⁇ 0 R ⁇ o, -CN, -NR ⁇ oC(O)R ⁇ o, -S(O) 2 NR ⁇ 0 R 10 , -NR ⁇ 0 S(O) 2 R ⁇ 0 , -NO 2 , phenyl, or substituted phenyl;
  • Heterocycloalkyl is a cyclic moiety having 4-7 atoms with 1-2 atoms within the ring being
  • Halogenated heterocycloalkyl is a cyclic moiety having from 4-7 atoms with 1-2 atoms within the ring being -S-, -N(R )-, or -O-, and having 1-4 substituents independently selected from -F, or -CI;
  • Substituted heterocycloalkyl is a cyclic moiety having from 4-7 atoms with 1-2 atoms within the ring being -S-, -N(R 3 )-, or -O- and having 0-3 substituents independently selected from -F, or -CI, and further having 1 substituent selected from -OR 10 , -SRio, -NR.oRio, -C(O)R 10 , -C(O)NR ⁇ oR ⁇ o, -CN, -NR, 0 C(O)R 10 , -NO 2) -S(O) 2 NR 10 R ⁇ o, -NR )0 S(O) 2 R ⁇ o, phenyl, or substituted phenyl;
  • R 5 is independently selected from the group consisting of -H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated alkenyl, halogenated alkynyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted heterocycloalkyl, limited substituted alkyl, limited substituted alkenyl, limited substituted alkynyl, aryl, -OR 8 , -OR J4 , -SR 8 , -SR )4 , -F, -CI, -Br, -I, -NR 8 R 8 , -NR ]4 R 14 , -C(O)R 8 , -C(O)Ri 4 , -C(O)NR 8 R 8
  • Limited substituted alkynyl is a substituted alkynyl having from 1-6 carbon atoms and having 0-3 substituents independently selected from -F, -CI, -Br, or -I, and further having 1 substituent on either only the ⁇ carbon and selected from -ORn, -SR, ,, -NR necessarilyR fate, -C(O)R u , -NO 2 , - OjNR ⁇ R,,, -CN, -NR, 0 C(O)R,,, -S(O) 2 NR ⁇ oR ⁇ o> or -NR ⁇ 0 S(O) 2 R ⁇ o, or on any carbon with sufficient valency but not on the ⁇ carbon and selected from -R 7 , -R , -ORio, -SRio, -NR
  • E is O, S, or NR 3 ,
  • E and G are independently selected from CR] 8 , O, S, or NR 3 , and A is CR ⁇ 8 or N, or wherein E and G are independently selected from CR ⁇ 8 , O, S, or NR 3 , and A is CR ⁇ 8 or N, each 9-membered fused-ring moiety having 0-1 substituent selected from -R ⁇ 2 and 0-3 substituent(s) independently selected from -F, -CI, -Br, or -I, and having a bond directly or indirectly attached to the core molecule where valency allows in either the 6-membered or the 5-membered ring of the fused-ring moiety;
  • Each R 8 is independently selected from -H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocycloalkyl, substituted heterocycloalkyl, -R 7 , -R , phenyl, or substituted phenyl;
  • Each Rio is independently selected from -H, alkyl, cycloalkyl, heterocycloalkyl, alkyl substituted with 1 substituent selected from Rj 3 , cycloalkyl substituted with 1 substituent selected from R ⁇ 3 , heterocycloalkyl substituted with 1 substituent selected from R ⁇ 3 , halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, phenyl, substituted phenyl, -R 7 , or -R ;
  • R ⁇ is independently selected from -H, alkyl, cycloalkyl, heterocyclo- alkyl, halogenated alkyl, halogenated cycloalkyl, or halogenated heterocycloalkyl
  • R 12 is selected from -ORn, -SRn, alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, -NRnRn, -C(O)Rn, -NO 2 , -C(O)NR
  • Ri 3 is selected from -OR n , -SRn, -NR,,Rn, -C(O)Rn, -
  • R ⁇ 4 is independently selected from -H, alkyl, halogenated alkyl, limited substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocycloalkyl, substituted heterocycloalkyl; and
  • Each Ris is independently selected from -H, alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, -ORn, -SRn, -NR ⁇ Ru, -C(O)Rn, -NO 2 , -C(
  • Compounds of Formula I are useful to treat any one of or combination of schizophrenia, or psychosis.
  • Ri is selected from -H, alkyl, cycloalkyl, halogenated alkyl, or aryl;
  • Alkyl is both straight and branched-chain moieties having from 1-6 carbon atoms;
  • Halogenated alkyl is an alkyl moiety having from 1-6 carbon atoms and having 1 to (2n+l) substituent(s) independently selected from -F, -CI, -Br, or -I where n is the maximum number of carbon atoms in the moiety; Cycloalkyl is a cyclic alkyl moiety having from 3-6 carbon atoms; Aiyl is phenyl, substituted phenyl, naphthyl, or substituted naphthyl;
  • Substituted phenyl is a phenyl either having 1-4 substituents independently selected from -F, -CI, -Br, or -I, or having 1 substituent selected from -Rj 2 and 0-3 substituents independently selected from -F, -CI, -Br, or -I;
  • Substituted naphthyl is a naphthalene moiety either having 1-4 substituents independently selected from -F, -CI, -Br, or -I, or having 1 substituent selected from -R 1 2 and 0-3 substituents independently selected from -F, -CI, -Br, or -I, where the substitution can be independently on either the same ring or different rings of said naphthalene moiety;
  • R 2 is -H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, benzyl, substituted benzyl, or aryl;
  • Substituted alkyl is an alkyl moiety having from 1-6 carbon atoms and having 0-3 substituents independently selected from -F, -CI, -Br, or -I, and further having 1 substituent selected from -R 7 , -R 9 , -ORio, -SRio, -NR
  • Substituted benzyl is a benzyl either having 1-4 substituents independently selected from -F, -CI, -Br, or -I, or having 1 substituent selected from -Rj 2 and 0-3 substituents independently selected from -F, -CI, -Br, or -I, provided that all substitution is on the phenyl ring of the benzyl;
  • X is O or S
  • W is a cyclic heteroaromatic moiety where the heteroatoms can be from 1-3 atoms selected from oxygen, sulfur, or nitrogen of the following structures:
  • Alkenyl is straight and branched-chain moieties having from 2-6 carbon atoms and having at least one carbon-carbon double bond;
  • Halogenated alkenyl is an unsaturated alkenyl moiety having from 2-6 carbon atoms and having 1 to (2n-l) substituent(s) independently selected from -F, -CI, -Br, or -I where n is the maximum number of carbon atoms in the moiety;
  • Substituted alkenyl is an unsaturated alkenyl moiety having from 2-6 carbon atoms and having 0-3 substituents independently selected from -F, or -CI, and further having 1 substituent selected from -R 7 , -R , -ORio, -SRio, -NRioRio, -C(O)R ⁇ o, -C(O)NR ⁇ oR ⁇ o, -CN, -NR ⁇ 0 C(O)R, 0) -S(O) 2 NR, 0 R l0 , -NR, 0 S(O) 2 R, 0 , phenyl, or substituted phenyl;
  • Alkynyl is straight and branched-chain moieties having from 2-6 carbon atoms and having at least one carbon-carbon triple bond;
  • Halogenated alkynyl is an unsaturated alkynyl moiety having from 3-6 carbon atoms and having 1 to (2n-3) substituent(s) independently selected from -F, -CI, -Br, or -I where n is the maximum number of carbon atoms in the moiety;
  • Substituted alkynyl is an unsaturated alkynyl moiety having from 3-6 carbon atoms and having 0-3 substituents independently selected from -F, or -CI, and further having 1 substituent selected from -R 7 , -R , -ORio, -SR ⁇ 0 , -NR i0 R ⁇ o, -C(O)R ⁇ 0 , -CN, -C(O)NR ⁇ oR ⁇ o, -NR K )C(O)R,o, -S(O) 2 NR ⁇ 0 R ⁇ o, -NR ⁇ 0 S(O) 2 R ⁇ o, phenyl, or substituted phenyl;
  • Halogenated cycloalkyl is a cyclic moiety having from 3-6 carbon atoms and having 1-4 substituents independently selected from -F, or -CI;
  • Substituted cycloalkyl is a cyclic moiety having from 3-6 carbon atoms and having 0-3 substituents independently selected from -F, or -CI, and further having 1 substituent selected from -ORio, -SRio, -NR, 0 R ⁇ o, -C(O)R ⁇ 0 , -C(O)NR ⁇ 0 R ⁇ o, -CN, -NRi 0 C(O)Rio, -S(O) 2 NRi 0 Rio, -NR ⁇ 0 S(O) 2 R ⁇ o, -NO 2 , phenyl, or substituted phenyl;
  • Heterocycloalkyl is a cyclic moiety having 4-7 atoms with 1-2 atoms within the ring being -S-
  • Halogenated heterocycloalkyl is a cyclic moiety having from 4-7 atoms with 1-2 atoms within the ring being -S-, -N(R 3 )-, or -O-, and having 1-4 substituents independently selected from -F, or -CI;
  • Substituted heterocycloalkyl is a cyclic moiety having from 4-7 atoms with 1-2 atoms within the ring being -S-, -N(R 3 )-, or -O- and having 0-3 substituents independently selected from -F, or -CI, and further having 1 substituent selected from -ORio, -SR.o, -NRioR.o, -C(O)R, 0 , -C(O)NR 10 R ⁇ o, -CN, -NR, 0 C(O)R 10 , -NO 2 , -S(O) 2 NR ⁇ oR ⁇ o, -NR ⁇ 0 S(
  • alkyl alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated alkenyl, halogenated alkynyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted heterocycloalkyl, limited substituted alkyl, limited substituted alkenyl, limited substituted alkynyl, aryl, -OR 8 , -ORu, -SR 8 , -SR , -F, -CI, -Br, -I, -NR 8 R 8 , -NR14R14, -C(O)R 8 , -C(O)R, 4 , -C(O)NR 8 R 8 , -C(O)NR, 4 R, 4 , -CN,
  • Limited substituted alkenyl is a substituted alkenyl having from 1-6 carbon atoms and having 0-3 substituents independently selected from -F, -CI, -Br, or -I, and further having 1 substituent on either only the ⁇ carbon and selected from -ORn, -SRn, -NR,,Rn, -C(O)RNase, -NO 2 , -C(O)NR necessarilyRn, -CN, -NR, 0 C(O)R n , -S(O) 2 NRi 0 Rio, or -NR ⁇ 0 S(O) 2 R ⁇ 0 , or on any carbon with sufficient valency but not on the ⁇ carbon and selected from -R 7 , -R 9 , -ORio, -SRio, ⁇ NR
  • Limited substituted alkynyl is a substituted alkynyl having from 1-6 carbon atoms and having 0-3 substituents independently selected from -F, -CI, -Br, or -I, and further having 1 substituent on either only the ⁇ carbon and selected from -ORn, -SR,,, -NRnRn, -C(O)Rlois, -NO 2 , -C(O)NR,,R,,, -CN, -NR 10 C(O)R punishment, -S(O)2NRi 0 Rio, or -NR ⁇ 0 S(O)2R ⁇ o, or on any carbon with sufficient valency but not on the ⁇ carbon and selected from -R 7 , -R 9 , -ORio, -SRio, -NRioRio, -C(O)R ⁇ 0 , -NO 2 , -C(O)NR ]0 Rio, -CN, -NR ⁇ 0 C
  • R 7 is a 9-membered fused-ring moiety having a 6-membered ring fused to a 5-membered ring and having the formula
  • E is O, S, or NR 3 ,
  • E and G are independently selected from CR ⁇ , O, S, or NR , and A is CR ⁇ 8 or N, or
  • E and G are independently selected from CR] 8 , O, S, or NR 3 , and A is CR ⁇ 8 or N, each 9-membered fused-ring moiety having 0-1 substituent selected from -R ⁇ 2 and 0-3 substituent(s) independently selected from -F, -CI, -Br, or -I, and having a bond directly or indirectly attached to the core molecule where valency allows in either the 6-membered or the 5-membered ring of the fused-ring moiety;
  • Each R 8 is independently selected from -H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocycloalkyl, substituted heterocycloalkyl, -R 7 , -R 9 , phenyl, or substituted phenyl;
  • Each Rio is independently selected from -H, alkyl, cycloalkyl, heterocycloalkyl, alkyl substituted with 1 substituent selected from R ⁇ 3 , cycloalkyl substituted with 1 substituent selected from R ⁇ 3 , heterocycloalkyl substituted with 1 substituent selected from Rj 3 , halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, phenyl, substituted phenyl, -R 7 , or -R 9 ;
  • Each R11 is independently selected from -H, alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, or halogenated heterocycloalkyl;
  • R1 2 is selected from -ORn, -SRn, alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, -NRnRn, -C(O)R ⁇ 1, -NO 2 , -C(O)NR ⁇ ⁇ , -CN, -NRnC(O)R, rule -S(O)2NR,,Rn, or -NRnS(O) 2 Rn;
  • Ri 3 is selected from -ORn, -SRn, -NRnRn, -C(O)Rn, -C(O)NR n Rn, -CN, -NR, ,C(O)Rn, -S(O) 2 NRnRn, -NR, ,S(O) 2 Rn, -CF 3 , or -NO 2 ;
  • R ⁇ 4 is independently selected from -H, alkyl, halogenated alkyl, limited substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocycloalkyl, substituted heterocycloalkyl;
  • 8 is independently selected from -H, alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, -ORn, -SR, ,, -NR, ,R, ⁇ , -C(O)Rn, -NO 2 , -C(O)NR n Rn, -CN, -NR, ⁇ C(O)R, ,, -S(O) 2 NR, iRn, or -NR ⁇ ,S(O) 2 Rn, -F, -CI, -Br, or -I, or a bond directly or indirectly attached to the core molecule, provided that there is only one said bond to the core molecule within the 9-membered fused-ring moiety, further provided that the fused-ring moiety has 0
  • Room temperature is within the range of 15-25 degrees Celsius.
  • AChR refers to acetylcholine receptor.
  • nAChR refers to nicotinic acetylcholine receptor.
  • 5HT 3 R refers to the serotonin-type 3 receptor.
  • FLIPR refers to a device marketed by Molecular Devices, Inc. designed to precisely measure cellular fluorescence in a high throughput whole-cell assay.
  • TLC refers to thin-layer chromatography
  • HPLC refers to high pressure liquid chromatography.
  • MeOH refers to methanol.
  • EtOH refers to ethanol.
  • IPA refers to isopropyl alcohol.
  • THF refers to tetrahydrofuran
  • DMSO dimethylsulfoxide
  • DMF refers to dimethylformamide.
  • EtOAc refers to ethyl acetate.
  • TMS refers to tetramethylsilane.
  • TEA refers to triethylamine
  • HATU refers to O-(7-azabenzotriazol-l-yl)-N,N,N', N'-tetramethyluronium hexafluorophosphate.
  • DIEA refers to N,N-diisopropylefhylarnine.
  • MLA refers to methyllycaconitine
  • Ether refers to diethyl ether.
  • KH 2 PO 4 refers to potassium phosphate, monobasic.
  • NaClO 2 refers to sodium chlorite.
  • t-BuOH refers to tert-butanol.
  • Na 2 SO 4 refers to sodium sulfate.
  • MgSO refers to magnesium sulfate.
  • K. 2 CO 3 refers to potassium carbonate.
  • NH 4 OH refers to ammonium hydroxide
  • NaHCO 3 refers to sodium bicarbonate.
  • CH 3 CN refers to acetonitrile
  • the ⁇ carbon is determined by counting the longest carbon chain of the alkyl moiety with the C-1 carbon being the carbon attached to the W moiety of the core molecule and the O carbon being the carbon furthest, e.g., separated by the greatest number of carbon atoms in the chain, from said C-1 carbon;
  • the core molecule is the quinuclidinyl-(carboxamide-type moiety)-W:
  • the O carbon is the carbon furthest from the core molecule and the C-1 carbon is the carbon attached to the core molecule by attachment to the W moiety of the core molecule.
  • the carbon atom content of various hydrocarbon-containing moieties is indicated by a prefix designating the minimum and maximum number of carbon atoms in the moiety, i.e., the prefix . j indicates a moiety of the integer 'i" to the
  • C ⁇ -6 alkyl refers to alkyl of one to six carbon atoms, inclusive.
  • Halogen is F, CI, Br, or I.
  • Alkyl is both straight and branched-chain moieties having from 1-6 carbon atoms.
  • Halogenated alkyl is an alkyl moiety having from 1-6 carbon atoms and having 1 to (2n+l) halogen atom(s) independently selected from -F, -CI, -Br, or -I where n is the maximum number of carbon atoms in the moiety.
  • Substituted alkyl is an alkyl moiety having from 1-6 carbon atoms and having 0-3 substituents independently selected from -F, -CI, -Br, or -I, and further having 1 substituent selected from -R 7 , -R 9 , -ORu,, -SR, 0 , -NRioRio, -C(O)R ⁇ 0 , -NO 2 , -C(O NR IO R ⁇ o, -CN, -NR,oC(O)R ⁇ o, -S(O) 2 NR ⁇ 0 R.o, -NR, 0 S(O) 2 R ⁇ o, phenyl, or substituted phenyl.
  • Limited substituted alkyl is a substituted alkyl having from 1-6 carbon atoms and having 0-3 substituents independently selected from -F, -CI, -Br, or -I, and further having 1 substituent on either only the co carbon and selected from -ORn, -SRn, -NRnRn, -C(O)R ⁇ ,, -NO 2 , -C(O)NR, ⁇ R, puzzle -CN, -NR J0 C(O)R, ,, -S(O) 2 NR 10 R ⁇ o, or -NR] 0 S(O) 2 R ⁇ o, or on any carbon with sufficient valency but not on the co carbon and selected from -R 7 , -R 9 , -OR, 0 , -SRio, -NR, 0 R ⁇ o, -C(O)R ⁇ 0 , -NO 2 , -C(O)NR 10 R, 0 , -CN, -NRio
  • Alkenyl is straight and branched-chain moieties having from 2-6 carbon atoms and having at least one carbon-carbon double bond.
  • Halogenated alkenyl is an unsaturated alkenyl moiety having from 2-6 carbon atoms and having 1 to (2n-l) halogen atom(s) independently selected from -F, -CI, -Br, or -I where n is the maximum number of carbon atoms in the moiety.
  • Substituted alkenyl is an unsaturated alkenyl moiety having from 2-6 carbon atoms and having 0-3 substituents independently selected from -F, or -CI, and further having 1 substituent selected from -R 7 , -R 9 , -ORio, -SRio, -NRioRio, -C(O)R ⁇ o, -C(O)NR ⁇ oR ⁇ o, -CN, -NR ⁇ 0 C(O)R, 0 , -S(O) 2 NR,oR 10 , -NR 10 S(O) 2 R ⁇ o, phenyl, or substituted phenyl.
  • Limited substituted alkenyl is a substituted alkenyl having from 1-6 carbon atoms and having 0-3 substituents independently selected from -F, -CI, -Br, or -I, and further having 1 substituent on either only the co carbon and selected from -ORn, -SRn, -NR necessarilyRn, -C(O)R réelle, -NO 2 , -C(O)NRnR n , -CN, -NR, 0 C(O)R, mecanic -S(O) 2 NRi 0 Rio, or -NR ⁇ 0 S(O) 2 R ⁇ 0 , or on any carbon with sufficient valency but not on the co carbon and selected from -R 7 , -R 9 , -OR ⁇ 0 , -SRio, -NRioRio, -C(O)R ⁇ 0 , -NO 2 , -C(O)NRi 0 R 10 , -CN, -NR
  • Alkynyl is straight and branched-chain moieties having from 2-6 carbon atoms and having at least one carbon-carbon triple bond.
  • Halogenated alkynyl is an unsaturated alkynyl moiety having from 3-6 carbon atoms and having 1 to (2n-3) halogen atom(s) independently selected from -F, -CI, -Br, or -I where n is the maximum number of carbon atoms in the moiety.
  • Substituted alkynyl is an unsaturated alkynyl moiety having from 3-6 carbon atoms and having 0-3 substituents independently selected from -F, or -CI, and further having 1 substituent selected from -R 7 , -R 9 , -ORio, -SRio, -NRioRio, -C(O)R ⁇ 0 , -CN, -C(O)NR ⁇ oR ⁇ o, -NR ⁇ oC(O)R,o, -S(O) 2 NR ⁇ 0 R ⁇ o, -NR, 0 S(O) 2 R ⁇ o, phenyl, or substituted phenyl.
  • Limited substituted alkynyl is a substituted alkynyl having from 1-6 carbon atoms and having 0-3 substituents independently selected from -F, -CI, -Br, or -I, and further having 1 substituent on either only the ⁇ carbon and selected from -ORn, -SR M , -NRnR , -C(O)RNase, -NO 2 , -C(O)NR necessarilyRn, -CN, -NR, 0 C(O)Rn, -S(O) 2 NR ⁇ oR ⁇ o, or -NR ⁇ oS(O) 2 R ⁇ o, or on any carbon with sufficient valency but not on the ⁇ carbon and selected from -R 7 , -R 9 , -ORj 0 , -SRio, -NRioRio, -C(O)R ⁇ o, -NO 2 , -C(O)NR, 0 Rio, -CN, -NR 10 C(
  • Cycloalkyl is a cyclic alkyl moiety having from 3-6 carbon atoms.
  • Halogenated cycloalkyl is a cyclic moiety having from 3-6 carbon atoms and having 1-4 substituents independently selected from -F, or -CI.
  • Substituted cycloalkyl is a cyclic moiety having from 3-6 carbon atoms and having 0-3 substituents independently selected from -F, or -CI, and further having 1 substituent selected from -OR
  • Heterocycloalkyl is a cyclic moiety having 4-7 atoms with 1-2 atoms within the ring being -S-, -N(R 3 )- or -O-.
  • Halogenated heterocycloalkyl is a cyclic moiety having from 4-7 atoms with 1-2 atoms within the ring being -S-, -N(R 3 )-, or -O-, and having 1-4 substituents independently selected from -F, or -CI.
  • Substituted heterocycloalkyl is a cyclic moiety having from 4-7 atoms with 1-2 atoms within the ring being -S-, -N(R 3 )-, or -O- and having 0-3 substituents independently selected from -F, or -CI, and further having 1 substituent selected from -ORio, -SRio, -NRioRio, -C(O)R 10 , -C(O)NR l0 R l0 , -CN, -NR, 0 C(O)R, 0 , -NO 2 , -S(0) 2 NR ⁇ 0 R ⁇ o, -NRi 0 S(O) 2 Rio, phenyl, or substituted phenyl.
  • Substituted benzyl is a benzyl either having 1-4 substituents independently selected from -F, -CI, -Br, or -I, or having 1 substituent selected from -R 12 and 0-3 substituents independently selected from -F, -CI, -Br, or -I, provided that all substitution is on the phenyl ring of the benzyl.
  • Aryl is phenyl, substituted phenyl, naphthyl, or substituted naphthyl.
  • Substituted phenyl is a phenyl either having 1-4 substituents independently selected from -F, -CI, -Br, or -I, or having 1 substituent selected from -R 12 and 0-3 substituents independently selected from -F, -CI, -Br, or -I.
  • Substituted naphthyl is a naphthalene moiety either having 1-4 substituents independently selected from -F, -CI, -Br, or -I, or having 1 substituent selected from -Ri 2 and 0-3 substituents independently selected from -F, -CI, -Br, or -I, where the substitution can be independently on either the same ring or different rings of said naphthalene moiety.
  • Mammal denotes human and other mammals.
  • Brine refers to an aqueous saturated sodium chloride solution.
  • IR refers to infrared spectroscopy.
  • Lv refers to leaving groups within a molecule, including Br, CI, OH, or mixed anhydride.
  • NMR nuclear (proton) magnetic resonance spectroscopy
  • MS refers to mass spectrometry expressed as m e or mass/charge unit.
  • HRMS refers to high resolution mass spectrometry expressed as m/e or mass/charge unit.
  • M+H + refers to the positive ion of a parent plus a hydrogen atom.
  • M-H " refers to the negative ion of a parent minus a hydrogen atom.
  • M+Na + refers to the positive ion of a parent plus a sodium atom.
  • M+K + refers to the positive ion of a parent plus a potassium atom.
  • El refers to electron impact.
  • ESI refers to electrospray ionization.
  • CI refers to chemical ionization.
  • FAB refers to fast atom bombardment.
  • compositions of the present invention may be in the form of pharmaceutically acceptable salts.
  • pharmaceutically acceptable salts refers to salts prepared from pharmaceutically acceptable non-toxic bases including inorganic bases and organic bases, and salts prepared from inorganic acids, and organic acids. Salts derived from inorganic bases include aluminum, ammonium, calcium, ferric, ferrous, lithium, magnesium, potassium, sodium, zinc, and the like.
  • Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, such as arginine, betaine, caffeine, choline, N, N- dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylamino- ethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, and the like.
  • cyclic amines such as arginine, betaine, caffeine, choline, N, N
  • Salts derived from inorganic acids include salts of hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, phosphorous acid and the like.
  • Salts derived from pharmaceutically acceptable organic non-toxic acids include salts of C ⁇ _6 alkyl carboxylic acids, di-carboxylic acids, and tri-carboxylic acids such as acetic acid, propionic acid, fumaric acid, succinic acid, tartaric acid, maleic acid, adipic acid, and citric acid, and aryl and alkyl sulfonic acids such as toluene sulfonic acids and the like.
  • an effective amount of a compound as provided herein is meant a nontoxic but sufficient amount of the compound(s) to provide the desired effect.
  • the exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the disease that is being treated, the particular compound(s) used, the mode of administration, and the like. Thus, it is not possible to specify an exact "effective amount.” However, an appropriate effective amount may be determined by one of ordinary skill in the art using only routine experimentation.
  • the compounds of Formula I have optically active center(s) on the quinuclidine ring. Although it is desirable that the stereochemical purity be as high as possible, absolute purity is not required.
  • This invention involves racemic mixtures and compositions of varying degrees of streochemical purities. It is preferred to carry out stereoselective syntheses and/or to subject the reaction product to appropriate purification steps so as to produce substantially optically pure materials. Suitable stereoselective synthetic procedures for producing optically pure materials are well known in the art, as are procedures for purifying racemic mixtures into optically pure fractions.
  • the preferred compounds of the present invention have the R configuration at the C3 position of the quinuclidine ring. It is also preferred for the compounds of the present invention that X is O. Another group of compounds of Formula I includes compounds wherein X is O and Ri is H. Another group of compounds of Formula I includes compounds wherein X is O and R 2 is H. Another group of compounds of Formula I includes compounds wherein X is O and R 2 is alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, benzyl, substituted benzyl, or aryl.
  • the amount of therapeutically effective compound(s) that is administered and the dosage regimen for treating a disease condition with the compounds and/or compositions of this invention depends on a variety of factors, including the age, weight, sex and medical condition of the subject, the severity of the disease, the route and frequency of administration, and the particular compound(s) employed, and thus may vary widely.
  • the compositions contain well know carriers and excipients in addition to a therapeutically effective amount of compounds of Formula I.
  • the pharmaceutical compositions may contain active ingredient in the range of about 0.001-100 mg/kg/day for an adult, preferably in the range of about 0.1-50 mg/kg/day for an adult. A total daily dose of about 1-1000 mg of active ingredient may be appropriate for an adult.
  • the daily dose can be administered in 1-4 doses per day.
  • the composition for therapeutic use may also comprise one or more non-toxic, pharmaceutically acceptable carrier materials or excipients.
  • carrier material or excipient herein means any substance, not itself a therapeutic agent, used as a carrier and/or diluent and/or adjuvant, or vehicle for delivery of a therapeutic agent to a subject or added to a pharmaceutical composition to improve its handling or storage properties or to permit or facilitate formation of a dose unit of the composition into a discrete article such as a capsule or tablet suitable for oral administration.
  • Excipients can include, by way of illustration and not limitation, diluents, disintegrants, binding agents, adhesives, wetting agents, polymers, lubricants, glidants, substances added to mask or counteract a disagreeable taste or odor, flavors, dyes, fragrances, and substances added to improve appearance of the composition.
  • Acceptable excipients include lactose, sucrose, starch powder, cellulose esters of alkanoic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate, polyvinyl- pyrrolidone, and/or polyvinyl alcohol, and then tableted or encapsulated for convenient administration.
  • Such capsules or tablets may contain a controlled-release formulation as may be provided in a dispersion of active compound in hydroxypropyl- methyl cellulose, or other methods known to those skilled in the art.
  • the pharmaceutical composition may be in the form of, for example, a tablet, capsule, suspension or liquid. If desired, other active ingredients may be included in the composition.
  • compositions of the present invention may be administered by any suitable route, in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended.
  • the compositions may, for example, be administered parenterally, e.g., intravascularly, intraperitoneally, subcutaneously, or intramuscularly.
  • parenteral administration e.g., saline solution, dextrose solution, or water may be used as a suitable carrier.
  • Formulations for parenteral administration may be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions.
  • solutions and suspensions may be prepared from sterile powders or granules having one or more of the carriers or diluents mentioned for use in the formulations for oral administration.
  • the compounds may be dissolved in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, and/or various buffers.
  • Other adjuvants and modes of administration are well and widely known in the pharmaceutical art.
  • the serotonin type 3 receptor is a member of a superfamily of ligand- gated ion channels, which includes the muscle and neuronal nAChR, the glycine receptor, and the ⁇ -aminobutyric acid type A receptor. Like the other members of this receptor superfamily, the 5HT 3 R exhibits a large degree of sequence homology with 7 nAChR but functionally the two ligand-gated ion channels are very different. For example, al nAChR is rapidly inactivated, is highly permeable to calcium and is activated by acetylcholine and nicotine. On the other hand, 5HT 3 R is inactivated slowly, is relatively impermeable to calcium and is activated by serotonin.
  • al nAChR and 5HT 3 R proteins have some degree of homology, but function very differently. Indeed the pharmacology of the channels is very different. For example, Ondansetron, a highly selective 5HT R antagonist, has little activity at the al nAChR. The converse is also true. For example, GTS-21, a highly selective ⁇ 7 nAChR agonist, has little activity at the 5HT R.
  • al nAChR is a ligand-gated Ca ++ channel formed by a homopentamer of al subunits.
  • al nAChR binds selectively to this homopetameric, al nAChR subtype, and that al nAChR has a high affinity binding site for both ⁇ -btx and methyllycaconitine (MLA).
  • al nAChR is expressed at high levels in the hippocampus, ventral tegmental area and ascending cholinergic projections from nucleus basilis to thalamocortical areas, al nAChR agonists increase neurotransmitter release, and increase cognition, arousal, attention, learning and memory.
  • Schizophrenia is a complex multifactorial illness caused by genetic and non- genetic risk factors that produce a constellation of positive and negative symptoms.
  • the positive symptoms include delusions and hallucinations and the negative symptoms include deficits in affect, attention, cognition and information processing.
  • No single biological element has emerged as a dominant pathogenic factor in this disease. Indeed, it is likely that schizophrenia is a syndrome that is produced by the combination of many low penetrance risk factors.
  • Clozapine an "atypical" antipsychotic drug, is novel because it is effective in treating both the positive and some of the negative symptoms of this disease. Clozapine' s utility as a drug is greatly limited because continued use leads to an increased risk of agranulocytosis and seizure. No other antipsychotic drag is effective in treating the negative symptoms of schizophrenia. This is significant because the restoration of cognitive functioning is the best predictor of a successful clinical and functional outcome of schizophrenic patients (Green, M.F., Am J Psychiatry, 153:321- 30, 1996). By extension, it is clear that better drugs are needed to treat the cognitive disorders of schizophrenia in order to restore a better state of mental health to patients with this disorder.
  • One aspect of the cognitive deficit of schizophrenia can be measured by using the auditory event-related potential (P50) test of sensory gating.
  • P50 auditory event-related potential
  • EEG electroencepholographic
  • Normal individuals respond to the first click with greater degree than to the second click.
  • schizophrenics and schizotypal patients respond to both clicks nearly the same (Cullum, CM. et. al., Schizophr. Res., 10:131-41, 1993).
  • biochemical data indicate that schizophrenics have 50% fewer of al nAChR receptors in the hippocampus, thus giving a rationale to partial loss of al nAChR functionality (Freedman, R. et. al., Biol. Psychiatry, 38:22-33, 1995).
  • genetic data indicate that a polymorphism in the promoter region of the al nAChR gene is strongly associated with the sensory gating deficit in schizophrenia (Freedman, R. et. al., Proc. Natl. Acad. Sci. USA, 94(2):587-92, 1997; Myles-Worsley, M. et. al, Am. J. Med.
  • schizophrenics express the same ⁇ 7 nAChR as non-schizophrenics.
  • Selective ⁇ 7 nAChR agonists may be found using a functional assay on FLIPR (see WO 00/73431 A2).
  • FLIPR is designed to read the fluorescent signal from each well of a 96 or 384 well plate as fast as twice a second for up to 30 minutes.
  • This assay may be used to accurately measure the functional pharmacology of ⁇ 7 nAChR and 5HT 3 R.
  • To conduct such an assay one uses cell lines that expressed functional forms of the ⁇ 7 nAChR using the ⁇ 7/5-HT 3 channel as the drug target and cell lines that expressed functional 5HT 3 R. In both cases, the ligand-gated ion channel was expressed in SH-EPl cells.
  • the compounds of the present invention are ⁇ 7 nAChR agonists and may be used to treat a wide variety of diseases. For example, they may be used in treating schizophrenia, and psychosis.
  • Schizophrenia is a disease having multiple aspects.
  • drugs are generally aimed at controlling the positive aspects of schizophrenia, such as delusions.
  • One drug, Clozapine is aimed at a broader spectrum of symptoms associated with schizophrenia. This drug has many side effects and is thus not suitable for many patients.
  • a drug to treat the cognitive and attention deficits associated with schizophrenia.
  • schizoaffective disorders or similar symptoms found in the relatives of schizophrenic patients.
  • Psychosis is a mental disorder characterized by gross impairment in the patient's perception of reality.
  • the patient may suffer from delusions, and hallucinations, and may be incoherent in speech. His behavior may be agitated and is often incomprehensible to those around him.
  • psychosis has been applied to many conditions that do not meet the stricter definition given above. For example, mood disorders were named as psychoses.
  • the conventional antipsychotic drugs include Chlo romazine, Fluphenazine, Haloperidol, Loxapine, Mesoridazine, Molindone, Peiphenazine, Pimozide, Thioridazine, Thiothixene, and Trifluoperazine. These drugs all have an affinity for the dopamine 2 receptor.
  • Atypical antipsychotic drugs generally are able to alleviate positive symptoms of psychosis while also improving negative symptoms of the psychosis to a greater degree than conventional antipsychotics. These drugs may improve neurocognitive deficits. Extrapyramidal (motor) side effects are not as likely to occur with the atypical antipsychotic drugs, and thus, these atypical antipsychotic drags have a lower risk of producing tardive dyskinesia. Finally these atypical antipsychotic drugs cause little or no elevation of prolactin. Unfortunately, these drags are not free of side effects.
  • the side effects include: agranulocytosis; increased risk of seizures, weight gain, somnolence, dizziness, tachycardia, decreased ejaculatory volume, and mild prolongation of QTc interval.
  • the compounds of the present invention may be used in combination therapy with typical and atypical anti-psychotic drugs. All compounds within the present invention are useful for and may also be used in combination with each other to prepare pharmaceutical compositions. Such combination therapy lowers the effective dose of the anti-psychotic drug and thereby reduces the side effects of the anti-psychotic drugs.
  • Some typical anti-psychotic drugs that may be used in the practice of the invention include Haldol.
  • Some atypical anti-psychotic drugs include Ziprasidone, Olanzapine, Resperidone, and Quetiapine.
  • the acid when W is a thiophene or in some furan cases, the acid is converted into a mixed anhydride by treatment with diphenylchlorophosphate in the presence of TEA and CH 2 C1 2 as the solvent.
  • the resulting anhydride solution is directly reacted with aminoquinuclidine using aqueous DMF as the solvent.
  • W is furan, oxazole, oxadiazole, pyrrole, 5-thiazole, thiophene, or triazole
  • the acid is activated with a uronium salt, preferably HATU (see J. Am. Chem.
  • the thiophene acids required in Examples 1-11, 13, and 41-42 can be synthesized from the corresponding aldehydes by oxidation with NaClO 2 as described in J. Chem. Soc. Perkin Trans. I., 789-794 (1999). The requisite aldehydes can be made as described in J. Med. Chem., 1585-1599 (1997).
  • An aryl boronic acid is reacted with a bromothiophene in the presence of a palladium (0) source, such as tetrakis- (triphenylphosphine)palladium (0), and a base, preferably aqueous sodium carbonate.
  • a palladium (0) source such as tetrakis- (triphenylphosphine)palladium (0)
  • a base preferably aqueous sodium carbonate.
  • the reaction works best if heated at reflux in THF/water for 24 hours.
  • the thiophene acids for Examples 31-40 are synthesized from the corresponding esters by base catalyzed hydrolysis. Typical hydrolysis procedures are well known in the art.
  • the thiophene ester is treated with aqueous lithium hydroxide in a solvent such as dioxane.
  • the esters are either commercially available or synthesized by reaction of a bromothiophene ester with the appropriate thiophenol or phenol as described in Coll. Czech. Chem. Comm., 2360-2363 (1980). Namely, the sodium salt of the thiophenol or phenol is formed by treatment with a strong base like sodium hydride. The sodium salt is then reacted with a bromothiophene in a solvent such as acetone.
  • the required acids for Examples 44-49 are prepared by nucleophilic addition of the requisite phenol or thiophenol to 2-bromo-l,3-thiazole-5- carboxylic ethyl ester according to the procedure described in Helv. Chim. Ada., 2002-2022 (1997).
  • EtOH utilizing K 2 CO 3 as a base (Scheme 3).
  • the esters are hydiolyzed to the corresponding acids by procedures well known in the art.
  • the 2-bromo-l,3-thiazole is prepared by the method described in Roczniki Chemii
  • the aryl 1,3-thiazole for Example 50 is prepared according to the procedure of Huntress and Pfister in J. Am. Chem. Soc, 2167-2169 (1943).
  • the requisite l,3-thiazoles-5-acids for Examples 51 and 58-62 are commercially available.
  • the l,3-thiazole-5-acids required in Examples 52-57 can be synthesized from the corresponding esters by base hydrolysis via procedures well known in the art.
  • the requisite esters can be prepared by a Suzuki reaction as described in J. Med. Chem., 4985-92 (1995).
  • aryl boronic acid is reacted with a bromothiazole ester in the presence of a palladium (0) source, such as tetrakis- (triphenylphosphine)palladium (0), and a base, preferably aqueous sodium carbonate.
  • a palladium (0) source such as tetrakis- (triphenylphosphine)palladium (0)
  • a base preferably aqueous sodium carbonate.
  • 1,3,4-thiadiazole esters for Examples 64-72 are synthesized by nucleophilic addition of the requisite phenol or thiophenol to 2-bromo-l,3,4-thiadiazolezole-5- carboxylic ethyl ester as described in Can. J. Chem., 243-250 (1977) (Scheme 3).
  • Example 75 and the oxadiazole for Example 76 are prepared by the methods of McKillop et al., Tetrahedron Lett. 23, 3357-3360 (1982) with modifications as described herein.
  • the oxadiazole for Example 77 is prepared following the procedures of Snyder in J. Org. Chem. 3257-3269 (1990), Muchowski in Can. J. Chem. 3079-3082 (1972), and Crenshaw in US 4,001,238.
  • the 5-substituted-l,3-oxazole-2-esters for Examples 79-88 are synthesized according to procedures described in J. Pharm. Soc. Japan, 305-7 (1956) as shown in Scheme 4.
  • the 5-substituted-l,3-thiazole-2-esters for Examples 89-102 are synthesized according to procedures described in Chem. Pharm. Bull., 4195-4198 (1982).
  • furans for Examples 103-130 are commercially available or can be prepared from their corresponding aldehydes or esters as described for the thiophenes (Examples 1-11). hi the event that the furan is not commercially available, it can be prepared by the method of Bussolari and Rehborn described in Org. Lett. 965-7 ( 1999).
  • Furan Examples 131 - 146 are prepared in a convergent means by a direct palladium catalyzed Suzuki coupling N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-bromo- furan-2-carboxamide with the requisite boronic acid by the method described in Org. Lett. 965-7 (1999), to yield directly the desired aryl amides (Scheme 5).
  • Examples 12, and 147- 149 are prepared by reduction of the corresponding aryl nitro compounds by methods well known in the art, preferably by reduction with Pd/C in an alcoholic solvent such as EtOH under H 2 .
  • the acid for example 150 is prepared by a Pd(0) catalyzed Sonogashira coupling of 5-bromo-2-furanal and phenyl acetylene as described in Tetrathedron Lett., 4467-70 (1975). The resulting aldehyde is converted to the desired analog by methods as described for Example 103.
  • Example 151 is prepared by addition of the sodium salt of phenol to N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- bromo-furan-2-carboxamide.
  • the requisite acid for Example 152 is prepared by bromination of methyl-5-bromo- 1 -methyl- 1 H-pyrrole-2-carboxylate, followed by similar Pd-catalyzed coupling as described for Example 1.
  • Example 153 The l,3-oxazole-2-carboxylic acid required for Example 153 is prepared by the method described in J. Pharm. Sci. Japan 305-7, (1956). 3-Phenyl- 1,2,4- oxadiazole-5-carboxylic acid required for Example 154 is prepared by the method of Wurm as described in Chem. Ber., 3133, (1889). The 2-phenyl-l,3-oxazole-5- carboxylic acid required for Example 155 is prepared by the method described in Chem. Heterocycl. Compd. (Engl.Transl.), 654-663, (1986).
  • Example 156 2-Phenyl-l,3-oxazole-4- carboxylic acid required for Example 156 is prepared as described by Korte and Stoeriko, in Chem. Ber., 1033-1042, (1960).
  • the 5-phenylisoxazole-3-carboxylic acid for Example 157 is prepared by the method of Vaughan and Spencer as described in J. Org. Chem. 1160-4, (1960).
  • Thioamides such as Example 159
  • the thioester can be prepared as described in J. Organometallic Chem., 95-98 (1987).
  • One of ordinary skill in the art would quickly identify that compounds such as Example 159 could also be prepared directly from the amides exemplified throughout this patent by direct treatment with a reagent such and Lawesson's reagent (see Lawesson et. al. in Bull. Soc. Chim. Belg., 229 (1978)) or P 4 S ⁇ 0 (see Chem. Rev., 45 (1961)).
  • Step 1 a Preparation of 5-phenylthiophene-2-carboxaldehyde.
  • 5-Bromothiophene-2-carboxaldehyde (l.Og, 5.2 mmol) is added to a solution of tetrakis(triphenylphosphine)palladium(0) (180 mg, 0.16 mmol) in degassed THF (lOmL). The resulting solution is stirred for 5 minutes. A solution of phenylboronic acid (760 mg, 6.2 mmol) in THF (lOmL) is added followed by aqueous Na 2 CO 3 (2M, 5.2mL). The mixture is heated at reflux for 24 hours. The reaction mixture is allowed to cool, poured into ether, and washed twice with water. The ether layer is dried over Na 2 SO 4 and concentrated in vaeuo.
  • Step lb Preparation of 5-phenylthiophene-2-carboxylic acid.
  • Step la The product of Step la (750 mg, 4 mmol) is dissolved in a mixture of THF, t- BuOH, and water (2: 1:1, 60 mL). KH 2 PO 4 (1.36 g, 10 mmol) is added followed by NaClO 2 (900 mg, 10 mmol). The mixture is stirred at room temperature for 5 days. Aqueous NaOH (2M, 10 mL) is added, and a majority of the organic solvents are removed in vaeuo yielding an aqueous suspension. This suspension is diluted with water and washed three times with CH 2 C1 2 . The aqueous layer is acidified to pH ⁇ 6 with 25% H 2 SO and the product is extracted three times with CH 2 C1 2 .
  • Step lc Preparation of N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-phenyl- thiophene-2-carboxamide hydrochloride.
  • TEA 210 ⁇ L, 1.5mmol
  • Example 2 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-chlorophenyl)-thiophene-2- carboxamide hydrochloride (from 4-chlorophenylboronic acid). Yield 24% for 3 steps. MS for C, 8 H ⁇ 9 ClN 2 OS (ESI) (M+H) + m/z 347.
  • Example 3 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-chlorophenyl)-thiophene-2- carboxamide hydrochloride (from 3-chlorophenylboronic acid). Yield 16%. MS for C, 8 H ⁇ 9 ClN 2 OS (ESI) (M+H) + m/z 347.
  • Example 5 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2,3'-bithiophene-5-carboxamide hydrochloride (from 3-thiopheneboronic acid). Yield 49%. HRMS (FAB) calculated for C 16 Hi 8 N 2 OS 2 +H 319.0939, found 319.0939.
  • Example 6 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-nitrophenyl)-thiophene-2- carboxamide hydrochloride (from 2-nitrophenylboronic acid). Yield 45%. HRMS (FAB) calculated for C l8 H ⁇ 9 N 3 O 3 S+H 358.1225, found 358.1224.
  • Example 8 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-4-phenyl-thiophene-2- carboxamide hydrochloride (starting with phenyl boronic acid and 4-bromothiophene- 2-carboxaldehyde in place of 5-bromothiophene-2-carboxaldehyde). Yield 35%. MS for C ⁇ 8 H 20 N 2 OS (ESI) (M+H) + m/z 313.
  • Example 10 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-benzyloxyphenyl)- thiophene-2-carboxamide hydrochloride (from 4-benzyloxyphenylboronic acid). Yield 34%. MS for C 25 H 26 N 2 O 2 S (ESI) (M+H) + m/z 419.
  • Example 11 N-[(3R)- 1 -azabicyclo[2.2.2]oct-3 ⁇ yl]-5-(3-fluoro-4-benzyloxyphenyl)- thiophene-2-carboxamide hydrochloride (from 3-fluoro-4-benzyloxyphenylboronic acid). Yield 41%. MS for C 25 H 25 FN 2 O 2 S (ESI) (M+H) + m/z 436.
  • Step 12a Preparation of 5-(2-aminophenyl)-N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]thiophene-2-carboxamide.
  • Example 6 In a 200 mL Parr flask is placed the compound Example 6 (0.200 g, 0.51 mmol), EtOH (5 mL) and CH 2 C1 2 (5 mL). The flask is shaken under 30 psi H 2 for 16 hours. The contents are then filtered through a pad of celite with 10% MeOH-CH 2 Cl 2 (150 mL). The solvents are removed in vaeuo. This lot is then combined with a second lot prepared in a similar manner on the scale of 0.25 mmol. The product is re- dissolved in MeOH and loaded onto a column of AG50Wx2 ion exchange resin (H+ form). The resin is washed with MeOH then the product is eluted with 5% TEA in MeOH.
  • H+ form AG50Wx2 ion exchange resin
  • Step 13a Preparation of 5-(3-pyridinyl)-2-thiophenecarboxaldehyde.
  • 3-pyridinediethylborane (0.81 g, 5.5 mmol)
  • 2- bromothiophene-5-carboxaldehyde (0.59 mL, 5.0 mmol)
  • Pd(PPh 3 ) 4 (0.17g, 0.15 mmol).
  • the flask is vacuum purged and nitrogen filled three times followed by addition of a 4: 1 mixture of toluene-EtOH (8.3 mL) by syringe.
  • Step 13b Preparation of N-[(3R)-1 -azabicyclo[2.2.2]oct-3-yl]-5- ⁇ yridin-3-yl- thiophene-2-carboxamide dihydiOchloride.
  • Step 14a Preparation of methyl 5 -methyl-2,2'-bithiophene-5-carboxylate.
  • Step 14b Preparation of 5 -methyl-2,2'-bithiophene-5-carboxylic acid.
  • Step 14a The product of Step 14a (0.37 g, 1.54 mmol), dioxane (5 mL) and LiOH (IN, 3.1 mL, 3.1 mmol) are placed in a flask. Additional dioxane (5 mL) is then added for solubility and stirred for 24 h at rt. IN HC1 is added slowly until pH ⁇ 6, whereupon a precipitate forms. The precipitate is then collected by filtration, rinsed with water, and dried in a 70°C vacuum oven to provide the product as a yellow solid (0.30 g, 86%). MS for Ci 0 H 8 O 2 S 2 (ESI) (M-H) + m/z 223.
  • Step 14c Preparation of N-[(3R)- l-azabicyclo[2.2.2]oct-3-yl]-5 -methyl-2,2 - bithiophene-5-carboxamide hydrochloride.
  • Step 15a Preparation of 5 -chloro-2,2'-bithiophene-5-carboxaldehyde.
  • Step 15b Preparation of N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5 -chloro-2,2 - bithiophene-5-carboxamide hydrochloride.
  • Step 16a Preparation of N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-nilrothiophene-
  • This compound is made from 2-nitrothiophene-5-carboxaldehyde by using the procedure discussed in Steps lb and lc, making non-critical variations. Yield for 2 steps 48%.
  • Step 17a Preparation of tert-butyl 2-thienylmethylcarbamate.
  • a 500 mL receiving flask is placed in an ice bath, and to the flask is added thiophene-2-methylamine (5.0 mL, 48.7 mmol), CH 2 C1 2 (250 mL) then di-tert-butyl dicarbonate (12.7 g, 73.0 mmol) in 2-3 g portions over 5 min.
  • the reaction mixture is stirred for 3 h then washed with IN HC1 (3X), IN NaOH (3X) and brine (2X).
  • the organic layer is dried over MgSO , filtered and concentrated to a yellow oil.
  • Step 17b Preparation of 5- ⁇ [(tert-butoxycarbonyl)amino]methyl ⁇ -2- thiophenecarboxylic acid.
  • Step 17a In a flask is placed the product of Step 17a (3.50 g, 16.4 mmol) and dry THF (80 mL) then cooled in an acetone/solid CO 2 bath. Lithium diisopropylamide (18.0 mL, 36.1 mmol, 2.0 M solution in heptane/THF/ethylbenzene) is added in a slow stream by syringe. The resulting orange solution is stirred for 10 min and then quenched with excess dry ice. The solution is warmed over lh and the THF removed in vaeuo. The crude product is diluted with CH 2 C1 2 and washed with IN HC1 (3X).
  • Step 17c Preparation of 5-(aminomethyl)-N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]thiophene-2-carboxamide dihydrochloride.
  • Step 18a Preparation of 5-cyano-thiophene-2-carboxylic acid.
  • thiophene-2-carbonitrile 5.0 mL, 53.8 mmol
  • THF 270 mL
  • Lithium diisopropylamide (40.3 mL, 80.7 mmol, 2.0M solution in heptane/THF/ethylbenzene) is added in a slow stream via syringe.
  • the solution is stirred for 10 min then quenched with an excess of dry ice.
  • the reaction mixture is warmed in a water bath and the THF removed in vaeuo.
  • the slurry is taken up in IN NaOH and extracted with ether (3X).
  • Step 20a TEA (50 ⁇ L, 0.35mmol) is added to a suspension of 5-(pyridin-2-yl)-2- thiophenecarboxylic acid (72mg, 0.35mmol) in CH 2 C1 2 :DMF (2: 1, 1.5mL). Diphenylchlorophosphate (62 ⁇ L, 0.3mmol) is added and the resulting solution is stirred at room temperature for 30 minutes. A solution of (R)-3-aminoquinuclidine (1M, 0.2mmol, 0.2mL) in DMF is added and the resulting solution is stirred overnight at room temperature. MeOH is added and the mixture is poured through a column of AG50Wx2 ion exchange resin (H + form).
  • Example 21 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-[2,2 : ]bithiophenyl-5-carboxamide (from 2,2 -bithiophene-5-carboxylic acid). Yield 13%. MS for C ⁇ 6 H ⁇ 8 N 2 OS 2 (ESI) (M+H) + m/z 319.
  • Example 22 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(methylsulfanyl)-thiophene-2- carboxamide (from 5-methylsulfanylthiophene-2-carboxylic acid). Yield 84%. MS for C 13 H 18 N 2 OS 2 (ESI) (M+H) + m/z 283.
  • Example 23 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-chloro-thiophene-2- carboxamide (from 5-chlorothiophene-2-carboxylic acid). Yield 6%. MS for C ⁇ 2 H ⁇ 5 ClN 2 OS (ESI) (M+H) + m/z 271.
  • Example 24 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-acetyl-thiophene-2- carboxamide (from 5-acetylthiophene-2-carboxylic acid). Yield 7%. MS for C ⁇ 4 H, 8 N 2 O 2 S (ESI) (M+H) + m/z 279.
  • Example 25 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-methyl-thiophene-2- carboxamide (from 5-methylthiophene-2-carboxylic acid). Yield 6%. MS for C, 3 H ⁇ 8 N 2 OS (ESI) (M+H) + m/z 251.
  • Example 26 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-bromo-thiophene-2- carboxamide (from 5-bromothiophene-2-carboxylic acid). Yield 8%. MS for C, 2 H ⁇ 5 BrN 2 OS (ESI) (M+H) + m/z 315/317.
  • Example 27 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(phenylsulfanyl)-thiophene-2- carboxamide (from 5-phenylsulfanylthiophene-2-carboxylic acid). Yield 68%. MS for Ci 8 H 2 oN 2 OS2 (ESI) (M+H) + m/z 345.
  • Example 28 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(acetylamino)-furan-2- carboxamide (from 5-acetylaminofuran-2-carboxylic acid). Yield 16%. MS for C ⁇ 4 H 19 N 3 O 3 (ESI) (M+H) + m/z 278.
  • Example 29 N-[(3R)- l-azabicyclo[2.2.2]oct-3-yl]-5-trifluoromethyl-furan-2- cai-boxamide (from 5-trifluoiOmelhylfuran-2-carboxylic acid). Yield 11%. MS for C, 3 H 15 F 3 N2 ⁇ 2 (ESI) (M+H) + m/z 289.
  • Example 30 N-[(3R)- l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methyl-5-trifluoromethyl- 2H-pyrazole-3-yl)-thiophene-2-carboxamide (from 5-(2-methyl-5-trifluoromethyl-2H- pyrazole-3-yl)thiophene-2-carboxylic acid). Yield 9%. MS for 7 ⁇ 9 F 3 N 4 OS (ESI)
  • Step 31a Preparation of 5-(2-methylthiazol-4-yl)-thiophene-2-carboxylic acid.
  • This compound is prepared from methyl 5-[2-(3-chlorophenyl) vinyl]- thiophene-2-carboxylate according to the procedure used to make the compound of Example 31, making non-critical variations. Yield 19%. MS for C 2 oH 2 iClN 2 OS (ESI) (M+H) + m/z 373.
  • Step 33a Preparation of 5-(4-chlorophenylsulfanyl)-thiophene-2- carboxaldehyde.
  • Step 33b Preparation of 5-(4-chlorophenylsulfanyl)-thiophene-2-carboxylic acid.
  • Step 33a The product of Step 33a (6.1g, 24mmol) is dissolved in a mixture of THF, t- BuOH, and water (3:3:1, 255mL). 2-Methyl-2-butene (20.3mL, 192mmol) is added followed by KH 2 PO 4 (9.8g, 72mmol) and then NaClO 2 (80%, 8.17g, 72.3mmol). The mixture is stirred at room temperature for 2 hours. Aqueous KHSO (0.5M, 200mL) is added and the organic solvents are removed in vaeuo to produce an aqueous suspension of the product. The precipitate is collected by filtration, dissolved in IN NaOH and washed two times with ether.
  • Step 33c Preparation of N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- chlorophenylsulfanyl)-thiophene-2-carboxamide.
  • Example 34 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2,4 difluorophenyl-sulfanyl)- thiophene-2 carboxamide hydrochloride (from 2,4-difluorothiophenol). Yield for 3 steps 9%. MS for C, 8 H 18 F2N 2 OS 2 (ESI) (M+H) + m/z 381.
  • Example 35 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-chlorophenyl-sulfanyl)- thiophene-2-carboxamide (from 3-chlorothiophenol). Yield 50%. MS for C l8 H ⁇ 9 ClN 2 OS 2 (ESI) (M+H) + m/z 379.
  • Example 36 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-chloro-4-fluoro- phenylsulfanyl)-thiophene-2-carboxamide (from 3-chloro-4-fluorothiophenol). Yield 29%. MS for C ] 8 H, 8 ClFN 2 OS 2 (ESI) (M+H) + m/z 397.
  • Example 37 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2,3-dichlorophenyl-sulfanyl)- thiophene-2-carboxamide hydrochloride (from 2,3-dichlorothiophenol). Yield 44%. MS for C ⁇ 8 H ⁇ 8 Cl 2 N 2 OS 2 (ESI) (M+H) + m/z 413.
  • Example 38 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2,4,5-trichlorophenyl- sulfanyl)-thiophene-2-carboxamide (from 2,4,5-trichlorothiophenol). Yield 53%. MS for C )8 H ⁇ 7 Cl 3 N 2 OS 2 (ESI) (M+H) + m/z 449.
  • Example 39 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,4-dichlorophenyl-sulfanyl)- thiophene-2-carboxamide (from 3,4-dichlorothiophenol). Yield 21%. MS for C, 8 H ⁇ 8 Cl 2 N 2 OS 2 (ESI) (M+H) + m/z 413.
  • Step 40a 5-Phenoxy-thiophene-2-carboxaldehyde.
  • Phenol (3.3g, 35mmol) is added in portions to a suspension of 60% NaH (1.3g, 35mmol) in DMSO (lOOmL). The resulting mixture is stirred for 30 minutes then 5- nitrothiophene-2-carboxaldehyde (5g, 32mmol) is added. After 1 hour the reaction mixture is poured into water (IL) and washed with ether (4x500mL). The combined organic layers are dried over Na 2 SO 4 , filtered and evaporated to dryness. The resulting material is dissolved in MeOH and passed through a column (2.5cm x 20cm) of Amberjet 4400 (OH " form). The eluent is dried in vaeuo then evaporated twice from CH 3 CN.
  • Step 40b 5-Phenoxy-thiophene-2-carboxylic acid.
  • 5-Phenoxy-thiophene-2-carboxaldehyde (325mg, l. ⁇ mmol) is dissolved in a mixture of THF (lOmL), t-BuOH (5mL) and water (5mL).
  • NaH 2 PO 4 (650mg, 4.8mmol) is added followed by NaClO 2 (432mg, 4.8mmol).
  • Aqueous NaOH (2M, 5mL) is added, and the organic solvents are removed in vaeuo.
  • the resulting aqueous suspension is poured into water (50mL) and washed with ether (3x50mL).
  • Step 40c N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-phenoxy-thiophene-2- carboxamide hydrochloride.
  • the compound is made according to the procedure of Step lc, starting with 5- phenoxy-thiophene-2-carboxylic acid and making non-critical variations. Yield (66%).
  • Step 41a 5-(2-Hydroxyphenyl)-thiophene-2-carboxylic acid.
  • Tetrakis(triphenylphosphine)palladium(0) (133mg, 0.12mmol) is added to a solution of 5-bromothiophene-2-carboxylic acid (850mg, 4.1 mmol) in degassed THF (lOmL). The resulting solution is stirred for 5 minutes and then 2-(4,4,5,5- tetramethyl)-l,3,2-dioxaborolan-2-yl) phenol (lg, 4.6mmol) is added followed by aqueous Na 2 CO 3 (2M, 6.9mL). The mixture is heated at reflux overnight. The reaction mixture is allowed to cool, poured into water (50mL), and washed with ether (3x50mL).
  • Step 41b N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-hydroxyphenyl)-thiophene- 2-carboxamide hydrochloride.
  • Step 43a The compound Example 11 (165mg, O.38mmol) is dissolved in MeOH and poured through a plug of Amberjet 4400 (OH " form). The solvent is removed in vaeuo and the product is redisolved in EtOH (2mL). This solution is added to a suspension of Pd/C (10%, 165mg) in EtOH (2mL). Cyclohexadiene (360mL, 3.8mmol) is added, and the reaction is heated at 60 ° C for 6 hours. The reaction mixture is diluted with MeOH and filtered through celite. The solvents are removed in vaeuo then the hydrochloride salt is formed and crystallized from MeOH/CH 3 CN to yield the desired product (52mg, 36%). MS for C ⁇ 8 H 20 FN 2 O 2 S (ESI) (M+H) + m/z 347.
  • Step 44a Preparation of 2-phenylsuIfanyl-thiazole-5-carboxylic acid ethyl ester.
  • Step 44b Preparation of 2-phenylsulfanyl-thiazole-5-carboxylic acid.
  • Potassium hydroxide 1.58 g, 28.2 mmol, 10 eq
  • 2- phenylsulfanyl-thiazole-5-carboxylic acid ethyl ester 0.748 g, 2.82 mmol, 1 eq
  • EtOH 15 mL
  • water 10.5 mL
  • the reaction is stirred for 1.5 hours, diluted with water (30 mL) and EtOH (30 mL), and acidified by addition of 3 N HCI until a white precipitate forms.
  • Step 44c N-[(3R)-l-a ⁇ abicyclo[2.2.2]oct-3-yl]-2-(phenylsulfanyl)-l,3-thia ⁇ ole- 5-carboxamide fumarate.
  • HATU 0.93 g, 1.30 mmol, 1 eq
  • 2-phenylsulfanyl- thiazole-5-carboxylic acid 0.307 g, 1.30 mmol, 1 eq
  • (R)-(+)-3-aminoquinuclidine dihydrochloride 0.258 g, 1.30 mmol, 1 eq
  • DIEA 0.677 L, 3.89 mmol, 3 eq
  • Example 45 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-[(4-chlorophenyl)-sulfanyl]- 1 ,3-thiazole-5-carboxamide fumarate (from 4-chlorothiophenol). Yield 39%.
  • HRMS (FAB) calculated for C ⁇ 7 H 18 ClN 3 OS 2 +H, 380.0658, found 380.0659.
  • Example 46 N-[(3R)l-azabicyclo[2.2.2]oct-3-yl]-2-phenoxy-l,3-thiazole-5- carboxamide fumarate (from phenol). Yield 81%. HRMS (FAB) calculated for C ⁇ 7 H ⁇ 9 N 3 O 2 S+H, 330.1276, found 330.1269.
  • Example 47 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-[(4-fluorophenyl)-sulfanyl]- l,3-thiazole-5-carboxamide fumarate (from 4-fluorothiophenol). Yield 43%. HRMS (FAB) calculated for C ⁇ 7 H
  • Example 48 N-[(3R)-l-azabicy ⁇ lo[2.2.2]oct-3-yl]-2-(methylsulfanyl)-l,3-thiazoIe- 5-carboxamide fumarate (from methanethiol). Yield 28%. HRMS (FAB) calculated for C ⁇ 2 H, 7 N 3 OS 2 +H ⁇ 284.0891, found 284.0894.
  • Example 49 N-[(3R)l-azabicyclo[2.2.2]oct-3-yl]-2-(4-chloro ⁇ henoxy)-l,3-thiazole- 5-carboxamide fumarate (from 4-chlorophenol). Yield 42%. HRMS (FAB) calculated for C ⁇ 7 H, 8 ClN 3 O 2 S+H, 364.0886, found 364.0885.
  • Step 50a Preparation of 2-phenyl-thiazole-5-carboxylic acid ethyl ester.
  • a solution of -formyl- ⁇ -chloroacetate (9.34 g, 49.5 mmol, 1 eq) and thiobenzamide (6.79 g, 49.5 mmol, 1 eq) in EtOH (37.0 mL) is refluxed for 1 hour.
  • the solution changes from an orange/brown color to a deep green.
  • This solution is washed with water and extracted with CH 2 C1 2 .
  • the organic fraction is dried over Na 2 SO , filtered, and the solvent removed in vaeuo.
  • Step 50b Preparation of N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-phenyl-l ,3- thiazole-5-carboxamide fumarate.
  • the 2-phenyl-thiazole-5-carboxylic acid (1-aza- bicyclo[2.2.2]oct-3-yl)-amide is prepared using Steps 44b and 44c, starting with 2- phenyl-thiazole-5-carboxylic acid ethyl ester.
  • the fumaric acid salt of the product is made and recrystallized from MeOH and ether to give the product as a white crystalline salt (77.4 mg, 22%).
  • HRMS (FAB) calculated for C ⁇ 7 H ⁇ 9 N 3 OS+H ⁇ 314.1327, found 314.1336.
  • Example 51 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2,4-dimethyl-l ,3-thiazole-5- carboxamide (from 2,3-dimethyl-thiazole-5-carboxylic acid as described in Step lc). Yield 18%.
  • HRMS (FAB) calculated for C, 3 H, 9 N 3 OS+H ⁇ 266.1327, found 266.1332.
  • Step 52a Preparation of ethyl 2-(2-fluorophenyl)- 1 ,3-thiazole-5-carboxylate.
  • Tetrakis(triphenylphosphine)palladium (0) (0.58 g, 0.5 mmol)
  • a degassed solution of 2.0M Na 2 CO 3 (10 mL)
  • 2-bromo-l,3- thiazole-5-carboxylic ethyl ester (1.18 g, 5.0 mmol)
  • 2-fluorophenylboronic acid (0.77 g, 5.5 mmol
  • Step 52b Preparation of N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-(2- fluorophenyl)- l,3-thiazole-5-carboxamide citrate.
  • Example 53 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-(3-fluorophenyl)-l,3-thiazole- 5-carboxamide 4-methylbenzenesulfonate (from 3-fluorophenylboronic acid). Yield 20%.
  • HRMS (FAB) calculated for C, 7 H (8 FN 3 OS+H 332.1233, found 332.1225.
  • Example 54 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-(4-fluorophenyl)-l,3-thiazole- 5-carboxamide 4-methylbenzenesulfonate (from 4-fluorophenylboronic acid). Yield 51%.
  • HRMS (FAB) calculated for C, 7 H ⁇ 8 FN 3 OS+H 332.1233, found 332.1239.
  • Example 55 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-(2-hydroxyphenyl)-l,3- thiazole-5-carboxamide hydrochloride (from 2-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)phenol). This compound was purified by reverse-phase preparative chromatography prior to the formation of the salt. Yield 0.5%. HRMS (FAB) calculated for C ⁇ 7 H ⁇ 9 N 3 O 2 S+H 330.1276, found 330.1268.
  • Example 56 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-(4-methylphenyl)-l,3-thiazole- 5-carboxamide hydrochloride (from 4-tolylphenylboronic acid). Yield 50%. MS (ESI) for C ⁇ 8 H 2 ⁇ N 3 OS m/z 328.2 (M+H) + .
  • Example 57 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-[4-(benzyloxy)phenyl]-l,3- thiazole-5-carboxamide hydrochloride (from (4-benzyloxyphenyl)boronic acid). Yield 98%. MS (ESI) for C 24 H 25 N 3 O 2 S m/z 420.3 (M+H) + .
  • Examples 58-62 The following compounds are prepared from their requisite carboxylic acids according the procedures from Step 44c.
  • the desired salt form is prepared directly from the crude reaction mixture without chromatography, and crystallized.
  • Example 58 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-pyridin-3-yl-l,3-thiazole-4- carboxamide dihydrochloride (from (2-pyrid-3-yl)thiazole-4-carboxylic acid).
  • HRMS (FAB) calculated for C ⁇ 6 H ⁇ 8 N 4 OS- ⁇ -H 315.1279, found 315.1289.
  • Example 59 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-4-methyl-2-phenyl-l ,3-thiazole- 5-carboxamide dihydrochloride (from 4-methyl-2-phenyl-l,3-thiazole-5-carboxylic acid). Yield 61%.
  • HRMS (El) calculated for C ⁇ 8 H 2 ,N 3 OS 327.1405, found 327.1403.
  • Example 60 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-(4-chlorophenyl)-4-methyl-l,3- thiazole-5-carboxamide 4-methylbenzenesulfonate (from 2-(4-chlorophenyl)-4- methyl-l,3-thiazole-5-carboxylic acid). Yield 85%. MS (ESI) for C )8 H 2 ⁇ N 3 OS m/z 328.2 (M+H) + .
  • Example 61 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-4-methyl-2-pyridin-2-yl-l,3- thiazole-5-carboxamide hydrochloride (from 4-methyl-2-pyridin-2-yl-l,3-thiazole-5- carboxylic acid). Yield 57%. MS (ESI) for C ⁇ sH 20 ClN 3 OS m/z 362.2 (M+H) + .
  • Example 62 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-4-methyl-2-pyridin-4-yl-l,3- thiazole-5-carboxamide dihydrochloride (from 4-methyl-2-pyridin-4-yl-l,3-thiazole- 5-carboxylic acid). Yield 87%. MS (ESI) for C ⁇ 7 H 20 N 4 OS m/z 329.2 (M+H) + .
  • Step 63a Preparation of ethyl 2-[(tert-butoxycarbonyl)amino]- 1 ,3-thiazole-5- carboxylate:
  • Step 63b Preparation of ethyl 2-[(tert-butoxycarbonyl)(methyl)amino]- 1 ,3- thiazole-5 -carboxylate .
  • Step 63c Preparation of 2-[(tert-butoxycarbonyl)(methyl)amino]-l ,3-thiazole-5- carboxylic acid.
  • Step 63b The product of Step 63b is hydrolyzed according lo Step 44b, making non-critical variations. Yield 49%.
  • HRMS (FAB) calculated for C ⁇ oH, 4 N 2 O 4 S+H 259.0752, found 259.0750.
  • Step 63d Preparation of tert-butyl 5- ⁇ [(3R)-l-azabicyclo[2.2.2]oct-3- ylaminojcarbonyl ⁇ -l ,3-lhiazol-2-yl(methyl)carbamate.
  • Step 63e Preparation of N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-2-(methylamino)-
  • Step 64a Preparation of 5-phenylsulfanyl-[ 1 ,3,4]thiadiazole-2-carboxylic acid ethyl ester.
  • Step 64b Preparation of 5-phenylsulfanyl-[ 1 ,3 ,4]thiadiazole-2-carboxylic acid.
  • Step 64a (1.0 g, 3.76 mmol, 1 eq) is dissolved in EtOH (40 mL), and cooled in an ice bath. To this, 2N NaOH (1.88 mL, 3.76 mmol, 1 eq) is added drop wise. The sodium salt of the acid precipitates out of solution. The reaction mixture is concentrated in vaeuo to give a white crystalline product. The reaction mixture is carried through to the next step in its crude form to make the acid chloride. MS (ESI) for C 9 H 6 N 2 S 2 O 2 m/z 237.0 (M-H) ⁇ .
  • Step 64c Preparation of N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(phenyl- sulfanyl)- 1 ,3 ,4-thiadiazole-2-carboxamide.
  • 5-Phenylsulfanyl-[l,3,4]thiadiazole-2-carboxylic acid (3.76 mmol) is placed in a flask and put under nitrogen. The acid is chilled in an ice bath. Oxalyl chloride (9 mL) that has also been cooled in an ice bath is added drop wise to the acid. The excess oxalyl chloride is removed under reduced pressure. The acid chloride is dissolved in about 5 mL CH 2 C1 2 .
  • Example 65 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-phenoxy-l,3,4-thiadiazole-2- carboxamide. This compound is prepared from phenol according to the procedures for Example 64, making non-critical variations. Yield 16%. HRMS (FAB) calculated for C 16 H 17 N 3 O 3 S 331.0991, found 331.1229 (M) + .
  • Example 66 (0.0254 g, 20%) as a pale oil.
  • HRMS (FAB) calculated for C I6 H, 7 ClN 4 OS 2 +H ⁇ 381.0610, found 381.0617.
  • Example 68 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-chlorophenoxy)- 1 ,3,4- thiadiazole-2-carboxamide (from 4-chlorophenol). Yield 18%. HRMS (FAB) calculated for C ⁇ 6 H ⁇ 7 ClN 4 O 2 S+H ⁇ 365.0839, found 365.0826.
  • Example 69 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[(3-fluorophenyl)-sulfanyl]- l,3,4-thiadiazole-2-carboxamide (from 3-fluorothiophenol). Yield 16%. HRMS (FAB) calculated for C ⁇ 6 H ⁇ 7 FN 4 OS 2 +H, 365.0906, found 365.0899.
  • Example 70 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[(2-chlorophenyl)-sulfanyl]- l,3,4-thiadiazoIe-2-carboxamide (from 2-chlorothiophenol). Yield 44%.
  • HRMS (FAB) calculated for C ⁇ 6 H ⁇ 7 ClN 4 OS 2 +H ⁇ 381.0610, found 381.0625.
  • Example 71 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[(4-fluorophenyl)-sulfanyl]- l,3,4-thiadiazole-2-carboxamide (from 4-fluorothiophenol). Yield 34%. HRMS (FAB) calculated for 365.0906, found 365.0921.
  • Example 72 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[(3-chlorophenyl)-sulfanyl]- l,3,4-thiadiazole-2-carboxamide (from 3-chlorothiophenol). Yield 34%.
  • HRMS (FAB) calculated for C ⁇ 6 H ⁇ 7 ClN OS 2 +H ⁇ 381.0610, found 381.0603.
  • Step 75a Preparation of ethyl (2Z)-amino(benzoylhydrazono)ethanoate.
  • Ethyl thioxamate (0.6g, 4.5mmol) and benzyl hydrazide 0.68g, 5.0mmol) in EtOH (20mL) are heated at reflux for 2 hours according to the procedure described in McKillop et al., Tetrahedron Lett. 23, 3357-3360 (1982). The resulting solids are collected and washed with EtOH, and dried in vaeuo to afford the desired product (0.5g, 50%).
  • Step 75b Preparation of ethyl 5-phenyl- 1 ,3,4-oxadiazole-2-carboxylate and ethyl 5-phenyl- 1 H- 1 ,2,4-triazole-3-carboxylate.
  • the resultant material is purified by silica gel chromatography (20% EtOAc/hexanes) to afford a 2.2: 1 mixture of ethyl 5-phenyl- 1, 3, 4-oxadiazole-2-carboxylate (310mg, 67%) and ethyl 5-phenyl- lH-l,2,4-triazole-3-carboxylate (140mg, 30%), respectively.
  • Step 75c Preparation of N-[(3R)-l-azabicyclo[2.2.2]oct-3-ylJ-5-phenyl-lH- 1 ,2,4-triazole-3-carboxamide dihydrochloride.
  • This material is prepared using ethyl 5-phenyl- 1 H- 1 ,2,4-triazole-3-carboxylate prepared in Step 75b and coupled to (R)-(+)-3-aminoquinuclidine.
  • the product is purified as described in Example 66, making non-critical variations, to afford the desired product (13mg, 7.3%).
  • Step 77a Preparation of ethyl- 1 ,3 ,4-oxadiazole-2-thione-5-carboxylate potassium salt dimethylsulfoxide solvate.
  • a mixture of ethyl hydrazino(oxo)acetate (3.7g, 28mmol), prepared as described by Benson, Gross, and Snyder in J. Org. Chem. 3257-3269 (1990), EtOH (25mL), carbon disulfide (8.5g, 6.6mL, 112mmol), DMSO (6mL) and a solution of KOH (1.57g, 28mmol) in water (2mL) are heated at reflux overnight, as described by Horning and Muchowski in Can. J. Chem. 3079-3082 (1972).
  • the resultant solid is collected by vacuum filtration and washed to afford the desired product as a DMSO solvate that was used without further purification (8.2g of a semi-solid).
  • Step 77b Preparation of methyl ethyl-l,3,4-oxadiazole-2-thione-5-carboxylate.
  • This material is prepared using methyl ethyl- 1,3, 4-oxadiazole-2-thione-5- carboxylate prepared in Step 77b and coupled to (R)-(+)-3-aminoquinuclidine as described in Example 66, making non-critical variations, to afford material that is purified by silica gel chromatography (10% MeOH/CHCl 3 + 0.5% NH 4 OH).
  • the hydrochloride salt is prepared upon crystallization of the desired product from 1M HCl/Et 2 O (65mg, 42%). MS for CnH ⁇ 6 N 4 O 2 S (ESI) (M+H) + m/z 269.
  • Step 79a Preparation of 2-amino-l-(3-chlorophenyl)ethanone hydrochloride.
  • Step 79b Preparation of ethyl [[2-(3-chlorophenyl)-2-oxoethyl] amino](oxo) acetate.
  • Step 79c Preparation of ethyl 5-(3-chlorophenyl)- 1 ,3-oxazole-2-carboxylate.
  • Step 79d Preparation of N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- chlorophenyl)- 1 ,3-oxazole-2-carboxamide 4-methylbenzenesulfonate.
  • Examples 80-88 The following compounds are prepared from the requisite acylhalides according to the procedures for Example 79, making non-critical variations.
  • the product of Step 79a is commercially available.
  • Example 80 N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(3-methoxyphenyl)-l ,3- oxazole-2-carboxamide 4-methylbenzenesulfonate (from 2-bromo-l-(3- methoxyphenyl)ethanone). Yield 20%.
  • HRMS (FAB) calculated for C ⁇ 8 H 2 ,N 3 O 3 +H ⁇ 328.1661, found 328.1660.
  • Example 81 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-nitrophenyl)-l,3-oxazole-2- carboxamide 4-methylbenzenesulfonate (from 2-amino-l-(3-nitrophenyl)ethanone hydrochloride). Yield 8%.
  • HRMS (FAB) calculated for C ⁇ 7 H ⁇ 8 N 4 O 4 +H, 343.1406, found 343.1405.
  • Example 82 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-methoxyphenyl)-l,3- oxazole-2-carboxamide 4-methylbenzenesulfonate (from 2-amino-l-(4- methoxyphenyl)ethanone hydrochloride). Yield 23%.
  • HRMS (FAB) calculated for C ⁇ iNsO hH! 328.1661, found 328.1662.
  • Example 83 N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(2-nitrophenyl)- 1 ,3-oxazole-2- carboxamide 4-methylbenzenesulfonate (from 2-bromo-l-(2-nitrophenyl)ethanone). Yield 4%.
  • HRMS (FAB) calculated for C, 7 H ⁇ 8 N 4 O 4 +H, 343.1406, found 343.1405.
  • Example 84 N-[(3R)-l-azabicyclo[2.2.2]ocl-3-yl]-5-(2-methoxyphenyl)-l,3- oxazole-2-carboxamide 4-methylbenzenesulfonate (from 2-bromo-l-(2- methoxyphenyl)ethanone). Yield 13%.
  • HRMS (FAB) calculated for C )8 H 2 ⁇ N 3 O 3 +H] 328.1661, found 328.1661.
  • Example 85 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-fluorophenyl)-l,3-oxazolc- 2-carboxamide 4-methylbenzenesulfonate (from 2-bromo-l-(4-fluorophenyl)- ethanone). Yield 5%.
  • HRMS (FAB) calculated for C ⁇ 7 H ⁇ 8 FN 3 O 2 +H ⁇ 316.1461, found 316.1470.
  • Example 86 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-chlorophenyl)-l,3-oxazole- 2-carboxamide 4-methylbenzenesulfonate (from 2-bromo-l-(2-chloiOphenyl)- ethanone). Yield 10%.
  • HRMS (FAB) calculated for C ⁇ 7 H, 8 ClN 3 O 2 -i-H ⁇ 332.1165, found 332.1168.
  • Example 87 N-[(3R)- l-azabicyclo[2.2.2]oct-3-yl]-5-(3-cyanophenyl)-l ,3-oxazole- 2-carboxamide 4-methylbenzenesulfonate (from 3-(bromoacetyl)-benzonitrile). Yield 3%.
  • HRMS (FAB) calculated for C 18 H 2 ⁇ N 3 O 3 +H ⁇ 323.1508, found 323.1516.
  • Example 88 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-bromophenyl)-l,3-oxazole- 2-carboxamide 4-methylbenzenesulfonate (from 2-amino-l-(4-bromophenyl)- ethanone hydrochloride). Yield 6%.
  • HRMS (FAB) calculated for C ⁇ H ⁇ B N ⁇ +H] 376.0661, found 376.0660.
  • 2-Bromo-l-phenylpropan-l-one (8.97g, 42. Immol, leq) is added dropwise to a suspension of diformylimide sodium salt (4.80g, 50.5mmol, 1.2eq) in 80mL CH 3 CN.
  • the reaction is stirred for 60h at 70-75°C.
  • the hot mixture is filtered to remove the salts and the solids are washed with CH CN.
  • the combined filtrates are concentrated in vaeuo, dissolved in 40mL 6N HCI and heated under reflux for 0.75h.
  • the solvents are removed under reduced pressure and the product is recrystallized from IPA to give 2-amino-l -phenylpropan- 1 -one hydrochloride (6.15g, 79%).
  • Step 89b Preparation of ethyl [(l-methyl-2-oxo-2-phenylethyl)amino] (oxo)acetate.
  • TEA (3.22mL, 0.023 lmol, 2. leq) is added dropwise to a suspension of the product from Step 89a (2.05g, 1 Ommol, leq) and ethyl oxalyl chloride (1.24mL, 1 Ommol, leq) in 50mL CH 2 CI 2 in an ice/water bath. The mixture is allowed to slowly warm to room temperature. After stirring overnight, water and 20mL IN HCI are added. The aqueous layer is extracted with CH 2 C1 2 .
  • Step 89d Preparation of N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-4-methyl-5- phenyl- l,3-thiazole-2-carboxamide 4-methylbenzenesulfonate.
  • the freebase of (R)-3-aminoquinuclidine (l.Og, 5.02mmol, 2.26eq) dissolved in THF ( ⁇ 5mL) is added to a solution of the product from Step 89c (0.55g, 2.22mmol, leq) in lOmL EtOH. The mixture is heated under reflux. After 48h, the mixture is cooled and concentrated in vaeuo.
  • Example 90 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-phenyl-l,3-thiazole-2- carboxamide (from 2-amino-l-phenylethanone hydrochloride). Yield 36%.
  • HRMS (FAB) calculated for C l7 H, 9 N 3 OS+H, 314.1327, found 314.1330.
  • Example 91 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-bromophenyl)-l,3-thiazole- 2-carboxamide 4-methylbenzenesulfonate (from 2-amino-l-(4-bromophenyl)- ethanone hydrochloride). Yield 18%.
  • HRMS (FAB) calculated for C, 7 H, 8 BrN 3 OS+H, 392.0432, found 392.0423.
  • Example 92 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-nitrophenyl)-l,3-thiazole-2- carboxamide 4-methylbenzenesulfonate (from 2-amino-l-(3-nitrophenyl)-ethanone hydrochloride). Yield 47%.
  • HRMS (FAB) calculated for C ⁇ 7 H, 8 N 4 O 3 S+H, 359.1178, found 359.1165.
  • Example 93 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-methoxyphenyl)-l,3- thiazole-2-carboxamide 4-methylbenzenesulfonate (from 2-bromo-l-(3- methoxyphenyl)-ethanone). Yield 14%.
  • HRMS (FAB) calculated for C ⁇ 8 H2iN 3 O 2 S+H, 344.1432, found 344.1423.
  • Example 94 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-chlorophenyl)-l,3-thiazole- 2-carboxamide 4-methylbenzenesulfonate (from 2-bromo- 1 -(2-chlorophenyl)- ethanone). Yield 28%.
  • HRMS (FAB) calculated for C, 7 H ⁇ 8 ClN 3 OS+H ⁇ 348.0937, found 348.0947.
  • Example 95 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-fluorophenyl)-l,3-thiazole- 2-carboxamide 4-melhylbenzenesulfonate (from 2-bromo-l-(4-fluorophenyl)- ethanone). Yield 16%.
  • HRMS (FAB) calculated for C, 7 H ) 8 FN 3 OS+H, 332.1233, found 332.1233.
  • Example 96 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methoxyphenyl)- 1 ,3- thiazole-2-carboxamide 4-methylbenzenesulfonate (from 2-bromo-l-(2- methoxyphenyl)ethanone). Yield 14%.
  • HRMS (FAB) calculated for C ⁇ 8 H 2 ⁇ N 3 O 2 S+H ⁇ 344.1432, found 344.1436.
  • Example 97 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-chlorophenyl)-l,3-thiazole- 2-carboxamide 4-methylbenzenesulfonate (from 2-bromo-l-(4-chlorophenyl)- ethanone). Yield 12%. HRMS (FAB) calculated for C ⁇ 7 H 18 ClN 3 OS+H ⁇ 348.0937, found 348.0934.
  • Example 98 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-methyl-l,3-thiazole-2- carboxamide 4-methylbenzenesulfonate (from 1-chloroacetone). Yield 2%. HRMS (FAB) calculated for C, 2 H l7 N 3 OS+H, 252.1171, found 252.1171.
  • Example 99 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-chlorophenyl)-l,3-thiazole- 2-carboxamide 4-methylbenzenesulfonate (from 2-bromo-l-(3-chlorophenyl)- ethanone). Yield 10%.
  • HRMS (FAB) calculated for C ⁇ 7 H ⁇ 8 ClN 3 OS+H ⁇ 348.0937, found 348.0936.
  • Example 100 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-fluorophenyl)-l,3-thiazole- 2-carboxamide 4-methylbenzenesulfonate (from 2-bromo-l-(2-fluorophenyl)- ethanone). Yield 0.4%. MS (ESI) for C, 7 H ]8 FN 3 OS m/z 332.2 (M+H) + .
  • ExampleTOl N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-fluorophenyl)-l,3-thiazole- 2-carboxamide 4-methylbenzenesulfonate (from 2-bromo-l-(3-fluorophenyl)- ethanone). Yield 6%.
  • Example 102 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-thien-2-yl- 1 ,3-thiazole-2- carboxamide 4-methylbenzenesulfonate (from 2-bromo-l-thien-2-yl-ethanone). Yield 10%. MS (ESI) for C 15 H ⁇ 7 N 3 OS 2 m/z 320.2 (M+H) + .
  • Example 103 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-thien-2-yl- 1 ,3-thiazole-2- carboxamide 4-methylbenzenesulfonate (from 2-bromo-l-thien-2-yl-ethanone). Yield 10%. MS (ESI) for C 15 H ⁇ 7 N 3 OS 2 m/z 320.2 (M+H) + .
  • Example 103 N-[(3R)-l-azabicyclo[2.2.2]o
  • Step 103a Synthesis of 5-phenyl-furan-2-carbaldehyde.
  • Step 103b Synthesis of 5-phenyl-furan-2-carboxylic acid.
  • Step 103c Preparation of N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-phenyl-2- furamidc 4-methylbenzenesulfonate.
  • the product of Step 103b (0.499 g, 2.65 mmol, 1 eq) and the dihydrochloride salt of R-(+)-aminoquinuclidine (0.528 g, 2.65 mmol, 1 eq) in DIEA (1.38 mL, 7.96 mmol, 3 eq), in THF (17.6 mL) are cooled to 0°C and HATU (1.01 g, 2.65 mmol, 1 eq) is added.
  • Example 104 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-chlorophenyl)-furan-2- carboxamide toluene sulfonate (from 5-(2-chlorophenyl)-2-furaldehyde). Yield 46%.
  • HRMS (FAB) calculated for C, 8 H, 9 ClN 2 O 2 +H, 331.1213, found 331.1208.
  • Example 105 N-[(3R)- l-azabicyclo[2.2.2]oct-3-yl]-5-(3-chlorophenyl)-furan-2- carboxamide toluene sulfonate (from 5-(3-chlorophenyl)-2-furaldehyde). Yield 72%.
  • HRMS (FAB) calculated for C ⁇ 8 H 19 ClN 2 O 2 +H, 331.1213, found 331.1212.
  • Example 106 N-[(3R)- l-azabicyclo[2.2.2]oct-3-yl]-5-(4-chlorophenyl)-furan-2- carboxamide fumarate (from 5-(4-chlorophenyl)-2-furoic acid). Yield 43%.
  • HRMS (FAB) calculated for C, 8 H, 9 ClN 2 O 2 +H ⁇ 331.1213, found 331.1216.
  • Example 107 N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(4-bromophenyl)-furan-2- carboxamide toluene sulfonate (from 5-(4-bromophenyl)-2-furaldehyde). Yield 38%.
  • Example 109 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[3-(trifluoromethyl)-phenyl]- furan-2-carboxamide fumarate (from 5-(3-(trifluoromethyl)-phenyl)-furan-2- carboxaldehyde). Yield 31%. MS (ESI) for (M+H) + .
  • Example 110 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-nitrophenyl)-furan-2- carboxamide 4-methylbenzenesulfonate (from 5-(2-nitro-phenyl)-furan-2-carboxylic acid). Yield 82%.
  • HRMS (FAB) calculated for C, 8 H ⁇ 9 N 3 O 4 +H, 342.1454, found 342.1469.
  • Example 111 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-nitrophenyl)-furan-2- carboxamide 4-methylbenzenesulfonate (from 5-(3-nitro-phenyl)-furan-2-carboxylic acid). Yield 66%.
  • HRMS (FAB) calculated for C 18 H ⁇ 9 N 3 O 4 +H ⁇ 342.1454, found 342.1463. '
  • Example 112 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-nitrophenyl)-furan-2- carboxamide 4-methylbenzenesulfonate (from 5-(4-nitro-phenyl)-furan-2-carboxylic acid). Yield 52%.
  • HRMS (FAB) calculated for C ⁇ 8 H ]9 N 3 O 4 +H, 342.1454, found 342.1465.
  • Example 113 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-fluorophenyl)-furan-2- carboxamide 4-methylbenzenesulfonate (from 2-fluorophenylboronic acid). Yield 12%.
  • HRMS (FAB) calculated for C 18 H 19 FN 2 O 2 +H, 315.1508, found 315.1519.
  • Example 114 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-fluorophenyl)-furan-2- carboxamide 4-methylbenzenesulfonate (from 3-fluorophenylboronic acid). Yield 29%.
  • HRMS (FAB) calculated for C, 8 H ⁇ 9 FN 2 O 2 - ⁇ -H ⁇ 315.1508, found 315.1519.
  • Example 115 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-fluorophenyl)-furan-2- carboxamide 4-methylbenzenesulfonate (from 4-fluorophenylboronic acid). Yield 16%.
  • HRMS (FAB) calculated for C, 8 H ⁇ 9 FN 2 O 2 +H, 315.1508, found 315.1500.
  • Example 116 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2,4-difluorophenyl)-furan-2- carboxamide hydrochloride (from 2,4-difluorophenylboronic acid). Yield 46%. MS (ESI) for C 18 H ⁇ 8 F 2 N 2 O 2 m/z 333.2 (M+H) + .
  • Example 117 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2,5-difluorophenyl)-furan-2- carboxamide hydrochloride (from 2,5-difluorophenylboronic acid). Yield 33%. MS (ESI) for C ⁇ 8 H I8 F 2 N 2 O 2 m/z 333.2 (M+H) + .
  • Example 119 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-methoxyphenyl)-furan-2- carboxamide 4-methylbenzenesulfonate (from 3-methoxyphenylboronic acid). Yield 83%.
  • HRMS (FAB) calculated for C ⁇ 9 H 22 N 2 O 3 +H ⁇ 327.1708, found 327.1714.
  • Example 120 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[3-(trifluoromethoxy)phenyl]- furan-2-carboxamide 4-methylbenzenesulfonate (from 3-trifluoromethoxyphenyl- boronic acid). Yield 58%.
  • HRMS (FAB) calculated for C ⁇ H ⁇ N ⁇ -i-H ! 381.1426, found 381.1440.
  • Example 121 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[2-chloro-5-(trifluoromethyl)- phenyl] -furan-2-carboxamide fumaric acid (from 2-chloro-5-trifluoromethylphenyl- boronic acid). Yield 55%.
  • HRMS (FAB) calculated for Ci 9 Hi 8 ClF N 2 O 2 +Hi 399.1087, found 399.1097.
  • Example 122 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-fluoro-3-methylphenyl)- furan-2-carboxamide 4-methylbenzenesulfonate (from 4-fluoro-3-methylphenyl- boronic acid). Yield 77%.
  • HRMS (FAB) calculated for C ⁇ 9 H 2 ⁇ FN 2 O 2 +H ⁇ 329.1665, found 329.1661.
  • Example 123 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-cyanophenyl)-furan-2- carboxamide hydrochloride (from 4-cyanophenyl-boronic acid). Yield 31%. MS (ESI) for C ⁇ 8 H ⁇ 9 N 3 O 2 m/z 322.2 (M+H) + .
  • Example 124 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-thien-2-yl-furan-2-carboxamide 4-methylbenzenesulfonate (from 2-thiophene-boronic acid). MS (ESI) for C l6 H ⁇ 8 N 2 O 2 S m/z 303.2 (M+H) + .
  • Example 125 N-[(3R)-l-azabicycIo[2.2.2]oct-3-yl]-5-thien-3-yl-furan-2-carboxamide 4-methylbenzenesulfonate (from 3-thiophene-boronic acid). MS (ESI) for C ⁇ 6 H, 8 N 2 O 2 S m/z 303.2 (M+H) + .
  • Example 126 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-bromo-furan-2-ca ⁇ -boxamide 4- methylbenzenesulfonate (from 5-bromo-furan-2-carboxylic acid). Yield 75%. MS (ESI) for C ⁇ H, 5 N 2 O 2 Br m/z 299.0 (M+H) + .
  • Example 127 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-nitro-furan-2 -carboxamide hydrochloride (from 5-nitro-furan-2-carboxylic acid). Yield 63%. MS (ESI) for C ⁇ 2 H, 5 N 3 O 4 m/z 265.1 (M+H) + .
  • Example 128 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-4,5-dimethyl-furan-2- carboxamide hydrochloride (from 4,5-dimethyl-furan-2-carboxylic acid). Yield 75%. HRMS (FAB) calculated for C ⁇ 4 H 2 oN 2 O 2 +H 249.1603, found 249.1593.
  • Example 129 N-[(3R)-l-azabicyclo[2.2.2Joct-3-yl]-5-(4-chloro-2-nitrophenyl)-furan- 2-carboxamide hydrochloride (from 4-chloro-2-nitrophenyl)-furan-2-carboxylic acid). Yield 7%. HRMS (FAB) calculated for C ⁇ 8 H ⁇ 8 ClN 3 O 4 +H 376.1064, found 376.1067.
  • Example 130 N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(4-methyl-2-nitrophenyl)- furan-2-carboxamide hydrochloride (from 4-methyl-2-nitrophenyl)-furan-2-carboxylic acid). Yield 56%. MS (ESI) for C !9 H 2 ⁇ N 3 O 4 m/z 356.2 (M+H) + .
  • Step 131a A solution of N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-bromo-furan-2- carboxamide (0.258 g, 0.85 mmol, 1 eq), 2,3-difluorophenylboiOnic acid (0.147g, 0.93 mmol, 1.1 eq), tetrabutylammonium bromide (0.244 g, 0.85 mmol, 1 eq), palladium acetate (3.8 mg, 0.017 mmol, 0.02 eq), K 2 CO 3 (0.41 g, 2.97 mmol, 3.5 mmol) and water 1.4 mL is stirred under argon overnight. The reaction forms a brownish insoluble lump, but is complete by HPLC. The reaction is purified by silica gel chromatography using a Biotage Flash 40 M column (10%MeOH/l%TEA/CH 2 Cl 2 ).
  • Example 132 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,4-difluorophenyl)-furan-2- carboxamide hydrochloride (from 3,4-difluorophenyl-boronic acid). Yield 24%.
  • HRMS (FAB) calculated for C, 8 H ⁇ 8 F 2 N 2 ⁇ 2 +H, 333.1414, found 333.1418.
  • Example 133 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,5-difluorophenyl)-furan-2- carboxamide hydrochloride (from 3, 5-difluorophenyl -boronic acid). Yield 60%.
  • HRMS (FAB) calculated for C, 8 H ⁇ 8 F 2 N 2 O 2 +H ⁇ 333.1414, found 333.1424.
  • Example 134 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-methoxy-phenyl)-furan-2- carboxamide hydrochloride (from 4-methoxy-phenyl-boronic acid). Yield 17%.
  • HRMS (FAB) calculated for C l9 H 22 N 2 O 3 +H ⁇ 327.1708, found 327.1707.
  • Example 135 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methylphenyl)-furan-2- carboxamide 4-methylbenzenesulfonate (from ⁇ -tolylboronic acid). Yield 26%. HRMS (FAB) calculated for C ⁇ 9 H 22 N 2 O 2 +H ⁇ 311.1759, found 311.1763.
  • Example 136 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-methylphenyl)-furan-2- carboxamide 4-methylbenzenesulfonate (from m-tolylboronic acid). HRMS (FAB) calculated for C ⁇ 9 H 22 N 2 O 2 +H, 311.1759, found 311.1752.
  • Example 137 N-[(3R)- l-azabicyclo[2.2.2]oct-3-yl]-5-(4-methylphenyl)-furan-2- carboxamide 4-methylbenzenesulfonate (from -tolylboronic acid). Yield 10 %.
  • HRMS (FAB) calculated for C ⁇ 9 H 22 N 2 O 2 +H ⁇ 311.1759, found 311.1752.
  • Example 138 N-[(3R)- l-azabicyclo[2.2.2]oct-3-yl]-5-[2-(trifluoromethoxy)phenyl]- furan-2-carboxamide 4-methylbenzenesulfonate (from 2-(trifluoromethoxy)phenyl- boronic acid). Yield 19%. MS (ESI) for C ⁇ 9 H ⁇ 9 F 3 N 2 O 3 m/z 381.3 (M + H) + .
  • Example 139 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[4-(trifluoromethoxy)phenyl]- furan-2-carboxamide 4-methylbenzenesulfonate (from 4-trifluoromethoxyphenyl- boronic acid). Yield 61%.
  • HRMS (FAB) calculated for C19H1 9 F 3 N 2 O3+H 1 381.1426, found 381.1434.
  • Example 140 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-tert-butylphenyl)-furan-2- carboxamide 4-methylbenzenesulfonate (from 4-tert-butylphenyl-boronic acid). Yield 73%.
  • HRMS (FAB) calculated for C 22 H 28 N 2 O 2 +H ⁇ 353.2229, found 353.2218.
  • Example 141 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(l-benzothien-2-yl)-furan-2- carboxamide 4-methylbenzenesulfonate (from benzothiophene-2-boronic acid). Yield 17%.
  • HRMS (FAB) calculated for C 20 H 20 N 2 O 2 S+H ⁇ 353.1324, found 353.1326.
  • Example 142 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-quinolin-3-yl-furan-2- carboxamide 4-methylbenzenesulfonate (from 3-quinoline-boronic acid). Yield 9%. MS (ESI) for C21H21N3O2 m/z 348.3 (M+H) + .
  • Example 143 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-ethylphenyl)-furan-2- carboxamide hydrochloride (from 4-ethylphenyl-boronic acid). MS (ESI) for C 20 H 24 N 2 O 2 m/z 325.3 (M+H) + .
  • Example 144 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-isopropylphenyl)-furan-2- carboxamide hydrochloride (from 4-isopropylphenyl-boronic acid). MS (ESI) for C 2 ⁇ H 26 N 2 O 2 m/z 339.3 (M+H) + .
  • Example 145 N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(3-fluoro-4-methoxyphenyl)- furan-2-carboxamide hydrochloride (from 3-fluoro-4-methoxy-boronic acid). MS (ESI) for C ⁇ 9 H 21 FN 2 O 2 m/z 345.2 (M+H) + .
  • Example 146 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(l-benzofuran-2-yl)-furan-2- carboxamide 4-methylbenzenesulfonate (from benzofuran-2-boronic acid). MS (ESI) for C 20 H 20 N 2 O 3 m/z 337.2 (M+H) + .
  • Step 147a To a solution of N-[(3R)-l-aza-bicyclo[2.2.2]oct-3-ylj-5-(2-nitro- phenyl)-furan-2-carboxamide (1.65 g, 3.22 mmol, 1 eq) in 100 mL EtOH was added Pd/C (50 mg). This mixture was placed on a Parr shaker under 40 psi hydrogen overnight. The palladium is removed by filtration over a pad of celite, and the solvent is removed.
  • Example 148 5-(4-aminophenyl)-N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-furan-2- carboxamide tris(4-methylbenzenesulfonate) (from N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(4-nitrophenyl)-2-furamide). Yield 84%.
  • HRMS (FAB) calculated for C I8 H 2 ,N 3 O 2 +H ⁇ 312.1712, found 312.1727.
  • Example 149 5-(2-amino-4-methylphenyl)-N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]- furan-2-carboxamide dihydrochloride (from 5-(4-methyl-2-nirophenyl)-N-[(3R)-l- azabicyclo[2.2.2]oct-3-yl]-2-furamide dihydrochloride). Yield 55%.
  • HRMS (FAB) calculated for C 19 H 23 N 3 O 2 +H 326.1868, found 326.1871.
  • Step 150a Preparation of 5-phenylethylnyl-furan-2-aldehyde.
  • Step 150b Preparation of N-[(3R)-l-azabicyclo[2.2.2]oct-3-yI]-5-(phenylethynyl)- furan-2-carboxamide 4-methylbenzcnesulfonate.
  • Step 151a Preparation of N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-phenoxy-furan- 2-carboxamide 4-methylbenzenesulfonate.
  • a solution of N-[(3R)-l-aza-bicyclo[2.2.2]oct-3-yl]-5-bromo-furan-2- carboxamide (0.200 g, 0.42 mmol, 1 eq), sodium phenoxide (0.500 g, 4.3 mmol, 10.1 eq), in DMSO (5 mL) is stirred under nitrogen at room temperature overnight.
  • the reaction is diluted with 25 mL water and extracted with CH 2 C1 2 (50 mL).
  • Step 152a Preparation of methyl 5-bromo- 1 -methyl- 1 H-pyrrole-2-carboxylate. To a dry flask is added methyl 1 -methyl- lH-pyrrole-2-carboxylate (12.0 g,
  • Step 152b Preparation of methyl l-methyl-5-phenyl-lH-pyrrole-2-carboxylate.
  • step 152a The product from step 152a is added to a solution of tetrakis(triphenylphosphine)palladium(0) (0.530 g, 0.459mmol) in 90 mL of ethylene glycol dimethyl ether. The resulting solution is stirred under nitrogen for 5 min and then phenylboronic acid (1.34 g, 11.0 mmol) is added followed by a solution of Na 2 CO 3 (19.5 g, 183 mmol) in 90 mL of H 2 O. The mixture is heated at reflux for 24 hours. The reaction mixture is allowed to cool to rt, 100 L of CH 2 C1 2 is added, and the layers are separated.
  • Lithium hydroxide (1.39 g, 33.2 mmol) is added to a solution of the product from Step 152b (1.43 g, 6.64 mmol) in 96 mL of a 1.25:1:1 H 2 O:MeOH:THF solvent mixture. The reaction is stirred at 50°C for 2 h. Aqueous HCI (IN, 50 mL) is added and the resultant precipitate is collected by filtration, washed with water, and dried to give 0.851 g of l-methyl-5-phenyl-lH-pyrrole-2-carboxylic acid as a tan solid (64% yield). MS for C, 2 H, ,NO 2 (ESI) (M-H) + m/z 200.1.
  • Step 152d Preparation of N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-l-methyl-5- phenyl- 1 H- ⁇ yrrole-2-carboxamide.
  • Example 153 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- ⁇ henyl-l,3-oxazole-2- carboxamide 4-methylbenzenesulfonate (from 5-phenyl- 1 ,3-oxazole-2-carboxylic acid, see Saito, S.; Tanaka, C. J. Pharm. Sci. Japan 76, 1956, 305-7). Yield 77%. HRMS (FAB) calculated for C ⁇ 7 H
  • Example 154 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-3-phenyl-l,2,4-oxadiazole-5- carboxamide 4-methylbenzenesulfonate (from 3-phenyl- l,2,4-oxadiazole-5-carboxylic acid, see Wurm. Chem. Ber.; 22; 1889; 3133). Yield 54%.
  • HRMS (FAB) calculated for C ⁇ 6 H ]8 ⁇ 4 O 2 +H ⁇ 299.1508, found 299.1512.
  • Example 155 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-phenyl-l,3-oxazole-5- carboxamide 4-methylbenzenesulfonate (from 2-phenyl- 1 ,3-oxazole-5-carboxylic acid, see Belenl ⁇ i, L. I.; Cheskis, M. A.; Zvolinskii, V. P.; Obukhov, A. E. Chem. Heterocycl. Compd. (Engl.TransL); 22; 1986; 654-663). Yield 16%.
  • HRMS (FAB) calculated for C ]7 H ⁇ 9 ⁇ 3 O 2 +H, 298.1555, found 298.1555.
  • Example 156 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-phenyl-l,3-oxazole-4- carboxamide 4-methylbenzenesulfonate (from 2-phenyl- 1 ,3-oxazole-4-carboxylic acid, see Korte, F.; Stoeriko, K. Chem.Ber.; 93; 1960; 1033-1042). Yield 22%.
  • HRMS (FAB) calculated for C, 7 H )9 ⁇ 3 O 2 +H ⁇ 298.1555, found 298.1559.
  • Example 157 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-phenylisoxazole-3- carboxamide 4-methylbenzenesulfonate (from 5-phenylisoxazole-3-carboxylic acid, see Vaughan, W.R.; Spencer, J.L. J.Org.Chem.; 25; 1960; 1160-1164). Yield 76%. HRMS (FAB) calculated for C, 7 H ⁇ 9 N 3 O 2 +H ⁇ 298.1555, found 298.1556.
  • Step 158a Preparation of 2-methylenequinuclidin-3-one.
  • Step 158c Preparation of (3E/Z)-2-methyl- 1 -azabicyclo[2.2.2Joctan-3-one oxime.
  • the product from Step 158b (3.2g, 23.0mmol, leq) and hydroxylamine hydrochloride (1.6g, 23.0mmol, leq) are dissolved in 20mL EtOH/pyridine (4:1) and stirred at room temperature. After 5 days, water and solid NaOH are added to adjust pH to pH 11. The mixture is extracted with several portions of CHC1 3 .
  • Step 158d Preparation of 2-methylquinuclidin-3-amine dihydrochloride
  • Step 158e Preparation of 5-bromo-N-(2-methyl-l-azabicyclo[2.2.2]oct-3- yl)thiophene-2-carboxamide 4-methylbenzenesulfonate.
  • Step 159a Preparation of methyl 5-phenyl-thio ⁇ hene-2-carbodithioate.
  • the resulting dark green solution is stirred at 0°C for 15 minutes, at which time, carbon disulfide (2.0 mL, 34.0 mmol) is added dropwise over 15 minutes.
  • carbon disulfide 2.0 mL, 34.0 mmol
  • iodomethane 2.9 mL, 46.4 mmol
  • the resulting dark brown solution is allowed to warm to room temperature and stirred for 1 hour, then is quenched with a solution of potassium cyanide in water (100 mL).
  • Step 159b Preparation of N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-phenyl- thiophene-2-carbothioamide fumarate.
  • a solution of the product of Step 159a (0.49 g, 2.0 mmol) and (R)-3- aminoquinulidine (0.55 g, 4.4 mmol) in THF is stirred at 50°C for 19 hours.
  • the crude reaction mixture is absorbed on to silica gel and purified by flash chromatography (gradient of 7% [9:1 MeOH/NH 4 OH]/CH 2 Cl 2 to 9%[9: 1 MeOH/NH OH]/CH 2 Cl 2 ).
  • the fumarate salt is prepared and crystallized.
  • the present invention also includes, by representation but not limitation, any one of the following or combination of the following compounds and pharmaceutically acceptable salts thereof, both of which can be made by one of ordinary skill in the art using the procedures provided making non-critical changes: N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-phenyl-thio ⁇ hene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-chlorophenyl)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- chlorophenyl)-thiophene-2-carboxamide; N-[[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- chloroph
  • Binding Assay For saturation studies, 0.4 mL homogenate are added to test tubes containing buffer and various concentrations of radioligand, and are incubated in a final volume of 0.5 mL for 1 hour at 25 °C. Nonspecific binding was determined in tissues incubated in parallel in the presence of 0.05 ml MLA for a final concentration of 1 ⁇ M MLA, added before the radioligand. hi competition studies, drugs are added in increasing concentrations to the test tubes before addition of 0.05 ml [ 3 H]-MLA for a final concentration of 3.0 to 4.0 nM [ 3 H]-MLA.
  • the incubations are terminated by rapid vacuum filtration through Whatman GF/B glass filter paper mounted on a 48 well Brandel cell harvester. Filters are pre-soaked in 50 mM Tris HCI pH 7.0 - 0.05 % polyethylenimine. The filters are rapidly washed two times with 5 mL aliquots of cold 0.9% saline and then counted for radioactivity by liquid scintillation spectrometry.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The invention provides compound of Formula (I): These compounds may be in the form of pharmaceutical salts or compositions, and racemic mixtures or pure enantiomers thereof. The compounds of Formula (I) are useful in pharmaceuticals in which α7 is known to be involved.

Description

QUJNUCLIDINE-SUBSTΓΓUTED HETEROARYL MOIETIES FOR TREATEMENT OF DISEASE
FIELD OF INVENTION Nicotinic acetylcholine receptors (nAChRs) play a large role in central nervous system (CNS) activity. Particularly, they are known to be involved in cognition, learning, mood, emotion, and neuroprotection. There are several types of nicotinic acetylcholine receptors, and each one appears to have a different role in regulating CNS function. Nicotine affects all such receptors, and has a variety of activities. Unfortunately, not all of the activities are desirable. In fact, one of the least desirable properties of nicotine is its addictive nature and the low ratio between efficacy and safety. The present invention relates to molecules that have a greater effect upon the al nAChRs as compared to other closely related members of this large ligand-gated receptor family. Thus, the invention provides compounds that are active drug molecules with fewer side effects.
BACKGROUND OF THE INNENTION
US Patent 5,977,144 discloses compositions for benzylidene- and cinnamylidene-anabaseines and methods for using these compositions for treating conditions associated with defects or malfunctioning of nicotinic subtypes brain receptors. These compositions target the al receptor subtype with little or no activation of the 4β2 or other receptor subtypes.
US Patent 5,837,489 discloses human neuronal nicotinic acetylcholine receptor and cells transformed with same DNA and mRNA encoding subunits. US Patent 5,712,270 discloses a group of 2-aroylaminothiazole derivatives which bind to and stimulate central muscarinic acetylcholine receptors and are useful agents for treating symptoms of cognitive disorders, specifically the impaired memory associated with a decrease in the neurotransmitter, acetylcholine. Some of the compounds of this invention also bind to 5HTιA receptors and dopamine D2 receptors, making them useful as antipsychotic agents.
US Patent 5,624,941 discloses pyrazole derivatives useful in pharmaceuticals in which cannabis is known to be involved. US Patent 5,561,149 discloses the use of a mono or bicyclic carbocyclic, or heterocyclic carboxylic, acid ester or amide or an imidazolyl carbazol in the manufacture of a medicament suitable for the treatment of stress-related psychiatric disorders, for increasing vigilance, for the treatment of rhinitis or serotonin-induced disorders and/or coadministralion with another active agent to increase the bioavailability thereof, or for nasal administration.
US Patent 5,510,478 discloses a group of 2-aroylaminothiazole derivatives which bind to and stimulate central muscarinic acetylcholine receptors and are useful agents for treating symptoms of cognitive disorders, specifically the impaired memory associated with a decrease in the neurotransmitter, acetylcholine. Some of the compounds of this invention also bind to 5HTIA receptors and dopamine D2 receptors, making them useful as antipsychotic agents.
US Patent 5,364,863 discloses bicyclic carboxylic esters and amides, their pharmaceutical formulations, and a method for their use in treating migraine, emesis, gastrointestinal disorders, schizophrenia, or anxiety in mammals.
US Patent 5,342,845 discloses indole derivatives and drugs effective as gastrointestinal motor activity regulator, antimigraine, antipsychotic or anti anxiety drugs.
US Patent 5,273,972 discloses novel 2-substituted-3-quinuclidinyl arylcarboxamides and arylthiocarboxamides and corresponding arylcarboxylates which have utility as therapeutic agents which exhibit gastric prokinetic, antiemetic, anxiolytic and 5-HT (serotonin) antagonist effects in warm blooded animals.
US Patent 5,246,942 discloses certain dibenzofurancarboxamides and their use as 5-HT3 antagonists having unique CNS, anti-emetic and gastric prokinetic activity void of any significant D2 receptor binding properties.
US Patent 5,237,066 discloses enantiomers of absolute configuration S of amide derivatives of 3-aminoquinuclidine, the process for preparing them and their use as medicinal products having activity in respect of gastric movements and antiemetic activity. US Patent 5,236,931 discloses novel 3-quinuclidinyl benzamides and benzoates which have utility as therapeutical agents which exhibit anxiolytic, antipsychotic, cognition improvement, antiemetic and gastric prokinetic effects in warm blooded animals. US Patent 5,217,975 discloses azabicyclic compounds for treating dementia.
US Patent 5,206,246 discloses anxiolytic-R-N-(l-azabicyclo[2.2.2]oct-3-yl) benzamides and thiobenzamides, their N-oxides and pharmaceutically acceptable salts thereof. A preferred compound is R-(+)-4-amino-N-(l-azabicyclo[2.2.2]oct-3-yl)-5- chloro-2-methoxybenzamide.
US Patent 5,183,822 discloses new heterocyclic compounds (3,4-annelated benzimidazole-2(lH)-ones) having an antagonistic activity on 5-hydroxytryptamine (5-HT) receptors.
US Patent 5,175,173 discloses carboxamides useful as antiemetic or antipsychotic agents.
US Patent 5,106,843 discloses heterocyclic compounds useful as 5-HT3 antagonists.
US Patent 5,070,095 discloses novel l-(azabicyclo[2.2.2]oct-3- or -4- yl)benzamides substituted on the benzene ring with the basic substituted aminomethyleneamino group which have been found to be useful in treating emesis, including emesis due to chemical and radiation anticancer therapy, anxiety, and impaired gastric emptying.
US Patent 5,057,519 discloses 5-HT3 antagonists as being useful in reducing opiate tolerance. US Patent 5,039,680 discloses 5-HT antagonists in preventing or reducing dependency on dependency-inducing agents.
US Patent 5,025,022 discloses a method of treating or preventing schizophrenia and/or psychosis using S-N-(l-azabicyclo[2.2.2]oct-3-yl)benzamides and thiobenzamides, their N-oxides and pharmaceutically acceptable salts thereof. A preferred compound is S(-)-4-amino-N-( 1 -azabicyclo[2.2.2]oct-3-yl)-5-chloro-2- methoxybenzamide.
US Patent 5,017,580 discloses memory enhancing R-N-(l- azabicyclo[2.2.2.]oct-3-yl)benzamides and thiobenzamides, their N-oxides and pharmaceutically acceptable salts thereof. A preferred compound is R-(+)-4-amino- N-( 1 -azabicyclo[2.2.2]oct-3-yl)-5-chloro-2-methoxybenzamide.
US Patent 4,988,691 discloses isoxazole-containing compounds exhibiting anti-serotonin activity. US Patent 4,921,982 discloses 5-halo-2,3-dihydro-2,2-dimethylbenzofuran-7- carboxylic acids which are useful as intermediates for 5-HT3 antagonists.
US Patent 4,835,162 discloses agonists and antagonists to nicotine as smoking deterrents. US Patent 4,822,795 discloses pharmaceutically useful esters and amides having 5-HT antagonist activity.
US Patent 4,803,199 discloses pharmaceutically useful heterocyclic acid esters and amides or alkylene bridged peperidines as serotonin M antagonists.
US Patent 4,798,829 discloses l-azabicyclo[3.2.2]nonane derivatives having gastric motility enhancing activity and/or anti -emetic activity and/or 5-HT receptor antagonist activity.
US Patent 4,789,673 discloses dicarboxylic, heterocyclic and substituted benzoic acid alkylene-bridged piperidyl amides and esters as being serotonin M antagonists. US Patent 4,721,720 discloses a method of treating emesis, anxiety and/or irritable bowel syndrome.
US Patent 4,657,911 discloses 3-amino quinuclidine derivatives and the application thereof as accelerators of gastro-intestinal motor function and as medicament potentiators. US Patent 4,605,652 discloses a method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes, and the pharmaceutically acceptable acid addition salts, hydrates and alcoholates thereof.
US Patent 3,702,324 discloses 3,4,5-trimethoxybenzamides of substituted anilines and of alkylpiperidines which exert a specific effect on the central nervous system and a somewhat lesser effect on muscle function, and thus have utility as tranquilizers.
WO 01/36417 Al discloses novel N-azabicyclo-amide derivatives and use in therapy, especially in the treatment of prophylaxis of psychotic disorders and intellectual impairment disorders. WO 00/73431 A2 discloses two binding assays to directly measure the affinity and selectivity of compounds at the al nAChR and the 5-HT3R. The combined use of these functional and binding assays may be used to identify compounds that are selective agonists of the al nAChR. WO 92/15579 discloses multicyclic tertiary a ine polyaromatic squalene synthase inhibitors and method of treatment for lowering serum cholesterol levels using the compounds.
WO 92/11259 discloses azabicyclic amides or esters of halogenated benzoic acids having 5-HT receptor antagonist activity.
WO 90/14347 A as abstracted in chemical abstract 1991 : 143,158 discloses N- quinuclidinyl-indolecarboxamide derivatives as being antiemetics.
EP 512 350 A2 discloses 3-(indolyl-2-carboxamido) quinuclidines useful for treating diseases characterized by an excess or enhanced sensitivity to serotonin, e.g., psychosis, nausea, vomiting, dementia or other cognitive diseases, migraine, diabetes. The compound may be used to control anxiety, aggression, depression, and pain. The compounds are disclosed as serotonin 5-HT antagonists.
DE 3810552 Al discloses esters and amides of indolyl-, benzo[b]thiophenyl-, benzo[b]furancarboxylic acids or 4-amino-2 methoxy-benzoic acids with N- heterocyclic or N-heterobicyclic alcohols or amines. The compounds disclosed have activity against pain especially migraine, as an anti-aιτhythmic for gastrointestinal disturbances, stomach disturbances, gastritis ulcer, gall bladder, spastic colon, Crohn's disease, ulcerative colitis, carcinoid syndrome, diarrhea of various types. The compounds are also disclosed as speeding stomach emptying, controlling gastro duodenal and gastro esophageal reflux, disturbances of esophageal motility, hiatal hernia, cardiac insufficiency, hypotonic stomach, paralytic ileus, manic depressive psychosis and other psychoses. The compounds are also disclosed as useful for stress related diseases, senility, and enhancement of nasal absorption of other agents, e.g., in the treatment of emesis. FR 2 625 678 discloses N-(quinuclidin-3-yl)-benzamides and thiobenzamides useful as diet-control agents.
In Bioorg. & Med.Chem. Lett. 11 (2001) 319-321, the 5-HT3 antagonist tropisetron (ICS 205-930) is discussed as a potent and selective α7 Nicotinic receptor partial agonist. In Behavioral Brain Res. , 113 (2000) 169- 181 , it is discussed that the brain al nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease using DMXBA which is known as GTS-21. SUMMARY OF THE INVENTION A compound of Formula I:
Formula I or pharmaceutically acceptable salts thereof wherein
Ri is selected from -H, alkyl, cycloalkyl, halogenated alkyl, or aryl; Alkyl is both straight and branched-chain moieties having from 1-6 carbon atoms;
Halogenated alkyl is an alkyl moiety having from 1-6 carbon atoms and having 1 to (2n+l) substituent(s) independently selected from -F, -CI, -Br, or -I where n is the maximum number of carbon atoms in the moiety;
Cycloalkyl is a cyclic alkyl moiety having from 3-6 carbon atoms; Aryl is phenyl, substituted phenyl, naphthyl, or substituted naphthyl; Substituted phenyl is a phenyl either having 1-4 substituents independently selected from -F, -CI, -Br, or -I, or having 1 substituent selected from -Rι2 and 0-3 substituents independently selected from -F, -CI, -Br, or -I;
Substituted naphthyl is a naphthalene moiety either having 1-4 substituents independently selected from -F, -CI, -Br, or -I, or having 1 substituent selected from -Ri2 and 0-3 substituents independently selected from -F, -CI, -Br, or -I, where the substitution can be independently on either the same ring or different rings of said naphthalene moiety;
R2 is -H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, benzyl, substituted benzyl, or aryl;
Substituted alkyl is an alkyl moiety having from 1-6 carbon atoms and having 0-3 substituents independently selected from -F, -CI, -Br, or -I, and further having 1 substituent selected from -R7, -R9, -ORio, -SRio, -NRioRio, -C(O)R10, -NO2, -C(O)NR10R.o, -CN, -NR10C(O)R10, -S(O)2NRι0Rιo, -NR10S(O)2R10, phenyl, or substituted phenyl;
Substituted benzyl is a benzyl either having 1-4 substituents independently selected from -F, -CI, -Br, or -I, or having 1 substituent selected from -Rι2 and 0-3 substituents independently selected from -F, -CI, -Br, or -I, provided that all substitution is on the phenyl ring of the benzyl;
X is O or S;
W is a cyclic heteroaromatic moiety where the heteroatoms can be from 1-3 atoms selected from oxygen, sulfur, or nitrogen of the following structures:
wherein U is -O-, -S-, or -N(R3)-;
V and Y are independently selected from =N-, or =C(R5)-; Z is =N-, or =CH-, provided that when both V and Y are =C(R5)- and Z is =CH-, only >5)- can be =CH-, and further provided that when U is -O-, Y is =C(R5)- and Z is =C(R5)-, V cannot be =N-,
R3 is -H, alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, limited substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, or aryl, and provided that when W is (b) and Z is =N- and U is N(R3), R3 cannot be phenyl or substituted phenyl;
Limited substituted alkyl is a substituted alkyl having from 1-6 carbon atoms and having 0-3 substituents independently selected from -F, -CI, -Br, or -I, and further having 1 substituent on either only the ω carbon and selected from -ORn, -SRn, -NR„Rιι, -C(O)Rn, -NO2, -C(O)NRπR„, -CN, -NRι0C(O)RH, -S(O)2NRi0Rιo, or -NRioS(O)2Rio, or on any carbon with sufficient valency but not on the ω carbon and selected from -R7, -R9, -ORjo, -SR10, -NR10Rιo, -C(O)R]0, -NO2, -C(O)NR!0R,0, -CN, -NRi0C(O)Rio, -S(O)2NRιoRιo, -NRι0S(O)2Rιo, phenyl, or substituted phenyl;
Alkenyl is straight and branched-chain moieties having from 2-6 carbon atoms and having at least one carbon-carbon double bond; Halogenated alkenyl is an unsaturated alkenyl moiety having from 2-6 carbon atoms and having 1 to (2n-l) substituent(s) independently selected from -F, -CI, -Br, or -I where n is the maximum number of carbon atoms in the moiety;
Substituted alkenyl is an unsaturated alkenyl moiety having from 2-6 carbon atoms and having 0-3 substituents independently selected from -F, or -CI, and further having 1 substituent selected from -R7, -R9, -OR10, -SR!0, -NRioRio, -C(O)R,0, -C(O)NR10R10, -CN, -NRioC(O)R,0, -S(O)2NR10Rιo, -NRlQS(O)2R10, phenyl, or substituted phenyl;
Alkynyl is straight and branched-chain moieties having from 2-6 carbon atoms and having at least one carbon-carbon triple bond; Halogenated alkynyl is an unsaturated alkynyl moiety having from 3-6 carbon atoms and having 1 to (2n-3) substituent(s) independently selected from -F, -CI, -Br, or -I where n is the maximum number of carbon atoms in the moiety;
Substituted alkynyl is an unsaturated alkynyl moiety having from 3-6 carbon atoms and having 0-3 substituents independently selected from -F, or -CI, and further having 1 substituent selected from -R7, -R9, -ORι0, -SRio, -NRioRio, -C(O)Rι0, -CN, -C(O)NR,oR.o, -NRi0C(O)R,o, -S(O)2NRι0Rιo, -NR10S(O)2Rιo, phenyl, or substituted phenyl;
Halogenated cycloalkyl is a cyclic moiety having from 3-6 carbon atoms and having 1-4 substituents independently selected from -F, or -CI; Substituted cycloalkyl is a cyclic moiety having from 3-6 carbon atoms and having 0-3 substituents independently selected from -F, or -CI, and further having 1 substituent selected from -ORio, -SRio, -NR,0Rιo, -C(O)Rι0, -C(O)NRι0Rιo, -CN, -NRιoC(O)Rιo, -S(O)2NRι0R10, -NRι0S(O)2Rι0, -NO2, phenyl, or substituted phenyl; Heterocycloalkyl is a cyclic moiety having 4-7 atoms with 1-2 atoms within the ring being -S-, -N(R3)-, or -O-;
Halogenated heterocycloalkyl is a cyclic moiety having from 4-7 atoms with 1-2 atoms within the ring being -S-, -N(R )-, or -O-, and having 1-4 substituents independently selected from -F, or -CI;
Substituted heterocycloalkyl is a cyclic moiety having from 4-7 atoms with 1-2 atoms within the ring being -S-, -N(R3)-, or -O- and having 0-3 substituents independently selected from -F, or -CI, and further having 1 substituent selected from -OR10, -SRio, -NR.oRio, -C(O)R10, -C(O)NRιoRιo, -CN, -NR,0C(O)R10, -NO2) -S(O)2NR10Rιo, -NR)0S(O)2Rιo, phenyl, or substituted phenyl;
R5 is independently selected from the group consisting of -H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated alkenyl, halogenated alkynyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted heterocycloalkyl, limited substituted alkyl, limited substituted alkenyl, limited substituted alkynyl, aryl, -OR8, -ORJ4, -SR8, -SR)4, -F, -CI, -Br, -I, -NR8R8, -NR]4R14, -C(O)R8, -C(O)Ri4, -C(O)NR8R8, -C(O)NRi4R,4, -CN, -NR8C(O)R, „ -S(O)2NR8R8, -OS(O)2Ru, -S(O)2R8, -S(O)2Rι4, -NR8S(O)2R8, -N(H)C(O)N(H)R8, -NO2, -R7, and -R9; Limited substituted alkenyl is a substituted alkenyl having from 1-6 carbon atoms and having 0-3 substituents independently selected from -F, -CI, -Br, or -I, and further having 1 substituent on either only the ω carbon and selected from -ORn, -SR„, -NRnR, ,, -C(O)R„, -NO2, -C(O)NRnRπ, -CN, -NR10C(O)Rn, -S(O)2NRιoRιo, or -NRιoS(O)2Rιo, or on any carbon with sufficient valency but not on the ω carbon and selected from -R7, -R9, -OR)0, -SR10, -NRioRio, -C(O)Rιo, -NO2, -C(O)NRi0Rio, -CN, -NR10C(O)R10, -S(O)2NR10R10, -NR10S(O)2R10, phenyl, or substituted phenyl;
Limited substituted alkynyl is a substituted alkynyl having from 1-6 carbon atoms and having 0-3 substituents independently selected from -F, -CI, -Br, or -I, and further having 1 substituent on either only the ω carbon and selected from -ORn, -SR, ,, -NR„R„, -C(O)Ru, -NO2, - OjNRπR,,, -CN, -NR,0C(O)R,,, -S(O)2NRιoRιo> or -NRι0S(O)2Rιo, or on any carbon with sufficient valency but not on the ω carbon and selected from -R7, -R , -ORio, -SRio, -NR|0Rιo, -C(O)Rι0, -NO2, -C(O)NR10Rlθ! -CN, -NR10C(O)Rio, -S(O)2NRIOR,o, -NR10S(O)2RI0, phenyl, or substituted phenyl;
R7 is 5-membered heteroaromatic mono-cyclic moieties containing within the ring 1-3 heteroatoms independently selected from the group consisting of -O-, =N-, -N(R3)-, and -S-, and having 0-1 substituent selected from -Rι2 and 0-3 substituents independently selected from -F, -CI, -Br, or -I, or R7 is a 9-membered fused-ring moiety having a 6-membered ring fused to a 5-membered ring and having the formula
wherein E is O, S, or NR3,
wherein E and G are independently selected from CR]8, O, S, or NR3, and A is CRι8 or N, or wherein E and G are independently selected from CRι8, O, S, or NR3, and A is CRι8 or N, each 9-membered fused-ring moiety having 0-1 substituent selected from -Rι2 and 0-3 substituent(s) independently selected from -F, -CI, -Br, or -I, and having a bond directly or indirectly attached to the core molecule where valency allows in either the 6-membered or the 5-membered ring of the fused-ring moiety;
Each R8 is independently selected from -H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocycloalkyl, substituted heterocycloalkyl, -R7, -R , phenyl, or substituted phenyl;
R is 6-membered heteroaromatic mono-cyclic moieties containing within the ring 1-3 heteroatoms selected from =N- and having 0-1 substituent selected from -Rι2 and 0-3 substituent(s) independently selected from -F, -CI, -Br, or -I, or 10-membered heteroaromatic bi-cyclic moieties containing within one or both rings 1-3 heteroatoms selected from =N-, including, but not limited to, quinolinyl or isoquinolinyl, each 10- membered fused-ring moiety having 0-1 substituent selected from -Rι2 and 0-3 substituent(s) independently selected from -F, -CI, -Br, or -I and having a bond directly or indirectly attached to the core molecule where valency allows;
Each Rio is independently selected from -H, alkyl, cycloalkyl, heterocycloalkyl, alkyl substituted with 1 substituent selected from Rj3, cycloalkyl substituted with 1 substituent selected from Rι3, heterocycloalkyl substituted with 1 substituent selected from Rι3, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, phenyl, substituted phenyl, -R7, or -R ;
Each Rπ is independently selected from -H, alkyl, cycloalkyl, heterocyclo- alkyl, halogenated alkyl, halogenated cycloalkyl, or halogenated heterocycloalkyl; R12 is selected from -ORn, -SRn, alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, -NRnRn, -C(O)Rn, -NO2, -C(O)NR„R„, -CN, -NR„C(O)Rιι, -S(O)2NRnRn, or -NRnSCO)^,; Ri3 is selected from -ORn, -SRn, -NR,,Rn, -C(O)Rn, -C(O)NR,ιRn, -CN,
-NRnC(O)R„, -S(O)2NRnR,ι, -NRπS(O)2R,,, -CF3, or -NO2; Rι4 is independently selected from -H, alkyl, halogenated alkyl, limited substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocycloalkyl, substituted heterocycloalkyl; and Each Ris is independently selected from -H, alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, -ORn, -SRn, -NRπRu, -C(O)Rn, -NO2, -C(O)NRnRn, -CN, -NRnC(O)Rιι, -S(O)2NR,ιRn, or -NRnS(O)2Rn, -F, -CI, -Br, or -I, or a bond directly or indirectly attached to the core molecule, provided that there is only one said bond to the core molecule within the 9-membered fused-ring moiety, further provided that the fused-ring moiety has 0-1 substituent selected from alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, -ORn, -SRn, -NRMRι ι, -C(O)Rπ > -NO2, -C(O)NRπRn, -CN, -NRι ιC(O)Rπ, -S(O)2NRι ιRn, or -NRπS(O)2Rπ, and further provided that the fused- ring moiety has 0-3 substituent(s) selected from -F, -CI, -Br, or -I.
Compounds of Formula I are useful to treat any one of or combination of schizophrenia, or psychosis.
DETAILED DESCRIPTION OF THE INVENTION
Surprisingly, we have found that compounds of Formula I:
Formula I wherein Ri is selected from -H, alkyl, cycloalkyl, halogenated alkyl, or aryl; Alkyl is both straight and branched-chain moieties having from 1-6 carbon atoms;
Halogenated alkyl is an alkyl moiety having from 1-6 carbon atoms and having 1 to (2n+l) substituent(s) independently selected from -F, -CI, -Br, or -I where n is the maximum number of carbon atoms in the moiety; Cycloalkyl is a cyclic alkyl moiety having from 3-6 carbon atoms; Aiyl is phenyl, substituted phenyl, naphthyl, or substituted naphthyl;
Substituted phenyl is a phenyl either having 1-4 substituents independently selected from -F, -CI, -Br, or -I, or having 1 substituent selected from -Rj2 and 0-3 substituents independently selected from -F, -CI, -Br, or -I; Substituted naphthyl is a naphthalene moiety either having 1-4 substituents independently selected from -F, -CI, -Br, or -I, or having 1 substituent selected from -R12 and 0-3 substituents independently selected from -F, -CI, -Br, or -I, where the substitution can be independently on either the same ring or different rings of said naphthalene moiety; ) R2 is -H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, benzyl, substituted benzyl, or aryl;
Substituted alkyl is an alkyl moiety having from 1-6 carbon atoms and having 0-3 substituents independently selected from -F, -CI, -Br, or -I, and further having 1 substituent selected from -R7, -R9, -ORio, -SRio, -NR|0Rιo, -C(O)R)0, -NO2, -C(O)NRιoRιo, -CN, -NR,0C(O)Rι0, -S(O)2NR10R10, -NR10S(O)2R,o, phenyl, or substituted phenyl;
Substituted benzyl is a benzyl either having 1-4 substituents independently selected from -F, -CI, -Br, or -I, or having 1 substituent selected from -Rj2 and 0-3 substituents independently selected from -F, -CI, -Br, or -I, provided that all substitution is on the phenyl ring of the benzyl;
X is O or S;
W is a cyclic heteroaromatic moiety where the heteroatoms can be from 1-3 atoms selected from oxygen, sulfur, or nitrogen of the following structures:
wherein U is -O-, -S-, or -N(R3)-;
V and Y are independently selected from =N-, or =C(R5)-;
Z is =N-, or =CH-, provided that when both V and Y are =C(R5)- and Z is =CH-, only >5)- can be =CH-, and further provided that when U is -O-, Y is =C(R5)- and Z is =C(R5)-, V cannot be =N-, R3 is -H, alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, limited substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, or aryl, and provided that when W is (b) and Z is =N- and U is N(R3), R3 cannot be phenyl or substituted phenyl; Limited substituted alkyl is a substituted alkyl having from 1-6 carbon atoms and having 0-3 substituents independently selected from -F, -CI, -Br, or -I, and further having 1 substituent on either only the CO carbon and selected from -ORn, -SRn, -NR, ,Rn, -C(O)Rn, -NO2, -C(O)NRι,R,,, -CN, -NR10C(O)Rn, -S(O)2NR10Rιo, or -NRιoS(O)2Rιo, or on any carbon with sufficient valency but not on the ω carbon and selected from -R7, -R9, -ORio, -SRio, -NR]0Rιo, -C(O)R)0, -NO2, -C(O)NRJORιo, -CN, -NRi0C(O)Rio, -S(O)2NRi0Rio, -NRι0S(O)2Rι0, phenyl, or substituted phenyl;
Alkenyl is straight and branched-chain moieties having from 2-6 carbon atoms and having at least one carbon-carbon double bond;
Halogenated alkenyl is an unsaturated alkenyl moiety having from 2-6 carbon atoms and having 1 to (2n-l) substituent(s) independently selected from -F, -CI, -Br, or -I where n is the maximum number of carbon atoms in the moiety;
Substituted alkenyl is an unsaturated alkenyl moiety having from 2-6 carbon atoms and having 0-3 substituents independently selected from -F, or -CI, and further having 1 substituent selected from -R7, -R , -ORio, -SRio, -NRioRio, -C(O)Rιo, -C(O)NRιoRιo, -CN, -NRι0C(O)R,0) -S(O)2NR,0Rl0, -NR,0S(O)2R,0, phenyl, or substituted phenyl;
Alkynyl is straight and branched-chain moieties having from 2-6 carbon atoms and having at least one carbon-carbon triple bond;
Halogenated alkynyl is an unsaturated alkynyl moiety having from 3-6 carbon atoms and having 1 to (2n-3) substituent(s) independently selected from -F, -CI, -Br, or -I where n is the maximum number of carbon atoms in the moiety;
Substituted alkynyl is an unsaturated alkynyl moiety having from 3-6 carbon atoms and having 0-3 substituents independently selected from -F, or -CI, and further having 1 substituent selected from -R7, -R , -ORio, -SRι0, -NRi0Rιo, -C(O)Rι0, -CN, -C(O)NRιoRιo, -NRK)C(O)R,o, -S(O)2NRι0Rιo, -NRι0S(O)2Rιo, phenyl, or substituted phenyl;
Halogenated cycloalkyl is a cyclic moiety having from 3-6 carbon atoms and having 1-4 substituents independently selected from -F, or -CI; Substituted cycloalkyl is a cyclic moiety having from 3-6 carbon atoms and having 0-3 substituents independently selected from -F, or -CI, and further having 1 substituent selected from -ORio, -SRio, -NR,0Rιo, -C(O)Rι0, -C(O)NRι0Rιo, -CN, -NRi0C(O)Rio, -S(O)2NRi0Rio, -NRι0S(O)2Rιo, -NO2, phenyl, or substituted phenyl; Heterocycloalkyl is a cyclic moiety having 4-7 atoms with 1-2 atoms within the ring being -S-, -N(R3)-, or -O-;
Halogenated heterocycloalkyl is a cyclic moiety having from 4-7 atoms with 1-2 atoms within the ring being -S-, -N(R3)-, or -O-, and having 1-4 substituents independently selected from -F, or -CI; Substituted heterocycloalkyl is a cyclic moiety having from 4-7 atoms with 1-2 atoms within the ring being -S-, -N(R3)-, or -O- and having 0-3 substituents independently selected from -F, or -CI, and further having 1 substituent selected from -ORio, -SR.o, -NRioR.o, -C(O)R,0, -C(O)NR10Rιo, -CN, -NR,0C(O)R10, -NO2, -S(O)2NRιoRιo, -NRι0S(O)2Rιo, phenyl, or substituted phenyl; R5 is independently selected from the group consisting of.-H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated alkenyl, halogenated alkynyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted heterocycloalkyl, limited substituted alkyl, limited substituted alkenyl, limited substituted alkynyl, aryl, -OR8, -ORu, -SR8, -SR , -F, -CI, -Br, -I, -NR8R8, -NR14R14, -C(O)R8, -C(O)R,4, -C(O)NR8R8, -C(O)NR,4R,4, -CN, -NR8C(O)R,,, -S(O)2NR8R8, -OS(O)2Rn, -S(O)2R8, -S(O)2R14, -NR8S(O)2R8, -N(H)C(O)N(H)R8, -NO2, -R7, and -R9;
Limited substituted alkenyl is a substituted alkenyl having from 1-6 carbon atoms and having 0-3 substituents independently selected from -F, -CI, -Br, or -I, and further having 1 substituent on either only the ω carbon and selected from -ORn, -SRn, -NR,,Rn, -C(O)R„, -NO2, -C(O)NR„Rn, -CN, -NR,0C(O)Rn, -S(O)2NRi0Rio, or -NRι0S(O)2Rι0, or on any carbon with sufficient valency but not on the ω carbon and selected from -R7, -R9, -ORio, -SRio, ~NR|0Rιo, -C(O)Rιo, -NO2, -C(O)NRi0Rio, -CN, -NR10C(O)R,0, -S(O)2NR10Rιo, -NR10S(O)2R10, phenyl, or substituted phenyl;
Limited substituted alkynyl is a substituted alkynyl having from 1-6 carbon atoms and having 0-3 substituents independently selected from -F, -CI, -Br, or -I, and further having 1 substituent on either only the ω carbon and selected from -ORn, -SR,,, -NRnRn, -C(O)R„, -NO2, -C(O)NR,,R,,, -CN, -NR10C(O)R„, -S(O)2NRi0Rio, or -NRι0S(O)2Rιo, or on any carbon with sufficient valency but not on the ω carbon and selected from -R7, -R9, -ORio, -SRio, -NRioRio, -C(O)Rι0, -NO2, -C(O)NR]0Rio, -CN, -NRι0C(O)Rιo, -S(O)2NR10R,o, -NRι0S(O)2Rιo, phenyl, or substituted phenyl;
R7 is 5-membered heteroaromatic mono-cyclic moieties containing within the ring 1-3 heteroatoms independently selected from the group consisting of -O-, =N-,
-N(R3)-, and -S-, and having 0-1 substituent selected from -R)2 and 0-3 substituents independently selected from -F, -CI, -Br, or -I, or R7 is a 9-membered fused-ring moiety having a 6-membered ring fused to a 5-membered ring and having the formula
wherein E is O, S, or NR3,
wherein E and G are independently selected from CRι , O, S, or NR , and A is CRι8 or N, or
wherein E and G are independently selected from CR]8, O, S, or NR3, and A is CRι8 or N, each 9-membered fused-ring moiety having 0-1 substituent selected from -Rι2 and 0-3 substituent(s) independently selected from -F, -CI, -Br, or -I, and having a bond directly or indirectly attached to the core molecule where valency allows in either the 6-membered or the 5-membered ring of the fused-ring moiety;
Each R8 is independently selected from -H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocycloalkyl, substituted heterocycloalkyl, -R7, -R9, phenyl, or substituted phenyl;
R is 6-membered heteroaromatic mono-cyclic moieties containing within the ring 1-3 heteroatoms selected from =N- and having 0-1 substituent selected from -Rι2 and 0-3 substituent(s) independently selected from -F, -CI, -Br, or -I, or 10-membered heteroaromatic bi-cyclic moieties containing within one or both rings 1-3 heteroatoms selected from =N-, including, but not limited to, quinolinyl or isoquinolinyl, each 10- membered fused-ring moiety having 0-1 substituent selected from -R12 and 0-3 substituent(s) independently selected from -F, -CI, -Br, or -I and having a bond directly or indirectly attached to the core molecule where valency allows;
Each Rio is independently selected from -H, alkyl, cycloalkyl, heterocycloalkyl, alkyl substituted with 1 substituent selected from Rι3, cycloalkyl substituted with 1 substituent selected from Rι3, heterocycloalkyl substituted with 1 substituent selected from Rj3, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, phenyl, substituted phenyl, -R7, or -R9;
Each R11 is independently selected from -H, alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, or halogenated heterocycloalkyl;
R12 is selected from -ORn, -SRn, alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, -NRnRn, -C(O)Rι 1, -NO2, -C(O)NRιι π, -CN, -NRnC(O)R,„ -S(O)2NR,,Rn, or -NRnS(O)2Rn;
Ri3 is selected from -ORn, -SRn, -NRnRn, -C(O)Rn, -C(O)NRnRn, -CN, -NR, ,C(O)Rn, -S(O)2NRnRn, -NR, ,S(O)2Rn, -CF3, or -NO2;
Rι4 is independently selected from -H, alkyl, halogenated alkyl, limited substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocycloalkyl, substituted heterocycloalkyl;
Each R|8 is independently selected from -H, alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, -ORn, -SR, ,, -NR, ,R, ι, -C(O)Rn, -NO2, -C(O)NRnRn, -CN, -NR,ιC(O)R, ,, -S(O)2NR, iRn, or -NRι ,S(O)2Rn, -F, -CI, -Br, or -I, or a bond directly or indirectly attached to the core molecule, provided that there is only one said bond to the core molecule within the 9-membered fused-ring moiety, further provided that the fused-ring moiety has 0-1 substituent selected from alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, -OR,,, -SR,,, -NRuRn, -C(O)R,,, -NO2, -C(O)NRnRιι, -CN, -NRιιC(O)R,,, -S(O)2NRιιRn, or -NRnS(O)2Ru, and further provided that the fused- ring moiety has 0-3 substituent(s) selected from -F, -CI, -Br, or -I; and pharmaceutically acceptable salts are useful to treat any one of or combination of schizophrenia, or psychosis.
Abbreviations which are well known to one of ordinary skill in the art may be used (e.g., "Ph" for phenyl, 'Me" for methyl, "Et" for ethyl, "h" for hour or hours, min for minute or minutes, and "rt" for room temperature).
All temperatures are in degrees Centigrade.
Room temperature is within the range of 15-25 degrees Celsius.
Eq refers to equivalents. Satd refers to saturated.
AChR refers to acetylcholine receptor. nAChR refers to nicotinic acetylcholine receptor.
5HT3R refers to the serotonin-type 3 receptor.
FLIPR refers to a device marketed by Molecular Devices, Inc. designed to precisely measure cellular fluorescence in a high throughput whole-cell assay. (Schroeder et. al., J. Biomolecidar Screening, 1(2), p 75-80, 1996).
TLC refers to thin-layer chromatography.
HPLC refers to high pressure liquid chromatography.
MeOH refers to methanol. EtOH refers to ethanol.
IPA refers to isopropyl alcohol.
THF refers to tetrahydrofuran.
DMSO refers to dimethylsulfoxide.
DMF refers to dimethylformamide. EtOAc refers to ethyl acetate.
TMS refers to tetramethylsilane.
TEA refers to triethylamine.
HATU refers to O-(7-azabenzotriazol-l-yl)-N,N,N', N'-tetramethyluronium hexafluorophosphate. DIEA refers to N,N-diisopropylefhylarnine.
MLA refers to methyllycaconitine.
Ether refers to diethyl ether.
KH2PO4 refers to potassium phosphate, monobasic. NaClO2 refers to sodium chlorite. t-BuOH refers to tert-butanol.
Na2SO4 refers to sodium sulfate.
MgSO refers to magnesium sulfate.
K.2CO3 refers to potassium carbonate.
NH4OH refers to ammonium hydroxide.
NaHCO3 refers to sodium bicarbonate.
CH3CN refers to acetonitrile.
The ω carbon is determined by counting the longest carbon chain of the alkyl moiety with the C-1 carbon being the carbon attached to the W moiety of the core molecule and the O carbon being the carbon furthest, e.g., separated by the greatest number of carbon atoms in the chain, from said C-1 carbon;
The core molecule is the quinuclidinyl-(carboxamide-type moiety)-W:
"core molecule"
Therefore, when speaking of the CO carbon, the O carbon is the carbon furthest from the core molecule and the C-1 carbon is the carbon attached to the core molecule by attachment to the W moiety of the core molecule.
One of the most conventionally accepted ways of naming the compound pictured below is 5-(2-aminophenyl)-N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]thiophene- 2-carboxamide, but for one ordinarily skilled in the art, the following name also describes the same compound, N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- aminophenyl)-thiophene-2-carboxamide:
The two are used interchangeably in this patent.
The carbon atom content of various hydrocarbon-containing moieties is indicated by a prefix designating the minimum and maximum number of carbon atoms in the moiety, i.e., the prefix .j indicates a moiety of the integer 'i" to the
- 15 integer "j" carbon atoms, inclusive. Thus, for example, Cι-6 alkyl refers to alkyl of one to six carbon atoms, inclusive.
Halogen is F, CI, Br, or I.
Alkyl is both straight and branched-chain moieties having from 1-6 carbon atoms.
Halogenated alkyl is an alkyl moiety having from 1-6 carbon atoms and having 1 to (2n+l) halogen atom(s) independently selected from -F, -CI, -Br, or -I where n is the maximum number of carbon atoms in the moiety.
Substituted alkyl is an alkyl moiety having from 1-6 carbon atoms and having 0-3 substituents independently selected from -F, -CI, -Br, or -I, and further having 1 substituent selected from -R7, -R9, -ORu,, -SR,0, -NRioRio, -C(O)Rι0, -NO2, -C(O NRIORιo, -CN, -NR,oC(O)Rιo, -S(O)2NRι0R.o, -NR,0S(O)2Rιo, phenyl, or substituted phenyl.
Limited substituted alkyl is a substituted alkyl having from 1-6 carbon atoms and having 0-3 substituents independently selected from -F, -CI, -Br, or -I, and further having 1 substituent on either only the co carbon and selected from -ORn, -SRn, -NRnRn, -C(O)Rι,, -NO2, -C(O)NR,ιR, „ -CN, -NRJ0C(O)R, ,, -S(O)2NR10Rιo, or -NR]0S(O)2Rιo, or on any carbon with sufficient valency but not on the co carbon and selected from -R7, -R9, -OR,0, -SRio, -NR,0Rιo, -C(O)Rι0, -NO2, -C(O)NR10R,0, -CN, -NRioC(O)Rlo, -S(O)2NRi0Rio, -NRι0S(O)2Rι0, phenyl, or substituted phenyl.
Alkenyl is straight and branched-chain moieties having from 2-6 carbon atoms and having at least one carbon-carbon double bond.
Halogenated alkenyl is an unsaturated alkenyl moiety having from 2-6 carbon atoms and having 1 to (2n-l) halogen atom(s) independently selected from -F, -CI, -Br, or -I where n is the maximum number of carbon atoms in the moiety.
Substituted alkenyl is an unsaturated alkenyl moiety having from 2-6 carbon atoms and having 0-3 substituents independently selected from -F, or -CI, and further having 1 substituent selected from -R7, -R9, -ORio, -SRio, -NRioRio, -C(O)Rιo, -C(O)NRιoRιo, -CN, -NRι0C(O)R,0, -S(O)2NR,oR10, -NR10S(O)2Rιo, phenyl, or substituted phenyl.
Limited substituted alkenyl is a substituted alkenyl having from 1-6 carbon atoms and having 0-3 substituents independently selected from -F, -CI, -Br, or -I, and further having 1 substituent on either only the co carbon and selected from -ORn, -SRn, -NR„Rn, -C(O)R„, -NO2, -C(O)NRnRn, -CN, -NR,0C(O)R, „ -S(O)2NRi0Rio, or -NRι0S(O)2Rι0, or on any carbon with sufficient valency but not on the co carbon and selected from -R7, -R9, -ORι0, -SRio, -NRioRio, -C(O)Rι0, -NO2, -C(O)NRi0R10, -CN, -NR10C(O)R,o, -S(O)2NR10R,o, -NR,oS(O)2R10, phenyl, or substituted phenyl.
Alkynyl is straight and branched-chain moieties having from 2-6 carbon atoms and having at least one carbon-carbon triple bond.
Halogenated alkynyl is an unsaturated alkynyl moiety having from 3-6 carbon atoms and having 1 to (2n-3) halogen atom(s) independently selected from -F, -CI, -Br, or -I where n is the maximum number of carbon atoms in the moiety.
Substituted alkynyl is an unsaturated alkynyl moiety having from 3-6 carbon atoms and having 0-3 substituents independently selected from -F, or -CI, and further having 1 substituent selected from -R7, -R9, -ORio, -SRio, -NRioRio, -C(O)Rι0, -CN, -C(O)NRιoRιo, -NRιoC(O)R,o, -S(O)2NRι0Rιo, -NR,0S(O)2Rιo, phenyl, or substituted phenyl.
Limited substituted alkynyl is a substituted alkynyl having from 1-6 carbon atoms and having 0-3 substituents independently selected from -F, -CI, -Br, or -I, and further having 1 substituent on either only the ω carbon and selected from -ORn, -SRM, -NRnR , -C(O)R„, -NO2, -C(O)NR„Rn, -CN, -NR,0C(O)Rn, -S(O)2NRιoRιo, or -NRιoS(O)2Rιo, or on any carbon with sufficient valency but not on the ω carbon and selected from -R7, -R9, -ORj0, -SRio, -NRioRio, -C(O)Rιo, -NO2, -C(O)NR,0Rio, -CN, -NR10C(O)R,0, -S(O)2NR,0R10, -NRι0S(O)2R,o, phenyl, or substituted phenyl.
Cycloalkyl is a cyclic alkyl moiety having from 3-6 carbon atoms. Halogenated cycloalkyl is a cyclic moiety having from 3-6 carbon atoms and having 1-4 substituents independently selected from -F, or -CI.
Substituted cycloalkyl is a cyclic moiety having from 3-6 carbon atoms and having 0-3 substituents independently selected from -F, or -CI, and further having 1 substituent selected from -OR|0, -SRio, -NR,0Rιo, -C(O)Rι0, -C(O)NR,0Rιo, -CN, -NRi0C(O)Rjo, -S(O)2NRi0Rio, -NRι0S(O)2R,0, -NO2, phenyl, or substituted phenyl.
Heterocycloalkyl is a cyclic moiety having 4-7 atoms with 1-2 atoms within the ring being -S-, -N(R3)- or -O-. Halogenated heterocycloalkyl is a cyclic moiety having from 4-7 atoms with 1-2 atoms within the ring being -S-, -N(R3)-, or -O-, and having 1-4 substituents independently selected from -F, or -CI.
Substituted heterocycloalkyl is a cyclic moiety having from 4-7 atoms with 1-2 atoms within the ring being -S-, -N(R3)-, or -O- and having 0-3 substituents independently selected from -F, or -CI, and further having 1 substituent selected from -ORio, -SRio, -NRioRio, -C(O)R10, -C(O)NRl0Rl0, -CN, -NR,0C(O)R,0, -NO2, -S(0)2NRι0Rιo, -NRi0S(O)2Rio, phenyl, or substituted phenyl.
Substituted benzyl is a benzyl either having 1-4 substituents independently selected from -F, -CI, -Br, or -I, or having 1 substituent selected from -R12 and 0-3 substituents independently selected from -F, -CI, -Br, or -I, provided that all substitution is on the phenyl ring of the benzyl.
Aryl is phenyl, substituted phenyl, naphthyl, or substituted naphthyl.
Substituted phenyl is a phenyl either having 1-4 substituents independently selected from -F, -CI, -Br, or -I, or having 1 substituent selected from -R12 and 0-3 substituents independently selected from -F, -CI, -Br, or -I.
Substituted naphthyl is a naphthalene moiety either having 1-4 substituents independently selected from -F, -CI, -Br, or -I, or having 1 substituent selected from -Ri2 and 0-3 substituents independently selected from -F, -CI, -Br, or -I, where the substitution can be independently on either the same ring or different rings of said naphthalene moiety.
Mammal denotes human and other mammals.
Compounds of the present invention may be in a form of pharmaceutically acceptable salts. Brine refers to an aqueous saturated sodium chloride solution.
IR refers to infrared spectroscopy.
Lv refers to leaving groups within a molecule, including Br, CI, OH, or mixed anhydride.
NMR refers to nuclear (proton) magnetic resonance spectroscopy, chemical shifts are reported in ppm (δ) downfield from TMS.
MS refers to mass spectrometry expressed as m e or mass/charge unit. HRMS refers to high resolution mass spectrometry expressed as m/e or mass/charge unit. M+H+ refers to the positive ion of a parent plus a hydrogen atom. M-H" refers to the negative ion of a parent minus a hydrogen atom. M+Na+ refers to the positive ion of a parent plus a sodium atom. M+K+ refers to the positive ion of a parent plus a potassium atom. El refers to electron impact. ESI refers to electrospray ionization. CI refers to chemical ionization. FAB refers to fast atom bombardment. Compounds of the present invention may be in the form of pharmaceutically acceptable salts. The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases including inorganic bases and organic bases, and salts prepared from inorganic acids, and organic acids. Salts derived from inorganic bases include aluminum, ammonium, calcium, ferric, ferrous, lithium, magnesium, potassium, sodium, zinc, and the like. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, such as arginine, betaine, caffeine, choline, N, N- dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylamino- ethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, and the like. Salts derived from inorganic acids include salts of hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, phosphorous acid and the like. Salts derived from pharmaceutically acceptable organic non-toxic acids include salts of Cι_6 alkyl carboxylic acids, di-carboxylic acids, and tri-carboxylic acids such as acetic acid, propionic acid, fumaric acid, succinic acid, tartaric acid, maleic acid, adipic acid, and citric acid, and aryl and alkyl sulfonic acids such as toluene sulfonic acids and the like.
By the term "effective amount" of a compound as provided herein is meant a nontoxic but sufficient amount of the compound(s) to provide the desired effect. As pointed out below, the exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the disease that is being treated, the particular compound(s) used, the mode of administration, and the like. Thus, it is not possible to specify an exact "effective amount." However, an appropriate effective amount may be determined by one of ordinary skill in the art using only routine experimentation. The compounds of Formula I have optically active center(s) on the quinuclidine ring. Although it is desirable that the stereochemical purity be as high as possible, absolute purity is not required. This invention involves racemic mixtures and compositions of varying degrees of streochemical purities. It is preferred to carry out stereoselective syntheses and/or to subject the reaction product to appropriate purification steps so as to produce substantially optically pure materials. Suitable stereoselective synthetic procedures for producing optically pure materials are well known in the art, as are procedures for purifying racemic mixtures into optically pure fractions. The preferred compounds of the present invention have the R configuration at the C3 position of the quinuclidine ring. It is also preferred for the compounds of the present invention that X is O. Another group of compounds of Formula I includes compounds wherein X is O and Ri is H. Another group of compounds of Formula I includes compounds wherein X is O and R2 is H. Another group of compounds of Formula I includes compounds wherein X is O and R2 is alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, benzyl, substituted benzyl, or aryl.
The amount of therapeutically effective compound(s) that is administered and the dosage regimen for treating a disease condition with the compounds and/or compositions of this invention depends on a variety of factors, including the age, weight, sex and medical condition of the subject, the severity of the disease, the route and frequency of administration, and the particular compound(s) employed, and thus may vary widely. The compositions contain well know carriers and excipients in addition to a therapeutically effective amount of compounds of Formula I. The pharmaceutical compositions may contain active ingredient in the range of about 0.001-100 mg/kg/day for an adult, preferably in the range of about 0.1-50 mg/kg/day for an adult. A total daily dose of about 1-1000 mg of active ingredient may be appropriate for an adult. The daily dose can be administered in 1-4 doses per day.
In addition to the compound(s) of Formula I, the composition for therapeutic use may also comprise one or more non-toxic, pharmaceutically acceptable carrier materials or excipients. The term "carrier" material or "excipient" herein means any substance, not itself a therapeutic agent, used as a carrier and/or diluent and/or adjuvant, or vehicle for delivery of a therapeutic agent to a subject or added to a pharmaceutical composition to improve its handling or storage properties or to permit or facilitate formation of a dose unit of the composition into a discrete article such as a capsule or tablet suitable for oral administration. Excipients can include, by way of illustration and not limitation, diluents, disintegrants, binding agents, adhesives, wetting agents, polymers, lubricants, glidants, substances added to mask or counteract a disagreeable taste or odor, flavors, dyes, fragrances, and substances added to improve appearance of the composition. Acceptable excipients include lactose, sucrose, starch powder, cellulose esters of alkanoic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate, polyvinyl- pyrrolidone, and/or polyvinyl alcohol, and then tableted or encapsulated for convenient administration. Such capsules or tablets may contain a controlled-release formulation as may be provided in a dispersion of active compound in hydroxypropyl- methyl cellulose, or other methods known to those skilled in the art. For oral administration, the pharmaceutical composition may be in the form of, for example, a tablet, capsule, suspension or liquid. If desired, other active ingredients may be included in the composition.
In addition to the oral dosing, noted above, the compositions of the present invention may be administered by any suitable route, in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended. The compositions may, for example, be administered parenterally, e.g., intravascularly, intraperitoneally, subcutaneously, or intramuscularly. For parenteral administration, saline solution, dextrose solution, or water may be used as a suitable carrier. Formulations for parenteral administration may be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions. These solutions and suspensions may be prepared from sterile powders or granules having one or more of the carriers or diluents mentioned for use in the formulations for oral administration. The compounds may be dissolved in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, and/or various buffers. Other adjuvants and modes of administration are well and widely known in the pharmaceutical art.
The serotonin type 3 receptor (5HT3R) is a member of a superfamily of ligand- gated ion channels, which includes the muscle and neuronal nAChR, the glycine receptor, and the γ-aminobutyric acid type A receptor. Like the other members of this receptor superfamily, the 5HT3R exhibits a large degree of sequence homology with 7 nAChR but functionally the two ligand-gated ion channels are very different. For example, al nAChR is rapidly inactivated, is highly permeable to calcium and is activated by acetylcholine and nicotine. On the other hand, 5HT3R is inactivated slowly, is relatively impermeable to calcium and is activated by serotonin. These experiments suggest that the al nAChR and 5HT3R proteins have some degree of homology, but function very differently. Indeed the pharmacology of the channels is very different. For example, Ondansetron, a highly selective 5HT R antagonist, has little activity at the al nAChR. The converse is also true. For example, GTS-21, a highly selective α7 nAChR agonist, has little activity at the 5HT R. al nAChR is a ligand-gated Ca++ channel formed by a homopentamer of al subunits. Previous studies have established that -bungarotoxin (α-btx) binds selectively to this homopetameric, al nAChR subtype, and that al nAChR has a high affinity binding site for both α-btx and methyllycaconitine (MLA). al nAChR is expressed at high levels in the hippocampus, ventral tegmental area and ascending cholinergic projections from nucleus basilis to thalamocortical areas, al nAChR agonists increase neurotransmitter release, and increase cognition, arousal, attention, learning and memory.
Data from human and animal pharmacological studies establish that nicotinic cholinergic neuronal pathways control many important aspects of cognitive function including attention, learning and memory (Levin, E.D., Psychopharmacology, 108:417-31, 1992; Levin, E.D. and Simon B.B., Psychopharmacology, 138:217-30, 1998). For example, it is well known that nicotine increases cognition and attention in humans. ABT-418, a compound that activates α4β2 and al nAChR, improves cognition and attention in clinical trials of Alzheimer's disease and attention-deficit disorders (Potter, A. et. al., Psychopharmacology (Bed)., 142(4): 334-42, Mar. 1999; Wilens, T. E. et. al., Am. J. Psychiatry, 156(12): 1931-7, Dec. 1999). It is also clear that nicotine and selective but weak al nAChR agonists increase cognition and attention in rodents and non-human primates. Schizophrenia is a complex multifactorial illness caused by genetic and non- genetic risk factors that produce a constellation of positive and negative symptoms. The positive symptoms include delusions and hallucinations and the negative symptoms include deficits in affect, attention, cognition and information processing. No single biological element has emerged as a dominant pathogenic factor in this disease. Indeed, it is likely that schizophrenia is a syndrome that is produced by the combination of many low penetrance risk factors. Pharmacological studies established that dopamine receptor antagonists are efficacious in treating the overt psychotic features (positive symptoms) of schizophrenia such as hallucinations and delusions. Clozapine, an "atypical" antipsychotic drug, is novel because it is effective in treating both the positive and some of the negative symptoms of this disease. Clozapine' s utility as a drug is greatly limited because continued use leads to an increased risk of agranulocytosis and seizure. No other antipsychotic drag is effective in treating the negative symptoms of schizophrenia. This is significant because the restoration of cognitive functioning is the best predictor of a successful clinical and functional outcome of schizophrenic patients (Green, M.F., Am J Psychiatry, 153:321- 30, 1996). By extension, it is clear that better drugs are needed to treat the cognitive disorders of schizophrenia in order to restore a better state of mental health to patients with this disorder.
One aspect of the cognitive deficit of schizophrenia can be measured by using the auditory event-related potential (P50) test of sensory gating. In this test, electroencepholographic (EEG) recordings of neuronal activity of the hippocampus are used to measure the subject's response to a series of auditory "clicks" (Adler, L.E. et. al., Biol. Psychiatry, 46:8-18, 1999). Normal individuals respond to the first click with greater degree than to the second click. In general, schizophrenics and schizotypal patients respond to both clicks nearly the same (Cullum, CM. et. al., Schizophr. Res., 10:131-41, 1993). These data reflect a schizophrenic's inability to "filter" or ignore unimportant information. The sensory gating deficit appears to be one of the key pathological features of this disease (Cadenhead, K.S. et. al., Am. J. Psychiatry, 157:55-9, 2000). Multiple studies show that nicotine normalizes the sensory deficit of schizophrenia (Adler, L.E. et. al., Am. J. Psychiatry, 150: 1856-61, 1993). Pharmacological studies indicate that nicotine's effect on sensory gating is via the al nAChR (Adler, L.E. et. al., Schizophr. Bull., 24: 189-202, 1998). Indeed, the biochemical data indicate that schizophrenics have 50% fewer of al nAChR receptors in the hippocampus, thus giving a rationale to partial loss of al nAChR functionality (Freedman, R. et. al., Biol. Psychiatry, 38:22-33, 1995). Interestingly, genetic data indicate that a polymorphism in the promoter region of the al nAChR gene is strongly associated with the sensory gating deficit in schizophrenia (Freedman, R. et. al., Proc. Natl. Acad. Sci. USA, 94(2):587-92, 1997; Myles-Worsley, M. et. al, Am. J. Med. Genet, 88(5):544-50, 1999). To date, no mutation in the coding region of the α7 nAChR has been identified. Thus, schizophrenics express the same α7 nAChR as non-schizophrenics.
Selective α7 nAChR agonists may be found using a functional assay on FLIPR (see WO 00/73431 A2). FLIPR is designed to read the fluorescent signal from each well of a 96 or 384 well plate as fast as twice a second for up to 30 minutes. This assay may be used to accurately measure the functional pharmacology of α7 nAChR and 5HT3R. To conduct such an assay, one uses cell lines that expressed functional forms of the α7 nAChR using the α7/5-HT3 channel as the drug target and cell lines that expressed functional 5HT3R. In both cases, the ligand-gated ion channel was expressed in SH-EPl cells. Both ion channels can produce robust signal in the FLIPR assay. The compounds of the present invention are α7 nAChR agonists and may be used to treat a wide variety of diseases. For example, they may be used in treating schizophrenia, and psychosis.
Schizophrenia is a disease having multiple aspects. Currently available drugs are generally aimed at controlling the positive aspects of schizophrenia, such as delusions. One drug, Clozapine, is aimed at a broader spectrum of symptoms associated with schizophrenia. This drug has many side effects and is thus not suitable for many patients. Thus, there is a need for a drug to treat the cognitive and attention deficits associated with schizophrenia. Similarly, there is a need for a drug to treat the cognitive and attention deficits associated with schizoaffective disorders, or similar symptoms found in the relatives of schizophrenic patients.
Psychosis is a mental disorder characterized by gross impairment in the patient's perception of reality. The patient may suffer from delusions, and hallucinations, and may be incoherent in speech. His behavior may be agitated and is often incomprehensible to those around him. In the past, the term psychosis has been applied to many conditions that do not meet the stricter definition given above. For example, mood disorders were named as psychoses.
There are a variety of antipsychotic drugs. The conventional antipsychotic drugs include Chlo romazine, Fluphenazine, Haloperidol, Loxapine, Mesoridazine, Molindone, Peiphenazine, Pimozide, Thioridazine, Thiothixene, and Trifluoperazine. These drugs all have an affinity for the dopamine 2 receptor.
These conventional antipsychotic drugs have several side effects, including sedation, weight gain, tremors, elevated prolactin levels, akathisia (motor restlessness), dystonia and muscle stiffness. These drugs may also cause tardive dyskinesia. Unfortunately, only about 70% of patients with schizophrenia respond to conventional antipsychotic drugs. For these patients, atypical antipsychotic drugs are available.
Atypical antipsychotic drugs generally are able to alleviate positive symptoms of psychosis while also improving negative symptoms of the psychosis to a greater degree than conventional antipsychotics. These drugs may improve neurocognitive deficits. Extrapyramidal (motor) side effects are not as likely to occur with the atypical antipsychotic drugs, and thus, these atypical antipsychotic drags have a lower risk of producing tardive dyskinesia. Finally these atypical antipsychotic drugs cause little or no elevation of prolactin. Unfortunately, these drags are not free of side effects. Although these drugs each produce different side effects, as a group the side effects include: agranulocytosis; increased risk of seizures, weight gain, somnolence, dizziness, tachycardia, decreased ejaculatory volume, and mild prolongation of QTc interval. Finally, the compounds of the present invention may be used in combination therapy with typical and atypical anti-psychotic drugs. All compounds within the present invention are useful for and may also be used in combination with each other to prepare pharmaceutical compositions. Such combination therapy lowers the effective dose of the anti-psychotic drug and thereby reduces the side effects of the anti-psychotic drugs. Some typical anti-psychotic drugs that may be used in the practice of the invention include Haldol. Some atypical anti-psychotic drugs include Ziprasidone, Olanzapine, Resperidone, and Quetiapine.
Compounds of Formula I can be prepared as shown in Scheme 1. The key step in the preparation of this class of compounds is the coupling of commercially available 3-aminoquinuclidine (R = H) with the requisite acid chloride (Lv = CI), mixed anhydride (e.g., Lv = diphenyl phosphoryl or acyloxy of the general formula of -O-C(O)-R v where RLv includes phenyl or t-butyl), ester (Lv = OMe or OEt), or carboxylic acid (Lv = OH) in the presence of an activating reagent. Suitable activating reagents are well known in the art, for examples see Kiso, Y.; Yajima, H. "Peptides" pp. 39-91, San Diego, CA, Academic Press, (1995), and include, but are not limited to, agents such as a carbodiimides, phosphonium and uronium salts (such as uronium salt HATU).
Scheme 1
One of ordinary skill in the art will recognize that the methods described for the reaction of the unsubstituted 3-aminoquinuclidine (R2=H) are equally applicable to substituted compounds (R2 ≠ H). Such compounds can be prepared by reduction of the oxime of the corresponding 3-quinuclidinone (see J. Labelled Compds. Radiopharm., 53-60 (1995) and J. Med. Chem. 988-995, (1998)). The oximes can be prepared by treatment of the 3-quinuclidinones with hydroxylamine hydrochloride in the presence of a base. The 3-quinuclidinones, where R2 = substituted alkyl, cycloalkyl, substituted benzyl, can be prepared by known procedures (see Tet. Lett. 1015-1018, (1972), J. Am. Chem. Soc. 1278-1291 (1994), J. Am. Chem. Soc. 4548- 4552 (1989), Tetrahedron, 1139-1146 (2000)). The 3-quinuclidinones, where R2 = aryl, can be prepared by palladium catalyzed arylation as described in J. Am. Chem. Soc. 1473-1478 (1999) and J Am. Chem. Soc. 1360-1370 (2000). Preferably, when W is a thiophene or in some furan cases, the acid is converted into a mixed anhydride by treatment with diphenylchlorophosphate in the presence of TEA and CH2C12 as the solvent. The resulting anhydride solution is directly reacted with aminoquinuclidine using aqueous DMF as the solvent. When W is furan, oxazole, oxadiazole, pyrrole, 5-thiazole, thiophene, or triazole, the acid is activated with a uronium salt, preferably HATU (see J. Am. Chem. Soc., 4397 (1993)), in the presence of a base such as DIEA in DMF, and reacted directly with aminoquinuclidine to afford the desired amides. In the case where W is a 2-thiazole, 2-oxazole, or a thiadiazole, the amide bond is formed by the reaction of the amine and ester (Lv = OEt) in an alcoholic solvent (see Liebigs Ann. Chem., 1216-1231 (1980)). It will be apparent to those skilled in the art that the requisite carboxylic acids can be obtained commercially or can be synthesized by known procedures. The thiophene acids required in Examples 1-11, 13, and 41-42 can be synthesized from the corresponding aldehydes by oxidation with NaClO2 as described in J. Chem. Soc. Perkin Trans. I., 789-794 (1999). The requisite aldehydes can be made as described in J. Med. Chem., 1585-1599 (1997). An aryl boronic acid is reacted with a bromothiophene in the presence of a palladium (0) source, such as tetrakis- (triphenylphosphine)palladium (0), and a base, preferably aqueous sodium carbonate. The reaction works best if heated at reflux in THF/water for 24 hours. The thiophene acids of Examples 14-19 are prepared by similar methods as in Example 1 with modifications as described herein. The furan and thiophene acids required for Examples 20-30 are available commercially.
Scheme 2
The thiophene acids for Examples 31-40 are synthesized from the corresponding esters by base catalyzed hydrolysis. Typical hydrolysis procedures are well known in the art. Preferably, the thiophene ester is treated with aqueous lithium hydroxide in a solvent such as dioxane. The esters are either commercially available or synthesized by reaction of a bromothiophene ester with the appropriate thiophenol or phenol as described in Coll. Czech. Chem. Comm., 2360-2363 (1980). Namely, the sodium salt of the thiophenol or phenol is formed by treatment with a strong base like sodium hydride. The sodium salt is then reacted with a bromothiophene in a solvent such as acetone.
When W is thiazole, the required acids for Examples 44-49 are prepared by nucleophilic addition of the requisite phenol or thiophenol to 2-bromo-l,3-thiazole-5- carboxylic ethyl ester according to the procedure described in Helv. Chim. Ada., 2002-2022 (1997). Preferably, in EtOH utilizing K2CO3 as a base (Scheme 3). The esters are hydiolyzed to the corresponding acids by procedures well known in the art.
The 2-bromo-l,3-thiazole is prepared by the method described in Roczniki Chemii
Ann. Soc. Chim. Polonorum, 1647-1658 (1972). The aryl 1,3-thiazole for Example 50 is prepared according to the procedure of Huntress and Pfister in J. Am. Chem. Soc, 2167-2169 (1943). The requisite l,3-thiazoles-5-acids for Examples 51 and 58-62 are commercially available. The l,3-thiazole-5-acids required in Examples 52-57 can be synthesized from the corresponding esters by base hydrolysis via procedures well known in the art. The requisite esters can be prepared by a Suzuki reaction as described in J. Med. Chem., 4985-92 (1995). An aryl boronic acid is reacted with a bromothiazole ester in the presence of a palladium (0) source, such as tetrakis- (triphenylphosphine)palladium (0), and a base, preferably aqueous sodium carbonate. The 1,3,4-thiadiazole esters for Examples 64-72 are synthesized by nucleophilic addition of the requisite phenol or thiophenol to 2-bromo-l,3,4-thiadiazolezole-5- carboxylic ethyl ester as described in Can. J. Chem., 243-250 (1977) (Scheme 3).
Scheme 3
The triazole for Example 75 and the oxadiazole for Example 76 are prepared by the methods of McKillop et al., Tetrahedron Lett. 23, 3357-3360 (1982) with modifications as described herein. The oxadiazole for Example 77 is prepared following the procedures of Snyder in J. Org. Chem. 3257-3269 (1990), Muchowski in Can. J. Chem. 3079-3082 (1972), and Crenshaw in US 4,001,238.
The 5-substituted-l,3-oxazole-2-esters for Examples 79-88 are synthesized according to procedures described in J. Pharm. Soc. Japan, 305-7 (1956) as shown in Scheme 4. The 5-substituted-l,3-thiazole-2-esters for Examples 89-102 are synthesized according to procedures described in Chem. Pharm. Bull., 4195-4198 (1982).
Scheme 4
The furans for Examples 103-130 are commercially available or can be prepared from their corresponding aldehydes or esters as described for the thiophenes (Examples 1-11). hi the event that the furan is not commercially available, it can be prepared by the method of Bussolari and Rehborn described in Org. Lett. 965-7 ( 1999). Furan Examples 131 - 146 are prepared in a convergent means by a direct palladium catalyzed Suzuki coupling N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-bromo- furan-2-carboxamide with the requisite boronic acid by the method described in Org. Lett. 965-7 (1999), to yield directly the desired aryl amides (Scheme 5).
Scheme 5
One of ordinary skill in the art would recognize that Examples 12, and 147- 149 are prepared by reduction of the corresponding aryl nitro compounds by methods well known in the art, preferably by reduction with Pd/C in an alcoholic solvent such as EtOH under H2. The acid for example 150 is prepared by a Pd(0) catalyzed Sonogashira coupling of 5-bromo-2-furanal and phenyl acetylene as described in Tetrathedron Lett., 4467-70 (1975). The resulting aldehyde is converted to the desired analog by methods as described for Example 103. Example 151 is prepared by addition of the sodium salt of phenol to N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- bromo-furan-2-carboxamide. The requisite acid for Example 152 is prepared by bromination of methyl-5-bromo- 1 -methyl- 1 H-pyrrole-2-carboxylate, followed by similar Pd-catalyzed coupling as described for Example 1.
The l,3-oxazole-2-carboxylic acid required for Example 153 is prepared by the method described in J. Pharm. Sci. Japan 305-7, (1956). 3-Phenyl- 1,2,4- oxadiazole-5-carboxylic acid required for Example 154 is prepared by the method of Wurm as described in Chem. Ber., 3133, (1889). The 2-phenyl-l,3-oxazole-5- carboxylic acid required for Example 155 is prepared by the method described in Chem. Heterocycl. Compd. (Engl.Transl.), 654-663, (1986). 2-Phenyl-l,3-oxazole-4- carboxylic acid required for Example 156 is prepared as described by Korte and Stoeriko, in Chem. Ber., 1033-1042, (1960). The 5-phenylisoxazole-3-carboxylic acid for Example 157 is prepared by the method of Vaughan and Spencer as described in J. Org. Chem. 1160-4, (1960).
Thioamides, such as Example 159, can be prepared from the requisite thioester by direct displacement of the thioester with aminoquinuclidine (Scheme 6). The thioester can be prepared as described in J. Organometallic Chem., 95-98 (1987). One of ordinary skill in the art would quickly identify that compounds such as Example 159 could also be prepared directly from the amides exemplified throughout this patent by direct treatment with a reagent such and Lawesson's reagent (see Lawesson et. al. in Bull. Soc. Chim. Belg., 229 (1978)) or P4Sι0 (see Chem. Rev., 45 (1961)).
Scheme 6
The following examples are provided as examples and are not intended to limit the scope of this invention to only those provided examples and named compounds. Also, the salts made in the examples are only exemplary and are not intended to limit the invention. Any pharmaceutically acceptable salt can be made by one of ordinary skill in the art. Further, the naming of specific stereoisomers is for exemplification, and is not intended to limit in anyway the scope of the invention. The invention includes the following examples in pure stereoisomeric form or as racemic mixtures.
Example 1
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-phenyl-thiophene-2-carboxamide hydrochloride:
Step 1 a: Preparation of 5-phenylthiophene-2-carboxaldehyde.
5-Bromothiophene-2-carboxaldehyde (l.Og, 5.2 mmol) is added to a solution of tetrakis(triphenylphosphine)palladium(0) (180 mg, 0.16 mmol) in degassed THF (lOmL). The resulting solution is stirred for 5 minutes. A solution of phenylboronic acid (760 mg, 6.2 mmol) in THF (lOmL) is added followed by aqueous Na2CO3 (2M, 5.2mL). The mixture is heated at reflux for 24 hours. The reaction mixture is allowed to cool, poured into ether, and washed twice with water. The ether layer is dried over Na2SO4 and concentrated in vaeuo. The crude product is purified by flash column chromatography (1:1 hexanes:CH2Cl2) to yield the desired product (900 mg, 91%). 1H NMR (300MHz, CDC13) 67.38-7.45, 7.65-7.68, 7.73, 9.88.
Step lb: Preparation of 5-phenylthiophene-2-carboxylic acid.
The product of Step la (750 mg, 4 mmol) is dissolved in a mixture of THF, t- BuOH, and water (2: 1:1, 60 mL). KH2PO4 (1.36 g, 10 mmol) is added followed by NaClO2 (900 mg, 10 mmol). The mixture is stirred at room temperature for 5 days. Aqueous NaOH (2M, 10 mL) is added, and a majority of the organic solvents are removed in vaeuo yielding an aqueous suspension. This suspension is diluted with water and washed three times with CH2C12. The aqueous layer is acidified to pH<6 with 25% H2SO and the product is extracted three times with CH2C12. The combined organic washes are dried over Na2SO4, filtered and concentrated in vaeuo to yield the desired product (417 mg, 51%). MS for C, ιH8O2S (ESI) (M-H)" m/z 203.
Step lc Preparation of N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-phenyl- thiophene-2-carboxamide hydrochloride. TEA (210μL, 1.5mmol) is added to a suspension of the product of Step lb
(304mg, 1.5mmol) in CH2C12 (5mL). Diphenylchlorophosphate (290μL, 1.4mmol) is added and the resulting solution is stirred at room temperature for 30 minutes. This solution is added to a solution of (R)-3-aminoquinuclidine dihydrochloride (279mg, 1.4mmol) and TEA (580μL, 4.2mmol) in DMF/water (5: 1, lOmL). The resulting solution is allowed to stir overnight. MeOH is added and the mixture is poured through a column of AG50Wx2 ion exchange resin (H+ form). The resin is washed with MeOH then the product is eluted with 5% TEA in MeOH. The eluent is evaporated to dryness. The hydrochloride salt is formed and crystallized from MeOH/IPA to yield the desired product (280mg, 57%). MS for Cι8H20N2OS (ESI) (M+H)+ m/z 313.
Examples 2-11 The following compounds are made from the corresponding boronic acids according to the procedure of Example 1, making non-critical variations.
Example 2: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-chlorophenyl)-thiophene-2- carboxamide hydrochloride (from 4-chlorophenylboronic acid). Yield 24% for 3 steps. MS for C,8Hι9ClN2OS (ESI) (M+H)+ m/z 347.
Example 3: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-chlorophenyl)-thiophene-2- carboxamide hydrochloride (from 3-chlorophenylboronic acid). Yield 16%. MS for C,8Hι9ClN2OS (ESI) (M+H)+ m/z 347.
Example 4: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-chlorophenyl)-thiophene-2- carboxamide hydrochloride (from 2-chlorophenylboronic acid). Yield 48%. MS for Cι8H]9ClN2OS (ESI) (M+H)+ m/z 347.
Example 5: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2,3'-bithiophene-5-carboxamide hydrochloride (from 3-thiopheneboronic acid). Yield 49%. HRMS (FAB) calculated for C16Hi8N2OS2+H 319.0939, found 319.0939. Example 6: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-nitrophenyl)-thiophene-2- carboxamide hydrochloride (from 2-nitrophenylboronic acid). Yield 45%. HRMS (FAB) calculated for Cl8Hι9N3O3S+H 358.1225, found 358.1224.
Example 7: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-nitrophenyl)-thiophene-2- carboxamide (from 3-nitrophenylboronic acid). Yield 25%. HRMS (FAB) calculated for C18H19N3O3S+H 358.1225, found 358.1217.
Example 8: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-4-phenyl-thiophene-2- carboxamide hydrochloride (starting with phenyl boronic acid and 4-bromothiophene- 2-carboxaldehyde in place of 5-bromothiophene-2-carboxaldehyde). Yield 35%. MS for Cι8H20N2OS (ESI) (M+H)+ m/z 313. Example 9: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-benzyloxyphenyl)- thiophene-2-carboxamide hydrochloride (from 3-benzyloxyphenylboronic acid). Yield 35%. MS for C25H26N2O2S (ESI) (M+H)+ m/z 419.
Example 10: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-benzyloxyphenyl)- thiophene-2-carboxamide hydrochloride (from 4-benzyloxyphenylboronic acid). Yield 34%. MS for C25H26N2O2S (ESI) (M+H)+ m/z 419. Example 11 : N-[(3R)- 1 -azabicyclo[2.2.2]oct-3~yl]-5-(3-fluoro-4-benzyloxyphenyl)- thiophene-2-carboxamide hydrochloride (from 3-fluoro-4-benzyloxyphenylboronic acid). Yield 41%. MS for C25H25FN2O2S (ESI) (M+H)+ m/z 436.
Example 12
5-(2-Aminophenyl)-N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-thiophenc-2- carboxamide:
Step 12a: Preparation of 5-(2-aminophenyl)-N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]thiophene-2-carboxamide.
In a 200 mL Parr flask is placed the compound Example 6 (0.200 g, 0.51 mmol), EtOH (5 mL) and CH2C12 (5 mL). The flask is shaken under 30 psi H2 for 16 hours. The contents are then filtered through a pad of celite with 10% MeOH-CH2Cl2 (150 mL). The solvents are removed in vaeuo. This lot is then combined with a second lot prepared in a similar manner on the scale of 0.25 mmol. The product is re- dissolved in MeOH and loaded onto a column of AG50Wx2 ion exchange resin (H+ form). The resin is washed with MeOH then the product is eluted with 5% TEA in MeOH. The eluent is evaporated to dryness to yield the desired product (0.17 g, 69%). MS for C,8H2ιN3OS (El ) m/z (rel. intensity) 327 (M+, 78), 327 (78), 203 (23), 202 (94), 130 (44), 125 (21), 117 (23), 109 (58), 96 (24), 83 (26), 70 (99).
Example 13
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-pyridin-3-yl-thiophene-2-carboxamide dihydrochloride:
Step 13a: Preparation of 5-(3-pyridinyl)-2-thiophenecarboxaldehyde. In a flask are placed 3-pyridinediethylborane (0.81 g, 5.5 mmol), 2- bromothiophene-5-carboxaldehyde (0.59 mL, 5.0 mmol), and Pd(PPh3)4 (0.17g, 0.15 mmol). The flask is vacuum purged and nitrogen filled three times followed by addition of a 4: 1 mixture of toluene-EtOH (8.3 mL) by syringe. After careful vacuum purge/nitrogen fill (3X), a solution of Na2CO3 (2M, 5mL, 10.0 mmol) is added by syringe, and the flask is vacuum purged and nitrogen filled (3X). The reaction mixture is heated to 90°C and stirred for 22h. The reaction mixture is cooled to rt and diluted with H2O. The aqueous solution is extracted with ether (3X). The combined ether layers are then washed with water (3X) and brine (2X). The organic layer is dried over MgSO4, diluted with EtOAc for solubility, then filtered and concentrated. The crude product is then chromatographed over silica gel (10/30/50% EtO Ac- heptane gradient) to provide the product as a yellow solid (0.34 g, 35%). NMR (400MHz, CDC13): 9.97, 9.05, 8.68, 8.13, 7.83, 7.59-7.54.
Step 13b: Preparation of N-[(3R)-1 -azabicyclo[2.2.2]oct-3-yl]-5-ρyridin-3-yl- thiophene-2-carboxamide dihydiOchloride.
This compound is made from the product of Step 13a by using the procedure discussed in Steps lb and lc, making non-critical variations. The yield from 2 steps is 20%. MS for C17HI9N3OS (ESI) (M+H)+ m/z 314.
Example 14
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5'-methyl-2,2'-bithiophene-5- carboxamide hydrochloride:
Step 14a: Preparation of methyl 5 -methyl-2,2'-bithiophene-5-carboxylate.
In a flask are placed 2-bromothiophene-5-carboxylic acid (1.20 g, 5.81 mmol), 5-methylthiophene-2-boronic acid (0.99 g, 6.97 mmol), and Pd(PPh3)4 (0.20 g, 0.17 mmol). The flask is then vacuum purged and nitrogen filled (3X). THF (12mL) is then added by syringe followed by vacuum purge and nitrogen fill (3X). A solution of Na2CO3 (2M, 5.8 mL, 11.6 mmol) is added followed by vacuum purge and nitrogen fill (3X). The reaction mixture is heated to reflux for 19h then cooled to rt and diluted with water. The aqueous solution is extracted with ether (3X). The aqueous layer is then acidified and extracted with EtOAc (3X). The combined organic layers are dried over MgSO4, filtered, and concentrated to provide an inseparable 3:1 mixture of 2- bromothiophene-5-carboxylic acid and bithiophene product. To separate the compounds the methyl esters are formed: In a flask are placed the aforementioned mixture, MeOH (50 mL) and cone H2SO4 (5 drops) and heated to reflux for 24 h. The solution is concentrated and chromatographed over silica gel (2% acetone-heptane) to provide the product as a solid (0.37 g, 26% 2 steps). 1H NMR (400MHz, CDC13) δ 7.69, 7.10, 7.07, 6.73, 3.91, 2.52.
Step 14b: Preparation of 5 -methyl-2,2'-bithiophene-5-carboxylic acid.
The product of Step 14a (0.37 g, 1.54 mmol), dioxane (5 mL) and LiOH (IN, 3.1 mL, 3.1 mmol) are placed in a flask. Additional dioxane (5 mL) is then added for solubility and stirred for 24 h at rt. IN HC1 is added slowly until pH<6, whereupon a precipitate forms. The precipitate is then collected by filtration, rinsed with water, and dried in a 70°C vacuum oven to provide the product as a yellow solid (0.30 g, 86%). MS for Ci0H8O2S2 (ESI) (M-H)+ m/z 223.
Step 14c: Preparation of N-[(3R)- l-azabicyclo[2.2.2]oct-3-yl]-5 -methyl-2,2 - bithiophene-5-carboxamide hydrochloride.
This compound is made using the product of Step 14b as the starting material and using the procedure discussed in Step lc, making non-critical variations. Yield 84%. MS Cι7H20N2OS2 (El ) m/z (rel. intensity) 332 (M+, 90), 332 (90), 207 (99), 135 (90), 125 (55), 109 (86), 108 (43), 96 (52), 84 (52), 83 (48), 70 (88).
Example 15
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5'-chloro-2,2'-bithiophene-5- carboxamide hydrochloride:
Step 15a: Preparation of 5 -chloro-2,2'-bithiophene-5-carboxaldehyde.
In a flask are placed 2-bromo-5-chlorothiophene (0.55 mL, 5.0 mmol) and Pd(PPh )4 (0.17 g, 0.15 mmol), and the flask is vacuum purged and nitrogen filled (3X). THF (10 mL) is added by syringe and stirred 10 min. In a separate flask is placed 5-formyl-2-thiopheneboronic acid (0.94 g, 6.0 mmol) and EtOH (2 mL) and stirred until dissolved. This mixture is added by syringe to the first flask followed by vacuum purge and nitrogen fill (3X). A solution of Na2CO (2M, 5.0 mL, 10.0 mmol) is added by syringe followed by vacuum purge and nitrogen fill (3X). The reaction mixture is heated at 85°C for 20 h. The reaction is cooled to rt and diluted with water. The aqueous solution is extracted with ether (3X). The combined ether layers are washed with water (3X) then brine (2X). The ether is dried over MgSO , filtered, and concentrated. The caide product is purified over silica gel (5% EtOAc-heptane) to provide the product as an orange solid (0.27 g, 24%). !H NMR (400MHz, CDC13) δ 9.89, 7.69, 7.20, 7.16, 6.93.
Step 15b: Preparation of N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5 -chloro-2,2 - bithiophene-5-carboxamide hydrochloride.
This compound is made from the product of Step 15a as the starting material by using the procedures discussed in Steps lb and lc, making non-critical variations. Yield for 2 steps 34%. HRMS (FAB) calculated for C,6H17ClN2OS2+H 353.0549, found 353.0545.
Example 16 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-nitro-thiophene-2-carboxamide hydrochloride:
Step 16a: Preparation of N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-nilrothiophene-
2-carboxamide hydrochloride.
This compound is made from 2-nitrothiophene-5-carboxaldehyde by using the procedure discussed in Steps lb and lc, making non-critical variations. Yield for 2 steps 48%. MS for Cι2H,5N3O3S (El) m/z (rel. intensity) 281 (M+, 16), 156 (37), 125 (37), 110 (34), 109 (80), 96 (33), 84 (29), 82 (41), 81 (16), 70 (99), 55 (17).
Example 17
5-(Aminomethyl)-N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-thiophene-2- carboxamide dihydrochloride:
Step 17a: Preparation of tert-butyl 2-thienylmethylcarbamate.
A 500 mL receiving flask is placed in an ice bath, and to the flask is added thiophene-2-methylamine (5.0 mL, 48.7 mmol), CH2C12 (250 mL) then di-tert-butyl dicarbonate (12.7 g, 73.0 mmol) in 2-3 g portions over 5 min. The reaction mixture is stirred for 3 h then washed with IN HC1 (3X), IN NaOH (3X) and brine (2X). The organic layer is dried over MgSO , filtered and concentrated to a yellow oil. The oil is chromatographed over silica gel (2.5-5% EtOAc-heptane gradient) to provide 8.70 g (84%) of the desired product as a clear oil. MS for C10H,5NO2S (ESI) (M+H)+ m/z 214.
Step 17b: Preparation of 5-{ [(tert-butoxycarbonyl)amino]methyl}-2- thiophenecarboxylic acid.
In a flask is placed the product of Step 17a (3.50 g, 16.4 mmol) and dry THF (80 mL) then cooled in an acetone/solid CO2 bath. Lithium diisopropylamide (18.0 mL, 36.1 mmol, 2.0 M solution in heptane/THF/ethylbenzene) is added in a slow stream by syringe. The resulting orange solution is stirred for 10 min and then quenched with excess dry ice. The solution is warmed over lh and the THF removed in vaeuo. The crude product is diluted with CH2C12 and washed with IN HC1 (3X). The CH2CI2 is removed in vaeuo and replaced with EtOAc due to insolubility. The organic solution is dried over MgSO , filtered, and concentrated to provide a dark orange oil, which is chromatographed over silica gel (25-90% EtO Ac-heptane gradient) to provide 0.873 g (21 %) of the product as an off-white foam. 1H NMR " (400MHz, CDC13) δ 12.96, 7.60, 7.56, 6.97, 4.28, 1.40.
Step 17c: Preparation of 5-(aminomethyl)-N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]thiophene-2-carboxamide dihydrochloride.
This compound is made by using the product of Step 17b as a starting material and using the procedure discussed in Step lc, making non-critical variations. Yield 55%. MS for C,3H19N3OS (El ) m/z (rel. intensity) 265 (M+, 6), 140 (24), 109 (79), 96 (24), 80 (31), 78 (99), 70 (80), 65 (28), 63 (99), 62 (39), 61 (77).
Example 18
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-cyano-thiophene-2-carboxamide hydrochloride:
Step 18a: Preparation of 5-cyano-thiophene-2-carboxylic acid.
In a 500 mL receiving flask are placed thiophene-2-carbonitrile (5.0 mL, 53.8 mmol) and THF (270 mL) and cooled in an acetone/solid CO2 bath. Lithium diisopropylamide (40.3 mL, 80.7 mmol, 2.0M solution in heptane/THF/ethylbenzene) is added in a slow stream via syringe. The solution is stirred for 10 min then quenched with an excess of dry ice. The reaction mixture is warmed in a water bath and the THF removed in vaeuo. The slurry is taken up in IN NaOH and extracted with ether (3X). The aqueous layer is then acidified to pH<6 with cone. HCI, whereupon a brown precipitate forms. This precipitate is filtered off and to the resulting eluent is added IN HCI which results in precipitation of the product. The product is collected by filtration then triturated with CH2C12. Purification over silica gel (1:2.5:100 formic acid:MeOH:CH2Cl2) provides the product as a solid (1.79 g, 22%). Η NMR (400MHz, CDC13) δ 14.10, 8.00, 7.80. Step 18b: Preparation of N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-cyano- thiophene-2-carboxamide hydrochloride.
This compound is made by using the product of Step 18a as a starting material and using the procedure discussed in Step lc, making non-critical variations. Yield 57%. HRMS (FAB) calculated for C13H15N3OS+H 262.1014, found 262.1003.
Example 19
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-methoxy-thiophene-2-carboxamide hydrochloride:
This compound is prepared from 2-methoxythiophene according to the procedure used to make the compound of Example 18, making non-critical variations. Yield for 2 steps 33%. HRMS (FAB) calculated for Cι3H,8N2O2S-i-H 267.1167, found 267.1167.
Example 20
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(pyridin-2-yl)-thiophene-2- carboxamide:
Step 20a: TEA (50μL, 0.35mmol) is added to a suspension of 5-(pyridin-2-yl)-2- thiophenecarboxylic acid (72mg, 0.35mmol) in CH2C12:DMF (2: 1, 1.5mL). Diphenylchlorophosphate (62μL, 0.3mmol) is added and the resulting solution is stirred at room temperature for 30 minutes. A solution of (R)-3-aminoquinuclidine (1M, 0.2mmol, 0.2mL) in DMF is added and the resulting solution is stirred overnight at room temperature. MeOH is added and the mixture is poured through a column of AG50Wx2 ion exchange resin (H+ form). The resin is washed with MeOH then the product is eluted with 5% TEA in MeOH. The eluent is evaporated to dryness to yield the desired product (15mg, 24%). MS for C17Hι9N3OS (ESI) (M+H)+ m/z 314. Examples 21-30
The following compounds are made from the corresponding carboxylic acids according to the procedure of Example 20, making non-critical variations. Example 21: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-[2,2:]bithiophenyl-5-carboxamide (from 2,2 -bithiophene-5-carboxylic acid). Yield 13%. MS for Cι6Hι8N2OS2 (ESI) (M+H)+ m/z 319.
Example 22: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(methylsulfanyl)-thiophene-2- carboxamide (from 5-methylsulfanylthiophene-2-carboxylic acid). Yield 84%. MS for C13H18N2OS2 (ESI) (M+H)+ m/z 283.
Example 23: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-chloro-thiophene-2- carboxamide (from 5-chlorothiophene-2-carboxylic acid). Yield 6%. MS for Cι2Hι5ClN2OS (ESI) (M+H)+ m/z 271.
Example 24: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-acetyl-thiophene-2- carboxamide (from 5-acetylthiophene-2-carboxylic acid). Yield 7%. MS for Cι4H,8N2O2S (ESI) (M+H)+ m/z 279.
Example 25: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-methyl-thiophene-2- carboxamide (from 5-methylthiophene-2-carboxylic acid). Yield 6%. MS for C,3Hι8N2OS (ESI) (M+H)+ m/z 251. Example 26: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-bromo-thiophene-2- carboxamide (from 5-bromothiophene-2-carboxylic acid). Yield 8%. MS for C,2Hι5BrN2OS (ESI) (M+H)+ m/z 315/317.
Example 27: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(phenylsulfanyl)-thiophene-2- carboxamide (from 5-phenylsulfanylthiophene-2-carboxylic acid). Yield 68%. MS for Ci8H2oN2OS2 (ESI) (M+H)+ m/z 345.
Example 28: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(acetylamino)-furan-2- carboxamide (from 5-acetylaminofuran-2-carboxylic acid). Yield 16%. MS for Cι4H19N3O3 (ESI) (M+H)+ m/z 278. Example 29: N-[(3R)- l-azabicyclo[2.2.2]oct-3-yl]-5-trifluoromethyl-furan-2- cai-boxamide (from 5-trifluoiOmelhylfuran-2-carboxylic acid). Yield 11%. MS for C,3H15F3N2θ2 (ESI) (M+H)+ m/z 289.
Example 30: N-[(3R)- l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methyl-5-trifluoromethyl- 2H-pyrazole-3-yl)-thiophene-2-carboxamide (from 5-(2-methyl-5-trifluoromethyl-2H- pyrazole-3-yl)thiophene-2-carboxylic acid). Yield 9%. MS for 7Ηι9F3N4OS (ESI)
(M+H)+ m/z 385.
Example 31 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methylthiazol-4-yl)-thiophene-2- carboxamide:
Step 31a: Preparation of 5-(2-methylthiazol-4-yl)-thiophene-2-carboxylic acid.
Aqueous LiOH (IN, 1.5mL) is added to a solution of methyl 5-(2- methylthiazol-4-yl)-thiophene-2-carboxylate (81mg, 0.34mmol) in dioxane (ImL). The reaction is stirred at room temperature for 2 hours. Aqueous HCI (IN, 4mL) is added and the resultant precipitate is collected by filtration, washed with water, and dried to give the desired product (53mg, 69%). Η NMR (300MHz, DMSO) δ 8.03, 7.69, 7.59, 2.70. Step 31b: Preparation of N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- methylthiazol-4-yl)-thiophene-2-carboxamide.
This compound is made by using the product of Step 31a as a starting material and using the procedure discussed in Step 20a, making non-critical variations. Yield 16%. MS for Cι6H,9N3OS2 (ESI) (M+H)+ m/z 334.
Example 32
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[2-(3-chloroρhenyl)-vinyl]-thiophene- 2-carboxamide:
This compound is prepared from methyl 5-[2-(3-chlorophenyl) vinyl]- thiophene-2-carboxylate according to the procedure used to make the compound of Example 31, making non-critical variations. Yield 19%. MS for C2oH2iClN2OS (ESI) (M+H)+ m/z 373.
Example 33
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-chlorophenylsulfanyl)-thiophene-2- carboxamide:
Step 33a: Preparation of 5-(4-chlorophenylsulfanyl)-thiophene-2- carboxaldehyde.
Sodium hydride (60%, 1.2g, 30mmol) is added to a solution of 4- chlorothiophenol (4.3g, 30mmol) in THF (30mL). The resulting solution is stirred for 10 minutes then the solvent is removed in vaeuo. Acetone (60mL) is added followed by 5-bromothiophene-2-carboxaldehyde (3.0mL, 25mmol). The mixture is stirred at room temperature for 2 hours. The solvent is removed in vaeuo and the resulting slurry diluted with CH2C12. This solution is washed three times with IN NaOH then dried over MgSO4, filtered and concentrated in vaeuo. The crude product is purified by flash column chromatography (gradient of 1 to 5% EtOAc in heptane) to give the desired product (6.2g, 98%). 1H NMR (300MHz, CDC13) δ 7.13, 7.31-7.39, 7.63, 9.78.
Step 33b: Preparation of 5-(4-chlorophenylsulfanyl)-thiophene-2-carboxylic acid.
The product of Step 33a (6.1g, 24mmol) is dissolved in a mixture of THF, t- BuOH, and water (3:3:1, 255mL). 2-Methyl-2-butene (20.3mL, 192mmol) is added followed by KH2PO4 (9.8g, 72mmol) and then NaClO2 (80%, 8.17g, 72.3mmol). The mixture is stirred at room temperature for 2 hours. Aqueous KHSO (0.5M, 200mL) is added and the organic solvents are removed in vaeuo to produce an aqueous suspension of the product. The precipitate is collected by filtration, dissolved in IN NaOH and washed two times with ether. The aqueous solution is then acidified to pH<6 with concentrated HCI and a precipitate formed. The precipitate is collected by filtration and washed with 0.5M KHSO4 then water. The solid is dried in vaeuo to give the product (5.7g, 87%). MS for C, ιH7ClO2S2 (ESI) (M-H)" m/z 269.
Step 33c: Preparation of N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- chlorophenylsulfanyl)-thiophene-2-carboxamide.
TEA (1.5mL, 10.9mmol) was added to a suspension of the product of Step 33b (2.7g, lOmmol) in CH2C12 (lOOmL). Diphenylchlorophosphate (2.08mL, lOmmol) was added and the resulting solution is stirred at room temperature for 30 minutes. To this solution is added a solution of (R)-3-aminoquinuclidine (1M in DMF, 9. ImL, 9.1 mmol). The resulting solution is stirred overnight at room temperature. MeOH is added and the mixture is poured through a column of AG50Wx2 ion exchange resin (H+ form). The resin is washed with MeOH, then the product is eluted with 5% TEA in MeOH. The eluent is evaporated to dryness and the resulting solid is triturated with ether and dried in vaeuo to yield the desired product (2.4g, 71%). Alternatively, these compounds can be converted to their hydrochloride salts and crystallized from MeOH/IPA. MS for C18H,9ClN2OS2 (ESI) (M+H)+ m/z 379.
Examples 34-39
The following compounds are made from the corresponding carboxylic acids according to the procedure of Example 33, making non-critical variations.
Example 34: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2,4 difluorophenyl-sulfanyl)- thiophene-2 carboxamide hydrochloride (from 2,4-difluorothiophenol). Yield for 3 steps 9%. MS for C,8H18F2N2OS2 (ESI) (M+H)+ m/z 381.
Example 35: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-chlorophenyl-sulfanyl)- thiophene-2-carboxamide (from 3-chlorothiophenol). Yield 50%. MS for Cl8Hι9ClN2OS2 (ESI) (M+H)+ m/z 379. Example 36: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-chloro-4-fluoro- phenylsulfanyl)-thiophene-2-carboxamide (from 3-chloro-4-fluorothiophenol). Yield 29%. MS for C] 8H,8ClFN2OS2 (ESI) (M+H)+ m/z 397.
Example 37: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2,3-dichlorophenyl-sulfanyl)- thiophene-2-carboxamide hydrochloride (from 2,3-dichlorothiophenol). Yield 44%. MS for Cι8Hι8Cl2N2OS2 (ESI) (M+H)+ m/z 413.
Example 38: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2,4,5-trichlorophenyl- sulfanyl)-thiophene-2-carboxamide (from 2,4,5-trichlorothiophenol). Yield 53%. MS for C)8Hι7Cl3N2OS2 (ESI) (M+H)+ m/z 449. Example 39: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,4-dichlorophenyl-sulfanyl)- thiophene-2-carboxamide (from 3,4-dichlorothiophenol). Yield 21%. MS for C,8Hι8Cl2N2OS2 (ESI) (M+H)+ m/z 413.
Example 40 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-phenoxy-thiophene-2-carboxamide hydrochloride:
Step 40a: 5-Phenoxy-thiophene-2-carboxaldehyde.
Phenol (3.3g, 35mmol) is added in portions to a suspension of 60% NaH (1.3g, 35mmol) in DMSO (lOOmL). The resulting mixture is stirred for 30 minutes then 5- nitrothiophene-2-carboxaldehyde (5g, 32mmol) is added. After 1 hour the reaction mixture is poured into water (IL) and washed with ether (4x500mL). The combined organic layers are dried over Na2SO4, filtered and evaporated to dryness. The resulting material is dissolved in MeOH and passed through a column (2.5cm x 20cm) of Amberjet 4400 (OH" form). The eluent is dried in vaeuo then evaporated twice from CH3CN. The crude product is purified by column chromatography in EtOAc- hexanes (1:1) to yield the desired aldehyde (304mg, 5%). Η NMR (300MHz, CDC13) δ 6.52, 7.20, 7.27, 7.45, 7.55, 9.75.
Step 40b: 5-Phenoxy-thiophene-2-carboxylic acid. 5-Phenoxy-thiophene-2-carboxaldehyde (325mg, l.όmmol) is dissolved in a mixture of THF (lOmL), t-BuOH (5mL) and water (5mL). NaH2PO4 (650mg, 4.8mmol) is added followed by NaClO2 (432mg, 4.8mmol). The resulting mixture is stirred for 24 hours at room temperature. Aqueous NaOH (2M, 5mL) is added, and the organic solvents are removed in vaeuo. The resulting aqueous suspension is poured into water (50mL) and washed with ether (3x50mL). The aqueous layer is acidified to pH<2 with 25% H2SO4 then washed with CH2C12 (3x50mL). The combined organic washes are dried over Na2SO , filtered and concentrated in vaeuo. The crude product is dissolved in hot aqueous acetone and filtered. The solvents are gradually removed until a precipitate forms. The solid is collected by filtration and dried in vaeuo to yield the desired product (192mg, 55%). MS for CnH7O3S (ESI) M- f m/z 219.
Step 40c: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-phenoxy-thiophene-2- carboxamide hydrochloride. The compound is made according to the procedure of Step lc, starting with 5- phenoxy-thiophene-2-carboxylic acid and making non-critical variations. Yield (66%). MS for Cι8H2,N2O2S (ESI) (M+H)+ m/z 329.
Example 41 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-hydroxyphenyl)-thiophene-2- carboxamide hydrochloride:
Step 41a: 5-(2-Hydroxyphenyl)-thiophene-2-carboxylic acid.
Tetrakis(triphenylphosphine)palladium(0) (133mg, 0.12mmol) is added to a solution of 5-bromothiophene-2-carboxylic acid (850mg, 4.1 mmol) in degassed THF (lOmL). The resulting solution is stirred for 5 minutes and then 2-(4,4,5,5- tetramethyl)-l,3,2-dioxaborolan-2-yl) phenol (lg, 4.6mmol) is added followed by aqueous Na2CO3 (2M, 6.9mL). The mixture is heated at reflux overnight. The reaction mixture is allowed to cool, poured into water (50mL), and washed with ether (3x50mL). The aqueous layer is acidified with concentrated HCI to ρH<2. The resulting precipitate is collected by filtration, washed with water and dried in vaeuo to yield the desired product (761rag, 83%). MS for C11H7O3S (ESI) (M-H)+ m/z 219.
Step 41b: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-hydroxyphenyl)-thiophene- 2-carboxamide hydrochloride.
5-(2-Hydroxyphenyl)thiophene-2-carboxylic acid (650mg, 2.95mmol) is dissolved in DMF (30mL). (ι )-3-Aminoquinuclidine dihydrochloride (587mg, 2.95mmol) is added followed by DIEA (1.6mL, 8.85mmol) and HATU (1.12g, 2.95mmol). The reaction is allowed to stir for 96 hours. The reaction mixture is diluted with MeOH and poured through a column of AG50Wx2. The column is washed with MeOH and then the product is eluted with 5% TEA in MeOH. The solvents are removed in vaeuo and the resulting material is dissolved in CH CN, concentrated and then dried in vaeuo. The hydrochloride salt is formed and triturated with MeOH to yield the desired product (784mg, 73%). MS for Cι8H2ιN2O2S (ESI) (M+H)+ m/z 329.
Example 42
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-hydroxyphenyl)-thiophene-2- carboxamide hydrochloride:
The compound is made from the 3-hydroxyphenylboronic acid according to the procedure of Example 41, making non-critical variations. Yield 46%. MS for Cι8H2ιN2O2S (ESI) (M+H)+ m/z 329.
Example 43
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-fluoro-4-hydroxyphenyl)-thiophene- 2-carboxamide hydrochloride:
Step 43a: The compound Example 11 (165mg, O.38mmol) is dissolved in MeOH and poured through a plug of Amberjet 4400 (OH" form). The solvent is removed in vaeuo and the product is redisolved in EtOH (2mL). This solution is added to a suspension of Pd/C (10%, 165mg) in EtOH (2mL). Cyclohexadiene (360mL, 3.8mmol) is added, and the reaction is heated at 60°C for 6 hours. The reaction mixture is diluted with MeOH and filtered through celite. The solvents are removed in vaeuo then the hydrochloride salt is formed and crystallized from MeOH/CH3CN to yield the desired product (52mg, 36%). MS for Cι8H20FN2O2S (ESI) (M+H)+ m/z 347.
Example 44
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-(phenylsulfanyl)-l,3-thiazole-5- carboxamide fumarate:
Step 44a: Preparation of 2-phenylsuIfanyl-thiazole-5-carboxylic acid ethyl ester.
A suspension of 2-bromo-l,3-thiazole-5-carboxylic acid ethyl ester (1.5 g, 6.15 mmol, 1 eq) and K2CO3 (1.7 g, 12.3 mmol, 2 eq) in EtOH (60 mL) is cooled in an ice bath, and thiophenol (0.631 mL, 6.15 mmol, 1 eq) is added. The reaction is monitored by HPLC until the starting material is consumed. The reaction mixture is filtered (to remove a solid by-product), and the solvent is removed in vaeuo. The crude mixture is purified by silica gel chromatography using a Biotage Flash 40S column using 2% EtOAc in hexanes to afford the product as an oil (0.784 g, 46%).
MS (ESI) for C12HuNO2S2 m/z 266.1 (M+H)+.
Step 44b: Preparation of 2-phenylsulfanyl-thiazole-5-carboxylic acid. Potassium hydroxide ( 1.58 g, 28.2 mmol, 10 eq) is added to a solution of 2- phenylsulfanyl-thiazole-5-carboxylic acid ethyl ester (0.748 g, 2.82 mmol, 1 eq) in EtOH (15 mL) and water (10.5 mL). The reaction is stirred for 1.5 hours, diluted with water (30 mL) and EtOH (30 mL), and acidified by addition of 3 N HCI until a white precipitate forms. The precipitate is filtered and purified by recrystallization from water and EtOH to give the product as a white crystalline solid (0.307 g). MS (ESI) for C,0H7NO2S2 m/z 235.9 (M-H)\
Step 44c: N-[(3R)-l-aζabicyclo[2.2.2]oct-3-yl]-2-(phenylsulfanyl)-l,3-thiaζole- 5-carboxamide fumarate. HATU (0.493 g, 1.30 mmol, 1 eq) is added to a solution of 2-phenylsulfanyl- thiazole-5-carboxylic acid (0.307 g, 1.30 mmol, 1 eq), (R)-(+)-3-aminoquinuclidine dihydrochloride (0.258 g, 1.30 mmol, 1 eq), and DIEA (0.677 L, 3.89 mmol, 3 eq) in DMF (9.8 mL), the flask containing which was in an ice bath. The reaction is stirred overnight. CH2C12 is added, and the mixture is washed with water three times. The organic layer is dried over MgSO , and the solvent removed in vaeuo. The product is purified using a Biotage Flash 40M column (1% NH4OH/9% MeOH/90%CH Cl2), affording a clear oil. The fumaric acid salt of the product is made, and recrystallized from MeOH and ether to give the product as a white crystalline solid (0.408 g, 72%). MS (ESI) for Cι7Hι9N3OS2 m/z 346.1 (M+H)+. Examples 45-49
The following compounds are prepared from the requisite phenols or thiophenols according to the procedures for Example 44, making non-critical variations.
Example 45: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-[(4-chlorophenyl)-sulfanyl]- 1 ,3-thiazole-5-carboxamide fumarate (from 4-chlorothiophenol). Yield 39%. HRMS (FAB) calculated for Cι7H18ClN3OS2+H, 380.0658, found 380.0659.
Example 46: N-[(3R)l-azabicyclo[2.2.2]oct-3-yl]-2-phenoxy-l,3-thiazole-5- carboxamide fumarate (from phenol). Yield 81%. HRMS (FAB) calculated for Cι7Hι9N3O2S+H, 330.1276, found 330.1269. Example 47: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-[(4-fluorophenyl)-sulfanyl]- l,3-thiazole-5-carboxamide fumarate (from 4-fluorothiophenol). Yield 43%. HRMS (FAB) calculated for Cι7H|8FN3OS2+Hι 363.0875, found 364.0945.
Example 48: N-[(3R)-l-azabicyςlo[2.2.2]oct-3-yl]-2-(methylsulfanyl)-l,3-thiazoIe- 5-carboxamide fumarate (from methanethiol). Yield 28%. HRMS (FAB) calculated for Cι2H,7N3OS2+Hι 284.0891, found 284.0894. Example 49: N-[(3R)l-azabicyclo[2.2.2]oct-3-yl]-2-(4-chloroρhenoxy)-l,3-thiazole- 5-carboxamide fumarate (from 4-chlorophenol). Yield 42%. HRMS (FAB) calculated for Cι7H,8ClN3O2S+H, 364.0886, found 364.0885.
Example 50
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-phenyl-l,3-thiazole-5-carboxamide fumarate:
Step 50a: Preparation of 2-phenyl-thiazole-5-carboxylic acid ethyl ester. A solution of -formyl-α-chloroacetate (9.34 g, 49.5 mmol, 1 eq) and thiobenzamide (6.79 g, 49.5 mmol, 1 eq) in EtOH (37.0 mL) is refluxed for 1 hour. The solution changes from an orange/brown color to a deep green. This solution is washed with water and extracted with CH2C12. The organic fraction is dried over Na2SO , filtered, and the solvent removed in vaeuo. The product is purified by column chromatography using a Biotage Flash 40M column (20% hexanes/EtOAc) to give the product as a deep orange oil (1.82 g, 15%). MS (ESI) for d2Hι3NO S m/z 252.1 (M+H)+.
Step 50b: Preparation of N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-phenyl-l ,3- thiazole-5-carboxamide fumarate. Making non-critical variations, the 2-phenyl-thiazole-5-carboxylic acid (1-aza- bicyclo[2.2.2]oct-3-yl)-amide is prepared using Steps 44b and 44c, starting with 2- phenyl-thiazole-5-carboxylic acid ethyl ester. The fumaric acid salt of the product is made and recrystallized from MeOH and ether to give the product as a white crystalline salt (77.4 mg, 22%). HRMS (FAB) calculated for Cι7Hι9N3OS+Hι 314.1327, found 314.1336.
Example 51 : N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2,4-dimethyl-l ,3-thiazole-5- carboxamide (from 2,3-dimethyl-thiazole-5-carboxylic acid as described in Step lc). Yield 18%. HRMS (FAB) calculated for C,3H,9N3OS+Hι 266.1327, found 266.1332.
Example 52 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-(2-fluorophenyl)-l,3-thiazole-5- carboxamide citrate:
Step 52a: Preparation of ethyl 2-(2-fluorophenyl)- 1 ,3-thiazole-5-carboxylate. Tetrakis(triphenylphosphine)palladium (0) (0.58 g, 0.5 mmol), and a degassed solution of 2.0M Na2CO3 (10 mL) are added to a degassed solution of 2-bromo-l,3- thiazole-5-carboxylic ethyl ester (1.18 g, 5.0 mmol) and 2-fluorophenylboronic acid (0.77 g, 5.5 mmol) in DME (lOmL). The resulting suspension is stirred under argon at 80°C for 4 hours. The reaction mixture is cooled, diluted with EtOAc, and then washed with two portions of 1.0 M NaOH, then one portion of brine. The combined organic phases are concentrated in vaeuo, and the resulting oil purified with flash chromatography. Yield 37%. HRMS (FAB) calculated for Cι2Hι0FNO2S+H 252.0495, found 252.0496.
Step 52b: Preparation of N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-(2- fluorophenyl)- l,3-thiazole-5-carboxamide citrate.
This compound is hydrolyzed and coupled according to Steps 44b and 44c, making non-critical variations. The citrate is prepared from the crude reaction mixture without chromatography, and crystallized. Yield 27%. HRMS (FAB) calculated for C,7Hι8FN3OS+H 332.1233, found 332.1239.
Examples 53-57
The following compounds are prepared from their requisite boronic acids according to the procedures for Example 52. The desired salt form is prepared directly from the crude reaction mixture without chromatography, and crystallized until the product is of analytical purity. Example 53: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-(3-fluorophenyl)-l,3-thiazole- 5-carboxamide 4-methylbenzenesulfonate (from 3-fluorophenylboronic acid). Yield 20%. HRMS (FAB) calculated for C,7H(8FN3OS+H 332.1233, found 332.1225.
Example 54: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-(4-fluorophenyl)-l,3-thiazole- 5-carboxamide 4-methylbenzenesulfonate (from 4-fluorophenylboronic acid). Yield 51%. HRMS (FAB) calculated for C,7Hι8FN3OS+H 332.1233, found 332.1239.
Example 55: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-(2-hydroxyphenyl)-l,3- thiazole-5-carboxamide hydrochloride (from 2-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)phenol). This compound was purified by reverse-phase preparative chromatography prior to the formation of the salt. Yield 0.5%. HRMS (FAB) calculated for Cι7Hι9N3O2S+H 330.1276, found 330.1268.
Example 56: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-(4-methylphenyl)-l,3-thiazole- 5-carboxamide hydrochloride (from 4-tolylphenylboronic acid). Yield 50%. MS (ESI) for Cι8H2ιN3OS m/z 328.2 (M+H)+. Example 57: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-[4-(benzyloxy)phenyl]-l,3- thiazole-5-carboxamide hydrochloride (from (4-benzyloxyphenyl)boronic acid). Yield 98%. MS (ESI) for C24H25N3O2S m/z 420.3 (M+H)+.
Examples 58-62: The following compounds are prepared from their requisite carboxylic acids according the procedures from Step 44c. The desired salt form is prepared directly from the crude reaction mixture without chromatography, and crystallized.
Example 58: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-pyridin-3-yl-l,3-thiazole-4- carboxamide dihydrochloride (from (2-pyrid-3-yl)thiazole-4-carboxylic acid). HRMS (FAB) calculated for Cι6Hι8N4OS-ι-H 315.1279, found 315.1289.
Example 59: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-4-methyl-2-phenyl-l ,3-thiazole- 5-carboxamide dihydrochloride (from 4-methyl-2-phenyl-l,3-thiazole-5-carboxylic acid). Yield 61%. HRMS (El) calculated for Cι8H2,N3OS 327.1405, found 327.1403.
Example 60: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-(4-chlorophenyl)-4-methyl-l,3- thiazole-5-carboxamide 4-methylbenzenesulfonate (from 2-(4-chlorophenyl)-4- methyl-l,3-thiazole-5-carboxylic acid). Yield 85%. MS (ESI) for C)8H2ιN3OS m/z 328.2 (M+H)+.
Example 61 : N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-4-methyl-2-pyridin-2-yl-l,3- thiazole-5-carboxamide hydrochloride (from 4-methyl-2-pyridin-2-yl-l,3-thiazole-5- carboxylic acid). Yield 57%. MS (ESI) for CιsH20ClN3OS m/z 362.2 (M+H)+.
Example 62: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-4-methyl-2-pyridin-4-yl-l,3- thiazole-5-carboxamide dihydrochloride (from 4-methyl-2-pyridin-4-yl-l,3-thiazole- 5-carboxylic acid). Yield 87%. MS (ESI) for Cι7H20N4OS m/z 329.2 (M+H)+.
Example 63
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-(methylamino)-l,3-thiazole-5- carboxamide hydrochloride:
Step 63a: Preparation of ethyl 2-[(tert-butoxycarbonyl)amino]- 1 ,3-thiazole-5- carboxylate:
A flask is charged with a solution of ethyl 2-amino-l,3-thiazole-5-carboxylate (2.65 g, 15.4 mmol) and 4-dimethylaminopyridine (10 mg) in THF (75 mL). Di(tert- butyl) dicarbonate (3.6 mL, 15.4 mmol,1.0 eq) and TEA (4.3 mL, 30.8 2.0 eq) are added, and the resulting solution is stirred at room temperature for 90 minutes. The reaction mixture is concentrated to dryness, and the crade product is crystallized from CHCl3/hexanes to give a light brown solid. Yield 68%. HRMS (FAB) calculated for C, ,Hι6N2O4S+H 273.0909, found 273.0897. Step 63b: Preparation of ethyl 2-[(tert-butoxycarbonyl)(methyl)amino]- 1 ,3- thiazole-5 -carboxylate .
A flask is charged with a suspension of sodium hydride (60% in mineral oil) (0.109 g, 2.72 mmol) in THF (5 mL). The ethyl 2-[(tert-butoxycarbonyl)amino]-l,3- thiazole-5-carboxylate (0.735 g, 2.70 mmol) is added, followed by iodomethane (175 μL, 2.70 mmol) and the resulting suspension is heated to reflux for 3 hours, then cooled to room temperature. Water is added, followed by 1.0 N NaOH. The basic phase is extracted with 3 portions of EtOAc. The combined organic phases are washed with brine, dried over Na2SO4, filtered, and concentrated to give a clear oil purified with flash chromatography. Yield 45%. HRMS (FAB) calculated for Cι2H,8N2O4S+H 287.1065, found 287.1068.
Step 63c: Preparation of 2-[(tert-butoxycarbonyl)(methyl)amino]-l ,3-thiazole-5- carboxylic acid.
The product of Step 63b is hydrolyzed according lo Step 44b, making non- critical variations. Yield 49%. HRMS (FAB) calculated for CιoH,4N2O4S+H 259.0752, found 259.0750.
Step 63d: Preparation of tert-butyl 5-{ [(3R)-l-azabicyclo[2.2.2]oct-3- ylaminojcarbonyl }-l ,3-lhiazol-2-yl(methyl)carbamate.
This compound is coupled according to Step 44c. The citrate is prepared from the crude reaction mixture without chromatography, and crystallized until the product is of analytical purity. Yield 32%. MS (ESI) for Cι7H26N4O3S m/z 367.2 (M+H)+.
Step 63e: Preparation of N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-2-(methylamino)-
1 ,3-thiazole-5-carboxamide hydrochloride.
A flask is charged with tert-butyl 5-{[(3R)-l-azabicyclo[2.2.2]oct-3- ylaminojcarbonyl } - 1 ,3-thiazol-2-yl(methyl)carbamate (72 mg, 0.18 mmol) in MeOH (5 mL). To this suspension is added a solution of 4.0N HCl/dioxane (10 mL) and the reaction mixture is stirred at room temperature for 3.5 hours. The solvents are removed in vaeuo and the residue crystallized from IP A/ether. Yield 63%. MS (ESI) for C,2Hι8N4OS m/z 267.2 (M+H)+.
Example 64 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(phenylsulfanyl)-l,3,4-thiadiazole-2- carboxamide:
Step 64a: Preparation of 5-phenylsulfanyl-[ 1 ,3,4]thiadiazole-2-carboxylic acid ethyl ester.
To a solution of 5-chloro-[l,3,4]thiadiazole-2-carboxylic acid ethyl ester (1.0 g, 5.2 mmol, 1 eq), and K2CO3 (1.44 g, 104 mmol, 2eq) in CH3CN (50 mL), thiophenol (0.53 mL, 5.2 mmol, 1 eq) is added. The reaction is stirred overnight at room temperature. The reaction is filtered to remove the salts, and the filtrate is washed with CH3CN. The solvents are removed under reduced pressure, and the product is recrystallized from EtOH to give 5-phenylsulfanyl-[l,3,4]thiadiazole-2- carboxylic acid ethyl ester (1.03 g, 74%). MS (ESI) for CHHιoN2θ2S2 m/z 267.0 (M+H)+.
Step 64b: Preparation of 5-phenylsulfanyl-[ 1 ,3 ,4]thiadiazole-2-carboxylic acid. The 5-phenylsulfanyl-[l,3,4]thiadiazole-2-carboxylic acid ethyl ester from
Step 64a (1.0 g, 3.76 mmol, 1 eq) is dissolved in EtOH (40 mL), and cooled in an ice bath. To this, 2N NaOH (1.88 mL, 3.76 mmol, 1 eq) is added drop wise. The sodium salt of the acid precipitates out of solution. The reaction mixture is concentrated in vaeuo to give a white crystalline product. The reaction mixture is carried through to the next step in its crude form to make the acid chloride. MS (ESI) for C9H6N2S2O2 m/z 237.0 (M-H)~.
Step 64c: Preparation of N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(phenyl- sulfanyl)- 1 ,3 ,4-thiadiazole-2-carboxamide.
5-Phenylsulfanyl-[l,3,4]thiadiazole-2-carboxylic acid (3.76 mmol) is placed in a flask and put under nitrogen. The acid is chilled in an ice bath. Oxalyl chloride (9 mL) that has also been cooled in an ice bath is added drop wise to the acid. The excess oxalyl chloride is removed under reduced pressure. The acid chloride is dissolved in about 5 mL CH2C12. The freebase of (i?)-3-aminoquinuclidine (0.5 g, 2.52 mmol, 0.67 eq) is also dissolved in CH2C12 (5 mL), and the solution containing the acid chloride is cannulated into the flask containing the aminoquinuclidine. The reaction is stirred overnight at room temperature. The reaction mixture is diluted with MeOH, and poured through a Dowex 50AGWX2 CH+ column. The impurities are removed by washing the column with MeOH, and the product is eluted by washing the column with a solution containing 5% TEA in MeOH. The solvent is removed under reduced pressure, and the product is further purified by silica gel chromatography using a Biotage Flash 40M column (5% MeOH/CH2Cl2). This gives Example 64 (0.289 g, 22%) as a tan oil. MS (ESI) for Cι6Hι8N4OS2 m/z 347.2 (M+H)+.
Example 65: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-phenoxy-l,3,4-thiadiazole-2- carboxamide. This compound is prepared from phenol according to the procedures for Example 64, making non-critical variations. Yield 16%. HRMS (FAB) calculated for C16H17N3O3S 331.0991, found 331.1229 (M)+.
Example 66
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[(4-chlorophenyl)-sulfanyl]-l,3,4- thiadiazole-2-carboxamide:
5-(4-Chloro-phenylsulfanyl)-[l,3,4]thiadiazole-2-carboxylic acid ethyl ester (0.1 g, 0.33 mmol, 1 eq), the free base of (R)-(+)-3-aminoquinuclidine (0.041 g, 0.33 mmol, 1 eq), and EtOH (0.66 mL) are added to a vial, and the solution is heated at 80°C. The reaction is complete after 4 hours as determined by HPLC. The product is purified by silica gel chromatography using a Biotage Flash 40S column (0.5% NH4OH/9.5% MeOH/CH2Cl2) to give Example 66 (0.0254 g, 20%) as a pale oil. HRMS (FAB) calculated for CI6H,7ClN4OS2+Hι 381.0610, found 381.0617.
Examples 67-72 The following compounds are prepared from the requisite phenols or thiophenols according to the procedures for Example 66, making non-critical variations.
Example 67: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-fluorophenoxy)- 1 ,3,4- thiadiazole-2-carboxamide (from 4-fluorophenol). Yield 27%. HRMS (FAB) calculated for C16Hι7FN4OS2+H, 365.0906, found 365.0899.
Example 68: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-chlorophenoxy)- 1 ,3,4- thiadiazole-2-carboxamide (from 4-chlorophenol). Yield 18%. HRMS (FAB) calculated for Cι6Hι7ClN4O2S+Hι 365.0839, found 365.0826. Example 69: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[(3-fluorophenyl)-sulfanyl]- l,3,4-thiadiazole-2-carboxamide (from 3-fluorothiophenol). Yield 16%. HRMS (FAB) calculated for Cι6Hι7FN4OS2+H, 365.0906, found 365.0899.
Example 70: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[(2-chlorophenyl)-sulfanyl]- l,3,4-thiadiazoIe-2-carboxamide (from 2-chlorothiophenol). Yield 44%. HRMS (FAB) calculated for Cι6Hι7ClN4OS2+Hι 381.0610, found 381.0625.
Example 71 : N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[(4-fluorophenyl)-sulfanyl]- l,3,4-thiadiazole-2-carboxamide (from 4-fluorothiophenol). Yield 34%. HRMS (FAB) calculated for 365.0906, found 365.0921.
Example 72: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[(3-chlorophenyl)-sulfanyl]- l,3,4-thiadiazole-2-carboxamide (from 3-chlorothiophenol). Yield 34%. HRMS (FAB) calculated for Cι6Hι7ClN OS2+Hι 381.0610, found 381.0603.
Example 75
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-phenyl-lH-l,2,4-triazole-3- carboxamide dihydrochloride:
Step 75a: Preparation of ethyl (2Z)-amino(benzoylhydrazono)ethanoate. Ethyl thioxamate (0.6g, 4.5mmol) and benzyl hydrazide 0.68g, 5.0mmol) in EtOH (20mL) are heated at reflux for 2 hours according to the procedure described in McKillop et al., Tetrahedron Lett. 23, 3357-3360 (1982). The resulting solids are collected and washed with EtOH, and dried in vaeuo to afford the desired product (0.5g, 50%).
Step 75b: Preparation of ethyl 5-phenyl- 1 ,3,4-oxadiazole-2-carboxylate and ethyl 5-phenyl- 1 H- 1 ,2,4-triazole-3-carboxylate.
Modification of the procedure described in McKillop et al., Tetrahedron Lett. 23, 3357-3360 (1982) affords a mixture of two products. In particular, heating ethyl (2Z)-amino(benzoylhydrazono)ethanoate (0.5g, 2. Immol) in mesitylene (15mL) at reflux overnight affords a clear solution that was concentrated in vaeuo. The resultant material is purified by silica gel chromatography (20% EtOAc/hexanes) to afford a 2.2: 1 mixture of ethyl 5-phenyl- 1, 3, 4-oxadiazole-2-carboxylate (310mg, 67%) and ethyl 5-phenyl- lH-l,2,4-triazole-3-carboxylate (140mg, 30%), respectively. MS for CnHιoN2O3 (ethyl 5-phenyl- 1, 3, 4-oxadiazole-2-carboxylate) (ESI) (M+H)+ m/z 219 and MS for CιιH10N2θ3 (ethyl 5-phenyl-lH-l,2,4-triazole-3-carboxylate) (ESI) (M+H)+ m/z 218.
Step 75c: Preparation of N-[(3R)-l-azabicyclo[2.2.2]oct-3-ylJ-5-phenyl-lH- 1 ,2,4-triazole-3-carboxamide dihydrochloride. This material is prepared using ethyl 5-phenyl- 1 H- 1 ,2,4-triazole-3-carboxylate prepared in Step 75b and coupled to (R)-(+)-3-aminoquinuclidine. The product is purified as described in Example 66, making non-critical variations, to afford the desired product (13mg, 7.3%). MS for C,6Hι9N5O (ESI) (M+H)+ m/z 298.
Example 76
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-phenyl-l,3,4-oxadiazole-2- carboxamide hydrochloride:
This material is prepared using ethyl 5-phenyl-l,3,4-oxadiazole-2-carboxylate prepared in Step 75b and coupled to (R)-(+)-3-aminoquinuclidine and the product is purified as described in Example 66, making non-critical variations. 7.3% Yield. MS for C,6H18N4O2 (ESI) (M+H)+ m/z 299.
Example 77 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(methylthio)-l,3,4-oxadiazole-2- carboxamide hydrochloride:
N-N < HCI
&
Step 77a: Preparation of ethyl- 1 ,3 ,4-oxadiazole-2-thione-5-carboxylate potassium salt dimethylsulfoxide solvate. A mixture of ethyl hydrazino(oxo)acetate (3.7g, 28mmol), prepared as described by Benson, Gross, and Snyder in J. Org. Chem. 3257-3269 (1990), EtOH (25mL), carbon disulfide (8.5g, 6.6mL, 112mmol), DMSO (6mL) and a solution of KOH (1.57g, 28mmol) in water (2mL) are heated at reflux overnight, as described by Horning and Muchowski in Can. J. Chem. 3079-3082 (1972). The resultant solid is collected by vacuum filtration and washed to afford the desired product as a DMSO solvate that was used without further purification (8.2g of a semi-solid).
Step 77b: Preparation of methyl ethyl-l,3,4-oxadiazole-2-thione-5-carboxylate.
Following the procedure of Partyka and Crenshaw in US 4,001,238, a solution of ethyl-l,3,4-oxadiazole-2-thione-5-carboxylate potassium salt dimethylsulfoxide solvate (4.1g, 24mmol) and iodomethane (6.7g, 47mmol) are heated for 1 hour at reflux in EtOH (20mL). A solid is removed by vacuum filtration, and the filtrate is concentrated. Water (40mL) is added to the resultant material, a solid is isolated by vacuum filtration, dried at 50 °C/0.5 mmHg overnight to afford the desired product (2.3g, 50%). Step 77c: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(methylthio)-l,3,4-oxadiazole-
2-carboxamide hydrochloride:
This material is prepared using methyl ethyl- 1,3, 4-oxadiazole-2-thione-5- carboxylate prepared in Step 77b and coupled to (R)-(+)-3-aminoquinuclidine as described in Example 66, making non-critical variations, to afford material that is purified by silica gel chromatography (10% MeOH/CHCl3 + 0.5% NH4OH). The hydrochloride salt is prepared upon crystallization of the desired product from 1M HCl/Et2O (65mg, 42%). MS for CnHι6N4O2S (ESI) (M+H)+ m/z 269.
Example 79 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-chlorophenyl)-l,3-oxazole-2- carboxamide 4-methylbenzenesulfonate:
Step 79a: Preparation of 2-amino-l-(3-chlorophenyl)ethanone hydrochloride.
A mixture of 3-chlorophenylacyl bromide (5.18 g, 22.2 mmol, leq), sodium diformylimide (2.11 g, 22.2 mmol, 1 eq) and CH3CΝ (125 mL) is heated in an 80°C oil bath. After 3.5 h, the mixture is filtered and evaporated. The residue is treated with EtOH (40 mL) and HCI (10 mL, 12 N). The mixture was then heated in a 50°C water bath for 30 min and evaporated. The resulting solid is triturated with acetone and collected by filtration to afford the title compound (2.86 g, 62%). MS (ESI) for C8H8ClNO m/z 170 (M+H)+.
Step 79b: Preparation of ethyl [[2-(3-chlorophenyl)-2-oxoethyl] amino](oxo) acetate.
A mixture of 2-amino-l-(3-chlorophenyl)ethanone hydrochloride from Step 79a (2.83 g, 13.7 mmol, 1 eq), ethyl chlorooxoacetate (1.87 g, 13.7 mmol, 1 eq), and CH2C12 (40 mL) is cooled in an ice-H2O bath. The mixture is treated with a solution of TEA (4.0 mL, 29 mmol, 2.1 eq) in CH2C12 (20 mL), and the reaction is warmed to room temperature overnight. Water is added and the organic layer is separated, dried over MgSO4, filtered, and evaporated. The resulting solid is triturated with hexane/2- propanol and dried in vaeuo to provide the title compound (2.70 g, 72%). MS (ESI) for C12Hι2ClNO4 m/z 270 (M+H)+.
Step 79c: Preparation of ethyl 5-(3-chlorophenyl)- 1 ,3-oxazole-2-carboxylate.
A mixture of the product from Step 79b (1.28 g, 4.70 mmol, 1 eq), benzene (8 mL), and POCl3 (2.0 mL, 21 mmol) is heated under reflux for 65 h and cooled. The mixture is then evaporated and extracted between CHC13 and water. The organic layer is separated, dried over MgSO4, filtered, and evaporated. The residue is crystallized from EtOH to give the title product (0.61 g, 51%). MS (ESI) for Cι2Hι0ClNO3 m/z 252 (M+H)+. Step 79d: Preparation of N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- chlorophenyl)- 1 ,3-oxazole-2-carboxamide 4-methylbenzenesulfonate.
A mixture of the product from Step 79c (0.419 g, 1.66 mmol, 1.0 eq), (R)-(+)- 3-aminoquinuclidine (0.221 g, 1.75 mmol, 1.05 eq) and EtOH (4.0 mL) is heated under reflux. After 64 h, the mixture is cooled and the contents are filtered through glass wool into -toluenesulfonic acid monohydrate (0.315g, 1.65 mmol, 1.0 eq). The resulting solid is filtered and dried in vaeuo to afford the title compound (0.59 g, 65%). HRMS (FAB) calculated for Cι7H,8ClΝ3O2+Hι 332.1165, found 332.1180.
Examples 80-88 The following compounds are prepared from the requisite acylhalides according to the procedures for Example 79, making non-critical variations. For some examples, the product of Step 79a is commercially available.
Example 80: N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(3-methoxyphenyl)-l ,3- oxazole-2-carboxamide 4-methylbenzenesulfonate (from 2-bromo-l-(3- methoxyphenyl)ethanone). Yield 20%. HRMS (FAB) calculated for Cι8H2,N3O3+Hι 328.1661, found 328.1660.
Example 81 : N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-nitrophenyl)-l,3-oxazole-2- carboxamide 4-methylbenzenesulfonate (from 2-amino-l-(3-nitrophenyl)ethanone hydrochloride). Yield 8%. HRMS (FAB) calculated for Cι7Hι8N4O4+H, 343.1406, found 343.1405.
Example 82: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-methoxyphenyl)-l,3- oxazole-2-carboxamide 4-methylbenzenesulfonate (from 2-amino-l-(4- methoxyphenyl)ethanone hydrochloride). Yield 23%. HRMS (FAB) calculated for CΛiNsO hH! 328.1661, found 328.1662. Example 83 : N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(2-nitrophenyl)- 1 ,3-oxazole-2- carboxamide 4-methylbenzenesulfonate (from 2-bromo-l-(2-nitrophenyl)ethanone). Yield 4%. HRMS (FAB) calculated for C,7Hι8N4O4+H, 343.1406, found 343.1405.
Example 84: N-[(3R)-l-azabicyclo[2.2.2]ocl-3-yl]-5-(2-methoxyphenyl)-l,3- oxazole-2-carboxamide 4-methylbenzenesulfonate (from 2-bromo-l-(2- methoxyphenyl)ethanone). Yield 13%. HRMS (FAB) calculated for C)8H2ιN3O3+H] 328.1661, found 328.1661.
Example 85: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-fluorophenyl)-l,3-oxazolc- 2-carboxamide 4-methylbenzenesulfonate (from 2-bromo-l-(4-fluorophenyl)- ethanone). Yield 5%. HRMS (FAB) calculated for Cι7Hι8FN3O2+Hι 316.1461, found 316.1470.
Example 86: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-chlorophenyl)-l,3-oxazole- 2-carboxamide 4-methylbenzenesulfonate (from 2-bromo-l-(2-chloiOphenyl)- ethanone). Yield 10%. HRMS (FAB) calculated for Cι7H,8ClN3O2-i-Hι 332.1165, found 332.1168.
Example 87: N-[(3R)- l-azabicyclo[2.2.2]oct-3-yl]-5-(3-cyanophenyl)-l ,3-oxazole- 2-carboxamide 4-methylbenzenesulfonate (from 3-(bromoacetyl)-benzonitrile). Yield 3%. HRMS (FAB) calculated for C18H2ιN3O3+Hι 323.1508, found 323.1516.
Example 88: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-bromophenyl)-l,3-oxazole- 2-carboxamide 4-methylbenzenesulfonate (from 2-amino-l-(4-bromophenyl)- ethanone hydrochloride). Yield 6%. HRMS (FAB) calculated for CπH^B N^+H] 376.0661, found 376.0660.
Example 89 N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-4-methyl-5-phenyl-l,3-thiazole-2- carboxamide 4-methylbenzenesulfonate:
S tep 89a: Preparation of 2- amino- 1 -phenylpropan- 1 -one hydrochloride.
2-Bromo-l-phenylpropan-l-one (8.97g, 42. Immol, leq) is added dropwise to a suspension of diformylimide sodium salt (4.80g, 50.5mmol, 1.2eq) in 80mL CH3CN. The reaction is stirred for 60h at 70-75°C. The hot mixture is filtered to remove the salts and the solids are washed with CH CN. The combined filtrates are concentrated in vaeuo, dissolved in 40mL 6N HCI and heated under reflux for 0.75h. The solvents are removed under reduced pressure and the product is recrystallized from IPA to give 2-amino-l -phenylpropan- 1 -one hydrochloride (6.15g, 79%). MS (ESI) for C9H, |NO m/z 150.2 (M+H)+. Step 89b: Preparation of ethyl [(l-methyl-2-oxo-2-phenylethyl)amino] (oxo)acetate.
TEA (3.22mL, 0.023 lmol, 2. leq) is added dropwise to a suspension of the product from Step 89a (2.05g, 1 Ommol, leq) and ethyl oxalyl chloride (1.24mL, 1 Ommol, leq) in 50mL CH2CI2 in an ice/water bath. The mixture is allowed to slowly warm to room temperature. After stirring overnight, water and 20mL IN HCI are added. The aqueous layer is extracted with CH2C12. The combined organic layers are dried over MgSO , filtered and concentrated to give ethyl [( 1 -methyl-2-oxo-2- phenylethyl)amino](oxo)acetate as a yellow oil (2.58g, 94%). MS (ESI) for Cι3H,5NO4 m/z 250.2 (M+H)+. Step 89c: Preparation of ethyl 4-methyl-5-phenyl-l,3-thiazole-2-carboxylate.
The product from Step 89b (2.58g, 10.4mmol, leq) and P2S5 (4.83g, 10.9mmol, 1.05eq) are suspended in 30mL CHC13. The mixture is heated under reflux. After 12h, water and solid K2CO are carefully added until all material dissolves. The aqueous layer is made sufficiently basic with IN NaOH (pH more than 10) and extracted with EtOAc. The combined organic layers are washed with IN
NaOH and brine, dried over MgSO , filtered and concentrated to give ethyl 4-methyl- 5-phenyl-l,3-thiazole-2-carboxylate as a yellow oil (2.5 lg, 98%). MS (ESI) for C,3Hι3NO2S m/z 248.1 (M+H)+.
Step 89d: Preparation of N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-4-methyl-5- phenyl- l,3-thiazole-2-carboxamide 4-methylbenzenesulfonate. The freebase of (R)-3-aminoquinuclidine (l.Og, 5.02mmol, 2.26eq) dissolved in THF (~5mL) is added to a solution of the product from Step 89c (0.55g, 2.22mmol, leq) in lOmL EtOH. The mixture is heated under reflux. After 48h, the mixture is cooled and concentrated in vaeuo. The residue is purified by silica gel chromatography using a Biotage Flash 40S column (90:9: 1 CHCl3/MeOH/NH4OH) to provide N-[(3R)-1 -azabicyclo[2.2.2]oct-3-yl]-4-methyl-5-phenyl-l,3-thiazole-2- carboxamide (0.40g, 55%) as a yellow oil. The p-toluenesulfonic acid salt of the product is made and recrystallized from IP A/ether to give the product as light yellow solid. MS (ESI) for C,8H2ιN3OS m/z 328.2 (M+H)+. Examples 90-102
The following compounds are prepared from the requisite ethyl 5-substituted-l,3- thiazole-2-carboxylates according to the procedures outlined in Example 79 or Example 66 (thiadiazole amide), making non-critical variations.
Example 90: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-phenyl-l,3-thiazole-2- carboxamide (from 2-amino-l-phenylethanone hydrochloride). Yield 36%. HRMS (FAB) calculated for Cl7H,9N3OS+H, 314.1327, found 314.1330.
Example 91: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-bromophenyl)-l,3-thiazole- 2-carboxamide 4-methylbenzenesulfonate (from 2-amino-l-(4-bromophenyl)- ethanone hydrochloride). Yield 18%. HRMS (FAB) calculated for C,7H,8BrN3OS+H, 392.0432, found 392.0423.
Example 92: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-nitrophenyl)-l,3-thiazole-2- carboxamide 4-methylbenzenesulfonate (from 2-amino-l-(3-nitrophenyl)-ethanone hydrochloride). Yield 47%. HRMS (FAB) calculated for Cι7H,8N4O3S+H, 359.1178, found 359.1165. Example 93: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-methoxyphenyl)-l,3- thiazole-2-carboxamide 4-methylbenzenesulfonate (from 2-bromo-l-(3- methoxyphenyl)-ethanone). Yield 14%. HRMS (FAB) calculated for Cι8H2iN3O2S+H, 344.1432, found 344.1423.
Example 94: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-chlorophenyl)-l,3-thiazole- 2-carboxamide 4-methylbenzenesulfonate (from 2-bromo- 1 -(2-chlorophenyl)- ethanone). Yield 28%. HRMS (FAB) calculated for C,7Hι8ClN3OS+Hι 348.0937, found 348.0947.
Example 95: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-fluorophenyl)-l,3-thiazole- 2-carboxamide 4-melhylbenzenesulfonate (from 2-bromo-l-(4-fluorophenyl)- ethanone). Yield 16%. HRMS (FAB) calculated for C,7H) 8FN3OS+H, 332.1233, found 332.1233.
Example 96: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methoxyphenyl)- 1 ,3- thiazole-2-carboxamide 4-methylbenzenesulfonate (from 2-bromo-l-(2- methoxyphenyl)ethanone). Yield 14%. HRMS (FAB) calculated for Cι8H2ιN3O2S+Hι 344.1432, found 344.1436.
Example 97: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-chlorophenyl)-l,3-thiazole- 2-carboxamide 4-methylbenzenesulfonate (from 2-bromo-l-(4-chlorophenyl)- ethanone). Yield 12%. HRMS (FAB) calculated for Cι7H18ClN3OS+Hι 348.0937, found 348.0934. Example 98: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-methyl-l,3-thiazole-2- carboxamide 4-methylbenzenesulfonate (from 1-chloroacetone). Yield 2%. HRMS (FAB) calculated for C,2Hl7N3OS+H, 252.1171, found 252.1171.
Example 99: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-chlorophenyl)-l,3-thiazole- 2-carboxamide 4-methylbenzenesulfonate (from 2-bromo-l-(3-chlorophenyl)- ethanone). Yield 10%. HRMS (FAB) calculated for Cι7Hι8ClN3OS+Hι 348.0937, found 348.0936.
Example 100: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-fluorophenyl)-l,3-thiazole- 2-carboxamide 4-methylbenzenesulfonate (from 2-bromo-l-(2-fluorophenyl)- ethanone). Yield 0.4%. MS (ESI) for C,7H]8FN3OS m/z 332.2 (M+H)+. ExampleTOl: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-fluorophenyl)-l,3-thiazole- 2-carboxamide 4-methylbenzenesulfonate (from 2-bromo-l-(3-fluorophenyl)- ethanone). Yield 6%. MS (ESI) for C,7Hι8FN3OS m z 332.2 (M+H)+.
Example 102: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-thien-2-yl- 1 ,3-thiazole-2- carboxamide 4-methylbenzenesulfonate (from 2-bromo-l-thien-2-yl-ethanone). Yield 10%. MS (ESI) for C15Hι7N3OS2 m/z 320.2 (M+H)+. Example 103
N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-phenyl-furan-2-carboxamide 4- methylbenzenesulfonate:
Step 103a: Synthesis of 5-phenyl-furan-2-carbaldehyde.
A solution of 5-bromo-furan-2-carbaldehyde (1.08 g, 6.16 mmol, 1 eq), phenylboronic acid (0.90 g, 7.39 mmol, 1.1 eq), tetrabutylammonium bromide (1.99 g, 6.16 mmol, 1 eq), palladium acetate (30 mg, 0.0.12 mmol 0.02 eq), K2CO3 (2.13 g, 15.4 mmol, 2.5 eq) in water (10 mL) is stirred under nitrogen at room temperature overnight. Upon completion, the reaction mixture turns into a black mass floating in the solution. The reaction is diluted with 40 mL water and extracted with EtOAc (3 x 100 mL). The organic layers are combined and stirred with charcoal for 30 min, then dried over MgSO4 and filtered. The solvent is removed under reduced pressure to give an oil. The product is purified by silica gel chromatography using a Biotage Flash 40M column (10% EtO Ac/heptane). Yield 70.1 %. HRMS (FAB) calculated for CπH8O2+H 173.0603, found 173.0607.
Step 103b: Synthesis of 5-phenyl-furan-2-carboxylic acid.
To a solution of the product from Step 103a (0.650 g, 3.78 mmol, 1 eq) in water (5.5 mL), t-BuOH (18.0 mL), and THF (18.0 mL) is added 2-methyl-2-butene (3.2 mL, 30.2 mmol, 8 eq), potassium phosphate monobasic ( 1.54 g, 11.3 mmol, 3 eq), then NaClO2 (1.03 g, 11.3 mmol, 3 eq) in that order. After four hours, the reaction is complete and diluted with 1 N NaOH (100 mL). The aqueous solution is extracted with ether (2 x 100 mL), and the aqueous layer is acidified with cone. HCI. The resulting solution is extracted with CH2C12 (3 x 100 mL). The organic layers are dried over MgSO4, and the solvent removed. The product is purified by silica gel chromatography using a Biotage Flash 40M column (10% EtO Ac/1% formic acid/heptane). The solid remaining after removal of the solvent is filtered and recrystallized from EtOH and water to give the acid as a white crystalline solid (0.499 g, 70.2%). HRMS (FAB) calculated for C, ,H8O3+H 189.0473, found 189.0403.
Step 103c: Preparation of N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-phenyl-2- furamidc 4-methylbenzenesulfonate. The product of Step 103b (0.499 g, 2.65 mmol, 1 eq) and the dihydrochloride salt of R-(+)-aminoquinuclidine (0.528 g, 2.65 mmol, 1 eq) in DIEA (1.38 mL, 7.96 mmol, 3 eq), in THF (17.6 mL) are cooled to 0°C and HATU (1.01 g, 2.65 mmol, 1 eq) is added. The reaction is stirred overnight. The reaction is diluted with CH2C12 (150 mL). The organic is washed with IN NaOH, satd NaHCO3, and water. The organic layer is dried over MgSO4, and the solvent is removed under reduced pressure. The product is purified by silica gel chromatography using a Biotage Flash 40M column (8%MeOH/l%NH4OH/CH2Cl2). The p-toluene sulfonic acid salt is made, which gave an amorphous solid (1.06 g, 42%). HRMS (FAB) calculated for C,8H2oN2O2+Hi 297.1603, found 297.1602.
Examples 104-130
The following compounds are prepared from the requisite boronic acid, furaldehyde, or furan-carboxylic acid according to the procedures for Example 103, making non-critical variations. Example 104: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-chlorophenyl)-furan-2- carboxamide toluene sulfonate (from 5-(2-chlorophenyl)-2-furaldehyde). Yield 46%. HRMS (FAB) calculated for C,8H,9ClN2O2+H, 331.1213, found 331.1208.
Example 105: N-[(3R)- l-azabicyclo[2.2.2]oct-3-yl]-5-(3-chlorophenyl)-furan-2- carboxamide toluene sulfonate (from 5-(3-chlorophenyl)-2-furaldehyde). Yield 72%. HRMS (FAB) calculated for Cι8H19ClN2O2+H, 331.1213, found 331.1212.
Example 106: N-[(3R)- l-azabicyclo[2.2.2]oct-3-yl]-5-(4-chlorophenyl)-furan-2- carboxamide fumarate (from 5-(4-chlorophenyl)-2-furoic acid). Yield 43%. HRMS (FAB) calculated for C,8H,9ClN2O2+Hι 331.1213, found 331.1216.
Example 107: N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(4-bromophenyl)-furan-2- carboxamide toluene sulfonate (from 5-(4-bromophenyl)-2-furaldehyde). Yield 38%.
HRMS (FAB) calculated for C18H19BrN2O2+Hι 375.0708, found 375.0713. Example 108: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[2-(trifluoromethyl)-phenyl]- furan-2-carboxamide fumarate (from 5-(2-(trifluoromethyl)-phenyl)-furan-2- carboxylic acid). Yield 78%. HRMS (FAB) calculated for C,9Hι9F N2O2+Hι 365.1477, found 365.1468. Example 109: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[3-(trifluoromethyl)-phenyl]- furan-2-carboxamide fumarate (from 5-(3-(trifluoromethyl)-phenyl)-furan-2- carboxaldehyde). Yield 31%. MS (ESI) for (M+H)+.
Example 110: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-nitrophenyl)-furan-2- carboxamide 4-methylbenzenesulfonate (from 5-(2-nitro-phenyl)-furan-2-carboxylic acid). Yield 82%. HRMS (FAB) calculated for C,8Hι9N3O4+H, 342.1454, found 342.1469.
Example 111: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-nitrophenyl)-furan-2- carboxamide 4-methylbenzenesulfonate (from 5-(3-nitro-phenyl)-furan-2-carboxylic acid). Yield 66%. HRMS (FAB) calculated for C18Hι9N3O4+Hι 342.1454, found 342.1463. '
Example 112: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-nitrophenyl)-furan-2- carboxamide 4-methylbenzenesulfonate (from 5-(4-nitro-phenyl)-furan-2-carboxylic acid). Yield 52%. HRMS (FAB) calculated for Cι8H]9N3O4+H, 342.1454, found 342.1465. Example 113: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-fluorophenyl)-furan-2- carboxamide 4-methylbenzenesulfonate (from 2-fluorophenylboronic acid). Yield 12%. HRMS (FAB) calculated for C18H19FN2O2+H, 315.1508, found 315.1519.
Example 114: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-fluorophenyl)-furan-2- carboxamide 4-methylbenzenesulfonate (from 3-fluorophenylboronic acid). Yield 29%. HRMS (FAB) calculated for C,8Hι9FN2O2-ι-Hι 315.1508, found 315.1519.
Example 115: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-fluorophenyl)-furan-2- carboxamide 4-methylbenzenesulfonate (from 4-fluorophenylboronic acid). Yield 16%. HRMS (FAB) calculated for C,8Hι9FN2O2+H, 315.1508, found 315.1500.
Example 116: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2,4-difluorophenyl)-furan-2- carboxamide hydrochloride (from 2,4-difluorophenylboronic acid). Yield 46%. MS (ESI) for C18Hι8F2N2O2 m/z 333.2 (M+H)+. Example 117: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2,5-difluorophenyl)-furan-2- carboxamide hydrochloride (from 2,5-difluorophenylboronic acid). Yield 33%. MS (ESI) for Cι8HI8F2N2O2 m/z 333.2 (M+H)+.
Example 118: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methoxyphenyl)-furan-2- carboxamide 4-methylbenzenesulfonate (from 2-methoxyphenylboronic acid). Yield 63%. HRMS (FAB) calculated for Cι9H22N2O3+H, 327.1708, found 327.1717.
Example 119: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-methoxyphenyl)-furan-2- carboxamide 4-methylbenzenesulfonate (from 3-methoxyphenylboronic acid). Yield 83%. HRMS (FAB) calculated for Cι9H22N2O3+Hι 327.1708, found 327.1714. Example 120: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[3-(trifluoromethoxy)phenyl]- furan-2-carboxamide 4-methylbenzenesulfonate (from 3-trifluoromethoxyphenyl- boronic acid). Yield 58%. HRMS (FAB) calculated for C^H^N^-i-H! 381.1426, found 381.1440.
Example 121: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[2-chloro-5-(trifluoromethyl)- phenyl] -furan-2-carboxamide fumaric acid (from 2-chloro-5-trifluoromethylphenyl- boronic acid). Yield 55%. HRMS (FAB) calculated for Ci9Hi8ClF N2O2+Hi 399.1087, found 399.1097.
Example 122: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-fluoro-3-methylphenyl)- furan-2-carboxamide 4-methylbenzenesulfonate (from 4-fluoro-3-methylphenyl- boronic acid). Yield 77%. HRMS (FAB) calculated for Cι9H2ιFN2O2+Hι 329.1665, found 329.1661.
Example 123: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-cyanophenyl)-furan-2- carboxamide hydrochloride (from 4-cyanophenyl-boronic acid). Yield 31%. MS (ESI) for Cι8Hι9N3O2 m/z 322.2 (M+H)+. Example 124: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-thien-2-yl-furan-2-carboxamide 4-methylbenzenesulfonate (from 2-thiophene-boronic acid). MS (ESI) for Cl6Hι8N2O2S m/z 303.2 (M+H)+.
Example 125: N-[(3R)-l-azabicycIo[2.2.2]oct-3-yl]-5-thien-3-yl-furan-2-carboxamide 4-methylbenzenesulfonate (from 3-thiophene-boronic acid). MS (ESI) for Cι6H,8N2O2S m/z 303.2 (M+H)+. Example 126: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-bromo-furan-2-caι-boxamide 4- methylbenzenesulfonate (from 5-bromo-furan-2-carboxylic acid). Yield 75%. MS (ESI) for Cι H,5N2O2Br m/z 299.0 (M+H)+.
Example 127: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-nitro-furan-2 -carboxamide hydrochloride (from 5-nitro-furan-2-carboxylic acid). Yield 63%. MS (ESI) for Cι2H,5N3O4 m/z 265.1 (M+H)+.
Example 128: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-4,5-dimethyl-furan-2- carboxamide hydrochloride (from 4,5-dimethyl-furan-2-carboxylic acid). Yield 75%. HRMS (FAB) calculated for Cι4H2oN2O2+H 249.1603, found 249.1593. Example 129: N-[(3R)-l-azabicyclo[2.2.2Joct-3-yl]-5-(4-chloro-2-nitrophenyl)-furan- 2-carboxamide hydrochloride (from 4-chloro-2-nitrophenyl)-furan-2-carboxylic acid). Yield 7%. HRMS (FAB) calculated for Cι8Hι8ClN3O4+H 376.1064, found 376.1067.
Example 130: N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(4-methyl-2-nitrophenyl)- furan-2-carboxamide hydrochloride (from 4-methyl-2-nitrophenyl)-furan-2-carboxylic acid). Yield 56%. MS (ESI) for C!9H2ιN3O4 m/z 356.2 (M+H)+.
Example 131
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2,3-difluorophenyl)-furan-2- carboxamide 4-methylbenzenesulfonate:
Step 131a: A solution of N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-bromo-furan-2- carboxamide (0.258 g, 0.85 mmol, 1 eq), 2,3-difluorophenylboiOnic acid (0.147g, 0.93 mmol, 1.1 eq), tetrabutylammonium bromide (0.244 g, 0.85 mmol, 1 eq), palladium acetate (3.8 mg, 0.017 mmol, 0.02 eq), K2CO3 (0.41 g, 2.97 mmol, 3.5 mmol) and water 1.4 mL is stirred under argon overnight. The reaction forms a brownish insoluble lump, but is complete by HPLC. The reaction is purified by silica gel chromatography using a Biotage Flash 40 M column (10%MeOH/l%TEA/CH2Cl2).
The p-toluenesulfonic acid salt of 5-(2,3-difluoro-phenyl)-furan-2-carboxylic acid (1- aza-bicyclo[2.2:2Joct-3-yl)-amide is synthesized and recrystallized from IPA MeOH/ether, and the product is recovered as a crystalline solid (0.135 g, 31%). HRMS (FAB) calculated for Cι8Hι8F2N2O2+Hι 333.1414, found 333.1418.
Examples 132-146 The following compounds are prepared from the requisite boronic acid and N-
[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-bromo-furan-2-carboxamide as stated for Example 131, making non-critical valuations.
Example 132: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,4-difluorophenyl)-furan-2- carboxamide hydrochloride (from 3,4-difluorophenyl-boronic acid). Yield 24%. HRMS (FAB) calculated for C,8Hι8F2N2θ2+H, 333.1414, found 333.1418.
Example 133: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,5-difluorophenyl)-furan-2- carboxamide hydrochloride (from 3, 5-difluorophenyl -boronic acid). Yield 60%. HRMS (FAB) calculated for C,8Hι8F2N2O2+Hι 333.1414, found 333.1424.
Example 134: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-methoxy-phenyl)-furan-2- carboxamide hydrochloride (from 4-methoxy-phenyl-boronic acid). Yield 17%. HRMS (FAB) calculated for Cl9H22N2O3+Hι 327.1708, found 327.1707.
Example 135: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methylphenyl)-furan-2- carboxamide 4-methylbenzenesulfonate (from σ-tolylboronic acid). Yield 26%. HRMS (FAB) calculated for Cι9H22N2O2+Hι 311.1759, found 311.1763. Example 136: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-methylphenyl)-furan-2- carboxamide 4-methylbenzenesulfonate (from m-tolylboronic acid). HRMS (FAB) calculated for Cι9H22N2O2+H, 311.1759, found 311.1752.
Example 137: N-[(3R)- l-azabicyclo[2.2.2]oct-3-yl]-5-(4-methylphenyl)-furan-2- carboxamide 4-methylbenzenesulfonate (from -tolylboronic acid). Yield 10 %. HRMS (FAB) calculated for Cι9H22N2O2+Hι 311.1759, found 311.1752.
Example 138: N-[(3R)- l-azabicyclo[2.2.2]oct-3-yl]-5-[2-(trifluoromethoxy)phenyl]- furan-2-carboxamide 4-methylbenzenesulfonate (from 2-(trifluoromethoxy)phenyl- boronic acid). Yield 19%. MS (ESI) for Cι9Hι9F3N2O3 m/z 381.3 (M + H)+.
Example 139: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[4-(trifluoromethoxy)phenyl]- furan-2-carboxamide 4-methylbenzenesulfonate (from 4-trifluoromethoxyphenyl- boronic acid). Yield 61%. HRMS (FAB) calculated for C19H19F3N2O3+H1 381.1426, found 381.1434.
Example 140: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-tert-butylphenyl)-furan-2- carboxamide 4-methylbenzenesulfonate (from 4-tert-butylphenyl-boronic acid). Yield 73%. HRMS (FAB) calculated for C22H28N2O2+Hι 353.2229, found 353.2218.
Example 141 : N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(l-benzothien-2-yl)-furan-2- carboxamide 4-methylbenzenesulfonate (from benzothiophene-2-boronic acid). Yield 17%. HRMS (FAB) calculated for C20H20N2O2S+Hι 353.1324, found 353.1326.
Example 142: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-quinolin-3-yl-furan-2- carboxamide 4-methylbenzenesulfonate (from 3-quinoline-boronic acid). Yield 9%. MS (ESI) for C21H21N3O2 m/z 348.3 (M+H)+.
Example 143: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-ethylphenyl)-furan-2- carboxamide hydrochloride (from 4-ethylphenyl-boronic acid). MS (ESI) for C20H24N2O2 m/z 325.3 (M+H)+. Example 144: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-isopropylphenyl)-furan-2- carboxamide hydrochloride (from 4-isopropylphenyl-boronic acid). MS (ESI) for C2ιH26N2O2 m/z 339.3 (M+H)+.
Example 145: N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(3-fluoro-4-methoxyphenyl)- furan-2-carboxamide hydrochloride (from 3-fluoro-4-methoxy-boronic acid). MS (ESI) for Cι9H21FN2O2 m/z 345.2 (M+H)+.
Example 146: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(l-benzofuran-2-yl)-furan-2- carboxamide 4-methylbenzenesulfonate (from benzofuran-2-boronic acid). MS (ESI) for C20H20N2O3 m/z 337.2 (M+H)+.
Example 147
5-(2-Aminophenyl)-N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-furan-2- caι-boxamide bis(4-methylbenzenesulfonate):
Step 147a: To a solution of N-[(3R)-l-aza-bicyclo[2.2.2]oct-3-ylj-5-(2-nitro- phenyl)-furan-2-carboxamide (1.65 g, 3.22 mmol, 1 eq) in 100 mL EtOH was added Pd/C (50 mg). This mixture was placed on a Parr shaker under 40 psi hydrogen overnight. The palladium is removed by filtration over a pad of celite, and the solvent is removed. The p-toluenesulfonic acid salt of 5-(2-amino-phenyl)-furan-2-carboxylic acid (l-aza-bicyclo[2.2.2]oct-3-yl)-amide is purified by recrystallization from IPA/MeOH/ether to give a crystalline solid (0.783 g, 50%). HRMS (FAB) calculated for Cι8H2ιN3O2+Hι 312.1712, found 312.1717.
Examples 148-149
The following compounds are prepared from the requisite nitro amide according to the procedures for Example 147, making non-critical variations. , Example 148: 5-(4-aminophenyl)-N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-furan-2- carboxamide tris(4-methylbenzenesulfonate) (from N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(4-nitrophenyl)-2-furamide). Yield 84%. HRMS (FAB) calculated for CI8H2,N3O2+Hι 312.1712, found 312.1727.
Example 149: 5-(2-amino-4-methylphenyl)-N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]- furan-2-carboxamide dihydrochloride (from 5-(4-methyl-2-nirophenyl)-N-[(3R)-l- azabicyclo[2.2.2]oct-3-yl]-2-furamide dihydrochloride). Yield 55%. HRMS (FAB) calculated for C19H23N3O2+H 326.1868, found 326.1871.
Example 150
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(phenylethynyl)-furan-2-carboxamide 4-methylbenzenesulfonate:
Step 150a: Preparation of 5-phenylethylnyl-furan-2-aldehyde.
To a solution of 5-bromofuraldehyde (1.0 g, 5.71 mmol, leq), copper (I) iodide (0.163 g, 0.857 mmol, 0.15 eq), trans-dichlorobis(triphenylphosphine) palladium(π) (0.20 g, 0.287 mmol, 0.05 eq), and TEA (3.98 mL, 28.6 mmol, 5 eq) in THF (45 mL) is added dropwise phenyl acetylene (1.25 mL, 11.4 mmol, 2 eq). After 48 hours, the reaction appears complete. The reaction is filtered over a pad of celite, and the solvent is removed under reduced pressure. The reaction is purified by silica gel chromatography using a Biotage Flash 40M column (10% EtOAc/heptane) to give a yellow orange crystalline solid (0.765 g, 68.3%). MS (ESI) for Cj3H8O2 m/z 197.1 (M+H)+.
Step 150b: Preparation of N-[(3R)-l-azabicyclo[2.2.2]oct-3-yI]-5-(phenylethynyl)- furan-2-carboxamide 4-methylbenzcnesulfonate.
Following the general procedure of Example 103, making non-critical variations but starting with 5-phenylethylnyl-furan-2-aldehyde, N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(phenylethynyl)-furan-2-carboxamide 4- methylbenzenesulfonate is synthesized and recovered as a crystalline solid (0.692 g, 74%). HRMS (FAB) calculated for C20H20N2O2+H1 321.1603, found 321.1595.
Example 151
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-phenoxy-furan-2-carboxamide 4- methylbenzenesulfonate:
Step 151a: Preparation of N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-phenoxy-furan- 2-carboxamide 4-methylbenzenesulfonate. A solution of N-[(3R)-l-aza-bicyclo[2.2.2]oct-3-yl]-5-bromo-furan-2- carboxamide (0.200 g, 0.42 mmol, 1 eq), sodium phenoxide (0.500 g, 4.3 mmol, 10.1 eq), in DMSO (5 mL) is stirred under nitrogen at room temperature overnight. The reaction is diluted with 25 mL water and extracted with CH2C12 (50 mL). The organic layer is washed with water (3x25 mL), satd NaHCO3, brine, and dried over MgSO . The p-loluenesulfonic acid salt is prepared and recrystallized from IPA MeOH/ether, and the product is recovered as a crystalline solid (70%). HRMS (FAB) calculated for Cι8H20N2O3+H 313.1552, found 313.1558.
Example 152
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-l-methyl-5-phenyl-lH-pyrrole-2- carboxamide:
Step 152a: Preparation of methyl 5-bromo- 1 -methyl- 1 H-pyrrole-2-carboxylate. To a dry flask is added methyl 1 -methyl- lH-pyrrole-2-carboxylate (12.0 g,
86.4mmol) and 150 mL of dry CH2C12, and the flask is wrapped in foil and purged with nitrogen. N-bromosuccinimide (16.2 g, 90.7 mmol) is added in one portion and the mixture is stirred at room temperature for 0.5 h. The reaction mixture is washed with water (50 mL) and brine (50 mL), dried over MgSO , filtered, and concentrated under reduced pressure. Fractional distillation gives 12.0 g of methyl 5-bromo- 1- methyl- lH-pyrrole-2-carboxy late as a yellow oil (64% yield). MS for C7H8ΝO2Br (ESI) (M)+ m/z 217.1.
Step 152b: Preparation of methyl l-methyl-5-phenyl-lH-pyrrole-2-carboxylate.
The product from step 152a is added to a solution of tetrakis(triphenylphosphine)palladium(0) (0.530 g, 0.459mmol) in 90 mL of ethylene glycol dimethyl ether. The resulting solution is stirred under nitrogen for 5 min and then phenylboronic acid (1.34 g, 11.0 mmol) is added followed by a solution of Na2CO3 (19.5 g, 183 mmol) in 90 mL of H2O. The mixture is heated at reflux for 24 hours. The reaction mixture is allowed to cool to rt, 100 L of CH2C12 is added, and the layers are separated. The aqueous layer is extracted with CH2C12 (3 x 50 mL) and combined organic layers are dried over MgSO , filtered, and concentrated in vaeuo. The crade product is purified by flash column chromatography (5 % EtOAc in hexane) to give 1.89 g of methyl l-methyl-5-phenyl-lH-pyrrole-2-carboxylate as a yellow oil (96% yield). MS for C,3Hι3NO2 (ESI) (M+H)+ m/z 216.1. Step 152c: Preparation of l-methyl-5-phenyl-lH-pyιτole-2-carboxylic acid.
Lithium hydroxide (1.39 g, 33.2 mmol) is added to a solution of the product from Step 152b (1.43 g, 6.64 mmol) in 96 mL of a 1.25:1:1 H2O:MeOH:THF solvent mixture. The reaction is stirred at 50°C for 2 h. Aqueous HCI (IN, 50 mL) is added and the resultant precipitate is collected by filtration, washed with water, and dried to give 0.851 g of l-methyl-5-phenyl-lH-pyrrole-2-carboxylic acid as a tan solid (64% yield). MS for C,2H, ,NO2 (ESI) (M-H)+ m/z 200.1.
Step 152d: Preparation of N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-l-methyl-5- phenyl- 1 H-ρyrrole-2-carboxamide.
To a solution of (7?)-(+)-3-aminoquinuclidine dihydrochloride (0.831 g, 4.17 mmol) in 55 mL of dry THF is added DIEA (2.08 mL, 11.9 mmol). After allowing the mixture to stir under nitrogen for 15 min, the product from Step 152c (0.800 g, 3.98 mmol) is added. The mixture is allowed to stir for another 15 min, cooled in an ice bath, and HATU (1.59 g, 4.17 mmol) is added. The reaction mixture is stirred on an ice bath for 0.5 h, then at rt for an additional 2 h. The mixture is diluted with 60 mL CH2C12, washed with 50 mL of IN NaOH and 50 mL of satd NaHCO3 solution, dried over MgSO4, filtered, and concentrated in vaeuo. The crude product is purified by flash column chromatography (10 % EtOAc, 1 % NH OH in CH2C12) to give 0.383 grams of N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-l-methyl-5-phenyl-lH-pyrrole-2- carboxamide (31%) as a white solid. MS for Cι9H23N3O (ESI) (M+H)+ m/z 310.3.
Examples 153-157
These examples are prepared using the coupling procedure for Example 103c, making non-critical variations and using the appropriate carboxylic acids.
Example 153: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-ρhenyl-l,3-oxazole-2- carboxamide 4-methylbenzenesulfonate (from 5-phenyl- 1 ,3-oxazole-2-carboxylic acid, see Saito, S.; Tanaka, C. J. Pharm. Sci. Japan 76, 1956, 305-7). Yield 77%. HRMS (FAB) calculated for Cι7H|9N3O2+H, 298.1555, found 298.1558.
Example 154: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-3-phenyl-l,2,4-oxadiazole-5- carboxamide 4-methylbenzenesulfonate (from 3-phenyl- l,2,4-oxadiazole-5-carboxylic acid, see Wurm. Chem. Ber.; 22; 1889; 3133). Yield 54%. HRMS (FAB) calculated for Cι6H]8Ν4O2+Hι 299.1508, found 299.1512.
Example 155: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-phenyl-l,3-oxazole-5- carboxamide 4-methylbenzenesulfonate (from 2-phenyl- 1 ,3-oxazole-5-carboxylic acid, see Belenlάi, L. I.; Cheskis, M. A.; Zvolinskii, V. P.; Obukhov, A. E. Chem. Heterocycl. Compd. (Engl.TransL); 22; 1986; 654-663). Yield 16%. HRMS (FAB) calculated for C]7Hι9Ν3O2+H, 298.1555, found 298.1555.
Example 156: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-phenyl-l,3-oxazole-4- carboxamide 4-methylbenzenesulfonate (from 2-phenyl- 1 ,3-oxazole-4-carboxylic acid, see Korte, F.; Stoeriko, K. Chem.Ber.; 93; 1960; 1033-1042). Yield 22%. HRMS (FAB) calculated for C,7H)9Ν3O2+Hι 298.1555, found 298.1559.
Example 157: N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-phenylisoxazole-3- carboxamide 4-methylbenzenesulfonate (from 5-phenylisoxazole-3-carboxylic acid, see Vaughan, W.R.; Spencer, J.L. J.Org.Chem.; 25; 1960; 1160-1164). Yield 76%. HRMS (FAB) calculated for C,7Hι9N3O2+Hι 298.1555, found 298.1556.
Example 158 5-Bromo-N-(2-methyl-l-azabicyclo[2.2.2]oct-3-yl)thiophene-2-carboxamide
4-methylbenzenesulfonate:
Step 158a: Preparation of 2-methylenequinuclidin-3-one.
A mixture of 2-methylene-3-quinuclidinone dihydrate hydrochloride (25.7g, 0.1225mol, leq) and K2CO3 (67.0g, 0.4848mol, 4eq) is dissolved in 125mL water and 200mL CH2Cl2 and is stirred vigorously. After 16h, the layers are separated and the aqueous layer is extracted with CH2CI2. The combined organic layers are dried over MgSO4, filtered and concentrated to give 14.75g (88%) of 2-methylenequinuclidin-3- one as a yellow oil. MS (ESI) for C8HπNO m/z 138.1 (M+H)+. Step 158b: Preparation of 2-methylquinuclidin-3-one hydrochloride.
The product from Step 158a (14.75g, 0.1075mol, leq), formic acid (10.4g, 0.2150mol, 2eq) and (Ph3P)3RuCl2 (0.21g, 0.2 Immol) are dissolved in lOOmL THF. The mixture is heated under reflux. Fresh portions of catalyst (0.58g, 0.59mmol, (total)) and formic acid (1.2g, 0.026mol) are added periodically over the course of the reaction. After 72h, the mixture is concentrated in vaeuo. The residue is taken up in ether and excess HCI in dioxane (27mL, 4.0M) is added. The solids are washed with ether and recrystallized from EtOH to afford 14.4g (76%) of 2-methylquinuclidin-3- one hydrochloride as a white solid. MS (ESI) for C8H,3NO m/z 140.2 (M+H)+.
Step 158c: Preparation of (3E/Z)-2-methyl- 1 -azabicyclo[2.2.2Joctan-3-one oxime. The product from Step 158b (3.2g, 23.0mmol, leq) and hydroxylamine hydrochloride (1.6g, 23.0mmol, leq) are dissolved in 20mL EtOH/pyridine (4:1) and stirred at room temperature. After 5 days, water and solid NaOH are added to adjust pH to pH 11. The mixture is extracted with several portions of CHC13. The combined organic layers are dried over MgSO4, filtered and concentrated to give 3.42g (96%) of 2-methyl-l-azabicyclo[2.2.2]octan-3-one oxime as a 1:2.6 mixture of oxime isomers. Partial Η NMR (CDC13, 300 MHz) δ 1.53ppm (d, 2-CH3, 0.8H), 1.38 (d, 2-CH3, 2.2H). MS (ESI) for C8Hι4N2O m/z 154.8 (M+H)+.
Step 158d: Preparation of 2-methylquinuclidin-3-amine dihydrochloride
Sodium (7.0g, 0.303mol, lOeq) is added in portions to a solution of 2-methyl- l-azabicyclo[2.2.2]octan-3-one oxime from Step 158c (4.65g, 30.2mmol, leq) in 100 mL n-propanol. The mixture is heated under reflux. After about 12h, the mixture is cooled and 80mL of water is added. The layers are separated, and the aqueous layer is extracted with CHC13. The combined organic layers are dried over MgSO4 and filtered. An excess of HCI in dioxane (15mL, 4.0M) is added to the solution and the solvent is removed to give 6.0g (93%) of 2-methyIquinuclidin-3-amine dihydrochloride as an oil. A hygroscopic solid was obtained by trituration of the oil in hot IPA. MS (ESI) for C8HI6N2 m/z 141.3 (M+H)+.
Step 158e: Preparation of 5-bromo-N-(2-methyl-l-azabicyclo[2.2.2]oct-3- yl)thiophene-2-carboxamide 4-methylbenzenesulfonate.
5-Bromothiophene-2-carboxylic acid (1.63g, 7.88mmol, leq), the product from Step 158d (1.68g, 7.88mmol, leq) and HATU (2.97g, 7.81mmol, leq) are suspended in 60mL CH3CN. The mixture is cooled in an ice bath and DIEA (8.2mL, 47.28mmol, 6eq) is added dropwise. The mixture is allowed to warm to room temperature and stirred overnight. EtOAc and satd NaHCO3 are added. The aqueous layer is extracted with EtOAc. The combined organic layers are washed with IN NaOH, dried over MgSO4, filtered and concentrated. The residue is purified by silica gel chromatography using a Biotage Flash 40S column (90:9: 1
CHCl3/MeOH/NH4OH) to provide 1.26g (49%) of 5-bromo-N-(2-methyl-l- azabicyclo[2.2.2]oct-3-yl)thiophene-2-carboxamide as a trans/cis mixture of isomers. The /?-toluenesulfonic acid salt of the product is made and recrystallized from IP A/ether to give the product as light yellow solid. MS (ESI) for Cι3Hι7BrN2OS m/z 328.9/330.9 (M+H)+. Reverse phase HPLC (ZORBAX Eclipse XDB-C8, 4.6mm x 15cm, 80: 12:8 H O/CH3CN/IPA) revealed a 95:5 trans/cis mixture of isomers. Example 159
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-phenyl-thiophene-2-carbothioamide fumarate:
Step 159a: Preparation of methyl 5-phenyl-thioρhene-2-carbodithioate.
To a cooled (-10 to 0°C) solution of n-BuLi (22.7 mL, 33.4 mmol) in THF (10 mL) is added dropwise a solution of 2-phenyl-thiophene (5.46 g, 34.0 mmol) in THF (15 mL). The resulting green solution is stirred at 0°C. After 30 minutes, a solution of copper (I) bromide (0.87 g, 6.1 mmol) and lithium bromide (1.29 g, 14.9 mmol) in THF (20 mL) is added to the cooled reaction solution over several minutes. The resulting dark green solution is stirred at 0°C for 15 minutes, at which time, carbon disulfide (2.0 mL, 34.0 mmol) is added dropwise over 15 minutes. The resulting dark brown solution is stirred for 30 minutes, then iodomethane (2.9 mL, 46.4 mmol) is added dropwise to the reaction solution over 5 minutes. The resulting dark brown solution is allowed to warm to room temperature and stirred for 1 hour, then is quenched with a solution of potassium cyanide in water (100 mL). The biphasic mixture was diluted with EtOAc and washed with brine, dried over MgSO4, filtered, and concentrated to give a dark orange solid (8.5 grams) which is purified with flash chromatography on' silica gel (eluent: gradient of heptane to 2% THF/heptane) to give an orange solid. Yield 34%. HRMS (FAB) calculated for Cι2Hι0S3+H 251.0023, found 251.0023.
Step 159b: Preparation of N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-phenyl- thiophene-2-carbothioamide fumarate. A solution of the product of Step 159a (0.49 g, 2.0 mmol) and (R)-3- aminoquinulidine (0.55 g, 4.4 mmol) in THF is stirred at 50°C for 19 hours. The crude reaction mixture is absorbed on to silica gel and purified by flash chromatography (gradient of 7% [9:1 MeOH/NH4OH]/CH2Cl2 to 9%[9: 1 MeOH/NH OH]/CH2Cl2). The fumarate salt is prepared and crystallized. Yield 75%. HRMS (FAB) calculated for C18H2oN2S2+H 329.1146, found 329.1 151. The present invention also includes, by representation but not limitation, any one of the following or combination of the following compounds and pharmaceutically acceptable salts thereof, both of which can be made by one of ordinary skill in the art using the procedures provided making non-critical changes: N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-phenyl-thioρhene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-chlorophenyl)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- chlorophenyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(2-chlorophenyl)-thiophene-2-carboxamide; N-[(2S,3R)- 2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2,3 -bithiophene-5-carboxamide; N-[(2S,3R)- 2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-nitrophenyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-nitrophenyl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-4-phenyl-thiophene- 2-carboxamide; N-[(2S,3R)-2-methyl- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(3- benzyloxyphenyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(4-benzyloxyphenyl)-thiophene-2-carboxamide; N- [(2S,3R)-2-methy]-l-azabicyclo[2.2.2Joct-3-yl]-5-(3-fluoro-4-benzyloxyphenyl)- thiophene-2-carboxamide; 5-(2-aminophenyl)-N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-pyridin-3-yl-thiophene-2-carboxamide; N-[(2S,3R)-2- methyl-l-azabicyclo[2.2.2]oct-3-yl]-5'-methyl-2,2'-bithiophene-5-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5'-chloro-2,2'-bithiophene-5- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-nitro-thiophene- 2-carboxamide; 5-(aminomethyl)-N- [(2S ,3R)-2-methyl- 1 -azabicyclo[2.2.2]oct-3-yl]- thiophene-2-cai'boxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5- cyano-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]- 5-methoxy-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3- yl]-5-(pyridin-2-yl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-[2,21bithiophenyl-5-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(methylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)- 2-methyl- 1 -azabicyclo[2.2.2]oct-3-yl]-5-chloro-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-acetyl-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-methyl-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl- 1 -azabicyclo[2.2.2]oct-3-yl]-5-bromo-thiophene- 2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]~5- (phenylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(acetylamino)-furan-2-carboxamide; N-[(2S,3R)-2- methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-trifluoromethyl-furan-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methyl-5-trifluoiOmethyl-2H- pyrazole-3-yl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-methylthiazol-4-yl)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[2-(3-chlorophenyl)-vinyl]- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- chlorophenylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2,4-difluorophenyl-sulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-chlorophenyl-sulfanyl)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- chloro-4-fluoro-phenylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2,3-dichlorophenyl-sulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2joct-3-yl]-5-(2,4,5-trichloiOphenyl-sulfanyl)- thiophene-2-carboxamide; N-[(2S,3R)-2-melhyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,4- dichlorophenyl-sulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-phenoxy-thiophene-2-carboxamide; N-[(2S,3R)-2- methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-hydroxyphenyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-hydroxyphenyl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-fluoro-4- hydroxyphenyl)-thiophene-2^carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-2-(phenylsulfanyl)-l,3-thiazole-5-carboxamide; N-
[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-[(4-chlorophenyl)-sulfanyl]-l,3- thiazole-5-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2- phenoxy-l,3-thiazole-5-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3- yl]-2-[(4-fluorophenyl)-sulfanyl]- 1 ,3-thiazole-5-carboxamide; N-[(2S ,3R)-2-methyl- l-azabicyclo[2.2.2]oct-3-yl]-2-(methylsulfanyl)-l ,3-thiazole-5-carboxamide; N-
[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-(4-chlorophenoxy)-l,3-thiazole-5- carboxamide; N-[(2S,3R)-2-methyl- l-azabicyclo[2.2.2]oct-3-yl]-2-phenyl- 1 ,3- thiazole-5-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2,4- dimethyl- 1 ,3-thiazole-5-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3- yl]-2-(2-fluoroρhenyl)-l,3-thiazole-5-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-2-(3-fluorophenyl)-l,3-lhiazole-5-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-(4-fluorophenyl)-l,3-thiazole-5- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-(2- hydroxyphenyl)-l,3-thiazole-5-carboxamide; N-[(2S,3R)~2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-2-(4-methylphenyl)- 1 ,3-thiazole-5-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-[4-(benzyloxy)phenyl]-l,3-thiazole- 5-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-pyridin-3-yl-l,3- thiazole-4-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-4-methyl- 2-phenyl- 1 ,3-thiazole-5-carboxamide; N-[(2S,3R)-2-methyl- l-azabicyclo[2.2.2]oct-3- yl]-2-(4-chlorophenyl)-4-methyl-l,3-thiazole-5-carboxamide; N-[(2S,3R)-2-methyl- l-azabicyclo[2.2.2Joct-3-yl]-4-methyl-2-pyridin-2-yl-l,3-thiazole-5-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-4-methyl-2-ρyridin-4-yl-l,3-thiazole- 5-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-(methylamino)- l,3-thiazole-5-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5- (phenylsulfanyl)-l,3,4-thiadiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-phenoxy-l,3,4-thiadiazole-2-carboxamide; N-[(2S,3R)- 2-methyl- 1 -azabicyclo[2.2.2]oct-3-yl]-5-[(4-chlorophenyl)-sulfanyl]- 1 ,3,4-thiadiazole- 2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicycIo[2.2.2]oct-3-yl]-5-(4- fluorophenoxy)-l,3,4-thiadiazole-2-caι-boxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(4-chlorophenoxy)-l,3,4-thiadiazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[(3-fluorophenyl)-sulfanyl]-l,3,4- thiadiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[(2- chlorophenyl)-sulfanyl]-l,3,4-thiadiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-[(4-fluorophenyl)-sulfanyl]-l,3,4-thiadiazole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[(3-chlorophenyl)- sulfanyl]-l,3,4-thiadiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-phenyl- 1H-1 ,2,4-triazole-3-carboxamide; N-[(2S,3R)-2- methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-phenyl-l,3,4-oxadiazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(methylthio)-l,3,4-oxadiazole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-chlorophenyl)- l,3-oxazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- methoxyphenyl)-l,3-oxazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(3-nitroρhenyl)-l,3-oxazole-2-carboxamide; N-[(2S,3R)- 2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-methoxyphenyl)-l,3-oxazole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-nitrophenyl)- l,3-oxazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- methoxyphenyl)-l,3-oxazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(4-fluorophenyl)-l,3-oxazoie-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-chlorophenyl)-l,3-oxazole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-cyanophenyl)- l,3-oxazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- bromophenyl)-l,3-oxazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-4-methyl-5-phenyl- 1 ,3-thiazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-phenyl-l,3-thiazoIe-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-bromophenyl)-l,3-thiazole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-nitrophenyl)- l,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-ylj-5-(3- methoxyphenyl)- 1 ,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(2-chlorophenyl)- 1 ,3-thiazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-fluorophenyl)-l,3-thiazole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclof2.2.2]oct-3-yl]-5-(2- methoxyphenyl)-l,3-thiazole-2-caι-boxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(4-chlorophenyl)-l,3-thiazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-methyl-l,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-chlorophenyl)-l,3-thiazole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-fluorophenyl)- l,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- fluorophenyl)- 1 ,3-thiazole-2-carboxamide; N- [(2S ,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-thien-2-yl-l,3-thiazole-2-carboxamide; N-[(2S,3R)-2- methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-phenyl-furan-2-carboxamide; N-[(2S,3R)-2- methyl- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(2-chlorophenyl)-furan-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-chlorophenyl)-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-chlorophenyl)- furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- bromophenyl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3- yl]-5-[2-(trifluoromethyl)-phenyl]-furan-2-carboxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]ocl-3-yl]-5-[3-(trifluoiOmethyl)-phenyl]-furan-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-nitrophenyl)-furan-2- carboxamide; N-[(2S,3R)-2-methy -l-azabicyclo[2.2.2]oct-3-yl]-5-(3-nilrophenyl)- furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- nitrophenyl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl- 1 -azabicyclo[2.2.2]oct-3- yl]-5-(2-fluorophenyl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(3-fluorophenyl)-furan-2-carboxamide; N-[(2S,3R)-2- methyl- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(4-fluorophenyl)-furan-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2,4-difluorophenyl)-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2,5- difluorophenyl)-f uran-2-carboxamide ; N- [(2S , 3 R)-2-methyl- 1 -azabicyclo[2.2.2] oct- 3-yl]-5-(2-methoxyphenyl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(3-methoxyphenyl)-furan-2-carboxamide; N-[(2S,3R)-2- methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[3-(trifluoromethoxy)phenyl]-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[2-chloro-5- (trifluoiOmethyl)phenyl]-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yI]-5-(4-fluoro-3-methylphenyl)-furan-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-cyanophenyl)-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicycIo[2.2.2]oct-3-yl]-5-thien-2-yl-furan-2- cai'boxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-thien-3-yl-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-bromo-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-nitro-furan-2- carboxamide; N-[(2S,3R)-2-methyl- 1 -azabicyclo[2.2.2]oct-3-yl]-4,5-dimethyl-furan- 2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-chloro-2- nitrophenyl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3- yl]-5-(4-methyl-2-nitrophenyl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2,3-difluorophenyl)-furan-2-carboxamide; N-[(2S,3R)- 2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,4-difluorophenyl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,5-difluorophenyl)-furan-2- carboxamide; N-[(2S,3R)-2-methyl- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(4-methoxy- phenyl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2Joct-3-yl]-5- (2-methylphenyl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct- 3-yl]-5-(3-methylphenyl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(4-methylphenyl)-furan-2-carboxamide; N-[(2S,3R)-2- methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[2-(trifluoromethoxy)phenyl]-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[4- (trifluoromethoxy)phenyl]-furan-2-carboxamide; N-[(2S ,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(4-tert-butylphenyl)-furan-2-carboxamide; N-[(2S,3R)- 2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(l-benzothien-2-yl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-quinolin-3-yl-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-ethylphenyl)- furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- isopropylphenyl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct- 3-yl]-5-(3-fluoro-4-methoxyphenyl)-furan-2-carboxamide; N- [(2S ,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(l-benzofuran-2-yl)-furan-2-carboxamide; 5-(2- aminophenyl)-N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-furan-2- carboxamide; 5-(4-aminophenyl)-N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]- furan-2-carboxamide; 5-(2-amino-4-methylphenyl)-N-[(2S ,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-furan-2-carboxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(phenylethynyl)-furan-2-carboxamide; N-[(2S,3R)-2- methyl- l-azabicyclo[2.2.2]oct-3-yl]-5-phenoxy-furan-2-carboxamide; N-[(2S,3R)-2- methyl-l-azabicyclo[2.2.2]oct-3-yl]-l-methyl-5-phenyl-lH-pyπOle-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-phenyl-l,3-oxazole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-3-phenyl-l,2,4- oxadiazole-5-carboxamide; N-[(2S,3R)-2-methyl- l-azabicyclo[2.2.2]oct-3-yl]-2-phenyl- 1 ,3-oxazole-5- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-phenyl-l,3- oxazole-4-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5- phenylisoxazole-3-carboxamide; 5-bromo-N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-thiophene-2-carboxamide;N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-phenyl-thiophene-2-carbothioamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-acetamidophenyl)-thiophene-2- carboxa ide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-acetamidophenyl)- thiophene-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(4- acetamidophenyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- (2-trifluoroacetamidophenyl)-thiophene-2-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(3-trifluoroacetamidophenyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-trifluoroacetamidophenyl)-thiophene-2- carboxamide; N-[(3R)-1 -azabicyclo[2.2.2]oct-3-yl]-5-(2- methanesulfonylaminophenyl)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(3-methanesulfonylaminophenyl)-thiophene-2- carboxamide; N-[(3R)- l-azabicyclo[2.2.2]oct-3-yl]-5-(4- methanesulfonylaminophenyl)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(2-trifluoromethanesulfonylaminophenyl)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- trifluoromethanesulfonylaminophenyl)-thiophene-2-carboxamide; N-[(3R)-1- azabicycIo[2.2.2]oct-3-yl]-5-(4-trifluoromethanesulfonylaminoρhenyl)-thiophene-2- carboxamide; N-[(3R)-1 -azabicyclo[2.2.2]oct-3-yl]-5-(2-difluoroacetamidophenyl)- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- difluoroacetamidophenyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct- 3-yl]-5-(4-difluoroacetamidophenyl)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(2-carbamoylphenyl)-thiophene-2-carboxamide; N- [(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(3-carbamoylphenyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-carbamoylphenyl)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-sulfamoylphenyl)-thiophene- 2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-sulfamoylphenyl)- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- sulfamoylphenyl)-thiophene-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5- (2-acetamidophenylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo [2.2.2] oct-3 -yl] -5-(3 -acetamidophenylsulf anyl)-thiophene-2-carboxamide ; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-acetamidophenylsulfanyl)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- trifluoroacetamidophenylsulfanyl)-thiophene-2-carboxamide; N-[(3R)- 1- azabicyclo[2.2.2]oct-3-yl]-5-(3-trifluoroacetamidophenylsulfanyl)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- trifluoroacetamidophenylsulfanyl)-thiophene-2-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(2-methanesulfonylaminophenylsulfanyl)-thiophene-2- carboxamide; N-[(3R)- l-azabicyclo[2.2.2]oct-3-yl]-5-(3- methanesulfonylaminophenylsulfanyl)-thiophene-2-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(4-methanesulfonylaminophenylsulfanyl)-thiophene-2- cai-boxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- trifluoromethanesulfonylaminophenylsulfanyl)-thiophene-2-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(3-trifluoromethanesulfonylaminophenylsulfanyl)- thiophene-2-carbox amide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- trifluoromethanesulfonylaminophenylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(2-difluoroacetamidophenylsuIfanyl)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- difluoroacetamidophenylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(4-difluoroacetamidophenylsulfanyl)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-carbamoylphenylsulfanyl)- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- carbamoylphenyIsulfanyl)-thiophene-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct- 3-yl]-5-(4-carbamoylphenylsulfanyl)-thiophene-2-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(2-sulfamoylphenylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-sulfamoylphenylsulfanyl)-thiophene-2- carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(4-sulfamoylphenylsulfanyl)- thioρhene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- hydroxyphenylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(3-hydroxyphenylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo [2.2.2]oct-3-yl]-5-(4-hydroxyphenylsulf anyl)-thiophene-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-aminophenylsulfanyl)-thiophene-2- carboxamide; N-[(3R)-l-azabicycIo[2.2.2]oct-3-yl]-5-(3-aminophenylsulfanyl)- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- aminophenylsulfanyl)-thiophene-2-caι-boxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(2-acetamidophenoxy)-thiophene-2-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(3-acetamidophenoxy)-thiophene-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-acetamidophenoxy)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-trifluoiOacetamidophenoxy)- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- trifluoroacetamidophenoxy)-thiophene-2-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(4-trifluoroacetamidophenoxy)-thiophene-2- carboxamide; N-[(3R)-l-azabicycIo[2.2.2]oct-3-yl]-5-(2- methanesulfonylaminophenoxy)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(3-methanesulfonylaminophenoxy)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- methanesulfonylaminophenoxy)-thiophene-2-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(2-trifluoromethanesulfonylaminophenoxy)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- trifluoromethanesulfonylaminophenoxy)-thiophene-2-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(4-trifluoromethanesulfonyIaminophenoxy)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-difluoroacetamidophenoxy)- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- difluoroacetamidophenoxy)-thiophene-2-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]~5-(4-difluoroacetamidophenoxy)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-carbamoylphenoxy)- thioρhene-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(3- carbamoylphenoxy)-thiophene-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]- 5-(4-carbamoylphenoxy)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct- 3-yl]-5-(2-sulfamoylphenoxy)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(3-sulfamoylphenoxy)-thiophene-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-sulfamoylphenoxy)-thiophene-2- carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(2-hydroxyphenoxy)- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- hydroxyphenoxy)-thiophene-2-carboxamide; N-[(3R)-1 -azabicyclo[2.2.2]oct-3-yl]-5- (4-hydroxyphenoxy)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(2-aminoρhenoxy)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct- 3-yl]-5-(3-aminophenoxy)-thiophene-2-carboxamide; N- [(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(4-aminophenoxy)-thiophene-2-carboxamide; N-[(3R)- l-azabicyclo[2.2.2]oct-3-yl]-5-(2-chlorophenoxy)-thiophene-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-chlorophenoxy)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-chlorophenoxy)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-cyanophenoxy)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-cyanophenoxy)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-cyanophenoxy)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methoxyphenyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-methoxyphenyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-methoxyphenyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methylphenyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-methylphenyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-methylphenyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-trifluoiOmethylphenyl)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-trifluoromethylphenyl)- thiophene-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(4- trifluoromethylphenyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(2-acetylphenyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(3-acetylphenyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(4-acetylphenyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(2-cyanophenyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(3-cyanophenyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(4-cyanophenyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(2-morpholin-4-yl-phenyl)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(3-morpholin-4-yl-phenyl)-thiophene-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-morpholin-4-yl-phenyl)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methoxyphenoxy)- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- methoxyphenoxy)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- (4-methoxyphenoxy)-thiophene-2-caι-boxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(2-methylphenoxy)-thioρhene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct- 3-yl]-5-(3-methylphenoxy)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(4-methylphenoxy)-thiophene-2-carboxamide; N-[(3R)- l-azabicyclo[2.2.2]oct-3-yl]-5-(2-trifluoromethylphenoxy)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-trifluoromethylphenoxy)-thiophene-2- carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(4-trifluoromethylphenoxy)- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- acetylyphenoxy)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- (3-acetylphenoxy)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- (4-acetylphenoxy)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- (2-cyanophenoxy)-thiophene-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5- (3-cyanophenoxy)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- (4-cyanophenoxy)-thiophene-2-cai"boxamide; N-[(3R)- l-azabicyclo[2.2.2]oct-3-yl]-5- (2-moιpholin-4-yl-phenoxy)-thiophene-2-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(3-morpholin-4-yI-phenoxy)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-morpholin-4-yl-phenoxy)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methoxyphenylsulfanyl)- thiophene-2-carboxamide; N-[(3R)- l-azabicyclo[2.2.2]oct-3-yl]-5-(3- methoxyphenylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct- 3-yl]-5-(4-methoxyphenylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(2-methylphenylsulfanyl)-thiophene-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-methylphenylsulfanyl)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-methyIphenylsulfanyl)- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- trifluoromethylphenylsulfanyl)-thiophene-2-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(3-trifluoromethylphenylsulfanyl)-thioρhene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- trifluoromethylphenylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(2-acetylyphenylsulfanyl)-thiophene-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-acetylphenylsulfanyl)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-acetylphenylsulfanyl)- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- cyanophenylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(3-cyanophenylsulfanyl)-thiophene-2-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(4-cyanophenylsulfanyl)-thiophene-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-morpholin-4-yl-phenylsulfanyl)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-moι holin-4-yl- phenylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- (4-moιpholin-4-yl-phenylsulfanyl)-thiophene-2-carboxamide; N- [(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(pyridin-4-yl)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(2-methylpyridin-4-yl)-thiophene-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(6-methylρyridin-3-yl)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-methylpyridin-2-yl)- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- methoxypyridin-4-yl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]ocl-3- yl]-5-(6-methoxypyridin-3-yl)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(5-methoxypyridin-2-yl)-thiophene-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-chloropyridin-4-yl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(6-chloropyridin-3-yl)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-chloropyridin-2-yl)- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-chloropyridin- 3-yl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(6- chloropyridin-2-yl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]- 5-(4-chloropyridin-2-yl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct- 3-yl]-5-(pyridin-4-yloxy)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct- 3-yl]-5-(pyridin-3-yloxy)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct- 3-yl]-5-(pyridin-2-yloxy)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct- 3~yl]-5-(2-methylpyridin-4-yloxy)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(6-methylpyridin-3-yloxy)-thiophene-2-carboxamidc; N- [(3R)-l-azabicyclo[2.2.2]oct-3-ylJ-5-(5-methylpyridin-2-yloxy)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methoxypyridin-4-yloxy)- thiophene-2-carbox amide ; N- [(3R)- 1 -azabicyclo [2.2.2]oct-3 -yl] -5-(6- methoxypyridin-3-yloxy)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct- 3-yl]-5-(5-methoxypyridin-2-yloxy)-thiophene-2-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(2-chloropyridin-4-yloxy)-thiophene-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(6-chloropyridin-3-yloxy)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-chloropyridin-2-yloxy)- thiophene-2-carboxamide; N-[(3R)-l-azabicycIo[2.2.2]oct-3-yl]-5-(2-chloropyridin- 4-yloxy)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(6- chloropyridin-3-yloxy)-thiophene-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3- yl]-5-(5-chloropyridin-2-yloxy)-thiophene-2-carboxamide; N-[(3R)- 1- azabicyclo[2.2.2]oct-3-yl]-5-(5-chloroρyridin-3-yloxy)-thiophene-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(6-chloropyridin-2-yloxy)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-chloropyridin-2-yloxy)- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(pyridin-4- ylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- (pyridin-3-ylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(pyridin-2-ylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(2-methylpyridin-4-ylsulfanyl)-thiophene-2-cai-boxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(6-methylpyridin-3-ylsulfanyl)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-methylpyridin-2-ylsulfanyl)- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- methoxypyridin-4-ylsulfanyl)-thiophene-2-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(6-methoxypyridin-3-ylsulfanyl)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-methoxypyridin-2- ylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- chloropyridin-4-ylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(6-chloropyridin-3-ylsuIfanyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-chloropyridin-2-ylsulfanyl)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-chloropyridin-4-ylsulfanyl)- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(6-chloropyridin- 3-ylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5- chloropyridin-2-ylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(5-chloropyridin-3-ylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(6-chloropyridin-2-ylsulfanyl)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-chloropyridin-2-ylsulfanyl)- thiophene-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(thiophen-4-yl)- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5- methylthiophen-2-yl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(5-methoxythiophen-2-yl)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(5-chlorothiophen-2-yl)-thiophene-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(furan-4-yl)-thioρhene-2-carboxamide; N-[(3R)- l-azabicyclo[2.2.2]oct-3-yl]-5-(5-methylfuran-2-yl)-thiophene-2-carboxamide; N- [(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(5-methoxyfuran-2-yl)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-chlorofuran-2-yl)-thiophene- 2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(oxazol-2-yl)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-methyloxazol-2-yl)- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-methoxyoxazol- 2-yl)-thiophene-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(5- chlorooxazol-2-yl)-fhiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]- 5-(oxazol-5-yl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- methyloxazol-5-yl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]- 5-(2-methoxyoxazol-5-yl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct- 3-yl]-5-(2-chlorooxazol-5-yl)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(thiazol-2-yl)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(5-methylthiazol-2-yl)-thiophene-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-methoxythiazol-2-yl)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-chlorothiazol-2-yl)- thioρhene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(thiazol-5-yl)- fhiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methylthiazol- 5-yl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- methoxythiazol-5-yl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(2-chlorothiazol-5-yl)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(4-methylthiazol-2-yl)-thiophene-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-methoxythiazol-2-yl)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-chlorothiazol-2-yl)- thiophene-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(4-methyloxazol- 2-yl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yI]-5-(4- methoxyoxazol-2-yl)-thiophene-2-carboxamide; N-[(3R)-l-azabicycIo[2.2.2]oct-3- yl]-5-(4-chlorooxazol-2-yl)-thiophene-2-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-([ 1 ,3,4]thiadiazol-2-yl)-thiophene-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-methyl[l,3,4]thiadiazol-2-yl)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-methoxy[l,3,4]thiadiazol-2- yl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5- chloro[l,3,4]thiadiazol-2-yl)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-([l,3,4]oxadiazol-2-yl)-thiophene-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-methyl[l,3,4]oxadiazol-2-yl)-thiophene-2- carboxamide; N-[(3R)- l-azabicyclo[2.2.2]oct-3-yl]-5-(5-methoxy[ 1 ,3,4]oxadiazol-2- yl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(57 chloro[l,3,4]oxadiazol-2-yl)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(thiophen-4-yloxy)-thiophene-2-carboxamide; N-[(3R)- l-azabicyclo[2.2.2]oct-3-yl]-5-(5-methylthiophen-2-yloxy)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-methoxythiophen-2-yloxy)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-chlorothiophen-2-yloxy)- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(furan-4-yloxy)- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-methylfuran-2- yloxy)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5- methoxyfuran-2-yloxy)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(5-chlorofuran-2-yloxy)-thiophene-2-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(oxazol-2-yloxy)-thiophene-2-carboxamidc; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(5-methyloxazol-2-yloxy)-thiophene-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-methoxyoxazol-2-yloxy)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-chlorooxazol-2-yloxy)- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(oxazol-5-yloxy)- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methyloxazol- 5-yloxy)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- methoxyoxazol-5-yloxy)-thiophene-2-carboxamidc; N-[(3R)-l-azabicyclo[2.2.2]oct- 3-yI]-5-(2-chlorooxazol-5-yloxy)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(thiazol-2-yloxy)-thiophene-2-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(5-methylthiazol-2-yloxy)-thiophene-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-methoxythiazol-2-yloxy)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-chlorothiazol-2-yloxy)- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(thiazol-5-yloxy)- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methylthiazol- 5-yloxy)-thiophene-2-carboxamide; N-[(3R)- l-azabicyclo[2.2.2]oct-3-yl]-5-(2- methoxythiazol-5-yloxy)-thiophene-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct- 3-yl]-5-(2-chlorothiazol-5-yloxy)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(4-methylthiazol-2-yloxy)-thiophene-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-methoxythiazol-2-yloxy)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-chlorothiazol-2-yloxy)- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-methyloxazol- 2-yloxy)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- methoxyoxazol-2-yloxy)-thiophene-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct- 3-yl]-5-(4-chlorooxazol-2-yloxy)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-([l,3,4]thiadiazol-2-yloxy)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-methyl[l,3,4]thiadiazol-2-yloxy)- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5- methoxy[l,3,4]thiadiazol-2-yloxy)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(5-chloro[l,3,4]thiadiazol-2-yloxy)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-([l,3,4]oxadiazol-2-yloxy)- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5- methyl[l,3,4]oxadiazol-2-yloxy)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(5-methoxy[l,3,4]oxadiazol-2-yloxy)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-chloro[l,3,4]oxadiazol-2- yloxy)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(thiophen- 4-ylsulfanyl)-thiophene-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(5- methyIthiophen-2-ylsulfanyl)-thiophene-2-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(5-methoxythiophen-2-ylsulfanyl)-thiophene-2- carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(5-chlorothiophen-2- ylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(furan- 4-ylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5- methylfuran-2-ylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct- 3-yl]-5-(5-methoxyfuran-2-ylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(5-chlorofuran-2-ylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(oxazol-2-ylsulfanyl)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-methyloxazol-2-ylsulfanyl)- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-methoxyoxazol- 2-ylsulfanyl)-thiophene-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(5- chlorooxazol-2-ylsulfanyl)-thiophene-2-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(oxazol-5-ylsulfanyl)-thiophene-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methyloxazol-5-ylsulfanyl)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methoxyoxazol-5- ylsulfanyl)-thioρhene-2-carboxamide; N-[(3R)- l-azabicyclo[2.2.2]oct-3-yl]-5-(2- chlorooxazol-5-ylsulfanyl)-thiophene-2-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(thiazol-2-ylsulfanyl)-thiophene-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-methylthiazol-2-ylsulfanyl)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-methoxythiazol-2- ylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5- chlorothiazol-2-ylsulfanyl)-thiophene-2-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(thiazol-5-ylsulfanyl)-thiophene-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methylthiazol-5-ylsulfanyl)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methoxythiazol-5- ylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- chlorothiazol-5-ylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(4-methylthiazol-2-ylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-methoxythiazol-2-ylsulfanyl)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-chlorothiazol-2-ylsulfanyl)- thiophene-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(4-methyloxazol- 2-ylsulfanyI)-thiophenc-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- methoxyoxazol-2-ylsulfanyl)-thiophene-2-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(4-chlorooxazol-2-ylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-([l,3,4]thiadiazol-2-ylsulfanyl)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-methyl[l,3,4]thiadiazol-2- ylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5- methoxy[l,3,4]thiadiazol-2-ylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(5-chloro[l,3,4]thiadiazol-2-ylsulfanyl)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-([l,3,4]oxadiazol-2-ylsulfanyl)- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5- methyl[l,3,4]oxadiazol-2-ylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(5-methoxy[l,3,4]oxadiazol-2-ylsulfanyl)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-chloro[l ,3,4]oxadiazoI-2- ylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- (pyrrole-2-yl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- (isothiazol-3-yl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- (isoxazol-3-yl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- (3H-imidazol-4-yl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yI]- 4-(4-hydroxyphenylsulfanyl)-thiophene-2-carboxamide; N- [(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-4-(3-acetamidophenylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-4-(2-methanesulfonylaminophenyl)-thiophene- 2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-4-(pyridin-2-yloxy)-thiophene- 2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-4-(2-methylpyridin-4-yloxy)- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-4-(4- trifluoromethylphenyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-4-(2-acetylphenyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-4-chloro-5-phenyl-thiophenc-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-4-methyl-5-phenyl-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-4-cyano-5-phenyl-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-4-methoxy-5-phenyl-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct- 3-yl]-5-chloro-4-phenyl-thiophene-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3- yl]-5-methyl-4-phenyl-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-cyano-4-ρhenyl-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-methoxy-4-phenyl-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct- 3-yl]-4-chloro-5-bromo-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-4-chloro-5-methylsulfanyl-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-4-chloro-5-methyl-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]ocl-3-yl]-4-chloro-5-cyano-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]ocl-3-yl]-5-chloro-4-bromo-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-chloro-4-methylsulfanyl-thiophene-2-carboxamide; N- [(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-chloro-4-methyl-thiophene-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-chloro-4-cyano-thiophene-2-carboxamide;
N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-acetamidophenyl)-thiophene- 2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- acetamidophenyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(4-acetamidophenyl)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-trifluoroacetamidophenyl)- thiophene-2-caι-boxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- trifluoroacetamidophenyl)-thiophene-2-carboxamide; N-[(2S ,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(4-trifluoroacetamidophenyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- methanesulfonylaminophenyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(3-methanesulfonylaminophenyl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- methanesulfonylaminophenyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-trifluoromethanesulfonylaminophenyl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- trifluoromethanesulfonylaminophenyl)-thiophene-2-carboxamide; N-[(2S ,3R)-2- methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-trifluoromethanesulfonylaminophenyl)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- difluoroacetamidophenyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]ocl-3-yl]-5-(3-difluoroacetamidophenyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-difluoroacetamidophenyl)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- carbamoylphenyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(3-carbamoylphenyl)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-carbamoylphenyl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl- l-azabicyclo[2.2.2]oct-3-yl]-5-(2- sulfamoylphenyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(3-sulfamoylphenyl)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-sulfamoylphenyl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- acetamidophenylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl- 1- azabicyclo[2.2.2]oct-3-yl]-5-(3-acetamidophenylsulfanyl)-thiophene-2-cai"boxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-acetamidophenylsulfanyl)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- trifluoroacetamidophenylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(3-trifluoroacetamidophenylsulfanyl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- trifluoroacetamidophenylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-methanesulfonylaminophenylsulfanyl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- methanesulfonylaminophenylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2- methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-methanesulfonylaminophenylsulfanyl)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- trifluoiOmethanesulfonylaminophenylsulfanyl)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- trifluoromethanesulfonylaminophenylsulfanyl)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- trifluoromethanesulfonylaminophenylsulfanyl)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- difluoroacetamidophenylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(3-difluoroacetamidophenylsulfanyl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- difluoroacetamidophenylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-carbamoylphenylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-carbamoylphenylsulfanyl)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- carbamoylphenylsulfanyl)-thiophene-2-caι-boxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-sulfamoylphenylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicycIo[2.2.2]oct-3-yl]-5-(3-sulfamoylphenylsulfanyl)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- sulfamoylphenylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-hydroxyphenylsulfanyl)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-hydroxyphenylsulfanyl)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- hydroxyphenylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-aminophenylsulfanyl)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-aminophenylsulfanyl)-thiophene- 2-caι-boxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- aminophenylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-acetamidophenoxy)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-acetamidophenoxy)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- acetamidophenoxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-trifluoroacetamidophenoxy)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- trifluoroacetamidophenoxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(4-trifluoroacetamidophenoxy)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- methanesulfonylaminophenoxy)-thiophene-2-carboxamide; N-[(2S ,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(3-methanesulfonylaminophenoxy)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- methanesulfonylaminophenoxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-trifluoromethanesulfonylaminophenoxy)-thiophene-2- carboxamide; N-[(2S,3R)-2-mcthyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- trifluoiOmethanesulfonylaminophenoxy)-thiophene-2-caι-boxamide; N-[(2S,3R)-2- methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-trifluoiOmethanesulfonylaminophenoxy)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- difluoroacetamidophenoxy)-thioρhene-2-carboxamide; N- [(2S ,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(3-difluoroacetamidophenoxy)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- difluoroacetamidophenoxy)-thiophene-2 -carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-carbamoylphenoxy)-thiophene-2-carboxamide; N-
[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-carbamoylphenoxy)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]ocl-3-yl]-5-(4- carbamoylphenoxy)-lhiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-sulfamoylphenoxy)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-sulfamoylphenoxy)-thiophene-2- carbόxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- sulfamoylphenoxy)-thiophene-2-caι-boxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-hydroxyphenoxy)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-hydroxyphenoxy)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- hydroxyphenoxy)-thiophene-2-caι-boxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-aminophenoxy)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-aminophenoxy)-thiophene-2- cai-boxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- aminophenoxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl- 1- azabicyclo[2.2.2]oct-3-yl]-5-(2-chlorophenoxy)-thiophene-2-carboxamide; N- [(2S ,3R)-2-methyl- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(3-chloroρhenoxy)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- chlorophenoxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-cyanoρhenoxy)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-cyanophenoxy)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- cyanophenoxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(2-methoxyphenyl)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-methoxyphenyl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- methoxyphenyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-methylphenyl)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl])-5-(3-methylphenyl-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-methylphenyl)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- trifluoromethylphenyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(3-trifluoromethylphenyl)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-trifluoromethylphenyl)- thioρhene-2-carboxamide; N-[(2S,3R)-2-methyl- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(2- acetylyphenyl)-thiophene-2-carboxamide; N- [(2S ,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(3-acetylphenyl)-thiophene-2-carboxamide; N-[(2S,3R)- 2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-acetylphenyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-cyanophenyl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-cyanophenyl)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- cyanophenyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-morpholin-4-yl-phenyl)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-morpholin-4-yl-phenyl)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- morpholin-4-yl-phenyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-methoxyphenoxy)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-methoxyphenoxy)-thiophene-2- carboxamide; , N-[(2S,3R)-2-methyl-l -azabicyclo[2.2.2]oct-3-yl]-5-(4- methoxyphenoxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-methylphenoxy)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-) 5-(3-methylphenoxy-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- methylphenoxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-trifluoromethylphenoxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-trifluoromethylphenoxy)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- trifluoiOmethylphenoxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-acetylphenoxy)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-acetylphenoxy)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- acetylphenoxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-cyanoρhenoxy)-thiophene-2-carboxamide; N- r(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-cyanophenoxy)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- cyanophenoxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-morpholin-4-yl-phenoxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-mo holin-4-yl-phenoxy)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- morpholin-4-yl-phenoxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-methoxyphenylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-methoxyphenylsulfanyl)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- methoxyphenylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-methylphenylsulfanyl)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-methylphenylsulfanyl)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- methylphenylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(2-trifluoromethylphenylsulfanyl)-thiophene-2- cai-boxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- trifluoromethylphenylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(4-trifluoromethylphenylsulfanyl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- acetylyphenylsulfanyl)-thiophene-2-caι-boxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(3-acetylphenylsulfanyl)-lhiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-acetylphenylsulfanyl)-thiophene- 2-carboxamide; N-[(2S,3R)-2-mcthyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- cyanophenylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2~methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(3-cyanophenylsulfanyl)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-cyanophenylsulfanyl)-thiophene- 2-carboxamide; N-[(2S,3R)-2-methyl- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(2-moφholin-4- yl-phenylsulfanyl)-thiophene-2-carboxamide; N-[(2S ,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(3-morpholin-4-yl-phenylsulfanyl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-moφholin-4- yl-phenylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(pyridin-4-yl)-thiophene-2-carboxamide; N-[(2S,3R)-2- methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methylpyridin-4-yl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(6-methylpyridin- 3-yl)-thiophene-2-carboxamide; N-f(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5- (5-methylpyridin-2-yl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-methoxypyridin-4-yl)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(6-methoxypyridin-3-yl)-thiophene- 2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5- methoxypyridin-2-yl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-chloropyridin-4-yl)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(6-chloropyridin-3-yl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-chloropyridin- 2-yl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5- (5-chloropyridin-3-yl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(6-chloropyridin-2-yl)-thiophene-2-cai'boxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-chloropyridin-2-yl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(pyridin-4-yloxy)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5- (pyridin-3-yloxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl- 1- azabicyclo[2.2.2]oct-3-yl]-5-(pyridin-2-yloxy)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methylpyridin-4-yloxy)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(6- methyIpyridin-3-yloxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(5-methyIpyridin-2-yloxy)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methoxypyridin-4-yloxy)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(6- methoxypyridin-3-yloxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(5-methoxypyridin-2-yloxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-chloropyridin-4-yloxy)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(6- chloropyridin-3-yloxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(5-chloropyridin-2-yloxy)-thiophene-2-carboxamide; N- [(2S ,3R)-2-methyl- 1 -azabicyclo[2.2.2] oct-3-yl] -5-(2-chloropyridin-4-yloxy)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(6- chloropyridin-3-yloxy)-thiophene-2 -carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(5-chloropyridin-2-yloxy)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-chloropyridin-3-yloxy)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(6- chloropyridin-2-yloxy)-thiophene-2-carboxamide; N-[(2S,3R)-2 -methyl- 1- azabicyclo[2.2.2]oct-3-yl]-5-(4-chloropyridin-2-yloxy)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(pyridin-4-ylsu]fanyl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(pyridin-3- ylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicycIo[2.2.2]oct-3-. yl]-5-(pyridin-2-ylsuIfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-methylρyridin-4-ylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(6-methylpyridin-3-ylsulfanyl)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5- methylpyridin-2-ylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-methoxypyridin-4-ylsulfanyl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(6- methoxypyridin-3-ylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(5-methoxypyridin-2-ylsulfanyl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(2-chloropyridin- 4-ylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]ρct- 3-yl]-5-(6-chloropyridin-3-ylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2- methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-chloropyridin-2-ylsulfanyl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-chloropyridin- 4-ylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct- 3-yl]-5-(6-chloropyridin-3-ylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2- methyl-l-azabicycIo[2.2.2]oct-3-yl]-5-(5-chloropyridin-2-ylsulfanyl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(5-chloropyridin- 3-ylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct- 3-yl]-5-(6-chIoropyridin-2-ylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2- methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-chloropyridin-2-ylsulfanyl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(thiophen-4-yl)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5- methyl-thiophen-2-yl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(5-methoxythiophen-2-yl)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-chlorothiophen-2-yl)-thiophene- 2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(furan-4-yl)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5- methylfuran-2-yl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(5-methoxyfuran-2-yl)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-chlorofuran-2-yl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl- l-azabicyclo[2.2.2]oct-3-yl]-5-(oxazol-2-yl)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5- methyloxazol-2-yl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(5-methoxyoxazol-2-yl)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-chlorooxazol-2-yl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(oxazol-5-yl)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- methyloxazol-5-yl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-methoxyoxazol-5-yl)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-chlorooxazol-5-yl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(thiazol-2-yl)- thiophene-2-carboxan de; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5- methylthiazol-2-yl)-thiophene-2-carbpxamide; N-[(2S ,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(5-methoxythiazol-2-yl)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-chlorothiazol-2-yl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(thiazol-5-yl)- thiophene-2-carboxamide; N-L(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- methylthiazol-5-yl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-methoxythiazol-5-yl)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-chlorothiazol-5-yl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-methylthiazol- 2-yl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5- (4-methoxythiazol-2-yl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(4-chlorothiazol-2-yl)-thiophene-2-carboxamide; N-
[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-methyloxazol-2-yl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- methoxyoxazol-2-yl)-thiophene-2-caι-boxamide; N- [(2S ,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(4-chlorooxazol-2-yl)-thiophene-2-carboxamide; N- [(2S,3R)-2-melhyl-l-azabicyclo[2.2.2]oct-3-yl]-5-([l,3,4]thiadiazol-2-yl)-thiophene- 2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5- methyl[l,3,4]thiadiazol-2-yl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(5-methoxy[l,3,4]thiadiazol-2-yl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5- chloro[ 1 ,3,4]thiadiazol-2-yl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-([ 1 ,3,4]oxadiazol-2-yl)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-methyl[l,3,4]oxadiazol-2-yl)- lhiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5- methoxy[l,3,4]oxadiazol-2-yl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(5-chloro[l,3,4]oxadiazol-2-yl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(thiophen-4- yloxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]- 5-(5-methylthiophen-2-yloxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(5-methoxythiophen-2-yloxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-chlorothiophen-2-yloxy)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5- (furan-4-yloxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(5-methylfuran-2-yloxy)-thioρhene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-methoxyfuran-2-yloxy)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5- chlorofuran-2-yloxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(oxazol-2-yloxy)-thiophene-2-carboxamide; N-[(2S,3R)- 2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-methyloxazol-2-yloxy)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5- methoxyoxazol-2-yloxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(5-chlorooxazol-2-yloxy)-thiophene-2-cai'boxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(oxazol-5-yloxy)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methyloxazol- 5-yloxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2Joct-3- yl]-5-(2-methoxyoxazol-5-yloxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-chlorooxazol-5-yloxy)-thioρhene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(thiazol-2-yloxy)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-methylthiazol- 2-yloxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3- yl]-5-(5-methoxythiazol-2-yloxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(5-chlorothiazol-2-yloxy)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(thiazol-5-yloxy)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methylthiazol- 5-yloxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3- yl]-5-(2-methoxythiazol-5-yloxy)-thiophene-2-carboxamide; N- [(2S ,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(2-chlorothiazol-5-yloxy)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-methylthiazol-2-yloxy)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- methoxythiazol-2-yloxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(4-chlorothiazol-2-yloxy)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-methyloxazol-2-yloxy)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- methoxyoxazol-2-yloxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(4-chlorooxazol-2-yloxy)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-([l,3,4]thiadiazol-2-yloxy)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5- methyl[l,3,4]thiadiazol-2-yloxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(5-methoxy[l,3,4]thiadiazol-2-yloxy)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5- chloro[l,3,4]thiadiazol-2-yloxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-([l,3,4]oxadiazol-2-yloxy)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-methyl[l,3,4]oxadiazol-2- yloxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2Joct-3-yl]- 5-(5-methoxy[ 1 ,3,4]oxadiazol-2-yloxy)-thiophene-2-carboxamide; N-[(2S,3R)-2- methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-chloro[l,3,4]oxadiazol-2-yloxy)-thiophene- 2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(thiophen-4- ylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3- yl]-5-(5-methylthiophen-2-ylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2- methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-methoxythiophen-2-ylsulfanyl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-ylJ-5-(5- chlorothiophen-2-ylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(furan-4-ylsulfanyl)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-methylfuran-2-ylsulfanyl)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5- methoxyfuran-2-ylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(5-chlorofuran-2-ylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(oxazol-2-ylsulfanyl)-thiophene- 2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5- methyloxazol-2-ylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(5-methoxyoxazol-2-ylsulfanyl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-chlorooxazol- 2-ylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl- 1 -azabicyclo[2.2.2]oct- 3-yl]-5-(oxazol-5-ylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-methyloxazol-5-ylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methoxyoxazol-5-ylsulfanyl)- thioρhene-2-caι-boxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- chlorooxazol-5-ylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(thiazol-2-ylsulfanyl)-thiophene-2-carboxarnide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]ocl-3-yl]-5-(5-methylthiazol-2-ylsulfanyl)-
- i l l - thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5- methoxythiazol-2-ylsulfanyl)-thioρhene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(5-chlorothiazol-2-ylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(thiazol-5-ylsulfanyl)-thiophene- 2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- methylthiazol-5-ylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-melhoxythiazol-5-ylsulfanyl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-chlorothiazol- 5-ylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct- 3-yl]-5-(4-methylthiazol-2-ylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2- methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-methoxythiazol-2-ylsulfanyl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-chlorothiazol- 2-ylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct- 3-yl]-5-(4-methyloxazol-2-ylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2- methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-methoxyoxazol-2-ylsulfanyl)-thiophene-2- cai-boxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-chlorooxazol- 2-yIsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct- 3-yl]-5-([l,3,4]thiadiazol-2-ylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2- methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-methyl[l,3,4]thiadiazol-2-ylsulfanyl)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5- methoxy[l,3,4]thiadiazol-2-ylsulfanyl)-thiophene-2-caι-boxamide; N-[(2S,3R)-2- methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-chloro[l,3,4]thiadiazol-2-ylsulfanyl)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5- ([l,3,4]oxadiazol-2-ylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(5-methyl[l,3,4]oxadiazol-2-ylsulfanyl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5- methoxy[l,3,4]oxadiazol-2-ylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2- methyl-l-azabicyclo[2.2.2]ocl-3-yl]-5-(5-chloro[l,3,4]oxadiazol-2-ylsulfanyl)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5- (pyrrole-2-yl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(isothiazol-3-yl)-thiophene-2-carboxamide; N-[(2S,3R)-
2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(isoxazol-3-yl)-thiophene-2-carboxamide;
N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3H-imidazol-4-yl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-4-(4- hydroxyphenylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-4-(3-acetamidophenylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-melhyl-l-azabicyclo[2.2.2]oct-3-yl]-4-(2- methanesulfonylaminophenyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-mcthyl- 1 - azabicyclo[2.2.2]oct-3-yl]-4-(pyridin-2-yloxy)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-4-(2-methylpyridin-4-yloxy)- thiophene-2-caι-boxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-4-(4- trifluoromethylphenyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-4-(2-acetylphenyl)-thiophene-2-carboxamide,N-[(2S,3R)-2- methyl-l-azabicyclo[2.2.2]oct-3-yl]-4-chloro-5-phenyl-thiophene-2-carboxamide; N[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-4-methyl-5-phenyl-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-4-cyano-5-phenyl- thiophene-2-carboxamide; N-[(2S,3R)-2-melhyl-l-azabicyclo[2.2.2]oct-3-yl]-4- methoxy-5-phenyl-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-chloro-4-phenyl-thiophene-2-carboxamide; N-[(2S,3R)- 2-nιethyl-l-azabicyclo[2.2.2]oct-3-yl]-5-methyl-4-phenyl-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-cyano-4-ρhenyl-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-methoxy-4- phenyl-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]- 4-chloro-5-bromo-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-4-chloro-5-methylsulfanyl-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-4-chloro-5-methyl-thiophene-2- cai-boxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-4-chloro-5-cyano- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5- chloro-4-bromo-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-chloro-4-methylsulfanyl-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-chloro-4-methyl-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-chloro-4-cyano- thiophene-2-carboxamide;
N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(2-bromophenyl)-furan-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-bromophenyl)-furan-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2,3-dichlorophenyl)-furan-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2,4-dichlorophenyl)-furan-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2,5-dichlorophenyl)-furan-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]ocl-3-yl]-5-(2,6-dichlorophenyl)-furan-2-carboxamide; N- [(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(3,4-dichlorophenyl)-furan-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,5-dichlorophenyl)-furan-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-amino-2-fluorophenyl)-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-amino-2-fluorophenyl)-furan-2- carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(4-amino-2-chlorophenyl)- furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-amino-2- chlorophenyl)-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- aminophenyl)-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- cyanophenyl)-furan-2 -carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- cyanophenyl)-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- hydroxyphenyl)-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- hydroxyphenyl)-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- hydroxyphenyl)-furan-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(2- fluoro-4-methylphenyl)-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]- 5-(2-fluoro-3-methoxyphenyl)-furan-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct- 3-yl]-5-(2-fluoro-4-methoxyphenyl)-furan-2-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(2-[(methylsulfonyl)amino]phenyl)-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-[(methylsulfonyl)amino]phenyl)-furan-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- [(methylsulfonyl)amino]phenyl)-furan-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(2-([(trifluoromethyl)sulfonyl]amino)phenyl)-furan-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- ([(trifluoromethyl)sulfonyl]amino)phenyl)-furan-2-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(4-([(trifluoromethyl)sulfonyl]amino)phenyl)-furan-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- [(phenylsulfonyl)amino]phenyl)-furan-2-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(3-[(phenylsulfonyl)amino]phenyl)-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-[(phenylsulfonyl)amino]phenyl)-furan-2- carboxamide; N-[(3R)-1 -azabicyclo[2.2.2]oct-3-yl]-5-(2- [(methylamino)carbonyl]phenyl)-furan-2-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(3-[(methylamino)carbonyl]phenyl)-furan-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- [(methylamino)carbonyl]phenyl)-furan-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(2-[(methylamino)sulfonyl]phcnyl)-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-[(methylamino)sulfonyl]phenyl)-furan-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- [(methylamino)sulfonyl]phenyl)-furan-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-[2-(methylamino)phenyl]-furan-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[3-(methylamino)phenyl]-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[4-(methylamino)phenyl]-furan-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[2-(ethylamino)phenyl]-furan- 2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[3-(ethylamino)phenyl]- furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[4- (ethylamino)phenyl]-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- (2-acetylphenyl)-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- acetylphenyl)-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- acetylphenyl)-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[2- (methylthio)phenyl]-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- [3-(methylthio)ρhenyl]-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]- 5-[4-(methylthio)phenyl]-furan-2-caι-boxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-[2-(phenylthio)phenyl]-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-[3-(phenylthio)phenyl]-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-[4-(phenylthio)phenyl]-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(2-phenoxyphenyl)-furan-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]- 5-(3-phenoxyphenyl)-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- (4-phenoxyphenyl)-fιιran-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- anilinophenyl)-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- anilinophenyl)-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- anilinophenyl)-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- (phenylthio)-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[(2- fluorophenyl)thio]-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[(3- fluorophenyl)thio]-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[(4- fluorophenyl)thio]-furan-2-caι-boxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[(2- chlorophenyl)thio]-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[(3- chlorophenyl)thio]-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[(4- chlorophenyl)thio]-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- fluorophenoxy)-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- fluorophenoxy)-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- fluorophenoxy)-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- chlorophenoxy)-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- chlorophenoxy)-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- chlorophenoxy)-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- pyridin-2-yl-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-pyridin-3- yl-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-pyridin-4-yl-furan-2- carboxamide N-[ (3R 1-azabicyclo [2.2.2]oct-3-yl]-5-l (3-fluoropyridin-2-yl)-furan-2- carboxamide N-l (3R 1-azabicyclo [2.2.2]oct-3-yl]-5 (4-fluoropyridin-2-yl)-furan-2- carboxamide N-[ (3R 1-azabicyclo [2.2.2]oct-3-yl]-5- (5-fluoropyridin-2-yl)-furan-2- carboxamide N-[ (3R 1-azabicyclo [2.2.2]oct-3-yl]-5 (6-fluoropyridin-2-yl)-furan-2- carboxamide N-[ (3R 1-azabicyclo [2.2.2]oct-3-yl]-5 (2-fluoropyridin-3-yl)-furan-2- carboxamide N-[ (3R 1-azabicyclo [2.2.2]oct-3-yl]-5 (4-fluoropyridin-3-yl)-furan-2- carboxamide N-[ (3R 1-azabicyclo [2.2.2]oct-3-yl]-5 (5-fluoropyridin-3-yl)-furan-2- carboxamide N-[ (3R 1-azabicyclo [2.2.2]oct-3-yl]-5- (6-fluoropyridin-3-yl)-furan-2- carboxamide N-[ (3R 1-azabicyclo [2.2.2]oct-3-yl]-5 (2-fluoropyridin-4-yl)-furan-2- carboxamide N-[ (3R 1-azabicyclo [2.2.2]oct-3-yl]-5- (3 -fluoropyridin-4-yl)-furan-2- carboxamide N-l (3R 1-azabicyclo [2.2.2]oct-3-yl]-5 (3-chloropyridin-2-yl)-furan-2- carboxamide N-l (3R 1-azabicyclo [2.2.2]oct-3-yl]-5- (4-chloropyridin-2-yl)-furan-2- carboxamide N-l ,(3R 1-azabicyclo [2.2.2]oct-3-yl]-5 (5-chloropyridin-2-yl)-furan-2- carboxamide N- (3R 1-azabicyclo [2.2.2]oct-3-yl]-5 (6-chloropyridin-2-yl)-furan-2- carboxamide N-l (3R 1-azabicyclo [2.2.2]oct-3-yl]-5 (2-chloropyridin-3-yl)-furan-2- carboxamide N-l (3R 1-azabicyclo [2.2.2]oct-3-yl]-5 (4-chloropyridin-3 -yl)-f uran-2- carboxamide N-l (3R 1-azabicyclo [2.2.2]oct-3-yl]-5 (5-chloropyridin-3-yl)-furan-2-
1 carboxamide N- .(3R 1-azabicyclo [2.2.2]oct-3-yl]-5 (6-chloropyridin-3-yl)-furan-2- carboxamide N- (3R 1-azabicyclo [2.2.2]oct-3-yl]-5 (2-chloropyridin-4-yl)-furan-2- carboxamide N-l X3R 1-azabicyclo [2.2.2]oct-3-yl]-5 (3-chloropyridin-4-yl)-furan-2- carboxamide: N- X3R 1-azabicyclo [2.2.2]oct-3-yl]-5 (2-ρiρeridin- 1 -ylphenyl)-furan- 2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-piρeridin-l-ylphenyl)- furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-piperidin-l- ylphenyI)-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- morpholin-4-ylphenyl)-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- (3-morpholin-4-ylphenyl)-furan-2-carboxamide; N-[(3R)-1 -azabicyclo[2.2.2]oct-3- yl]-5-(4-moιpholin-4-ylphenyI)-furan-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(2-pyrrolidin- 1 -ylphenyl)-furan-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-pyrrolidin-l-ylphenyl)-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-pyrrolidin-l-ylphenyl)-furan-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[2-(lH-pyrrol-2-yl)phenyl]- furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[3-(lH-pyrrol-2- yl)phenyl]-furan-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-[4-(lH- pyrrol-2-yl)phenyl]-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[2- (2-fuιyl)phenyl]-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[2-(3- fuιyl)phenyl]-furan-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-[2-(5- methyl-2-furyl)phenyl]-furan-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]- 5-[3-(2-furyl)phenyl]-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- [3-(3-fuιyl)phenyl]-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[3- (5-methyl-2-furyl)phenyl]-furan-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3- yl]-5-[4-(2-furyl)phenyl]-furan-2-carboxamide; N-[(3R)- l-azabicyclo[2.2.2]oct-3-yl]- 5-[4-(3-furyl)phenyl]-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- [4-(5-methyl-2-furyI)phenyl]-furan-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct- 3-yl]-5-[2-(l,3-thiazol-2-yl)phenyl]-furan-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-[3-(l,3-thiazol-2-yl)phenyl]-furan-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[4-(l,3-thiazol-2-yl)ρhenyl]-furan-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[2-(l,3-oxazol-2-yl)phenyl]- furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[3-(l,3-oxazol-2- yl)phenyl]-furan-2-carboxamide; N-[(3R)- l-azabicyclo[2.2.2]oct-3-yl]-5-[4-( 1 ,3- oxazol-2-yl)phenyl]-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- isothiazol-5-ylphenyl)-furan-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5- (3-isothiazol-5-ylphenyl)-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]- 5-(4-isothiazol-5-ylphenyl)-furan-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3- yl]-5-[4-( 1 H-indol-2-yl)phenyl]-furan-2-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-[4-( 1 H-indol-3-yl)phenyl]-furan-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(lH-indol-5-yl)-furan-2-carboxamide; N-[(3R)- l-azabicyclo[2.2.2]oct-3-yl]-5-(lH-indol-6-yl)-furan-2-carboxamide;
N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-bromophenyl)-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-bromophenyl)- furan-2-carboxamide; N-[(2S,3R)-2-methyl- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(2,3- dichlorophenyl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct- 3-yl]-5-(2,4-dichlorophenyl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2,5-dichlorophenyl)-furan-2-carboxamide; N-[(2S,3R)- 2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2,6-dichlorophenyl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,4-dichloroρhenyl)-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,5- dichlorophenyl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct- 3-yl]-5-(4-amino-2-fluorophenyl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(3-amino-2-fluorophenyl)-furan-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicycIo[2.2.2]oct-3-yl]-5-(4-amino-2-chlorophenyl)-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-amino-2- chlorophenyl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl- 1 -azabicyclo[2.2.2]oct-3- yl]-5-(3-aminophenyl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(2-cyanophenyl)-furan-2-carboxamide; N-[(2S,3R)-2- methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-cyanophenyl)-furan-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]ocl-3-yl]-5-(2-hydroxyphenyl)-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- hydroxyphenyl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l -azabicyclo[2.2.2]oct- 3-yl]-5-(4-hydroxyphenyl)-furan-2-caι-boxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-fluoro-4-methylphenyl)-furan-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-fluoro-3-methoxyphenyl)-furan- 2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-fluoro-4- methoxyphenyl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct- 3-yl]-5-(2-[(methylsulfonyl)amino]phenyl)-furan-2-carboxamide; N-[(2S,3R)-2- methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-[(methylsulfonyl)amino]phenyl)-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- [(methylsulfonyl)amino]phenyl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-[2-([(trifluoromethyl)sulfonyl]amino)phenyl]-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[3- ([(trifluoromethyl)sulfonyl]amino)phenyl]-furan-2-carboxamide; N-[(2S,3R)-2- methyl- l-azabicyclo[2.2.2]oct-3-yl]-5-(4-([(trifluoromethyl)sulfonyl]amino)phenyl)- furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- [(phenylsulfonyl)amino]phenyl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(3-[(phenylsulfonyl)amino]phenyl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- r(phenylsulfonyl)amino]phenyl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl- 1- azabicyclo[2.2.2]oct-3-yl]-5-(2-[(methylamino)carbonyl]phenyl)-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- [(methylamino)carbonyl]phenyl)-fύran-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(4-[(methylamino)carbonyl]phenyl)-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-
[(methylamino)sulfonyl]phenyl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(3-[(methylamino)sulfonyl]phenyl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- [(methylamino)sulfonyl]phenyl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-[2-(methylamino)phenyl]-furan-2-carboxamide; N-
[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[3-(methylamino)phenyl]-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[4- (methylamino)phenyl]-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-[2-(ethylamino)phenyl]-furan-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[3-(ethylamino)phenyl]-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[4- (ethylamino)phenyl]-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-acetylphenyl)-furan-2-carboxamide; N-[(2S,3R)-2- methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-acetylphenyl)-furan-2-carboxamide; N- • [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-acetylphenyl)-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[2- (methylthio)phenyl]-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-[3-(methylthio)phenyl]-furan-2-caι-boxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[4-(methyIthio)phenyl]-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[2- (phenylthio)phenyl]-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-[3-(phenylthio)phenyl]-furan-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[4-(phenylthio)phenyl]-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- phenoxyphenyl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct- 3-yl]-5-(3~phenoxyphenyl)-furan-2-carboxamide; N-[(2S,3R)-2-mefhyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(4-phenoxyphenyl)-furan-2-carboxamide; N-[(2S,3R)-2- methyl- l-azabicyclo[2.2.2]oct-3-yl]-5-(2-anilinophenyl)-furan-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-anilinophenyl)-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-anilinophenyl)- furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5- (phenyllhio)-furan-2-caι-boxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3- yl]-5-[(2-fluorophenyl)thio]-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-[(3-fluorophenyl)thio]-furan-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[(4-fluorophenyl)thio]-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[(2- chIorophenyl)thio]-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-[(3-chlorophenyl)thio]-furan-2-carboxamide; N-
[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[(4-chlorophenyl)thio]-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- fluorophenoxy)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3- yl]-5-(3-fluorophenoxy)-furan-2-carboxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(4-fluorophenoxy)-furan-2-carboxamide; N-[(2S,3R)-2- methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-chlorophenoxy)-furan-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-chlorophenoxy)-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- chlorophenoxy)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct- 3-yl]-5-pyridin-2-yl-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-pyridin-3-yl-furan-2-carboxamide; N-[(2S,3R)-2-methyl- l-azabicyclo[2.2.2]oct-3-yl]-5-pyridin-4-yl-furan-2-carboxamide; N-[(2S,3R)-2- methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-fluoiOpyridin-2-yl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-fluoiOpyridin-2-yl)-furan-2- carboxamide; N-[(2S,3R)-2-melhyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-fluoropyridin- 2-yl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(6- fluoropyridin-2-yl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-fluoropyridin-3-yl)-furan-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-fluoropyridin-3-yl)-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-fluoropyridin- 3-yl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(6- fluoropyridin-3-yl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-fluoropyridin-4-yl)-furan-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-fluoropyridin-4-yl)-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-chloropyridin- 2-yl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- chloropyridin-2-yI)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(5-ch!oropyridin-2-yl)-furan-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(6-chloropyridin-2-yl)-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-chloropyridin- 3-yl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- chloropyridin-3-yl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]ocl-3-yl]-5-(5-chloropyridin-3-yl)-furan-2-carboxamide; N-
[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(6-chloropyridin-3-yl)-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-chloropyridin- 4-yl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- chloropyridin-4-yl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(2-piperidin-l-ylphenyl)-furan-2-caι-boxamide; N-
[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-piperidin-l-ylphenyl)-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-piperidin-l- ylphenyl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5- (2-moιpholin-4-ylphenyl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(3-moφholin-4-ylphenyl)-furan-2-carboxamide; N-
[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-moφholin-4-ylphenyl)-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-pyrrolidin-l- ylphenyl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5- (3-pyrrolidin- 1 -ylphenyl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(4-pyrrolidin-l-ylphenyl)-furan-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[2-(lH-pyrrol-2-yl)phenyl]-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[3-(lH-pyrrol-2- yl)phenyl]-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]- 5-[4-(lH-pyrrol-2-yl)phenyl]-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-[2-(2-furyl)phenyl]-furan-2-carboxamide; N-[(2S,3R)-2- methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[2-(3-fuιyl)phenyl]-furan-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[2-(5-methyl-2-furyl)phenyl]-furan- 2-carboxamid; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[3-(2- furyl)phenyl]-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3- yl]-5-[3-(3-furyl)phenyl]-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-[3-(5-methyl-2-furyl)phenyl]-furan-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[4-(2-furyl)phenyl]-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[4-(3- furyl)phenyl]-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3- yl]-5-[4-(5-methyl-2-furyl)phenyl]-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-[2-(l,3-thiazol-2-yl)phenyl]-furan-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[3-(l,3-thiazol-2-yl)phenyl]-furan- 2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[4-(l,3-thiazol- 2-yl)phenyl]-furan-2-carboxamide; N-[(2S,3R)-2-methyl- 1 -azabicyclo[2.2.2]oct-3- yl]-5-[2-(l,3-oxazol-2-yl)phenyl]-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-[3-( 1 ,3-oxazol-2-yl)phenyl]-furan-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[4-(l,3-oxazol-2-yl)phenyl]-furan- 2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-isothiazol-5- ylphenyl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5- (3-isothiazol-5-ylphenyl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(4-isothiazol-5-ylphenyl)-furan-2-caι-boxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[4-(lH-indol-2-yl)phenyl]-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[4-(lH-indol-3- yl)phenyl]-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]- 5-(lH-indol-5-yl)-furari-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct- 3-yl]-5-(lH-indol-6-yl)-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-(2,3-difluorophenyl)-l,3-thiazole-5- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-(2,4-difluorophenyl)-l,3- thiazole-5-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-(2,5- difluorophenyl)-l,3-thiazole-5-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2- (2,6-difluorophenyl)-l,3-thiazole-5-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-2-(3,4-difluorophenyl)-l,3-thiazole-5-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-2-(3,5-difluorophenyl)-l,3-thiazole-5-carboxamide; N- [(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-2-(2-chlorophenyl)- 1 ,3-thiazole-5-carboxamide; 1 -azabicyclo[2.2.2] ocl t-3-yl -2- 3-chlorophenyl)- 1 ,3-thiazole-5-carboxamide; l-azabicyclo[2.2.2]ocl t-3-yl -2- 4-chlorophenyl)- 1 ,3-thiazole-5-carboxamide; l-azabicyclo[2.2.2]oc -3-yl -2- 2-bromophenyl)- 1 ,3-thiazole-5-carboxamide; l-azabicyclo[2.2.2]ocl t-3-yl -2- 3-bromophenyl)-l,3-thiazole-5-carboxamide; l-azabicyclo[2.2.2]ocl :-3-yl -2- 4-bromophenyl)- 1 ,3-thiazole-5-carboxamide; l-azabicyclo[2.2.2]od .-3-yl -2- 2-cyanophenyl)-l,3-thiazole-5-carboxamide; l-azabicyclo[2.2.2]ocl :-3-yl -2- 3-cyanophenyl)- 1 ,3-thiazole-5-carboxamide; l-azabicyclo[2.2.2]ocl .-3-yl -2- 4-cyanophenyl)- 1 ,3-thiazole-5-caι-boxamide; l-azabicyclo[2.2.2]ocl .-3-yl -2- 2-nitrophenyl)-l,3-thiazole-5-carboxamide; l-azabicyclo[2.2.2]ocl 3-yl -2- 3-nitrophenyl)- 1 ,3-thiazole-5-carboxamide; l-azabicyclo[2.2.2]ocl [-3-yl -2- 4-nitrophenyl)- 1 ,3-thiazole-5-carboxamide; 1 -azabicyclo[2.2.2]od .-3-yl -2- 2-methylphenyl)- 1 ,3-thiazole-5-carboxamide; l-azabicyclo[2.2.2]ocl .-3-yl -2- 3-methylphenyl)- 1 ,3-thiazole-5-carboxamide;. l-azabicyclo[2.2.2]ocl .-3-yl -2- 2-aminophenyl)- 1 ,3-thiazole-5-carboxamide; l-azabicyclo[2.2.2]ocl .-3-yl -2- 3-aminophenyl)-l,3-thiazole-5-carboxamide; l-azabicyclo[2.2.2]ocl :-3-yl -2- 4-aminophenyl)- 1 ,3-thiazole-5-carboxamide; l-azabicyclo[2.2.2]od t-3-yl -2- [2-(methylamino)phenyl]-l,3-thiazole-5- carboxamide; N- [(3 R)- 1-azabicyclo [2.2.2]oct-3-yl]-2-[3-(methylamino)phenyl]- 1 ,3- thiazole-5-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-[4- (methylamino)phenyl]-l,3-thiazole-5-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct- 3-yl]-2-[2-(acetylamino)phenyl]-l,3-thiazole-5-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-2-[3-(acetylamino)phenyl]-l,3-thiazole-5-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-[4-(acetylamino)phenyl]-l,3-thiazole-5- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-(2- [(trifluoroacetyl)amino]phenyl)- 1 ,3-thiazole-5-carboxamide; N-[(3R)- 1- azabicyclo[2.2.2]oct-3-yl]-2-(3-[(trifluoroacetyl)amino]phenyl)-l,3-thiazole-5- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-(4- [(trifluoroacetyl)amino]phenyl)-l,3-thiazole-5-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-2-(2-[(methylsulfonyl)amino]phenyl)-l,3-thiazole-5- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-(3- [(methylsulfonyl)amino]phenyl)-l,3-thiazole-5-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-2-(4-[(methylsulfonyl)amino]phenyl)-l,3-thiazole-5- carboxamide; N-[(3R)-l-azabicycIo[2.2.2]oct-3-yl]-2-(3-hydroxyphenyl)-l,3- thiazole-5-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-2-(4-hydroxyphenyl)- 1 ,3-thiazole-5-carboxamide; N-[(3R)-1 -azabicyclo[2.2.2]oct-3-yl]-2-(2- methoxyphenyl)-l,3-thiazole-5-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2- (3-methoxyphenyl)-l,3-thiazole-5-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-2-(4-methoxyphenyl)-l,3-thiazole-5-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-2-[2-(trifluoromethoxy)phenyl]-l,3-thiazole-5- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-[3-(trifluoromethoxy)phenyl]- l,3-thiazole-5-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-[4- (trifluoromethoxy)phenyl]- 1 ,3-thiazole-5-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-2-pyridin-2-yl-l,3-thiazole-5-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-2-pyridin-3-yl-l,3-thiazole-5-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-2-pyridin-4-yl-l,3-thiazoIe-5-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-2-(6-fluoropyridin-2-yl)- 1 ,3-thiazole-5-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-(5-fluoropyridin-2-yl)-l,3-thiazole-5- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-(4-fluoropyridin-2-yl)-l,3- thiazole-5-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-(3-fluoropyridin-2- yl)-l,3-thiazole-5-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-(2- fluoropyridin-2-yl)- 1 ,3-thiazole-5-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-2-(6-fluoropyridin-3-yl)-l,3-thiazole-5-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-2-(5-fluoropyridin-3-yl)-l,3-thiazole-5-carboxamide; N- [(3R)- l-azabicyclo[2.2.2]oct-3-yl]-2-(4-fluoropyridin-3-yl)- 1 ,3-thiazole-5- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-(2-fluoropyridin-3-yl)-l,3- thiazole-5-caι-boxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-(2-fluoropyridin-4- yl)- 1 ,3-thiazole-5-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-(3- fluoropyridin-4-yl)- 1 ,3-thiazole-5-carboxamide;
N-[(3R)- l-azabicyclo[2.2.2]oct-3-yl]-5-(methylthio)-l ,3-thiazole-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-chloro-l,3-thiazole-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-bromo-l,3-thiazole-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(phenylthio)-l,3-thiazole-2-caι-boxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-[(2-fluorophenyl)thio]-l,3-thiazole-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[(3-fluorophenyl)thio]-l,3-thiazole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[(4-fluorophenyl)thio]-l,3- thiazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[(2- chlorophenyl)thio]-l,3-thiazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-[(3-chlorophenyl)thio]-l,3-thiazole-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-[(4-chlorophenyl)thio]-l,3-thiazole-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-phenoxy-l,3-thiazole-2-carboxamide; N-[(3R)- l-azabicyclo[2.2.2]oct-3-yl]-5-(2-fluorophenoxy)-l,3-thiazole-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-fluorophenoxy)-l,3-thiazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-fluorophenoxy)-l,3-thiazole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-chlorophenoxy)-l,3- thiazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-chlorophenoxy)- 1 ,3-thiazole-2-carboxamide; N-[(3R)- l-azabicyclo[2.2.2]oct-3-yl]-5-(4- chlorophenoxy)-l,3-thiazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl)]- 5-thien-3-yl-l,3-thiazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- (2,4-difluorophenyl)-l,3-thiazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(3,5-difluorophenyl)-l,3-thiazole-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(2,4-dichlorophenyl)-l,3-thiazole-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,5-dichlorophenyl)-l,3-thiazole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-bromophenyl)-l,3-thiazole- 2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-bromophenyl)-l,3- thiazole-2-carboxamide; N-[(3R)- l-azabicyclo[2.2.2]oct-3-yl]-5-(2-cyanophenyl)- l,3-thiazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- cyanophenyl)- 1 ,3-thiazole-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5- (4-cyanophenyl)-l,3-thiazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]- 5-(2-hydroxyphenyl)-l,3-thiazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(3-hydroxyphenyl)-l ,3-thiazole-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(4-hydroxyphenyl)-l,3-thiazole-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-nitrophenyl)-l,3-thiazole-2 -carboxamide; N- [(3R)-1 -azabicyclo[2.2.2]oct-3-yl]-5-(4-nitrophenyl)-l ,3-thiazole-2-carboxamide; N- [(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(2-methylphenyl)- 1 ,3-thiazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-methylphenyl)-l,3-thiazole-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(4-methylphenyl)- 1 ,3-thiazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-aminophenyl)-l,3-thiazole-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl j-5-(3-aminophenyl)- 1 ,3-thiazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-aminophenyl)-l,3-thiazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[(2-(acetylamino)ρhenyl]-l,3-thiazole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[3-(acetylamino)phenyl]-l,3- thiazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[4- (acetylamino)phenyl]-l,3-thiazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(pyridin-2-yl)-l,3-thiazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(pyridin-3-yl)-l,3-thiazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(pyridin-4-yI)-l,3-thiazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(3-fluoropyridin-2-yl)-l,3-thiazole-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(4-fluoropyridin-2-yl)-l ,3-thiazole-2-carboxamide; N- [(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(5-fluoropyridin-2-yl)- 1 ,3-thiazole-2- cai-boxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(6-fluoropyridin-2-yl)-l,3- thiazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-fluoropyridin-3- yl)-l,3-thiazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- fluoropyridin-3-yl)-l,3-thiazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(5-fluoropyridin-3-yl)-l,3-thiazole-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(6-fluoropyridin-3-yl)- 1 ,3-thiazole-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-fluoropyridin-4-yl)-l,3-thiazole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[(2-methoxyphenyl)thio]-l,3- thiazole-2-carboxamide; N-[(3R)- l-azabicyclo[2.2.2]oct-3-yl]-5-[(3- methoxyphenyl)thio]-l ,3-thiazole-2-carboxamide; N-[(3R)-1 -azabicyclo[2.2.2]oct-3-. yl]-5-[(4-methoxyphenyl)thio]- 1 ,3-thiazole-2-carboxamide; N-[(3R)- 1- azabicyclo[2.2.2]oct-3-yl]-5-[(2-methylphenyl)thio]- 1 ,3-thiazole-2-carboxamide; N- [(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-[(3-methylphenyl)thio]- 1 ,3-thiazole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[(4-methylphenyl)thio]-l,3- thiazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-([4- (acetylamino)phenyl]thio)-l,3-thiazole-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-[(4-aminophenyl)thio]-l,3-thiazole-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[(4-hydroxyphenyl)thio]-l,3-thiazole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methylphenoxy)-l,3- thiazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-methylphenoxy)- 1 ,3-thiazole-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(4- methylphenoxy)-l,3-thiazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- (2-methoxyphenoxy)-l,3-thiazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(3-methoxyphenoxy)-l,3-thiazole-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(4-methoxyphenoxy)- 1 ,3-thiazole-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-hydroxyphenoxy)-l,3-thiazole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-aminophenoxy)-l,3- thiazole-2-caι-boxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[4- (acetylamino)phenoxy]-l,3-thiazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct- 3-yl]-5-(2-fluorophenyl)-4-methyl-l,3-thiazole-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(3-fluorophenyl)-4-methyl-l,3-thiazole-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(2-chlorophenyl)-4-methyl- 1 ,3-thiazole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-chlorophenyl)-4-methyl-l,3- thiazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methoxyphenyl)- 4-methyl-l,3-thiazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- methoxyphenyl)-4-methyl- 1 ,3-thiazole-2-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-4-methyl-5-thien-2-yl-l,3-thiazole-2-carboxamide,
N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-(2,3-difluorophenyl)-l,3- thiazole-5-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-(2,4- difluorophenyl)-l,3-thiazole-5-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-2-(2,5-difluorophenyl)-l,3-thiazole-5-caιboxamide; N-
[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-(2,6-difluorophenyl)-l,3-thiazole-5- cai-boxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-(3,4- difluorophenyl)-l,3-thiazole-5-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-2-(3,5-difluorophenyl)-l,3-thiazole-5-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-(2-chlorophenyl)-l,3-thiazole-5- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-(3-chlorophenyl)- l,3-thiazole-5-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-(4- chlorophenyl)-l,3-thiazole-5-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-2-(2-bromophenyl)-l,3-thiazole-5-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yI]-2-(3-bromoρhenyl)-l,3-thiazole-5- cai-boxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-(4-bromophenyl)- l,3-thiazole-5-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-(2- cyanophenyl)-l,3-thiazole-5-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-2-(3-cyanophenyl)-l,3-thiazole-5-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-(4-cyanophenyl)-l,3-thiazole-5- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-(2-nitrophenyl)- l,3-thiazole-5-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-(3- nitrophenyl)-l,3-thiazole-5-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-2-(4-nitroρhenyl)-l,3-thiazole-5-carboxamide; N- [(2S,3R)-2-methyl- 1 -azabicyclo[2.2.2]oct-3-yl]-2-(2-methylphenyl)- 1 ,3-thiazole-5- carboxamide; N-[(2S,3R)-2-methyl- 1 -azabicyclo[2.2.2]oct-3-yl]-2-(3-methylphenyl)- l,3-thiazole-5-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-(2- aminophenyl)-l,3-thiazole-5-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-2-(3-aminophenyl)-l,3-thiazole-5-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-(4-aminophenyl)-l,3-thiazole-5- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-[2- (methylamino)phenyl]-l,3-thiazole-5-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-2-[3-(methylamino)phenyl]- 1 ,3-thiazole-5-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-[4-(methylamino)phenyl]-l,3- thiazole-5-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-[2- (acetylamino)phenyl]-l,3-thiazole-5-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-2-[3-(acetylamino)phenyl]-l,3-thiazole-5-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-[4-(acetylamino)phenyl]-l,3- thiazoIe-5-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-(2- [(trifluoroacetyl)amino]phenyl)-l,3-thiazole-5-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-2-(3-[(trifluoroacetyl)amino]phenyl)-l,3-thiazole-5- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-(4- [(trifluoroacetyl)amino]phenyl)-l,3-thiazole-5-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2Joct-3-yl]-2-(2-[(methylsulfonyl)amino]phenyl)-l,3-thiazole-5- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-(3- [(methylsulfonyl)amino]phenyl)-l,3-thiazole-5-carboxamide; N-[(2S,3R)-2-methyl- l-azabicyclo[2.2.2]oct-3-yl]-2-(4-[(methylsulfonyl)amino]phenyl)-l,3-thiazole-5- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-(3- hydroxyphenyl)-l,3-thiazole-5-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-2-(4-hydroxyphenyl)-l,3-thiazole-5-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-(2-methoxyρhenyl)-l,3-thiazole-5- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-(3- methoxyphenyl)-l,3-thiazole-5-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-2-(4-melhoxyphenyl)-l,3-thiazole-5-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-[2-(trifluoromethoxy)phenyl]-l,3- thiazole-5-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]ocl-3-yl]-2-[3- (trifluoromethoxy)phenyl]-l,3-thiazole-5-carboxamide; N- [(2S,3R)-2 -methyl- 1- azabicyclo[2.2.2]oct-3-yl]-2-[4-(trifluoromethoxy)phenyl]-l,3-thiazole-5- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-pyridin-2-yl-l,3- lhiazole-5-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-pyridin- 3-yl-l,3-thiazole-5-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]- 2-pyridin-4-yl-l,3-thiazole-5-caιtoxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-2-(6-fluoropyridin-2-yl)- 1 ,3-thiazole-5-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-(5-fluoroρyridin-2-yl)-l,3-thiazole- 5-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-(4- fluoropyridin-2-yl)-l,3-thiazole-5-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-2-(3-fluoropyridin-2-yl)-l,3-thiazole-5-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-(2-fluoroρyridin-2-yl)-l,3-thiazole- 5-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-(6- fluoropyridin-3-yl)- 1 ,3-thiazole-5-carboxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-2-(5-fluoropyridin-3-yl)-l,3-thiazole-5-carboxamide; N- [(2S,3R)-2-methyl-l-azabicycIo[2.2.2]oct-3-yl]-2-(4-fluoroρyridin-3-yl)-l,3-thiazole- 5-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-(2- fluoropyridin-3-yl)- 1 ,3-thiazole-5-carboxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-2-(2-fluoropyridin-4-yl)- 1 ,3-thiazole-5-carboxamide; N-
[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-(3-fluoropyridin-4-yl)-l,3-thiazole-
5-carboxamide;
N-[(2S,3R)-2-methyl- l-azabicyclo[2.2.2]oct-3-yl]-5-(methylthio)-l ,3-thiazole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-chloro-l,3- thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-bromo- l,3-thiazole-2-carboxamide, N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5- (phenylthio)- 1 ,3-thiazole-2-carboxamide; N-[(2S ,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-[(2-fluorophenyl)thio]-l,3-thiazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[(3-fluorophenyl)thio]-l,3-thiazole- 2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[(4- fluorophenyl)thio]-l,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]ocl-3-yl]-5-[(2-chlorophenyl)thio]- 1 ,3-thiazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[(3-chlorophenyl)thio]-l,3-thiazole- 2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[(4- chlorophenyl)lhio]-l,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-phenoxy-l,3-thiazole-2-carboxamide; N-[(2S,3R)-2- methyl- l-azabicyclo[2.2.2]oct-3-yl]-5-(2-fluoroρhenoxy)- 1 ,3-thiazoIe-2-carboxamide; N-[(2S,3R)-2-methyl- l-azabicyclo[2.2.2]oct-3-yl]-5-(3-fluorophenoxy)- 1 ,3-thiazole- 2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- fluorophenoxy)-l,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-chlorophenoxy)- 1 ,3-thiazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-chlorophenoxy)-l,3-thiazole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- chlorophenoxy)-l,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-thien-3-yl-l,3-thiazole-2-carboxamide; N-[(2S,3R)-2- methyl- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(2,4-difluorophenyl)- 1 ,3-thiazole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,5- difluorophenyl)- 1 ,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(2,4-dichlorophenyl)- 1 ,3-thiazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,5-dichlorophehyl)-l,3-thiazole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-bromophenyl)- l,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- bromophenyl)-l,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-cyanophenyl)-l,3-thiazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]ocl-3-yl]-5-(3-cyanophenyl)-l,3-thiazole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-cyanophenyl)- l,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- hydroxyphenyl)-l,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(3-hydroxyphenyl)- 1 ,3-thiazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-hydroxyphenyl)-l,3-thiazole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-nitrophenyl)- l,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- nitrophenyl)-l,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-methylphenyl)- 1 ,3-thiazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-methylphenyl)-l,3-thiazole-2- carboxamide; N-[(2S,3R)-2-methyl- l-azabicyclo[2.2.2]oct-3-yl]-5-(4-methylphenyl)- l,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- aminophenyl)-l,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(3-aminophenyl)- 1 ,3-thiazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-aminophenyl)-l,3-thiazole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[2-
(acetylamino)phenyl]- 1 ,3-thiazole-2-carboxamide; N-[(2S ,3R)-2-methyl- 1 - azabicyclo[2.2.2]ocl-3-yl]-5-[3-(acetylamino)phenyl]- 1 ,3-thiazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[4-(acetylamino)phenyl]-l,3- thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5- (pyridin-2-yl)-l,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(pyridin-3-yl)-l,3-thiazole-2-carboxamide; N-[(2S,3R)- 2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(pyridin-4-yl)-l,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-fluoropyridin-2-yl)-l,3- thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- fluoiOpyridin-2-yl)-l,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(5-fluoropyridin-2-yl)- 1 ,3-thiazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(6-fluoropyridin-2-yl)-l,3-thiazole- 2-carboxamide; N-[(2S,3R)-2-methyl- 1 -azabicydo[2.2.2]oct-3-yl]-5-(2- fluoropyridin-3-yl)-l,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(4-fluoropyridin-3-yl)-l,3-thiazole-2-carboxamide; N- [(2S,3R)-2-mcthyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-fluoropyridin-3-yl)-l,3-thiazole- 2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(6- fluoropyridin-3-yl)-i ,3-thiazole-2 -carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-fluoropyridin-4-yl)-l,3-thiazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[(2-methoxyphenyl)thio]-l,3- thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yI]-5-[(3- mcthoxyphenyl)thio]-l,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-[(4-methoxyphenyl)thio]- 1 ,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[(2-methylphenyI)thio]-l,3- thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[(3- methylphenyl)thio]-l,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-[(4-methylphenyl)thio]-l,3-thiazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-([4-(acetylamino)phenyl]thio)-l,3- thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[(4- aminophenyl)thio]-l,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl- 1- azabicyclo[2.2.2]oct-3-yl]-5-[(4-hydroxyphenyI)thio]-l,3-thiazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methylphenoxy)-l,3-thiazole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- methylphenoxy)- 1 ,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(4-methylphenoxy)- 1 ,3-thiazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methoxyphenoxy)-l,3-thiazole- 2-carboxamide; N-[(2S,3R)-2-methyl- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(3- methoxyphenoxy)-l,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(4-methoxyphenoxy)-l,3-thiazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-hydroxyphenoxy)-l,3-thiazole-2- carboxamide; N-[(2S,3R)-2-methyl- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(4- aminophenoxy)-l,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-[4-(acetylamino)phenoxy]-l,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-fluorophenyl)-4-methyl-l,3- thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- fluorophenyl)-4-methyl-l,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-chlorophenyl)-4-methyl-l,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-chlorophenyl)-4-methyl-l,3- lhiazole-2-carboxamide; N-[(2S,3R)-2-melhyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- methoxyphenyl)-4-methyl-l,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(3-methoxyphenyl)-4-methyl-l,3-thiazole-2- carboxamide;
N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-4-methyl-5-thien-2-yl-l,3-thiazole- 2-carboxamide, N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-phenyl-l,3- thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-phenyl- 4-methyl-l,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct- 3-yl]-5-(2-fluorophenyI)-l,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(3-fluorophenyl)-l,3-thiazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-fluorophenyl)-l,3-thiazole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-thien-2-yl-l,3- thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- chlorophenyl)- 1 ,3 -thiazole-2-carboxamide; N-[(2S ,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(3-chlorophenyl)-l,3-thiazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-chlorophenyl)-l,3-thiazole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-bromophenyl)- l,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- nitrophenyl)-l,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-methoxyphenyl)-l,3-thiazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-methoxyphenyl)-l,3-thiazole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- methoxyphenyl)- 1 ,3-thiazole-2-carboxamide; N-[(2S ,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-2-(2-hydroxyρhenyl)-l,3-thiazole-5-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-(4-methylphenyl)-l,3-thiazole-5- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-phenyl- 1 ,3- thiazole-5-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-(2- fluorophenyl)- 1 ,3-thiazole-5-carboxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-2-(3-fluorophenyl)-l,3-thiazole-5-carboxamide; N-
[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-(4-fluoroρhenyl)-l,3-thiazole-5- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-phenylsulfanyl-l,3-oxazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-fluorophenylsulfanyl)-l,3-oxazole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-fluorophenylsulfanyl)-l,3- oxazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- fluorophenylsulfanyl)-l,3-oxazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]ocl-3- yl]-5-(3,4-difluorophenylsulfanyl)- 1 ,3-oxazole-2-carboxamide; N-[(3R)-1 - azabicyclo[2.2.2]oct-3-yl]-5-(2,4-difluorophenylsulfanyl)-l,3-oxazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,5-difluorophenylsulfanyl)-l ,3-oxazole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-chlorophenylsulfanyl)-l,3- oxazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- chlorophenylsulfanyl)-l,3-oxazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(4-chlorophenylsulfanyl)-l,3-oxazole-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(3,4-dichlorophenylsulfanyl)-l,3-oxazole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2,4-dichlorophenylsulfanyl)- l,3-oxazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,5- dichlorophenylsulfanyl)-l,3-oxazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct- 3-yl]-5-(2-fluorophenyl)-l,3-oxazole-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(3-fluorophenyl)-l,3-oxazole-2-carboxamide; N-[(3R)- l-azabicyclo[2.2.2]oct-3-yl]-5-(3,4-difluorophenyl)-l,3-oxazole-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2,4-difluorophenyl)-l,3-oxazole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,5-difluorophenyl)-l,3- oxazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-chlorophenyl)- l,3-oxazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,4- dichlorophenyl)-l,3-oxazole-2 -carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- (2,4-dichlorophenyl)-l,3-oxazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(3,5-dichlorophenyl)-l,3-oxazole-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(2-bromophenyl)- 1 ,3-oxazole-2-carboxamide; N-[(3R)- l-azabicyclo[2.2.2]oct-3-yl]-5-(3-bromophenyl)- 1 ,3-oxazole-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-cyanophenyl)-l,3-oxazole-2-carboxamide; N- [(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(4-cyanophenyl)- 1 ,3-oxazole-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-hydroxyphenyl)-l,3-oxazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-hydroxyphenyl)-l,3-oxazole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-hydroxyphenyl)-l,3- oxazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-nitrophenyl)-l,3- oxazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methylphenyl)- l,3-oxazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- methylphenyl)-l,3-oxazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- (4-methylphenyl)-l,3-oxazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]- 5-(2-methylaminophenyl)- 1 ,3-oxazole-2-carboxamide; N-[(3R)- 1- azabicyclo[2.2.2]oct-3-yl]-5-(3-methylaminoρhenyl)- 1 ,3-oxazole-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-methylaminophenyl)-l,3-oxazole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-aminophenyl)-l,3-oxazole- 2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(3-aminophenyl)- 1 ,3- oxazole-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(4-aminophenyl)- l,3-oxazole-2-carboxamide; N-[(3R)-l-azabicycIo[2.2.2]oct-3-yl]-5-[2- (acetylamino)phenyl]-l,3-oxazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-[3-(acetylamino)phenyl]-l,3-oxazole-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-[4-(acetylamino)phenyl]-l,3-oxazole-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(pyridin-2-yl)-l,3-oxazole-2-carboxamide; N- [(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(pyridin-3-yl)- 1 ,3-oxazole-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(pyridin-4-yl)-l,3-oxazole-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-fluoropyridin-2-yl)-l,3-oxazole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-fluoropyridin-2-yl)-l,3- oxazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-fluoropyridin-2- yl)-l,3-oxazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(6- fluoropyridin-2-yl)-l,3-oxazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(2-fluoropyridin-3-yl)-l,3-oxazole-2-carboxamide; N-[(3R)-1- azabicycIo[2.2.2]oct-3-yl]-5-(4-fluoropyridin-3-yl)- 1 ,3-oxazole-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-fluoropyridin-3-yl)-l,3-oxazole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(6-fluoropyridin-3-yl)-l,3- oxazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-fluoiOpyridin-4- yl)-l ,3-oxazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- fluoropyridin-3-yI)- 1 ,3-oxazole-2-carboxamide; N-[(3R)- 1 -azabicydo[2.2.2]oct-3- yl]-5-phenoxy- 1 ,3-oxazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- (2-fluorophenoxy)-l,3-oxazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]- 5-(3-fluorophenoxy)-l,3-oxazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(4-fluorophenoxy)-l,3-oxazole-2-carboxamide; N~[(3R)-l-azabicyclo[2.2.2]oct- 3-yl]-5-(3,4-difluorophenoxy)-l,3-oxazole-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(2,4-difluorophenoxy)-l,3-oxazole-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,5-difluorophenoxy)-l,3-oxazole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-chlorophenoxy)-l,3- oxazole-2 -carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-chlorophenoxy)- l,3-oxazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- chlorophenoxy)-l,3-oxazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- (3,4-dichlorophenoxy)-l,3-oxazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct- 3-yl]-5-(2,4-dichlorophenoxy)-l,3-oxazole-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(3,5-dichlorophenoxy)-l,3-oxazole-2-carboxamide;
N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-phenyIsulfanyl-l,3-oxazole-2- carboxamide; N-[(2S,3R)~2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- fluorophenylsulfanyl)-l,3-oxazole-2-caι-boxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(3-fluorophenylsulfanyl)- 1 ,3-oxazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-fluorophenylsulfanyl)-l,3- oxazole-2-carboxamide; N-[(2S,3R)-2-methyl- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(3,4- difluorophenylsulfanyl)- 1 ,3-oxazole-2-carboxamide; N- [(2S ,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(2,4-difluorophenylsulfanyl)-l,3-oxazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,5-difluorophenylsulfanyl)-l,3- oxazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- chlorophenylsulfanyl)- 1 ,3-oxazole-2-carboxamide; N-[(2S ,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(3-chlorophenylsulfanyl)-l,3-oxazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-chlorophenylsulfanyl)-l,3- oxazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,4- dichlorophenylsulfanyl)-l,3-oxazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2,4-dichlorophenylsulfanyl)-l,3-oxazole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,5- dichlorophenylsulfanyl)-l,3-oxazole-2-caι-boxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-fluorophenyl)-l,3-oxazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-fluorophenyl)-l,3-oxazole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,4- difluorophenyl)- 1 ,3-oxazole-2-carboxamide; N-[(2S ,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(2,4-difluorophenyl)-l,3-oxazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,5-difluorophenyl)-l,3-oxazole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-chloroρhenyl)- l,3-oxazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5- (3,4-dichlorophenyl)-l,3-oxazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2,4-dichlorophenyl)-l ,3-oxazole-2-cai'boxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,5-dichlorophenyl)-l,3-oxazole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-bromophenyl)- l,3-oxazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- bromophenyl)- 1 ,3-oxazole-2-carboxamide; N-[(2S,3R)-2-methyl- 1- azabicyclo[2.2.2]oct-3-yl]-5-(2-cyaήophenyl)-l,3-oxazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-cyanophenyl)-l,3-oxazole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- hydroxyphenyl)-l,3-oxazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(3-hydroxyphenyl)- 1 ,3-oxazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-hydroxyphenyl)-l,3-oxazole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-nitrophenyl)- 1 ,3-oxazole-2-carboxamide; N-[(2S,3R)-2-methyl- l-azabicyclo[2.2.2]oct-3-yl]-5-(2- methylphenyl)-l,3-oxazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(3-methylphenyl)- 1 ,3-oxazole-2-carboxamide; N- [(2S,3R)-2-methyl- l-azabicyclo[2.2.2]oct-3-yl]-5-(4-methylphenyl)- 1 ,3-oxazole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- methyl aminophenyl)-l ,3-oxazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(3-methylaminophenyl)-l,3-oxazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-methylaminophenyl)-l,3- oxazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- aminophenyl)-l,3-oxazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(3-aminophenyl)-l ,3-oxazole-2-carboxamide; N-
[(2S,3R)-2-methyl- l-azabicyclo[2.2.2]oct-3-yl]-5-(4-aminophenyl)- 1 ,3-oxazole-2- carboxamide; N-[(2S,3R)-2-methyI-l-azabicyclo[2.2.2]oct-3-yl]-5-[2- (acetylamino)phenyl]-l,3-oxazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-[3-(acetylamino)phenyl]-l,3-oxazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[4-(acetylamino)phenyl]-l,3- oxazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5- (pyridin-2-yl)-l,3-oxazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(pyridin-3-yl)-l,3-oxazole-2-carboxamide; N-[(2S,3R)- 2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(pyridin-4-yl)-l,3-oxazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-fluoropyridin-2-yl)-l,3- oxazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- fluoiOpyridin-2-yl)-l,3-oxazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(5-fluoropyridin-2-yl)-l,3-oxazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(6-fluoropyridin-2-yl)-l,3-oxazole- 2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- fluoropyridin-3-yl)-l,3-oxazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(4-fluoropyridin-3-yl)- 1 ,3-oxazole-2-carboxamide; N- l(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-fluoropyridin-3-yl)-l,3-oxazole- 2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(6- fluoropyridin-3-yl)- 1 ,3-oxazole-2-carboxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(2-fluoropyridin-4-yl)-l,3-oxazole-2-caι-boxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-fluoropyridin-3-yl)-l,3-oxazole- 2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-phenoxy-l,3- oxazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yI]-5-(2- fluorophenoxy)-l,3-oxazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(3-fluorophenoxy)- 1 ,3-oxazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-fluorophenoxy)-l,3-oxazole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,4- difluorophenoxy)- 1 ,3-oxazole-2-carboxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(2,4-difluorophenoxy)-l,3-oxazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,5-difluorophenoxy)-l,3-oxazole- 2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- chlorophenoxy)- 1 ,3-oxazole-2-carboxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(3-chlorophenoxy)-l,3-oxazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-chlorophenoxy)-l,3-oxazole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,4- dichlorophenoxy)-l,3-oxazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2,4-dichlorophenoxy)- 1 ,3-oxazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,5-dichlorophenoxy)-l,3-oxazole- 2-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-bromo-l-methyl-lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[2-(methylthio)phenyl]-l-methyl-lH-pyrrole- 2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[4-(methylthio)ρhenyl]-l- methyl- lH-pyrrole-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-phenyl- lH-pyrrole-2-carboxamide; N-[(3R)- l-azabicycIo[2.2.2]oct-3-yI]-5-(2-fluorophenyl)- 1 -methyl- lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- fluorophenyl)- 1 -methyl- 1 H-pyrrole-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct- 3-yl]-5-(4-fluorophenyl)-l -methyl- lH-pyrrole-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(2,3-difluorophenyl)-l-methyl-lH-pyrrole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2,4-difluorophenyl)-l-methyl- lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2,6- difluorophenyl)- 1 -methyl- 1 H-pyrrole-2-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(3,4-difluorophenyl)-l-methyl-lH-pyrrole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,5-difluorophenyl)-l-methyl- lH-ρyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2,4,6- trifluorophenyl)-l -methyl- lH-pyrrole-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(2-chlorophenyl)-l-methyl-lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-chlorophenyl)-l-methyl-lH-pyrrole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-chlorophenyl)-l-methyl-lH- pyπ-ole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2,4-dichlorophenyl)- 1 -methyl- lH-pyrrole-2-carbox amide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,4- dichlorophenyl)- 1 -methyl- 1 H-pyrrole-2-carboxamide; N- [(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(3,5-dichlorophenyl)-l-methyl-lH-pyrrole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-bromophenyl)-l-methyl-lH- ρyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-bromophenyl)-l- methyl-lH-ρyrrole-2-caι-boxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- bromophenyl)-l -methyl- lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct- 3-yl]-5-(2-hydroxyphenyl)- 1-methyl- 1 H-pyrrole-2-carboxamide; N- [(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(3-hydroxyphenyl)-l-methyl-lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-hydroxyphenyl)-l-methyl-lH-pyrrole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methoxyphenyl)-l-methyl- lH-pyιτole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- methoxyphenyl)-l-methyl-lH-pyrrolc-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(4-methoxyphenyl)-l-methyl-lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methylρhenyl)-l-methyl-lH-pyrrole-2- carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(3-methylphenyl)- 1-methyl- 1H- pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-methylphenyl)-l- methyl-lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- methylaminophenyl)- 1 -methyl- 1 H-pyrrole-2-carboxamide; N- [(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(3-methylaminophenyl)-l-methyl-lH-pyrroIe-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-methylaminophenyl)-l- methyl-lH-pyιτole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- nitrophenyl)- 1-methyl- lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(3-nitrophenyl)- 1 -methyl- 1 H-pyrrole-2-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(4-nitrophenyl)- 1 -methyl- 1 H-pyrrole-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-aminophenyl)- 1-methyl- lH-pyrrole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-aminophenyl)-l-methyl-lH- pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-aminophenyl)-l- methyl-lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[2- (acetylamino)phenyl]- 1-methyl- 1 H-pyrrole-2-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-[3-(acetylamino)phenyl]-l-methyl-lH-pyrrole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[4-(acetylamino)phenyl]-l- methyl- lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicycIo[2.2.2]oct-3-yl]-5-(pyrid-2- yl)-l -methyl- lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- (pyrid-3-yl)- 1 -methyl- 1 H-pyrrole-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3- yl]-5-(pyridin-4-yl)-l-methyl-lH-pyrrole-2-caιboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(3-fluoropyrid-2-yl)-l-methyl-lH-ρyrrole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-fluoropyrid-2-yl)-l-methyl- lH-pyrrole-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(5-fluoropyrid-2- yl)-l-methyl-lH-ρyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(6- fluoropyrid-2-yl)- 1 -methyl- 1 H-pyrrole-2-carboxamide; N- [(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(2-fluoiOpyrid-3-yl)-l-methyl-lH-pyriOle-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-fluoropyrid-3-yl)-l-methyl- lH-pyrrole-2-carboxamidc; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-fluoropyrid-3- yl)-l-methyl-lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(6- fluoropyrid-3-yl)- 1-methyl- lH-pyrrole-2-carboxamide; N-[(3R)- 1- azabicyclo[2.2.2]oct-3-yl]-5-(2-fluoropyrid-4-yl)-l-methyl-lH-pyrrole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-fluoropyrid-4-yl)-l-methyl- lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-cyanophenyl)- l-methyl-lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- cyanophenyl)-l -methyl- lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct- 3-yl]-5-(4-cyanophenyl)-l-methyl-lH-pyrrole-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(2-fluorophenyl)-lH-pyrrole-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(3-fluoiOphenyl)-lH-pyrrole-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(4-fluorophenyl)-lH-pyrrole-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(3,5-difluorophenyl)-lH-pyrrole-2-carboxamide; N-
[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,4-difluoiOphenyl)-lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2,4-difluorophenyl)-lH-pyrrole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-chlorophenyl)-lH-pyrrole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-chlorophenyl)-lH-pyrrole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-chlorophenyl)-lH-pyrrole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,5-dichlorophenyl)-lH- pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,4-dichloiOphenyl)- lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2,4- dichlorophenyl)-lH-pyιτole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- (2-bromophenyl)- 1 H-pyrrole-2-carboxamide; r -[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5- (3-bromophenyl)-lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- (4-bromophenyl)-lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- (2-hydroxyphenyl)-lH-pyriOle-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]- 5-(3-hydroxyphenyl)-lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(4-hydroxyphenyl)- 1 H-pyrroIe-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct- 3-yl]-5-(2-methoxyphenyl)- 1 H-pyrrole-2-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(3-methoxyphenyl)- 1 H-pyrrole-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(4-methoxyphenyl)- 1 H-pyrrole-2-carboxamide; N- [(3R)-l-azabicycIo[2.2.2]oct-3-yl]-5-(2-methylphenyI)-lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-methylρhenyl)-lH-pyιτole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-methylphenyl)-lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methylaminophenyl)-lH-pyrrole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-methylaminophenyl)-lH- ρyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]ocl-3-yl]-5-(4- methylaminophenyl)-lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(2-nitrophenyl)-lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(3-nitrophenyl)-lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(4-nitrophenyl)-lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(2-aminophenyl)-lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(3-aminophenyl)-lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(4-aminophenyl)- 1 H-pyrrole-2 -carboxamide; N-[(3R)- l-azabicyclo[2.2.2]oct-3- yl]-5-[2-(acetylamino)phenyl]-lH-pyrrole-2-cai-boxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-[3-(acetylamino)phenyl]-lH-pyrrole-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[4-(acetylamino)phenyl]-lH-pyrrole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(pyrid-2-yl)-lH-ρyrrole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(pyrid-3-yl)-lH-pyrrole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(pyrid-4-yl)-lH-pyrrole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-fluoiOpyrid-2-y])-^lH- pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-fluoropyrid-2-yl)- 1 H-pyrrole-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(5-fluoropyrid-2- yl)-lH-pyrrole-2-caι-boxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(6- fluoropyrid-2-yl)-lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- (2-fluoiOpyrid-3-yl)-lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(4-fluoropyrid-3-yl)- 1 H-pyrrole-2-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(5-fluoiOpyrid-3-yl)-lH-pyrrole-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(6-fluoropyrid-3-yl)-lH-pyrrole-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(2-fluoropyrid-4-yl)- 1 H-pyrrole-2- carboxamide; N-[(3R)- l-azabicyc]o[2.2.2]oct-3-yl]-5-(3-fluoroρyrid-4-yl)- 1H- pynole-2-caι-boxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-cyanophenyl)-lH- pyrrole-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(3-cyanophenyl)- 1 H- pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-cyanophenyl)-lH- pyrrole-2-carboxamide;
N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-bromo-l-methyl-lH-pyrrole-2- carboxamide; N-[(2S,3R)-2-methyl-l -azabicyclo[2.2.2]oct-3-yl]-5-[2-
(methylthio)phenyl]- 1 -methyl- 1 H-pyrrole-2-carboxamide; N-[(2S ,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-[4-(methylthio)phenyl]- 1 -methyl- lH-pyrroler2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-phenyl-lH- pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicycIo[2.2.2]oct-3-yl]-5-(2- fluorophenyl)- 1 -methyl- 1 H-pyrrole-2-carboxamide ; N-[(2S ,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(3-fluoropheny])-l-methyl-lH-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-fluorophenyl)-l-methyl-lH- pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2,3- difluorophenyl)- 1 -methyl- lH-pyrrole-2-carboxamide; N-[(2S ,3R)-2 -methyl- 1 - azabicycIo[2.2.2]oct-3-yl]-5-(2,4-difluorophenyl)- 1-methyl- lH-pyrrole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2,6- difluorophenyl)-l-methyl-lH-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(3,4-difluorophenyl)-l-methyl-lH-pyrrole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,5- difluorophenyl)- 1 -methyl- 1 H-pyrrole-2-carboxamide; N- [(2S ,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(2,4,6-trifluorophenyl)- 1 -methyl- lH-pyrrole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-chlorophenyl)- 1 -methyl- lH-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3- yl]-5-(3-chlorophenyl)- 1 -methyl- 1 H-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(4-chlorophenyl)- 1 -methyl- 1 H-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2,4-dichlorophenyl)-l-methyl- lH-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,4- dichlorophenyl)-l-methyl-lH-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(3,5-dichlorophenyl)-l-methyl-lH-pyrrole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-bromophenyl)- l-methyl-lH-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3- yl]-5-(3-bromophenyl)-l -methyl- lH-pyιτole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(4-bromophenyl)- 1 -methyl- lH-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-hydroxyphenyl)-l-methyl-lH- pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- hydroxyphenyl)- 1 -methyl- lH-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo [2.2.2] oct-3-yl] -5-(4-hydroxyphenyl)- 1 -methyl- 1 H-pyrrole-2-carboxamide ; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-melhoxyphenyl)-l-methyl-lH- pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- methoxyphenyl)- 1 -methyl- 1 H-pyrrole-2-carboxamide; N-[(2S ,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yI]-5-(4-methoxyphenyl)-l-methyl-lH-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methylphenyl)-l-methyl-lH- pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- methylphenyl)-l-methyl-lH-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl 1- azabicyclof2.2.2]oct-3-yl]-5-(4-methylphenyl)-l -methyl- lH-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]ocl-3-yl]-5-(2-methyaminophenyl)-l-methyl- lH-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- methylaminophenyl)-l-methyl-lH-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(4-methylaminophenyl)-l-methyl-lH-pyrrole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]ocl-3-yl]-5-(2-nitrophenyl)-l- methyl-lH-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3- yl]-5-(3-nitiOphenyl)-l-methyl-lH-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(4-nitrophenyl)- 1 -methyl- 1 H-pyrrole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-aminophenyl)-l-methyl-lH- pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- aminophenyl)-l-methyl-lH-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(4-aminophenyl)-l-methyl-lH-pyrrole-2-caι-boxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[2-(acetylamino)ρhenyl]-l- methyl-lH-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3- yl]-5-[3-(acetylamino)phenyl]-l -methyl- lH-pyrrole-2-carboxamide; N-[(2S,3R)-2- methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[4-(acetylamino)phenyl]-l-methyl-lH-pyrrole- 2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(ρyrid-2-yl)-l- methyl- lH-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3- yl]-5-(pyricl-3-yl)- 1 -methyl- 1 H-pyrrole-2-carboxamide; N-[(2S ,3R)-2-methyI- 1 - azabicyclo[2.2.2]oct-3-yl]-5-pyridin-4-yl-l-methyl-lH-pyrrole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-fluoropyrid-2-yl)-l-methyl-lH- pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(4- fluoropyrid-2-yl)- 1 -methyl- lH-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(5-fluoropyrid-2-yl)- 1 -methyl- 1 H-pyrrole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(6-fluoiOpyrid-2- yl)- 1 -methyl- lH-ρyrrole-2-carboxamide; N-[(2S,3R)-2-methyI- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(2-fluoropyrid-3-yl)- 1 -methyl- lH-pyrrole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-fluoropyrid-3- yl)- 1 -methyl- 1 H-pyrrole-2-carboxamide; N- [(2S ,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(5-fluoropyrid-3-yl)- 1-methyl- lH-pyrrole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(6-fluoropyrid-3- yl)- 1 -methyl-1 H-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(2-fluoiOpyrid-4-yl)-l-methyl-lH-pyrrole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-fluoropyrid-4- yl)- 1 -methyl- 1 H-pyrrole-2-carboxamide; N- [(2S ,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(2-cyanophenyl)-l-methyl-lH-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-cyanophenyl)-l-methyl-lH- pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- cyanophenyl)-l-methyl-lH-pyriOle-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-fluorophenyl)-lH-pyrrole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-fluorophenyl)-lH-pyrrole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-fluorophenyl)- lH-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,5- difluorophenyl)- 1 H-pyrrole-2-carboxamide; N-[(2S ,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(3,4-difluorophenyl)-lH-pyrrole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2,4-difluorophenyl)-lH-pyrrole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-chlorophenyl)- lH-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- chlorophenyl)-lH-pynOle-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(4-chlorophenyl)- 1 H-pyrrole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,5-dichlorophenyl)-lH-pyrrole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,4- dichlorophenyl)-lH-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2,4-dichloroρhenyl)-lH-pyrrole-2-carboxamide; N- [(2S,3R)-2-methyl- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(2-bromophenyl)- lH-pyrrole-2- carboxamide; N-[(2S,3R)-2-methyl- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(3-bromophenyl)- 1 H-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l -azabicyclo[2.2.2]oct-3-yl]-5-(4- bromophenyl)- 1 H-pyrrole-2-carboxamide; N- [(2S ,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(2-hydroxyphenyl)- 1 H-pyrrole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-hydroxyphenyl)-lH-pyrrole-2- carboxamide; N-[(2S,3R)-2-methyI-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- hydroxyphenyl)-lH-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-methoxyphenyl)-lH-pyrrole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-methoxyphenyl)-lH-pyrrole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- methoxyphenyl)- lH-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl- 1- azabicyclo[2.2.2]oct-3-yl]-5-(2-methylphenyl)-lH-pyrrole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-methylphenyl)-lH-pyrrole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-methylphenyl)- lH-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- methyaminophenyl)- lH-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl- 1- azabicyclo[2.2.2]oct-3-yl]-5-(3-methylaminophenyl)-lH-pyrrole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-methylaminoρhenyl)-lH-pyrrole- 2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yI]-5-(2-nitrophenyl)- lH-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- nitrophenyl)-lH-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(4-nitrophenyl)- 1 H-pyrrole-2-carboxamide; N-[(2S,3R)- 2-methyl- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(2-aminophenyl)- 1 H-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(3-aminophenyl)- 1 H-pyrrole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-aminophenyl)- lH-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[2- (acetylamino)phenyl]-lH-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-[3-(acetylamino)phenyl]-lH-pyrrole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[4-(acetylamino)phenyl]-lH- pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(pyrid- 2-yl)-lH-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]- 5-(pyrid-3-yl)-lH-pyrrole-2-cai-boxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(pyrid-4-yl)-lH-pyrrole-2-carboxamide; N-[(2S,3R)-2- methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-fluoroρyrid-2-yl)-lH-pyrrole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-fluoropyrid-2- yl)-lH-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5- (5-fluoropyrid-2-yl)-lH-pyriOle-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(6-fluoropyrid-2-yl)- 1 H-pyrrole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-fluoropyrid-3-yl)-lH-pyrrole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-fluoiOpyrid-3- yl)-lH-ρyrrole-2-caι-boxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5- (5-fluoropyrid-3-yl)-lH-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(6-fluoropyrid-3-yl)-lH-pyrrole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-fluoropyrid-4-yl)-lH-pyπOle-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-fluoropyrid-4- yl)-lH-ρyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5- (2-cyanophenyl)- 1 H-pyrrole-2-carboxamide; N- [(2S ,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(3-cyanophenyl)-lH-pyrrole-2-carboxamide; or N-
[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-cyanophenyl)-lH-pyrrole-2- cai-boxamide.
Materials and Methods for identifying binding constants:
Membrane Preparation. Male Sprague-Dawley rats (300-350g) are sacrificed by decapitation and the brains (whole brain minus cerebellum) are dissected quickly, weighed and homogenized in 9 volumes/g wet weight of ice-cold 0.32 M sucrose using a rotating pestle on setting 50 (10 up and down strokes). The homogenate is centrifuged at 1,000 x g for 10 minutes at 4 °C. The supernatant is collected and centrifuged at 20,000 x g for 20 minutes at 4 °C. The resulting pellet is resuspended to a protein concentration of 1 - 8 mg/mL. Aliquots of 5 mL homogenate are frozen at -80 °C until needed for the assay. On the day of the assay, aliquots are thawed at room temperature and diluted with Kreb's - 20 mM Hepes buffer pH 7.0 (at room temperature) containing 4.16 mM NaHCO3, 0.44 mM KH2PO4, 127 mM NaCI, 5.36 mM KCl, 1.26 mM CaCl2, and 0.98 mM MgCl , so that 25 - 150 μg protein are added per test tube. Proteins are determined by the Bradford method (Bradford, M.M., Anal. Biochem., 72, 248-254, 1976) using bovine serum albumin as the standard. Binding Assay. For saturation studies, 0.4 mL homogenate are added to test tubes containing buffer and various concentrations of radioligand, and are incubated in a final volume of 0.5 mL for 1 hour at 25 °C. Nonspecific binding was determined in tissues incubated in parallel in the presence of 0.05 ml MLA for a final concentration of 1 μM MLA, added before the radioligand. hi competition studies, drugs are added in increasing concentrations to the test tubes before addition of 0.05 ml [3H]-MLA for a final concentration of 3.0 to 4.0 nM [3H]-MLA. The incubations are terminated by rapid vacuum filtration through Whatman GF/B glass filter paper mounted on a 48 well Brandel cell harvester. Filters are pre-soaked in 50 mM Tris HCI pH 7.0 - 0.05 % polyethylenimine. The filters are rapidly washed two times with 5 mL aliquots of cold 0.9% saline and then counted for radioactivity by liquid scintillation spectrometry.
Data Analysis. In competition binding studies, the inhibition constant (Ki) was calculated from the concentration dependent inhibition of [3H]-MLA binding obtained from non-linear regression fitting program according to the Cheng-Prusoff equation (Cheng, Y.C. and Prussoff, W.H., Biochem. Pharmacol, 22, p. 3099-3108, 1973). Hill coefficients were obtained using non-linear regression (GraphPad Prism sigmoidal dose-response with variable slope).
The aforementioned examples have the provided Ki values:
30
20
25

Claims

CLAIMSWhat is claimed:
1. A compound of formula I:
Formula I or pharmaceutically acceptable salts thereof, wherein
Ri is selected from -H, alkyl, cycloalkyl, halogenated alkyl, or aryl; Alkyl is both straight and branched-chain moieties having from 1-6 carbon atoms; Halogenated alkyl is an alkyl moiety having from 1-6 carbon atoms and having
1 to (2n+l) substituent(s) independently selected from -F, -CI, -Br, or -I where n is the maximum number of carbon atoms in the moiety;
Cycloalkyl is a cyclic alkyl moiety having from 3-6 carbon atoms; Aryl is phenyl, substituted phenyl, naphthyl, or substituted naphthyl; Substituted phenyl is a phenyl either having 1-4 substituents independently selected from -F, -CI, -Br, or -I, or having 1 substituent selected from -Rι2 and 0-3 substituents independently selected from -F, -CI, -Br, or -I;
Substituted naphthyl is a naphthalene moiety either having 1-4 substituents independently selected from -F, -CI, -Br, or -I, or having 1 substituent selected from -R!2 and 0-3 substituents independently selected from -F, -CI, -Br, or -I, where the substitution can be independently on either the same ring or different rings of said napthalene moiety;
R2 is -H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, benzyl, substituted benzyl, or aryl; Substituted alkyl is an alkyl moiety having from 1-6 carbon atoms and having
0-3 substituents independently selected from -F, -CI, -Br, or -I, and further having 1 substituent selected from -R7, -R9, -ORio, -SRio, -NRι0Rιo, -C(O)Ri0, -NO2, -C(O)NR,oRιo, -CN, -NRIOC(O)Rιo, -S(O)2NR,0Rιo, -NR,0S(O)2Rιo, phenyl, or substituted phenyl; Substituted benzyl is a benzyl either having 1-4 substituents independently selected from -F, -CI, -Br, or -I, or having 1 substituent selected from -R)2 and 0-3 substituents independently selected from -F, -CI, -Br, or -I;
X is O or S; W is a cyclic heteroaromatic moiety where the heteroatoms can be from 1-3 atoms selected from oxygen, sulfur, or nitrogen of the following structures:
wherein U is -O-, -S-, or -N(R3)-;
V and Y are independently selected from =N-, or =C(R5)-; Z is =N-, or =CH-, provided that when both V and Y are =C(R5)- and Z is
=CH-, only >5)- can be =CH-, and further provided that when U is -O-, Y is =C(R5)- and Z is =C(R5)-, V cannot be =N-;
R3 is -H, alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, or aryl, and provided that when W is (b) and Z is =N- and U is N(R ), R3 cannot be phenyl or substituted phenyl
Alkenyl is straight and branched-chain moieties having from 2-6 carbon atoms and having at least one carbon-carbon double bond;
Halogenated alkenyl is an unsaturated alkenyl moiety having from 2-6 carbon atoms and having 1 to (2n-l) substituent(s) independently selected from -F, -CI, -Br, or -I where n is the maximum number of carbon atoms in the moiety;
Substituted alkenyl is an unsaturated alkenyl moiety having from 2-6 carbon atoms and having 0-3 substituents independently selected from -F, or -CI, and further having 1 substituent selected from -R7, -R9, -ORio, -SRio, -NRioRio, -C(O)Rι0, -C(O)NR,oR,o, -CN, -NR10C(O)R,0, -S(O)2NR,0Rιo, -NR,0S(O)2Rιo, phenyl, or substituted phenyl;
Alkynyl is straight and branched-chain moieties having from 2-6 carbon atoms and having at least one carbon-carbon triple bond; Halogenated alkynyl is an unsaturated alkynyl moiety having from 3-6 carbon atoms and having 1 to (2n-3) substituent(s) independently selected from -F, -CI, -Br, or -I where n is the maximum number of carbon atoms in the moiety;
Substituted alkynyl is an unsaturated alkynyl moiety having from 3-6 carbon atoms and having 0-3 substituents independently selected from -F, or -CI, and further having 1 substituent selected from -R7, -R , -ORio, -SRio, -NRioRio, -C(O)Rιo, -CN, -C(O)NR10R,o, -NR,oC(O)R,o, -S(O)2NRι0Rιo, -NR,0S(O)2R10, phenyl, or substituted phenyl;
Halogenated cycloalkyl is a cyclic moiety having from 3-6 carbon atoms and having 1-4 substituents independently selected from -F, or -CI;
Substituted cycloalkyl is a cyclic moiety having from 3-6 carbon atoms and having 0-3 substituents independently selected from -F, or -CI, and further having 1 substituent selected from -ORio, -SRio, -NRJORJO, -C(O)Rι0, -C(O)NR,0Rιo, -CN, -NR10C(O)Rιo, -S(O)2NR10Rιo, -NRι0S(O)2Rι0, -NO2, phenyl, or substituted phenyl; Heterocycloalkyl is a cyclic moiety having 4-7 atoms with 1-2 atoms within the ring being -S-, -N(R3)-, or -O-;
Halogenated heterocycloalkyl is a cyclic moiety having from 4-7 atoms with 1- 2 atoms within the ring being -S-, -N(R3)-, or -O-, and having 1-4 substituents independently selected from -F, or -CI; Substituted heterocycloalkyl is a cyclic moiety having from 4-7 atoms with 1-2 atoms within the ring being -S-, -N(R3)-, or -O- and having 0-3 substituents independently selected from -F, or -CI, and further having 1 substituent selected from -ORio, -SR10, -NR.oRio, -C(O)Rιo, -C(O)NR,0R10, -CN, -NR,0C(O)R10, -NO2, -S(O)2NRi0Rio, -NRi0S(O)2Rio, phenyl, or substituted phenyl; R5 is independently selected from the group consisting of -H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated alkenyl, halogenated alkynyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted heterocycloalkyl, aryl, -OR8, -SR8, -F, -CI, -Br, -I, -NR8RS, -C(O)R8, -C(O)NR8R8, -CN, -NR8C(O)Rι ,, -S(O)2NR8R8, -OS(O)2R. i, -S(O)2R8, -NR8S(O)2R8, -N(H)C(O)N(H)R8, -NO2, -R7, and -R9;
R7 is 5-membered heteroaromatic mono-cyclic moieties containing within the ring 1-3 heteroatoms independently selected from the group consisting of -O-, =N-, -N(R3)-, and -S-, and having 0-1 substituent selected from -Rι2 and 0-3 substituents independently selected from -F, -CI, -Br, or -I, or R7 is a 9-membered fused-ring moiety having a 6-membered ring fused to a 5-membered ring and having the formula
wherein E is O, S, or NR3,
wherein E and G are independently selected from CRι8, O, S, or NR3, and A is CRι8 or N, or
wherein E and G are independently selected from CR[8, O, S, or NR3, and A is CRι8 or N, each 9-membered fused-ring moiety having 0-1 substituent selected from -R12 and 0-3 substituent(s) independently selected from -F, -CI, -Br, or -I, and having a bond directly or indirectly attached to the core molecule where valency allows in either the 6-membered or the 5-membered ring of the fused-ring moiety; Each R8 is independently selected from -H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocycloalkyl, substituted heterocycloalkyl, -R , -R9, phenyl, or substituted phenyl;
R9 is 6-membered heteroaromatic mono-cyclic moieties containing within the ring 1-3 heteroatoms selected from =N- and having 0-1 substituent selected from -Rι2 and 0-3 substituent(s) independently selected from -F, -CI, -Br, or -I, or 10-membered heteroaromatic bi-cyclic moieties containing within one or both rings 1-3 heteroatoms selected from =N~, including quinolinyl or isoquinolinyl, each 10-membered fused- ring moiety having 0-1 substituent selected from -R12 and 0-3 substituent(s) independently selected from -F, -CI, -Br, or -I and having a bond directly or indirectly attached to the core molecule where valency allows;
Each Rio is independently selected from -H, alkyl, cycloalkyl, heterocycloalkyl, alkyl substituted with 1 substituent selected from Rj3, cycloalkyl substituted with 1 substituent selected from Rι3, heterocycloalkyl substituted with 1 substituent selected from Rι3, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, phenyl, substituted phenyl, -R7, or -R9;
Each Rn is independently selected from -H, alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, or halogenated heterocycloalkyl; Ri2 is selected from -ORn, -SRn, alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, -NRnRn, -C(O)Rn, -NO2, -C(O)NR„R, ι, -CN, -NRiiC(O)Rn, -S(O)2NR, ,Rn, or -NR, ιS(O)2Rιι;
Rι3 is selected from -ORn, -SRn, -NRnRn, -C(O)Ru, -C(O)NR,ιR,ι, -CN, -NR„C(O)R„, -S(O)2NRMRΠ , -NRι,S(O)2R, „ -CF3, or -NO2;
Rι is independently selected from -H, alkyl, halogenated alkyl, limited substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocycloalkyl, substituted heterocycloalkyl; Each R|8 is independently selected from -H, alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, -ORn, -SRn, -NRnRn, -C(O)R,ι, -NO2, -C(O)NRnRn, -CN, -NRi ιC(O)Rn, -S(O)2NR, ,R, ,, or -NR, ιS(O)2Rι i, -F, -CI, -Br, or -I, or a bond directly or indirectly attached to the core molecule, provided that there is only one said bond to the core molecule within the 9-membered fused-ring moiety, further provided that the fused-ring moiety has 0-1 substituent selected from alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, -ORu, -SRM, -NRnRn, -C(O)Rn, -NO2, -C(O)NRnR,ι, -CN, -NR,iC(O)Rn, -S(O)2NRiiRn, or -NRnS(O)2Rιι, and further provided that the fused- ring moiety has 0-3 substituent(s) selected from -F, -CI, -Br, or -I.
Limited substituted alkyl is a substituted alkyl having from 1-6 carbon atoms and having 0-3 substituents independently selected from -F, -CI, -Br, or -I, and further having 1 substituent on either only the ω carbon and selected from -ORn, -SRn, -NR,,R,,, -C(O)R, „ -NO2, -C(O)NRnRn, -CN, -NR10C(O)R, ,, -S(O)2NR10Rιo, or -NRιoS(O)2Rιo, or on any carbon with sufficient valency but not on the ω carbon and selected from -R7, -R9, -ORio, -SRio, -NRJORIO, -C(O)Rι0, -NO2, -C(O)NR,0Rιo, -CN, -NRιoC(O)Rιo, -S(O)2NRi0Rio, -NRι0S(O)2Rιo, phenyl, or substituted phenyl; Limited substituted alkenyl is a substituted alkenyl having from 1-6 carbon atoms and having 0-3 substituents independently selected from -F, -CI, -Br, or -I, and further having 1 substituent on either only the cø carbon and selected from -ORn, -SR,,, -NR,,R,ι, -C(O)Rπ, -NO2, -C(O)NR„R„, -CN, -NR10C(O)R,,, -S(O)2NRjoRιo, or -NRιoS(O)2Rιo, or on any carbon with sufficient valency but not on the ω carbon and selected from -R7, -R , -ORio, -SRio, -NRioRio, -C(O)Rι0, -NO2, -C(O)NR,0Rio, -CN, -NR!0C(O)R10, -S(O)2NRι0Rιo, -NR,0S(O)2Rιo, phenyl, or substituted phenyl; and
Limited substituted alkynyl is a substituted alkynyl having from 1-6 carbon atoms and having 0-3 substituents independently selected from -F, -CI, -Br, or -I, and further having 1 substituent on either only the ω carbon and selected from -ORn, -SRn, -NR, ,Rii, -C(O)R„, -NO2, -C(O)NR Rn, -CN, -NR,QC(O)Rn, -S(O)2NRιoRιo, or -NRι0S(O)2Rιo, or on any carbon with sufficient valency but not on the co carbon and selected from -R7, -R9, -OR]0, -SRio, -NRioRio, -C(O)R]0, -NO2, -C(O)NR,0Rio, -CN, -NR10C(O)R10, -S(O)2NR10Rιo, -NRι0S(O)2R,0, phenyl, or substituted phenyl.
2. The compounds according to claim 1, wherein X is O.
3. The compounds according to claim 2, wherein R2 is one of alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, benzyl, substituted benzyl, or aryl;
4. The compounds according to claim 2, wherein R| and R2 are both H.
5. The compounds according to claim 4, wherein R5 is independently selected from the group consisting of -H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated alkenyl, halogenated alkynyl, halogenated cycloalkyl, halogenated heterocycloalkyl, limited substituted alkyl, limited substituted alkenyl, limited substituted alkynyl, substituted cycloalkyl, substituted heterocycloalkyl, -ORi4, -SR.4, -F, -CI, -Br, -I, -NRι4R,4, -C(O)Rι4, -C(O)NRi4Rι4, -CN, -NR8C(O)Rπ, -S(O)2NR8R8, -OS(O)2R,,, -S(O)2R14, -NR8S(O)2R8, -N(H)C(O)N(H)R8, and -NO2.
6. The compounds according to claim 5, wherein R is -H, alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, limited substituted alkyl, substituted cycloalkyl, or substituted heterocycloalkyl.
7. The compounds according to claim 4, wherein W is selected from the following:
provided that at least one R5 is not H.
8. The compounds according to claim 4, wherein W is selected from the following:
9. The compounds according to claim 4, wherein W is selected from the following:
10. The compounds according to claim 1, wherein the compounds are the R steroisomer at the C3 position of the quinuclidine of Formula I:
or pharmaceutically acceptable salts thereof.
11. The compounds according to claim 10, wherein X is O.
12. The compounds according to claim 11, wherein R2 is alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, benzyl, substituted benzyl, or aryl.
13. The compounds according to claim 12, wherein R2 is alkyl, cycloalkyl, or aryl.
14. The compounds according to claim 11, wherein Ri and R2 are both H.
15. The compounds according to claim 14, wherein W is selected from the following:
provided that at least one R5 is not H.
16. The compounds according to claim 14, wherein W is selected from the following:
17. The compounds according to claim 14, wherein W is selected from the following:
18. The compounds according to claim 10, wherein the compounds are selected from the group consisting of:
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-phenyl-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-chlorophenyl)-thiophene-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-chlorophenyl)-thiophene-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-chlorophenyl)-thiophene-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2,3'-bithiophene-5-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-nitrophenyl)-thioρhene-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-nitrophenyl)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-4-phenyl-thiophene-2-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-benzyloxyphenyl)-thiophene-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-benzyloxyphenyl)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-fluoro-4-benzyloxyphenyl)- thiophene-2-carboxamide;
5-(2-aminophenyl)-N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-thiophene-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-pyridin-3-yI-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5'-methyl-2,2'-bithiophene-5- carboxamide;
N- [(3R)- 1 -azabicyclo [2.2.2] oct-3-yl]-5 '-chloro-2,2 -bithiophene-5- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-nitro-thiophene-2-carboxamide; 5-(aminomethyl)-N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-thiophene-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-cyano-thiophene-2-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-methoxy-thiophene-2-caιboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(pyridin-2-yl)-thiophene-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-[2,2r]bithiophenyl-5-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(methylsulfanyl)-thiophene-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-chloro-thioρhene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-acetyl-thiophene-2-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-methyl-thiophene-2-caι-boxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-bromo-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(phenylsulfanyl)-thiophene-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl -5-(acetylamino)-furan-2-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl -5-trifluoiOmethyl-furan-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl -5-(2-methyl-5-trifluoromethyI-2H- pyrazole-3-yl)-thiophene-2-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yI -5-(2-methylthiazol-4-yl)-thiophene-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl -5-[2-(3-chlorophenyl)-vinyl]-thiophene- 2-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl -5-(4-chlorophenylsulfanyl)-thiophene-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl -5-(2,4-difluorophenyl-sulfanyl)- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl -5-(3-chlorophenyl-sulfanyl)-thiophene-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yI -5-(3-chloro-4-fluoro-phenylsulfanyl)- thiophene-2-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl -5-(2,3-dichlorophenyl-sulfanyl)- thiophene-2-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl -5-(2,4,5-trichlorophenyl-sulfanyl)- thiophene-2-carboxamide;
N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl -5-(3,4-dichlorophenyl-sulfanyl)- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl -5-phenoxy-thiophene-2-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl -5-(2-hydroxyphenyl)-thiophene-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl -5-(3-hydroxyphenyl)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl -5-(3-fluoro-4-hydroxyphenyl)-thiophene-
2-carboxamide;
N-[(3R)-1 -azabicyclo[2.2.2]oct-3-yl -2-(phenylsulf anyl)- 1 ,3-thiazole-5- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-[(4-chlorophenyl)-sulfanyl]-l,3- ' thiazole-5-carboxamide;
N-[(3R)- 1-azabicycl 2-phenoxy- 1 ,3-thiazole-5-carboxamide;
N-[(3R)- 1-azabicycl 2-[(4-fluorophenyl)-sulfanyl]-l,3- thiazole-5-carboxamide;
N-[(3R)~ 1-azabicycl 2-(methylsulfanyl)- 1 ,3-thiazole-5- carboxamide;
N-[(3R)-l-azabicycl 2-(4-chlorophenoxy)- 1 ,3-thiazole-5- carboxamide; N-[(3R)- 1-azabicycl 2-phenyl- 1 ,3-thiazole-5-carboxamide;
N-[(3R)- 1-azabicycl 2,4-dimethyl- 1 ,3-thiazole-5- carboxamide;
N-[(3R)- 1-azabicycl 2-(2-fluorophenyl)- 1 ,3-thiazole-5- carboxamide; N-[(3R)- 1-azabicycl 2-(3-fluorophenyl)-l,3-thiazole-5- carboxamide;
N-[(3R)- 1-azabicycl 2-(4-fluorophenyl)- 1 ,3-thiazole-5- carboxamide;
N-[(3R)-l-azabicycl 2-(2-hydroxyphenyl)- 1 ,3-thiazole-5- carboxamide;
N-[(3R)- 1-azabicycl 2-(4-methylphenyl)- 1 ,3-thiazole-5- carboxamide;
N-[(3R)- 1-azabicycl 2-[4-(benzyloxy)phenyl]-l,3-thiazole-5- carboxamide; N-[(3R)- 1-azabicycl 2-pyridin-3-yl- 1 ,3-thiazoIe-4- carboxamide;
N-[(3R)- 1 -azabicycl 4-methyl -2-phenyl- 1 ,3-thiazole-5- carboxamide;
N-[(3R)- 1-azabicycl 2-(4-chlorophenyl)-4-methyl- 1 ,3- thiazole-5-carboxamide;
N-[(3R)- 1-azabicycl 4-methyl-2-pyridin-2-yl- 1 ,3-thiazole-5- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-4-methyl-2-pyridin-4-yl-l,3-thiazole-5- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-(methylamino)-l,3-thiazole-5- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(phenylsulfanyl)-l,3,4-thiadiazole-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-phenoxy-l,3,4-thiadiazole-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[(4-chlorophenyl)-sulfanyl]- 1,3,4- thiadiazole-2-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-fluorophenoxy)-l,3,4-thiadiazole-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-chlorophenoxy)-l,3,4-thiadiazole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[(3-fluorophenyl)-sulfanyl]-l,3,4- thiadiazole-2-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[(2-chlorophenyl)-sulfanyl]-l,3,4- thiadi azole-2-carboxamide ;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[(4-fluorophenyl)-sulfanyl]-l,3,4- thiadiazole-2-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[(3-chlorophenyl)-sulfanyl]-l,3,4- thiadiazole-2-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-phenyl-lH-l,2,4-triazole-3- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-phenyI-l,3,4-oxadiazole-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(methylthio)-l,3,4-oxadiazole-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-chlorophenyl)-l,3-oxazole-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-methoxyphenyl)-l,3-oxazole-2- caiboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct -3-yl] -5-(3-nitrophenyl)-l,3-oxazole-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct -3-yl] -5-(4-methoxyphenyl)- 1 ,3-oxazole-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct -3-yl] -5-(2-nilrophenyl)- 1 ,3-oxazole-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct -3-yl] -5-(2-methoxyphenyl)-l,3-oxazole-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct -3-yl] -5-(4-fluorophenyl)- 1 ,3-oxazole-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct -3-yl] -5-(2-chlorophenyl)-l,3-oxazole-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct -3-yl] -5-(3-cyanophenyl)- 1 ,3-oxazole-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct -3-yl] -5-(4-bromophenyl)- 1 ,3-oxazole-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct -3-yl] -4-methyl-5-phenyl- 1 ,3-thiazole-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct -3-yl] -5-phenyl- 1 ,3-thiazole-2-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct -3-yl] -5-(4-bromophenyl)- 1 ,3-thiazole-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct -3-yl] -5-(3-nitrophenyI)- 1 ,3-thiazole-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct -3-yl] -5-(3-methoxyphenyl)- 1 ,3-thiazole-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct -3-yl] -5-(2-chlorophenyl)-l,3-thiazole-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct -3-yl] -5-(4-fluorophenyl)- 1 ,3-thiazole-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct -3-yl] -5-(2-methoxyphenyl)- 1 ,3-thiazole-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct -3-yl] -5-(4-chlorophenyl)- 1 ,3-thiazole-2- carboxamide; N-[(3R)-1 -azabicyclo[2.2.2]oct-3-yl] -5-methyl-l,3-thiazole-2-carboxamide;
N-[(3R)-1 -azabicyclo[2.2.2]ocl-3-yl] -5-(3-chloroρhenyl)- 1 ,3-thiazole-2- carboxamide;
N-[(3R)-1 -azabicyclo[2.2.2]oct-3-yl]' -5-(2-fluorophenyl)- 1 ,3-thiazole-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl] -5-(3-fluorophenyl)- 1 ,3-thiazole-2- carboxamide;
N-[(3R)-1 -azabicyclo[2.2.2]oct-3-yl] -5-thien-2-yl- 1 ,3-thiazole-2-carboxamide;
N-[(3R)-1 -azabicyclo[2.2.2]oct-3-yl] -5-phenyl-furan-2-carboxamide; N-[(3R)-1 -azabicyclo[2.2.2]oct-3-yl] -5-(2-chlorophenyl)-furan-2- carboxamide;
N-[(3R)-1 -azabicyclo[2.2.2]oct-3-yl] -5-(3-chlorophenyl)-furan-2- carboxamide;
N-[(3R)-1 -azabicyclo[2.2.2]oct-3-yl] -5-(4-chlorophenyl)-furan-2- carboxamide;
N-[(3R)-1 -azabicyclo[2.2.2]oct-3-yl] -5-(4-bromophenyl)-furan-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl] -5-[2-(trifluoromethyl)-phenyl]-furan-2- carboxamide; N-[(3R)-1 -azabicyclo[2.2.2]oct-3-yl] -5-[3-(trifluoromethyl)-phenyl]-furan-2- carboxamide;
N-[(3R)-1 -azabicyclo[2.2.2]oct-3-yl] -5-(2-nitrophenyl)-furan-2-caι-boxamide;
N-[(3R)-1 -azabicyclo[2.2.2]oct-3-yl] -5-(3-nitrophenyl)-furan-2-carboxamide;
N-[(3R)-1 -azabicyclo[2.2.2]oct-3-yl] -5-(4-nitrophenyl)-furan-2-carboxamide; N-[(3R)-1 -azabicyclo[2.2.2]oct-3-yl] -5-(2-fluorophenyl)-furan-2-carboxamide;
N-[(3R)-1 -azabicyclo[2.2.2]oct-3-yl] -5-(3-fluorophenyl)-furan-2-carboxamide;
N-[(3R)-1 -azabicyclo[2.2.2]oct-3-yl] -5-(4-fluorophenyl)-furan-2-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl] -5-(2,4-difluorophenyl)-furan-2- caiboxamide; N-[(3R)-1 -azabicyclo[2.2.2]oct-3-yl] -5-(2,5-difluorophenyl)-furan-2- carboxamide;
N-[(3R)-1 -azabicyclo[2.2.2]oct-3-yl] -5-(2-methoxyphenyl)-furan-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-methoxyphenyl)-furan-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[3-(trifluoromethoxy)phenyl]-furan-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[2-chloro-5-(trifluoiOmethyl)phenyl]- furan-2-caι-boxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-fluoro-3-methylphenyl)-furan-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-cyanophenyl)-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-thien-2-yl-furan-2-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-thien-3-yl-furan-2-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-bromo-furan-2-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-nitro-furan-2-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-4,5-dimethyl-furan-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(4-chloro-2-nitrophenyl)-furan-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-methyl-2-nitroρhenyl)-furan-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2,3-difluorophenyl)-furan-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,4-difluorophenyl)-furan-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,5-difluorophenyl)-furan-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-methoxy-ρhenyl)-furan-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methylphenyl)-furan-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-methylphenyl)-furan-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-methylρhenyl)-furan-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[2-(trifluoromethoxy)phenyl]-furan-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[4-(trifluoromethoxy)ρhenyl]-furan-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-tert-butylphenyl)-furan-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(l-benzothien-2-yl)-furan-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-quinolin-3-yI-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-ethylphenyl)-furan-2-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-isopropylphenyl)-furan-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-fluoro-4-methoxyphenyl)-furan-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(l-benzofuran-2-yl)-furan-2- carboxamide;
5-(2-aminophenyl)-N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-furan-2- carboxamide;
5-(4-aminophenyl)-N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-furan-2- carboxamide;
5-(2-amino-4-methylphenyl)-N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-furan-2- carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(phenylethynyl)-furan-2-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-phenoxy-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-l-methyl-5-phenyl-lH-ρyrrole-2- carboxamide; •■
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-phenyl-l,3-oxazole-2-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-3-phenyl-l,2,4-oxadiazole-5- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-phenyl-l,3-oxazole-5-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-phenyl-l,3-oxazole-4-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-phenylisoxazole-3-carboxamide;
5-bromo-N-(2-methyl-l-azabicyclo[2.2.2]oct-3-yl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-phenyl-thioρhene-2-carbothioamide; and pharmaceutically acceptable salts thereof.
19. The compounds according lo claim 10, wherein anyone of or combination of the compounds including: N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-phenyl-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(4-chlorophenyl)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- chlorophenyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(2-chlorophenyl)-thiophene-2-carboxamide; N-[(2S,3R)- 2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2,3'-bithiophene-5-carboxamide; N-[(2S,3R)- 2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-nitrophenyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-nitrophenyl)-thioρhene-2- carboxamide; N-[(2S,3R)-2-methyl- 1 -azabicyclo[2.2.2]oct-3-yl]-4-phenyl-thiophene- 2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- benzyloxyphenyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(4-benzyloxyphenyl)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-fluoro-4-benzyloxyphenyl)- thiophene-2-carboxamide; 5-(2-aminophenyl)-N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl- 1- azabicyclo[2.2.2]oct-3-yl]-5-pyridin-3-yl-thiophene-2-carboxamide; N-[(2S,3R)-2- methyl-l-azabicyclo[2.2.2]oct-3-yl]-5'-methyl-2,2'-bithiophene-5-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5 -chloro-2,2'-bithiophene-5- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-nitro-thiophene- 2-carboxamide; 5-(aminomethyl)-N-[(2S,3R)-2-methyl- 1 -azabicyclo[2.2.2]oct-3-yl]- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5- cyano-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]- 5-methoxy-thiophene-2-caιboxamide; N-[(2S,3R)-2-methyl- 1 -azabicyclo[2.2.2]oct-3- yl]-5-(pyridin-2-yl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-[2,21bithiophenyl-5-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(methylsulfanyl)-thiophene-2-carboxamide; N-[(2S ,3R)- 2-methyl- 1 -azabicyclo[2.2.2]oct-3-yl]-5-chloro-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-acetyl-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-methyl-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-bromo-thiophene- 2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5- (phenylsulfanyl)-lhiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(acetylamino)-furan-2-carboxamide; N-[(2S,3R)-2- methyl- 1 -azabicyclo[2.2.2]oct-3-yl]-5-trifluoromethyl-furan-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methyl-5-trifluoromethyl-2H- pyrazole-3-yl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-methylthiazol-4-yl)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[2-(3-chlorophenyl)-vinyl]- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- chlorophenylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(2,4-difluorophenyl-sulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-chlorophenyl-sulfanyl)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- chloro-4-fluoro-phenylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl- 1- azabicyclo[2.2.2]oct-3-yl]-5-(2,3-dichlorophenyl-sulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2,4,5-trichlorophenyl-sulfanyl)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,4- clichlorophenyl-sulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-phenoxy-thiophene-2-carboxamide; N-[(2S,3R)-2- methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-hydroxyphenyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-hydroxyphenyl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-fluoro-4- hydroxyphenyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-2-(phenylsulfanyl)- 1 ,3-thiazole-5-carboxamide; N-
[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-[(4-chlorophenyl)-sulfanyl]-l,3- thiazole-5-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2- phenoxy-l,3-thiazole-5-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3- yl]-2-[(4-fluorophenyl)-sulfanyl]-l,3-thiazole-5-carboxamide; N-[(2S,3R)-2-methyl- l-azabicyclo[2.2.2]oct-3-yl]-2-(methylsulfanyl)-l ,3-thiazole-5-carboxamide; N-
[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-(4-chlorophenoxy)-l,3-thiazole-5- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-phenyl-l,3- thiazole-5-caιtoxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2,4- dimethyl- 1 ,3-thiazole-5-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3- yl]-2-(2-fluorophenyl)-l,3-thiazole-5-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-2-(3-fluorophenyl)- 1 ,3-thiazole-5-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-(4-fluorophenyl)-l,3-thiazole-5- carboxamide; N-[(2S,3R)-2-methyl- l-azabicyclo[2.2.2]oct-3-yl]-2-(2- hydroxyphenyl)-l,3-thiazole-5-carboxamide; N-l(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-2-(4-methylphenyl)-l,3-thiazole-5-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-[4-(benzyloxy)phenyl]-l,3-thiazole- 5-caι-boxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-pyridin-3-yl-l,3- thiazole-4-carboxamide; N-[(2S,3R)-2-methyl- l-azabicyclo[2.2.2]oct-3-yl]-4-methyl- 2-phenyl-l,3-thiazole-5-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3- yl]-2-(4-chlorophenyl)-4-methyl- 1 ,3-thiazole-5-carboxamide; N-[(2S,3R)-2-methyl- l-azabicyclo[2.2.2]oct-3-yl]-4-methyl-2-pyridin-2-yl-l,3-thiazole-5-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-4-methyl-2-pyridin-4-yl-l,3-thiazole- 5-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-(methylamino)- l,3-thiazole-5-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5- (phenylsulfanyl)-l,3,4-thiadiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-phenoxy-l,3,4-thiadiazole-2-carboxamide; N-[(2S,3R)- 2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[(4-chlorophenyl)-sulfanyl]-l,3,4-thiadiazole- 2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- fluorophenoxy)-l,3,4-thiadiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(4-chlorophenoxy)-l,3,4-thiadiazole-2-caι-boxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[(3-fluoiOphenyl)-sulfanyl]-l,3,4- thiadiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[(2- chlorophenyl)-sulf anyl]- 1 ,3 ,4-thiadiazole-2-carboxamide; N- [(2S ,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-[(4-fluorophenyl)-sulfanyl]-l,3,4-thiadiazole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[(3-chlorophenyl)- sulfanyl]-l,3,4-thiadiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-phenyl-lH-l,2,4-triazole-3-carboxamide; N-[(2S,3R)-2- methyl- 1 -azabicyclo[2.2.2]oct-3-yl]-5-phenyl- 1 ,3 ,4-oxadiazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(methylthio)-l,3,4-oxadiazole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-chloroρhenyl)- l,3-oxazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- methoxyphenyl)- 1 ,3-oxazole-2-carboxamide; N-[(2S ,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(3-nitrophenyl)-l,3-oxazole-2-carboxamide; N-[(2S,3R)- 2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-methoxyphenyl)-I,3-oxazole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-nitrophenyl)- l,3-oxazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- methoxyphenyl)-l,3-oxazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(4-fluorophenyl)-l,3-oxazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-chlorophenyl)-l,3-oxazole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-cyanophenyl)- l,3-oxazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- bromophenyl)-l,3-oxazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-4-methyl-5-phenyl-l,3-thiazole-2-cai'boxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-phenyl-l,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-bromophenyl)-l,3-thiazole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-nitrophenyl)- l,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- methoxyphenyl)-l,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-chlorophenyl)- 1 ,3-thiazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yI]-5-(4-fluorophenyl)-l,3-thiazole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- methoxyphenyl)-l,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(4-chlorophenyl)- 1 ,3-thiazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-methyl-l,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-chlorophenyl)-l,3-thiazole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-fluorophenyl)- l,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- fluorophenyl)-l,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-thien-2-yl-l,3-thiazole-2-carboxamide; N-[(2S,3R)-2- methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-phenyl-furan-2-carboxamide; N-[(2S,3R)-2- methyl- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(2-chlorophenyl)-furan-2-caιboxamide; N- [(2S ,3R)-2-methyl- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(3-chlorophenyl)-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-chlorophenyl)- furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- bromophenyl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl- 1 -azabicyclo[2.2.2]oct-3- yl]-5-[2-(trifluoromethyl)-ρhenyl]-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-[3-(trifluoromethyl)-phenyl]-furan-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-nitrophenyl)-furan-2- carboxamide; N-[(2S,3R)-2-methy -l-azabicyclo[2.2.2]oct-3-yl]-5-(3-nitrophenyl)- furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- nitrophenyl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3- yl]-5-(2-fluorophenyl)-furan-2-carboxamide; N-[(2S ,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(3-fluorophenyl)-furan-2-carboxamide; N-[(2S,3R)-2- methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-fluorophenyl)-furan-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2,4-difluorophenyl)-furan-2-. carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2,5- difluorophenyl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct- 3-yl]-5-(2-methoxyphenyl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(3-methoxyphenyl)-furan-2-caι-boxamide; N-[(2S,3R)-2- methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[3-(trifluoromethoxy)phenyl]-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[2-chloro-5- (trifluoromethyl)phenyl]-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(4-fluoro-3-methylphenyl)-furan-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-cyanophenyl)-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-thien-2-yl-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-thien-3-yl-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-bromo-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-nitro-furan-2- cai-boxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-4,5-dimethyl-furan- 2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-chloro-2- nitrophenyl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl- 1 -azabicyclo[2.2.2]oct-3- yl]-5-(4-methyl-2-nitrophenyl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(2,3-difluorophenyl)-furan-2-carboxamide; N-[(2S,3R)- 2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,4-difluorophenyl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,5-difluorophenyl)-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-methoxy- phenyl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5- (2-methylphenyl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct- 3-yl]-5-(3-methylphenyl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(4-methylphenyl)-furan-2-carboxamide; N-[(2S,3R)-2- methyl-l-azabicyclof2.2.2]oct-3-yl]-5-[2-(trifluoromethoxy)phenyl]-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[4- (trifluoromethoxy)phenyl]-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(4-tert-butylphenyl)-furan-2-carboxamidc; N-[(2S,3R)- 2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(l-benzothien-2-yl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-quinolin-3-yl-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-ethylphenyl)- furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- isopropylphenyl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct- 3-yl]-5-(3-fluoro-4-melhoxyphenyl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(l-benzofuran-2-yl)-furan-2-carboxamide; 5-(2- aminophenyl)-N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-furan-2- carboxamide; 5-(4-aminophenyl)-N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]- furan-2-carboxamide; 5-(2-amino-4-methylphenyl)-N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(phenylethynyl)-furan-2-carboxamide; N-[(2S,3R)-2- methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-phenoxy-furan-2-carboxamide; N-[(2S,3R)-2- methyl- 1 -azabicyclo[2.2.2]oct-3-yl]- 1 -methyl-5 -phenyl- 1 H-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-phenyl-l,3-oxazole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-3-phenyl-l,2,4- oxadiazole-5-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2- phenyl- l,3-oxazole-5-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3- yl]-2-phenyl-l,3-oxazole-4-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-phenylisoxazole-3-carboxamide; 5-bromo-N-[(2S,3R)-2- methyl-l-azabicyclo[2.2.2]ocl-3-yl]-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl- l-azabicyclo[2.2.2]oct-3-yl]-5-phenyl-thiophene-2-carbothioamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-acetamidophenyl)-thiophene-2- caiboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-acetamidophenyl)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-acetamidophenyl)- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- trifluoroacetamidophenyl)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(3-trifluoroacetamidophenyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-trifluoiOacetamidophenyl)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- methanesulfonylaminophenyl)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(3-methanesulfonyIaminophenyl)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- methanesulfonylaminophenyl)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(2-trifluoromethanesulfonylaminophenyl)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- trifluoromethanesulf onylaminophenyl)-thiophene-2-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(4-trifluoromethanesulfonylaminophenyl)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-difluoroacetamidophenyl)- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- difluoroacetamidophenyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct- 3-yl]-5-(4-difluoroacetamidophenyl)-thiophene-2-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(2-carbamoylphenyl)-thiophene-2-carboxamide; N-
[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-carbamoylphenyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-carbamoylphenyl)-thiophene-2- carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(2-sulfamoylphenyl)-thiophene- 2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-sulfamoylphenyl)- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- sulfamoylphenyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- (2-acetamidophenylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(3-acetamidophenylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-acetamidophenylsulfanyl)-thiophene-2- cai-boxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- trifluoroacetamidophenylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5.-(3-trifluoroacetamidophenylsulfanyl)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- trifluoiOacetamidophenylsulfanyl)-thiophene-2-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(2-methanesulfonylaminophenylsulfanyl)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- methanesulfonylaminophenylsulfanyl)-thiophene-2-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(4-methanesulfonylaminophenylsulfanyl)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- trifluoiOmethanesulfonylaminophenylsulfanyl)-thiophene-2-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(3-trifluoromethanesulfonylaminophenylsulfanyl)- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- trifluoromethanesulfonylaminophenylsulfanyl)-thiophene-2-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(2-difluoroacetamidophenylsulfanyl)-thiophene-2- carboxamide; N-[(3R)-ϊ-azabicyclo[2.2.2]oct-3-yl]-5-(3- difluoroacetamidophenylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(4-difluoroacetamidophenylsulfanyl)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-carbamoylphenylsulfanyl)- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- carbamoylphenylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct- 3-yl]-5-(4-cai'bamoylphenylsulfanyl)-thioρhene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(2-sulfamoylphenylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-sulfamoylphenylsulfanyl)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-sulfamoylphenyIsulfanyl)- thioχΛene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- hydroxyphenylsulfanyl)-thiophene-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3- yl]-5-(3-hydroxyphenylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(4-hydroxyphenylsulfanyl)-thiophene-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-aminophenylsulfanyl)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-aminophenylsulfanyl)- thiophene-2-caι-boxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- aminophenylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(2-acetamidophenoxy)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(3-acetamidophenoxy)-thiophene-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-acetamidophenoxy)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-trifluoroacetamidophenoxy)- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- trifluoroacetamidophenoxy)-thiophene-2-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(4-trifluoroacetamidophenoxy)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- methanesulfonylaminophenoxy)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(3-methanesulfonylaminophenoxy)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- methanesulfonylaminophenoxy)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(2-trifluoromethanesulfonylaminophenoxy)-thiophene-2- cai-boxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- trifluoromethanesulfonylaminophenoxy)-thiophene-2-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(4-trifluoromethanesulfonylaminophenoxy)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-difluoroacetamidophenoxy)- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- difluoroacetamidophenoxy)-thiophene-2-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(4-difluoroacetamidophenoxy)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-carbamoylphenoxy)- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- carbamoylphenoxy)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]- 5-(4-carbamoylphenoxy)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct- 3-yl]-5-(2-sulfamoylphenoxy)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(3-sulfamoylphenoxy)-thiophene-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-sulfamoylphenoxy)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-hydroxyphenoxy)- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- hydroxyphenoxy)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- (4-hydroxyphenoxy)-thiophene-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3- yl]-5-(2-aminophenoxy)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct- 3-yl]-5-(3-aminophenoxy)-thiophene-2-carboxamide; N-[(3R)- 1- azabicyclo[2.2.2]oct-3-yl]-5-(4-aminophenoxy)-thiophene-2-carboxamide; N-[(3R)- l-azabicyclo[2.2.2]oct-3-yl]-5-(2-chlorophenoxy)-thiophene-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-chlorophenoxy)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-chlorophenoxy)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-cyanophenoxy)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-cyanophenoxy)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-cyanophenoxy)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methoxyphenyl)-thiophene-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(3-methoxyphenyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-methoxyphenyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methylphenyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-methylphenyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-methylphenyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-trifluoromethylphenyl)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-trifluoromethylphenyl)- thiophene-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(4- trifluoiOmethylphenyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(2-acetylphenyl)-thiophene-2-carboxarnide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(3-acetylphenyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(4-acetylphenyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(2-cyanophenyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(3-cyanophenyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(4-cyanophenyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(2-morpholin-4-yl-phenyl)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(3-moφholin-4-yl-phenyl)-thiophene-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-moφholin-4-yl-phenyI)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methoxyphenoxy)- thiophene-2-caι-boxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- methoxyphenoxy)-thiophene-2-caι-boxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- (4-methoxyphenoxy)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(2-methylphenoxy)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct- 3-yl]-5-(3-methylphenoxy)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(4-methylphenoxy)-thiophene-2-carboxamide; N-[(3R)- l-azabicyclo[2.2.2]oct-3-yl]-5-(2-trifluoromethylphenoxy)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-trifluoromethylphenoxy)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-trifluoromethylphenoxy)- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- acetylyphenoxy)-thiophene-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5- (3-acetylphenoxy)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- (4-acetylphenoxy)-thiophenc-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- (2-cyanophenoxy)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- (3-cyanophenoxy)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- (4-cyanophenoxy)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- (2-moιpholin-4-yl-phenoxy)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(3-moφholin-4-yl-phenoxy)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-moφholin-4-yl-phenoxy)-lhiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methoxyphenylsulfanyl)- thiophene-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(3- methoxyphenylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct- 3-yl]-5-(4-methoxyphenylsulfanyl)-thiophene-2-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(2-methylphenylsulfanyl)-thiophene-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-methylphenylsulfanyl)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-methylphenylsulfanyl)- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- trifluoromethylphenylsulfanyl)-thiophene-2-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(3-trifluoromethylphenylsulfanyl)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- trifluoromethylphenylsulfanyl)-thiophene-2-carboxamide; N-l(3R)-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-acetylyphenylsulfanyl)-thiophene-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-acetylphenylsulfanyl)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-acetylphenylsulfanyl)- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- cyanophenylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(3-cyanophenylsulfanyl)-thiophene-2-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(4-cyanophenylsulfanyl)-thiophene-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-morpholin-4-yl-phenylsulfanyl)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-moιpholin-4-yl- phenylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- (4-moφholin-4-yl-phenylsulfanyl)-thiophene-2-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(pyridin-4-yl)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(2-methylpyridin-4-yl)-thiophene-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(6-methylpyridin-3-yl)-thiophene-2- carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(5-methylpyridin-2-yl)- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- methoxypyridin-4-yl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(6-methoxypyridin-3-yl)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(5-methoxypyridin-2-yl)-thiophene-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-chloropyridin-4-yl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(6-chloroρyridin-3-yl)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-chloropyridin-2-yl)- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-chloropyridin- 3-yl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(6- chloroρyridin-2-yl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]- 5-(4-chloropyridin-2-yl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct- 3-yl]-5-(pyridin-4-yloxy)-thiophene-2-carboxamidc; N-[(3R)- 1 -azabicyclo[2.2.2]oct- 3-yl]-5-(pyridin-3-yloxy)-thiophene-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct- 3-yl]-5-(pyridin-2-yloxy)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct- 3-yl]-5-(2-methylpyridin-4-yloxy)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(6-methylpyridin-3-yloxy)-thiophene-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-methylpyridin-2-yloxy)-thioρhene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methoxypyridin-4-yloxy)- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(6- methoxypyridin-3-yloxy)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct- 3-yl]-5-(5-methoxypyridin-2-yloxy)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(2-chloropyridin-4-yloxy)-lhiophene-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(6-chloropyridin-3-yloxy)-thiophene-2- cai-boxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-chloropyridin-2-yloxy)- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-chloropyridin- 4-yloxy)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(6- chloropyridin-3-yloxy)-thiophene-2-carboxamide; N-[(3R)- l-azabicyclo[2.2.2]oct-3- yl]-5-(5-chloropyridin-2-yloxy)-ιhiophene-2-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(5-chloropyridin-3-yloxy)-thiophene-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(6-chloropyridin-2-yloxy)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl3-5-(4-chloiOpyridin-2-yloxy)- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(pyridin-4- ylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- (pyridin-3-ylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(pyridin-2-ylsulfanyl)-thiophene-2-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(2-methylpyridin-4-ylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(6-methylpyridin-3-ylsulfanyl)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-methylpyridin-2-ylsulfanyl)- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- methoxypyridin-4-ylsulfanyl)-thiophene-2-carboxamide; N-[(3R)- 1- azabicyclo[2.2.2]oct-3-yl]-5-(6-methoxypyridin-3-ylsulfanyl)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-methoxypyridin-2- ylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- chloropyridin-4-ylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(6-chloiOpyridin-3-ylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-chloiOpyridin-2-ylsulfanyl)-lhiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-chloropyridin-4-ylsulfanyl)- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(6-chloropyridin- 3-ylsulfanyl)-thiophene-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(5- chloropyridin-2-ylsulf nyl)-thiophene-2-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(5-chloropyridin-3-ylsulfanyl)-thioρhene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(6-chloropyridin-2-ylsulfanyl)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-chloropyridin-2-ylsulfanyl)- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(thiophen-4-yl)- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5- methylthiophen-2-yl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(5-methoxythiophen-2-yl)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(5-chlorothiophen-2-yl)-thiophene-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(furan-4-yl)-thiophene-2-carboxamide; N-[(3R)- l-azabicyclo[2.2.2]oct-3-yl]-5-(5-methylfuran-2-yl)-thiophene-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-methoxyfuran-2-yl)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-chlorofuran-2-yl)-thiophene- 2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(oxazol-2-yl)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-methyloxazol-2-yl)- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-methoxyoxazol- 2-yl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5- chlorooxazol-2-yl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]- 5-(oxazol-5-yl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- methyloxazol-5-yl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]- 5-(2-methoxyoxazol-5-yl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct- 3-yl]-5-(2-chlorooxazol-5-yl)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(thiazol-2-yl)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(5-methylthiazol-2-yl)-thiophene-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-methoxythiazol-2-yl)-thiophene-2- cai-boxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-chlorothiazol-2-yl)- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(thiazol-5-yl)- fhiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methyllhiazol- 5-yl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- methoxythiazol-5-yl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(2-chlorothiazol-5-yl)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(4-methylthiazol-2-yl)-thiophene-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-methoxythiazol-2-yl)-thiophene-2- cai-boxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-chlorothiazol-2-yl)- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-methyloxazol- 2-yl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- methoxyoxazol-2-yl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(4-chlorooxazol-2-yl)-thiophene-2-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-([ 1 ,3,4]thiadiazol-2-yl)-thiophene-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-methyl[l,3,4]thiadiazol-2-yl)-thiophene-2- cai-boxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-methoxy[l,3,4]thiadiazol-2- yl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5- chloro[l,3,4]thiadiazol-2-yl)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-([l,3,4]oxadiazol-2-yl)-thiophene-2-carboxamide; N- [(3R)- l-azabicyclo[2.2.2]oct-3-yl]-5-(5-methyl[ 1 ,3,4]oxadiazol-2-yl)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-methoxy[l,3,4]oxadiazol-2- yl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5- chloro[l,3,4]oxadiazol-2-yl)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(lhiophen-4-yloxy)-thiophene-2-carboxamide; N-[(3R)- l-azabicyclo[2.2.2]oct-3-yl]-5-(5-methylthiophen-2-yloxy)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-methoxythiophen-2-yloxy)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-chlorothiophen-2-yloxy)- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(furan-4-yloxy)- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-methylfuran-2- yloxy)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5- methoxyfuran-2-yloxy)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(5-chlorofuran-2-yloxy)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(oxazol-2-yloxy)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(5-methyloxazol-2-yloxy)-thiophene-2-caι-boxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-methoxyoxazol-2-yloxy)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-chlorooxazol-2-yloxy)- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(oxazol-5-yloxy)- thiophene-2-carboxamide; N-[(3R)-l-azabicycIo[2.2.2]oct-3-yl]-5-(2-methyloxazol- 5-yloxy)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- methoxyoxazol-5-yloxy)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct- 3-yl]-5-(2-chlorooxazol-5-yloxy)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(thiazol-2-yloxy)-thioρhene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(5-methylthiazol-2-yloxy)-thiophene-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-methoxythiazol-2-yloxy)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-chlorothiazol-2-yloxy)- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(thiazol-5-yloxy)- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methylthiazol- 5-yloxy)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- methoxythiazol-5-yloxy)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct- 3-yl]-5-(2-chlorothiazol-5-yloxy)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(4-methylthiazol-2-yloxy)-thiophene-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-methoxythiazol-2-yloxy)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-chlorothiazol-2-yloxy)- thipphene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-methyloxazol- 2-yloxy)-thiophene-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(4- methoxyoxazol-2-yloxy)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct- 3-yl]-5-(4-chlorooxazol-2-yloxy)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-([l,3,4]thiadiazol-2-yloxy)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]ocl-3-yl]-5-(5-methyl[l,3,4]thiadiazol-2-yloxy)- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5- methoxy[l,3,4]thiadiazol-2-yloxy)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(5-chloro[l,3,4]thiadiazol-2-yloxy)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-([l,3,4]oxadiazol-2-yloxy)- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5- methyl[l,3,4]oxadiazol-2-yloxy)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(5-methoxy[l,3,4]oxadiazol-2-yloxy)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-chloro[l,3,4]oxadiazol-2- yloxy)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(thiophen- 4-ylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5- methylthiophen-2-ylsulfanyl)-thiophene-2-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(5-methoxythiophen-2-ylsulfanyl)-thiophcne-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-chlorothiophen-2- ylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(furan- 4-ylsulfanyl)-thiophene-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(5- methylfuran-2-ylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct- 3-yl]-5-(5-methoxyfuran-2-ylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(5-chlorofuran-2-ylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(oxazol-2-ylsulfanyl)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-methyloxazol-2-ylsulfanyl)- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-methoxyoxazol- 2-ylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5- chlorooxazol-2-ylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(oxazol-5-ylsulfanyl)-thiophene-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methyloxazol-5-ylsulfanyl)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methoxyoxazol-5- ylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- chlorooxazol-57ylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(thiazol-2-ylsulfanyl)-thiophene-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-methylthiazol-2-ylsulfanyl)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-methoxythiazol-2- ylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5- chlorothiazol-2-ylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(thiazol-5-ylsulfanyl)-thiophene-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methylthiazol-5-ylsulfanyl)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methoxythiazol-5- ylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- chlorothiazol-5-ylsulfanyl)-thiophene-2-caι-boxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(4-methylthiazol-2-ylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-methoxythiazol-2-ylsuIfanyl)-lhiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-chlorothiazol-2-ylsulfanyI)- thiophene-2 -carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(4-methyloxazol- 2-ylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- methoxyoxazol-2-ylsulfanyl)-thiophene-2-carboxamide; N- [(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(4-chlorooxazol-2-ylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-([l,3,4]thiadiazol-2-ylsulfanyl)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-methyl[l,3,4]thiadiazol-2- ylsulfanyl)-thiophene-2-carboxamide; N-[(3R)~l-azabicyclo[2.2.2]oct-3-yl]-5-(5- methoxyf 1 ,3,4]thiadiazol-2-ylsulfanyl)-thiophene-2-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(5-chloro[l,3,4]thiadiazol-2-ylsulfanyl)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-([ 1 ,3,4]oxadiazol-2-ylsulfanyl)- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5- methylf 1 ,3,4]oxadiazol-2-ylsulfanyl)-thiophene-2-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(5-methoxy[ 1 ,3,4]oxadiazol-2-ylsulfanyl)-thiophene-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-chloro[l,3,4]oxadiazol-2- ylsulfanyl)-thiophene-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5- (pyrrole-2-yl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- (isothiazol-3-yl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- (isoxazol-3-yl)-thiophene-2-carboxamide; N-[(3R)- 1-azabicyclo [2.2.2]oct-3-yl] -5- (3H-imidazol-4-yl)-thiophene-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]- 4-(4-hydroxyphenylsulfanyl)-thiophene-2-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-4-(3-acetamidophenylsulfanyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-4-(2-methanesulfonylaminophenyl)-thiophene- 2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-4-(pyridin-2-yloxy)-thiophene- 2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-4-(2-methylpyridin-4-yloxy)- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-4-(4- trifluoromethylphenyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]ocl-3- yI]-4-(2-acetylphenyl)-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-4-chloro-5-phenyl-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-4-methyl-5-phenyl-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-4-cyano-5-phenyl-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-4-methoxy-5-phenyl-thiophene-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct- 3-yl]-5-chloro-4-phenyl-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-methyl-4-phenyl-thiophene-2-caι-boxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3- yl]-5-cyano-4-phenyl-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-methoxy-4-phenyl-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct- 3-yl]-4-chloro-5-bromo-thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-4-chloro-5-methylsulfanyl-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-4-chloro-5-methyl-thiophene-2-caι-boxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-4-chloro-5-cyano-thiophene-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-chloro-4-bromo-thiophene-2-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-chloro-4-methylsulfanyl-thiophene-2-carboxamide; N- [(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-chloro-4-methyl-thiophene-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-chloiO-4-cyano-thiophene-2-carboxamide;
N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-acetamidophenyl)-thiophene- 2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- acetamidophenyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(4-acetamidophenyl)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-trifluoiOacetamidoρhenyl)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- trifluoroacetamidophenyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(4-trifluoroacetamidophenyl)-thioρhene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- methanesulfonylaminophenyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(3-methanesulfonylaminophenyl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- methanesulfonylaminophenyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-trifluoromethancsulfonylaminophenyl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- trifluoromethanesulfonylaminophenyl)-thiophene-2-carboxamide; N-[(2S,3R)-2- methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-trifluoromethanesulfonylaminophenyl)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- difluoroacetamidophenyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(3-difluoroacetamidophenyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-difluoroacetamidophenyl)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- carbamoylphenyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(3-carbamoy!phenyl)-thiophene-2 -carboxamide; N- l(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-carbamoylphenyl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- sulfamoylphenyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(3-sulfamoylphenyl)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-sulfamoylphenyl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- acetamidophenylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(3-acetamidophenylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-acetamidophenylsulfanyl)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- trifluoiOacetamidophenylsulfanyl)-thiophene-2-carboxamide; N-[(2S ,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(3-trifluoroacetamidophenylsulfanyl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- trifluoroacetamidophenylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-methanesulfonylaminophenylsulfanyl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- methanesulfonylaminophenylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2- methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-methanesulfonylaminophenylsulfanyl)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- trifluoromethanesulfonylaminophenylsulfanyl)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- trifluoromethanesulfonylaminophenylsulfanyl)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- trifluoromethanesulfonylaminophenylsulfanyl)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- difluoroacetamidophenylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(3-difluoroacetamidophenylsulfanyl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- difluoroacetamidophenylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-carbamoylphenylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-carbamoylphenylsulfanyl)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- carbamoylphenylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-sulfamoylphenylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-sulfamoylphenylsulfanyl)- thiophcne-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- sulfamoylphenylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-hydroxyphenylsulfanyl)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-hydroxyphenylsulfanyl)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- hydroxyphenylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-aminophenylsulfanyl)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-aminophenylsulfanyl)-thiophene- 2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- aminophenylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-acetamidophenoxy)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-acetamidophenoxy)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- acetamidophenoxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(2-trifluoroacetamidophenoxy)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- trifluoroacetamidophenoxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(4-trifluoroacetamidophenoxy)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- methanesulfonylaminophenoxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-melhyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(3-methanesulfonylaminophenoxy)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- methanesulfonylaminophenoxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-trifluoiOmethanesulfonylaminophenoxy)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- trifluoromethanesulfonylaminophenoxy)-thiophene-2-carboxamide; N-[(2S,3R)-2- methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-trifluoiOmethanesulfonylaminophenoxy)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- difluoroacetamidophenoxy)-thiophene-2-caι-boxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(3-difluoroacetamidophenoxy)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- difluoroacetamidophenoxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-carbamoylphenoxy)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-carbamoylphenoxy)-thioρhene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- carbamoylphenoxy)-thiophene-2-carboxamide; N-[(2S ,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(2-sulfamoylphenoxy)-thiophene-2-carboxamide; N-
[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-sulfamoylphenoxy)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- sulfamoylphenoxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(2-hydroxyphenoxy)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-hydroxyphenoxy)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(4- hydroxyphenoxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-aminophenoxy)-thiophene-2-caι-boxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-aminophenoxy)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- aminophenoxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-chlorophenoxy)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-chloroρhenoxy)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- chlorophenoxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-cyanoρhenoxy)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-cyanophenoxy)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(4- cyanophenoxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-methoxyphenyl)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-methoxyphenyl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- methoxyphenyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-methylphenyl)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl])-5-(3-methylphenyl-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-methylphenyl)- thioρhene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- trifluoromethylphenyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(3-trifluoromethylphenyI)-thiophene-2-caι-boxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-trifluoromethylphenyl)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- acetylyphenyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl- 1- azabicyclo[2.2.2]oct-3-yl]-5-(3-acetylphenyl)-thiophene-2-carboxamide; N-[(2S,3R)- 2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-acetylphenyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-cyanophenyl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(3-cyanophenyl)- thioρhene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- cyanophenyl)-thiophene-2-carboxamide; N-[(2S ,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(2-morpholin-4-yl-phenyl)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-moιpholin-4-yl-phenyl)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(4- moφholin-4-yl-phenyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-methoxyphenoxy)-thiophene-2-carboxamide; N-
[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-methoxyphenoxy)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- methoxyphenoxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-methylphenoxy)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-) 5-(3-methylphenoxy-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- methylphenoxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(2-trifluoromethylphenoxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-trifluoromethylphenoxy)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- trifluoromethylphenoxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-acetylphenoxy)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-acetylphenoxy)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- acetylphenoxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(2-cyanophenoxy)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-cyanophenoxy)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- cyanophenoxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(2-morpholin-4-yl-phenoxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-moφholin-4-yl-phenoxy)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- moιpholin-4-yl-phenoxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-methoxyphenylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-methoxyρhenylsulfønyl)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(4- methoxyphenylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-methylphenylsulfanyl)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-methylphenylsulfanyl)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- methylphenylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-trifluoromethylphenylsulfanyl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- trifluoromethylphenylsulfanyl)-thiophene-2-carboxamide; N- [(2S ,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(4-trifluoromethylphenylsulfanyl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- acetylyphenylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(3-acetylphenylsulfanyl)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-acetylphenylsulfanyl)-thiophene- 2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- cyanophenylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(3-cyanophenylsulfanyl)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-cyanophenylsulfanyl)-thiophene- 2-caι-boxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-morpholin-4- yl-phenylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(3-moιpholin-4-yl-phenylsulfanyl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-moφholin-4- yl-phenylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(pyridin-4-yl)-thiophene-2-carboxamide; N-[(2S,3R)-2- methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methylpyridin-4-yl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl- l-azabicyclo[2.2.2]oct-3-yl]-5-(6-methylpyridin- 3-yl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5- (5-methylpyridin-2-yl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(2-methoxypyridin-4-yl)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(6-methoxypyridin-3-yl)-thiophene- 2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5- methoxypyridin-2-yl)-thiophene-2-carboxamide; N-[(2S ,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(2-chloropyridin-4-yl)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(6-chloroρyridin-3-yl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-chloropyridin- 2-yl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5- (5-chloropyridin-3-yl)-thiophene-2-carboxamide; N-[(2S, 3R)-2- methyl- 1- azabicyclo[2.2.2]oct-3-yl]-5-(6-chloropyridin-2-yl)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-chloropyridin-2-yl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(pyridin-4-yloxy)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5- (pyridin-3-yloxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(pyridin-2-yloxy)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methylpyridin-4-yloxy)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(6- methylpyridin-3-yloxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(5-methylpyridin-2-yloxy)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methoxypyridin-4-yloxy)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl- l-azabicyclo[2.2.2]oct-3-yl]-5-(6- methoxypyridin-3-yloxy)-thiophene-2-caι-boxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(5-methoxypyridin-2-yloxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-chloropyridin-4-yloxy)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(6- chloroρyridin-3-yloxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(5-chloropyridin-2-yloxy)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyi-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-chloiOpyridin-4-yloxy)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(6- chloropyridin-3-yloxy)-thiophene-2-caι-boxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(5-chloropyridin-2-yloxy)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-chloropyridin-3-yloxy)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(6- chloropyridin-2-yloxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(4-chloropyridin-2-yloxy)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(ρyridin-4-ylsulfanyl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(ρyridin-3- ylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3- yl]-5-(pyridin-2-ylsulfanyl)-thiophene-2-carboxamide; N-[(2S ,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yI]-5-(2-methylpyridin-4-ylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(6-methylpyridin-3-ylsulfanyl)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5- methylpyridin-2-ylsulfanyI)-thiophene-2-caι-boxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yI]-5-(2-methoxypyridin-4-ylsulfanyl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(6- methoxypyridin-3-ylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(5-methoxypyridin-2-ylsulfanyl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-chloropyridin- 4-ylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct- 3-yl]-5-(6-chloropyridin-3-ylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2- methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-chloropyridin-2-ylsulfanyl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-chloropyridin- 4-ylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct- 3-yl]-5-(6-chloropyridin-3-ylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2- methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-chloropyridin-2-ylsulfanyl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-chloropyridin- 3-ylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct- 3-yl]-5-(6-chloropyridin-2-ylsulfanyl)-thiophene-2-caι-boxamide; N-[(2S,3R)-2- methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-chloropyridin-2-ylsulfanyl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(thiophen-4-yl)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicycIo[2.2.2]oct-3-yl]-5-(5- methyl-thiophen-2-yl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(5-methoxythiophen-2-yl)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-chIorothiophen-2-yl)-thiophene- 2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(furan-4-yl)- thiophene-2-carboxamide; N-[(2S,3R)-2-melhyl-l-azabicyclof2.2.2]oct-3-yl]-5-(5- methylfuran-2-yl)-thiophene-2-carboxamide; N-[(2S ,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(5-methoxyfuran-2-yl)-thiophene-2-carboxamicle; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-chlorofuran-2-yl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(oxazol-2-yl)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5- methyloxazol-2-yl)-thiophene-2-carboxamide; N-[(2S ,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(5-methoxyoxazol-2-yl)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-chlorooxazol-2-yl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(oxazol-5-yl)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- methyloxazol-5-yl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-methoxyoxazol-5-yl)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-chlorooxazol-5-yl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(thiazol-2-yl)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5- methylthiazol-2-yl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(5-methoxythiazol-2-yl)-thiophene-2-caι-boxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-chlorothiazol-2-yl)-thiophene-2- cai-boxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(thiazol-5-yl)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(2- methylthiazol-5-yl)-thiophene-2-carboxamide; N- [(2S ,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(2-methoxythiazol-5-yl)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-chlorothiazol-5-yl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-methylthiazol- 2-yl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5- (4-methoxythiazol-2-yl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(4-chlorothiazol-2-yl)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-methyloxazol-2-yl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- methoxyoxazol-2-yl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(4-chlorooxazol-2-yl)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-([l,3,4]thiadiazol-2-yl)-thioρhene- 2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5- methyl[l,3,4]thiadiazol-2-yl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(5-methoxy[l,3,4]thiadiazol-2-yl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5- chloro[l,3,4]thiadiazol-2-yl)-thioρhene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-([l,3,4]oxadiazol-2-yl)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-methyl[l,3,4]oxadiazol-2-yl)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5- methoxy[ 1 ,3,4]oxadiazol-2-yl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(5-chloro[l,3,4]oxadiazol-2-yI)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(thiophen-4- yloxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]- 5-(5-methylthiophen-2-yloxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(5-methoxythiophen-2-yloxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-chlorothiophen-2-yloxy)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5- (furan-4-yloxy)-thiophene-2-carboxamide; N-[(2S ,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(5-methylfuran-2-yloxy)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-methoxyfuran-2-yloxy)- thiophene-2-caι-boxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5- chlorofuran-2-yloxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(oxazol-2-yloxy)-thiophene-2-carboxamide; N-[(2S,3R)- 2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-methyloxazol-2-yloxy)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5- methoxyoxazol-2-yloxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yI]-5-(5-chlorooxazol-2-yloxy)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(oxazol-5-yloxy)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methyloxazol- 5-yloxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3- yl]-5-(2-methoxyoxazol-5-yloxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-chlorooxazol-5-yloxy)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(thiazol-2-yloxy)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-methylthiazol- 2-yloxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3- yl]-5-(5-methoxythiazol-2-yloxy)-thiophene-2-caι-boxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(5-chlorolhiazol-2-yloxy)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(thiazol-5-yloxy)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methylthiazol- 5-yloxy)-thiophene-2-caι-boxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3- yl]-5-(2-methoxythiazol-5-yloxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(2-chlorothiazol-5-yloxy)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-methylthiazol-2-yloxy)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- methoxythiazol-2-yloxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(4-chlorothiazol-2-yloxy)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-methyloxazol-2-yloxy)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- methoxyoxazol-2-yloxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(4-chlorooxazol-2-yloxy)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-([l,3,4]thiadiazol-2-yloxy)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5- methyl[l,3,4]thiadiazol-2-yloxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(5-methoxy[l,3,4]thiadiazol-2-yloxy)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5- chloro[l,3,4]thiadiazol-2-yloxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-([l,3,4]oxadiazol-2-yloxy)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-methyl[l,3,4]oxadiazol-2- yloxy)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]- 5-(5-methoxy[l,3,4]oxadiazol-2-yloxy)-thiophene-2-carboxamide; N-[(2S,3R)-2- methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-chloro[l,3,4]oxadiazol-2-yloxy)-thiophene- 2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(thiophen-4- ylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-mcthyl-l-azabicyclo[2.2.2]oct-3- yl]-5-(5-methylthiophen-2-ylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2- methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-methoxythiophen-2-ylsulfanyl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5- chlorothiophen-2-ylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(furan-4-ylsulfanyl)-thiophene-2-carboxamide; N- f(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-methylfuran-2-ylsulfanyl)- thioρhene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5- methoxyfuran-2-ylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl- 1- azabicyclo[2.2.2]oct-3-yl]-5-(5-chlorofuran-2-ylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(oxazol-2-ylsulfanyl)-thiophene- 2-caι-boxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5- methyloxazol-2-ylsulfanyl)-thiophene-2-carboxamide; N-[(2S ,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(5-methoxyoxazol-2-ylsulfanyl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-chlorooxazol- 2-ylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct- 3-yl]-5-(oxazol-5-ylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-methyloxazol-5-ylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methoxyoxazol-5-ylsulfanyl)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- chlorooxazol-5-ylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(thiazol-2-ylsulfanyl)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-methylthiazol-2-ylsulfanyl)- thiophene-2-carboxamide; N-[(2S,3R)-2-mcthyl- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(5- methoxylhiazol-2-ylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(5-chlorothiazol-2-ylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(thiazol-5-ylsulfanyl)-thiophene- 2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- methylthiazol-5-ylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-methoxythiazol-5-ylsulfanyl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-chlorothiazol- 5-ylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct- 3-yl]-5-(4-methylthiazol-2-ylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2- methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-methoxythiazol-2-ylsulfanyl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-chlorothiazol- 2-ylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct- 3-yl]-5-(4-methyloxazol-2-ylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2- methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-methoxyoxazol-2-ylsulfanyl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-chlorooxazol- 2-ylsulfanyl)-thiophene-2-caι-boxamide; N-[(2S,3R)-2-methyl- 1 -azabicyclo[2.2.2]oct- 3-yl]-5-([l,3,4]thiadiazol-2-ylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2- methyl-l-azabicyclo[2.2.2]ocl-3-yl]-5-(5-methyl[l,3,4]thiadiazol-2-ylsulfanyl)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5- methoxy[ 1 ,3,4]thiadiazol-2-ylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2- methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-chloro[l,3,4]thiadiazol-2-ylsulfanyl)- thiophene-2-caι-boxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5- ([l,3,4]oxadiazol-2-ylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(5-methyl[l,3,4]oxadiazol-2-ylsulfanyl)-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5- methoxy[l,3,4]oxadiazol-2-ylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2- methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-chloro[l,3,4]oxadiazol-2-ylsulfanyl)- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5- (pyrrole-2-yl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(isothiazol-3-yl)-thiophene-2-carboxamide; N-[(2S,3R)- 2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(isoxazol-3-yl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3H-imidazol-4-yl)-thioρhene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-4-(4- hydroxyphenylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-4-(3-acetamidophenylsulfanyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-4-(2- methanesulfonylaminophenyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-4-(pyridin-2-yloxy)-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-4-(2-methylpyridin-4-yloxy)- - thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicycIo[2.2.2]oct-3-yl]-4-(4- trifluoiOmethylphenyl)-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-4-(2-acetylphenyl)-thiophene-2-carboxamide; N-[(2S,3R)- 2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-4-chloro-5-phenyl-thiophene-2-carboxamide; N[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-4-methyl-5-phenyl-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicycIo[2.2.2]oct-3-yl]-4-cyano-5-phenyl- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-4- methoxy-5-phenyl-thiophene-2-carboxamide; N-[(2S,3R)-2-mcthyl- 1 -, azabicyclo[2.2.2]oct-3-yl]-5-chloro-4-phenyl-thiophene-2-carboxamide; N-[(2S,3R)- 2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-methyl-4-phenyl-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-cyano-4-phenyl-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-methoxy-4- phenyl-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]- 4-chloro-5-bromo-thiophene-2-carboxamide ; N- [(2S ,3 R)-2-methyL 1 - azabicyclo[2.2.2]oct-3-yl]-4-chloro-5-methylsulfanyl-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-4-chloro-5-methyl-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl- 1 -azabicyclo[2.2.2]oct-3-yl]-4-chloro-5-cyano- thiophene-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5- chloro-4-bromo-thiophene-2-carboxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-chloro-4-methylsulfanyl-thiophene-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-chloro-4-methyl-thiophene-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-chloro-4-cyano- thiophene-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-bromophenyl)-furan-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-bromophenyl)-furan-2-carboxamide; N- [(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(2,3-dichlorophenyl)-furan-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2,4-dichlorophenyl)-furan-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2Joct-3-yl]-5-(2,5-dichlorophenyl)-furan-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2,6-dichlorophenyl)-furan-2-carboxamide; N- [(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(3,4-dichlorophenyl)-furan-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,5-dichlorophenyl)-furan-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-amino-2-fluorophenyl)-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-amino-2-fluorophenyl)-furan-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]ocl-3-yl]-5-(4-amino-2-chlorophenyl)- furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-amino-2- chlorophenyl)-furan-2-caι-boxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- aminophenyl)-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- cyanophenyl)-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- cyanophenyl)-furan-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(2- hydroxyphenyl)-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- hydroxyphenyl)-furan-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(4- hydroxyphenyl)-furan-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(2- fluoro-4-methylphenyl)-furan-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]- 5-(2-fluoiO-3-methoxyphenyl)-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct- 3-yl]-5-(2-fluoro-4-methoxyphenyl)-furan-2-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(2-[(methylsulfonyl)amino]phenyl)-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-[(methylsulfonyl)amino]phenyl)-furan-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-
[(methylsulfonyl)amino]phenyl)-furan-2-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(2-([(trifluoiOmethyl)sulfonyl]amino)phenyl)-furan-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- ([(t ifluoromethyl)sulfonyl] amino)phenyl)-furan-2-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(4-([(trifluoromethyl)sulfonyl]amino)phenyl)-furan-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- [(phenylsulfonyl)amino]phenyl)-furan-2-carboxaιnide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(3-[(phenylsulfonyl)amino]phenyl)-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-[(phenylsulfonyl)amino]phenyl)-furan-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- [(methylamino)carbonyl]phenyl)-furan-2-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(3-[(methylamino)carbonyl]phenyl)-furan-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-
[(methylamino)carbonyl]phenyl)-furan-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(2-[(methylamino)sulfonyl]phenyl)-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-[(methylamino)sulfonyl]phenyl)-furan-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- [(methylamino)sulfonyl]phenyl)-furan-2-carboxamide; N-[(3R)- 1- azabicyclo[2.2.2]oct-3-yl]-5-[2-(methylamino)phenyl]-furan-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[3-(methylamino)phenyl]-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[4-(methylamino)phenyl]-furan-2- carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-[2-(ethylamino)phenyl]-furan- 2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[3-(ethylamino)phenyl]- furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[4- (ethylamino)phenyl]-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- (2-acetylphenyl)-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- acetylphenyl)-furan-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(4- acetylphenyl)-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[2-
(methylthio)phenyl]-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- [3-(methylthio)phenyl]-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]- 5-[4-(methylthio)phenyl]-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-[2-(phenylthio)phenyl]-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-[3-(phenylthio)phenyl]-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-[4-(phenylthio)phenyl]-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(2-phenoxyphenyl)-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]- 5-(3-phenoxyphenyl)-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- (4-phenoxyphenyl)-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- anilinophenyl)-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- anilinophenyl)-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- anilinophenyl)-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- (phenylthio)-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[(2- fluorophenyI)thio]-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[(3- fluorophenyl)thio]-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[(4- fluoiOphenyl)thio]-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[(2- chlorophenyl)thio]-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[(3- chlorophenyl)thio]-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[(4- chlorophenyl)thio]-furan-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(2- fluorophenoxy)-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- fluorophenoxy)-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- fluorophenoxy)-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- chlorophenoxy)-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- chloiOphenoxy)-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- chlorophenoxy)-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- pyridin-2-yl-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-pyridin-3- yl-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-pyridin-4-yl-furan-2- carboxamide N-l (3R) l-azabicyclo[2.2.2]ocl .-3-yl]-5-( (3-fluoropyridin-2-yl)-furan-2- carboxamide N- (3R) l-azabicyclo[2.2.2]oc .-3-yl]-5-((4-fluoropyridin-2-yl)-furan-2- cai-boxamide N- X3R) 1 -azabicyclo[2.2.2]ocl t-3-yl]-5-((5-fluoropyridin-2-yl)-furan-2- carboxamide N-l (3R) l-azabicyclo[2.2.2]od -3-yl]-5-((6-fluoropyridin-2-yl)-furan-2- carboxamide N-l (3R) l-azabicyclo[2.2.2]ocl :-3-yl]-5-((2-fluoropyridin-3-yl)-furan-2- carboxamide N-l (3R) l-azabicyclo[2.2.2]od .-3-yl]-5- (4-fluoropyridin-3-yl)-furan-2- carboxamide N-l (3R) l-azabicyclo[2.2.2]ocl .-3-yl]-5-((5-fluoropyridin-3-yl)-furan-2- carboxamide N-l (3R) l-azabicyclo[2.2.2]ocl .-3-yl]-5-((6-fluoropyridin-3-yl)-furan-2- carboxamide N-l (3R) l-azabicyclo[2.2.2]ocl .-3-yl]-5-((2-fluoiOpyridin-4-yl)-furan-2- carboxamide N- (3R) l-azabicyclo[2.2.2]od t-3-yl]-5-((3-fluoropyridin-4-yl)-furan-2- carboxamide N- "(3R) l-azabicyclo[2.2.2]od t-3-yl]-5-((3-chloropyridin-2-yl)-furan-2- carboxamide N- X3R) l-azabicyclo[2.2.2]od t-3-yl]-5-((<4-chloropyridin-2-yl)-furan-2- carboxamide N- (3R) l-azabicyclo[2.2.2]od t-3-yl]-5-((5-chloropyridin-2-yl)-furan-2- carboxamide N- .(3R) l-azabicyclo[2.2.2]oc t-3-yl]-5-((6-chloropyridin-2-yl)-furan-2- carboxamide N- X3R) l-azabicyclo[2.2.2]oc t-3-yl]-5-((2-chloropyridin-3-yl)-furan-2- carboxamide N-l (3R) l-azabicyclo[2.2.2]oc t-3-yl]-5-((4-chloropyridin-3-yl)-furan-2- carboxamide N- (3R) l-azabicyclo[2.2.2]od .-3-yl]-5-((5-chloropyridin-3-yl)-furan-2- carboxamide N- X3R) 1 -azabicyclo[2.2.2]oc t-3-yl]-5.-((6-chloropyridin-3-yl)-furan-2- carboxamide N- X3R) 1 -azabicyclo[2.2.2]oc t-3-yl]-5-((2-chloropyridin-4-yl)-furan-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-chloropyridin-4-yl)-furan-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-piperidin-l-ylphenyl)-furan- 2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-piperidin-l-ylphenyl)- furan-2-caι-boxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-piperidin-l- ylphenyl)-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- moφholin-4-ylphenyl)-furan-2-caι-boxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- (3-moφholin-4-ylphenyl)-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(4-moφholin-4-ylphenyl)-furan-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(2-pyrrolidin-l-ylphenyl)-furan-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-pyrrolidin-l-ylphenyl)-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-pyrrolidin-l-ylphenyl)-furan-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[2-(lH-pyrrol-2-yl)phenyl]- furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[3-(lH-pyrrol-2- yl)phenyl]-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[4-(lH- pyrrol-2-yl)phenyl]-furan-2-carboxamide; N-[(3R)- l-azabicyclo[2.2.2]oct-3-yl]-5-[2- (2-furyl)phenyl]-furan-2-caι-boxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[2-(3- furyI)phenyl]-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[2-(5- methyl-2-furyl)phenyl]-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]- 5-[3-(2-furyl)phenyl]-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- [3-(3-furyl)phenyl]-furan-2-carboxamicle; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[3- (5-methyl-2-furyl)phenyl]-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-[4-(2-furyl)phenyl]-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]- 5-[4-(3-furyl)ρhenyl]-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- [4-(5-methyl-2-furyl)phenyl]-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct- 3-yl]-5-[2-( 1 ,3-thiazol-2-yl)phenyl]-furan-2-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-[3-(l,3-thiazol-2-yl)phenyl]-furan-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[4-(l,3-thiazol-2-yl)phenyl]-furan-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[2-(l,3-oxazol-2-yl)phenyl]- furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[3-(l,3-oxazol-2- yl)phenyl]-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[4-( 1 ,3- oxazol-2-yl)phenyl]-furan-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(2- isothiazol-5-ylphenyl)-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- (3-isothiazol-5-ylphenyl)-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]ocl-3-yl]- 5-(4-isothiazol-5-ylphenyl)-furan-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-[4-(lH-indol-2-yl)phenyl]-furan-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-[4-(lH-indol-3-yl)phenyl]-furan-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(lH-indol-5-yl)-furan-2-carboxamide; N-[(3R)- l-azabicyclo[2.2.2]oct-3-yl]-5-(lH-indol-6-yl)-furan-2-carboxamide; N-[(2S,3R)-2- methyl- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(2-bromophenyl)-furan-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-bromophenyl)-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2,3- dichlorophenyl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct- 3-yl]-5-(2,4-dichlorophenyl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2,5-dichlorophenyl)-furan-2-carboxamide; N-[(2S,3R)- 2-methyl- 1-azabicyclo [2.2.2]ocl-3-yl]-5-(2,6-dichlorophenyl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,4-dichlorophenyl)-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,5- dichlorophenyl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct- 3-yl]-5-(4-amino-2-fluorophenyl)-furan-2 -carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(3-amino-2-fluorophenyl)-furan-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-amino-2-chlorophenyl)-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-amino-2- chlorophenyl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3- yl]-5-(3-aminophenyl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-cyanophenyl)-furan-2-carboxamide; N-[(2S,3R)-2- methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-cyanophenyl)-furan-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-hydroxyphenyl)-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- hydroxyphenyl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct- 3-yl]-5-(4-hydroxyphenyl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-fluoro-4-methylphenyl)-furan-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-fluoro-3-methoxyphenyl)-furan- 2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-fluoro-4- methoxyphenyl)-furan-2-carboxamide; N-[(2S ,3R)-2-methyl- 1 -azabicyclo[2.2.2]oct- 3-yl]-5-(2-[(methylsulfonyl)amino]ρhenyl)-furan-2-carboxamide; N-[(2S,3R)-2- methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-[(methylsulfonyl)amino]phenyl)-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- [(methylsulfonyl)amino]phenyl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-[2-([(trifluoiOmethyl)sulfonyl]amino)phenyl]-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[3- ([(trifluoromethyl)sulfonyl]amino)phenyl]-furan-2-carboxamide; N-[(2S,3R)-2- methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-([(trifluoromethyl)sulfonyl]amino)phenyl)- furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- [(phenylsulfonyl)amino]phenyl)-furan-2-carboxamide; N-[(2S ,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(3-[(phenylsulfonyl)amino]phenyl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-
[(phenylsulfonyl)amino]phenyl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-[(methylamino)carbonyl]phenyl)-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- [(methylamino)carbonyl]phenyl)-furan-2-caι-boxamide; N-[(2S ,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(4-[(methylamino)carbonyl]phenyl)-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- [(methylamino)sulfonyl]phenyl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(3-[(methylamino)sulfonyl]phenyl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- [(methylamino)sulfonyl]phenyl)-furan-2-caι-boxamide; N- [(2S ,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-[2-(methylamino)phenyl]-furan-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[3-(methylamino)phenyl]-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[4- (methylamino)phenyl]-furan-2-carboxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-[2-(ethylamino)phenyl]-furan-2-carboxamide; N-
[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[3-(ethylamino)phenyl]-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[4- (ethylamino)phenyl]-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-acetylphenyl)-furan-2-carboxamide; N-[(2S,3R)-2- methyl- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(3-acetylphenyl)-furan-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-acetylphenyl)-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[2- (methylthio)phenyl]-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-[3-(methylthio)phenyl]-furan-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[4-(methylthio)phenyl]-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-y]]-5-[2- (phenylthio)phenyl]-furan-2-caι-boxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-[3-(phenylthio)phenyl]-furan-2 -carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[4-(phenylthio)phenyl]-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- phenoxyphenyl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct- 3-yl]-5-(3-phenoxyphenyl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yI]-5-(4-phenoxyphenyl)-furan-2-carboxamide; N-[(2S,3R)-2- methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-anilinophenyl)-furan-2-caι-boxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-anilinophenyl)-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-anilinophenyl)- furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5- (phenylthio)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3- yl]-5-[(2-fluoiOphenyl)thio]-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-[(3-fluoι-ophenyl)thio]-furan-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[(4-Ωuorophenyl)thio]-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[(2- chlorophenyl)thio]-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-[(3-chlorophenyl)thio]-furan-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[(4-chlorophenyl)thio]-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- fluorophenoxy)-furan-2-caι-boxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3- yl]-5-(3-fluoiOphenoxy)-furan-2-carboxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(4-fluorophenoxy)-furan-2-carboxamide; N-[(2S,3R)-2- methyl- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(2-chlorophenoxy)-furan-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-chlorophenoxy)-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- chlorophenoxy)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct- 3-yl]-5-pyridin-2-yl-furan-2-carboxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-pyridin-3-yl-furan-2-carboxamide; N-[(2S,3R)-2-methyl- l-azabicyclo[2.2.2]oct-3-yl]-5-ρyridin-4-yl-furan-2-carboxamide; N-[(2S,3R)-2- methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-fluoropyridin-2-yl)-furan-2-caι-boxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-fluoropyridin-2-yl)-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-fluoropyridin- 2-yl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(6- fluoiOpyridin-2-yl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo [2.2.2] oct-3 -yl] -5-(2-fluoropyridin-3 -yl)-furan-2-carboxami de ; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-fluoropyridin-3-yl)-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-fluoropyridin- 3-yl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(6- fluoiOpyridin-3-yl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-fluoi-opyridin-4-yl)-furan-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-fluoropyridin-4-yl)-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-chloropyridin- 2-yl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- chloropyridin-2-yl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(5-chloropyridin-2-yl)-furan-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(6-chloropyridin-2-yI)-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-chloropyridin- 3-yl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- chloropyridin-3-yl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(5-chloropyridin-3-yl)-furan-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(6-chloropyridin-3-yl)-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-chloropyridin- 4-yl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- chloiOpyridin-4-yl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl- 1- azabicyclo[2.2.2]oct-3-yl]-5-(2-piperidin-l-ylphenyl)-furan-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-piperidin-l-ylphenyl)-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-piperidin-l- ylphenyl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5- (2-moφholin-4-ylphenyl)-furan-2-carboxamide; N-[(2S ,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(3-moιpholin-4-ylphenyl)-furan-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-moιρholin-4-ylphenyl)-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-pyrrolidin-l- ylphenyl)-furan-2-carboxamide; N~[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5- (3-pyrrolidin-l-ylphenyl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(4-pyrrolidin-l-ylphenyl)-furan-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[2-(lH-pyrrol-2-yl)phenyl]-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l -azabicyclo[2.2.2]oct-3-yl]-5-[3-(lH-pyrrol-2- yl)phenyl]-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]- 5-[4-(lH-pyrrol-2-yl)ρhenyl]-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-[2-(2-furyl)phenyl]-furan-2-carboxamide; N-[(2S,3R)-2- methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[2-(3-furyl)phenyl]-furan-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[2-(5-methyl-2-furyl)phenyl]-furan- 2-carboxamid; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[3-(2- furyl)phenyl]-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3- yl]-5-[3-(3-furyl)phenyl]-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-[3-(5-methyl-2-furyl)phenyl]-furan-2-carboxamide; N- [(2S,3R)-2-methyl- 1 -azabicyclo[2.2.2]oct-3-yl]-5-[4-(2-furyl)phenyl]-furan-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[4-(3- furyl)phenyl]-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3- yl]-5-[4-(5-methyl-2-furyl)phenyl]-furan-2-carboxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-[2-(l,3-thiazol-2-yl)phenyl]-furan-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[3-(l,3-thiazol-2-yl)phenyl]-furan- 2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[4-(l,3-thiazol- 2-yl)phenyl]-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3- yl]-5-[2-(l,3-oxazol-2-yl)phenyl]-furan-2-carboxamide; N-[(2S,3R)-2-methyI-l- azabicyclo[2.2.2]oct-3-yl]-5-[3-( 1 ,3-oxazol-2-yl)phenyl]-furan-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[4-(l,3-oxazol-2-yl)phenyl]-furan- 2-caι-boxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-isothiazol-5- ylphenyl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5- (3-isothiazol-5-ylphenyl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(4-isothiazol-5-ylphenyl)-furan-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[4-(lH-indol-2-yI)phenyl]-furan-2- caiboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[4-(lH-indol-3- yl)phenyl]-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]- 5-(lH-indol-5-yl)-furan-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct- 3-yl]-5-(lH-indol-6-yl)-furan-2-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-(2,3-difluorophenyl)-l,3-thiazole-5- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-(2,4-difluorophenyl)-l,3- thiazole-5-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-(2,5- difluorophenyl)- 1 ,3-thiazole-5-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-2- (2,6-difluorophenyl)-l,3-thiazole-5-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-2-(3,4-difluorophenyl)-l,3-thiazole-5-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-2-(3,5-difluorophenyl)-l,3-thiazole-5-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-(2-chlorophenyl)-l,3-thiazole-5-carboxamide;
[(3R) -l-azabicyclo[2.2.2]oc t-3-yl] ]-2- 3-chlorophenyl)- 1 ,3-thiazole-5-carboxamide;
[(3R) -1 -azabicyclo[2.2.2]oc t-3-yl] J-2- 4-chlorophenyl)- 1 ,3-thiazole-5-carboxamide;
[(3R) -l-azabicyclo[2.2.2]od t-3-yl] ]-2- 2-bromophenyl)- 1 ,3-thiazole-5-carboxamide;
[(3R) -l-azabicyclo[2.2.2]od t-3-yl] ]-2- 3-bromophenyl)-l,3-thiazole-5-carboxamide;
[(3R) -l-azabicyclo[2.2.2]ocl --3-yl] ]-2- 4-bromophenyl)- 1 ,3-thiazole-5-carboxamide;
[(3R) -l-azabicyclo[2.2.2]ocl .-3-yl] ]-2- 2-cyanophenyl)-l,3-thiazole-5-carboxamide;
[(3R) - 1 -azabicyclo[2.2.2]oc t-3-yl] ]-2- 3-cyanophenyl)- 1 ,3-thiazole-5-carboxamide;
[(3R) -l-azabicyclo[2.2.2]od t-3-yl] ]-2- 4-cyanophenyl)- 1 ,3-thiazole-5-carboxamide;
[(3R) -l-azabicyclo[2.2.2]ocl t-3-yl] ]-2- 2-nitrophenyl)- 1 ,3-thiazole-5-carboxamide;
[(3R) - 1 -azabicyclo[2.2.2]ocl -3-yl] ]-2 3-nitrophenyl)-l,3-thiazole-5-carboxamide;
[(3R) -l-azabicyclo[2.2.2]od -3-yl ]]-2- 4-nitrophenyl)-l,3-thiazole-5-caιboxamide;
[(3R) -1 -azabicyclo[2.2.2]oc -3-yl] ]-2- 2-methylphenyl)- 1 ,3-thiazole-5-carboxamide;
[(3R) -l-azabicyclo[2.2.2]oc t-3-yl] ]-2- 3-methylphenyl)- 1 ,3-thiazole-5-carboxamide;
[(3R) -l-azabicyclo[2.2.2]od t-3-yl] ]-2- 2-aminophenyl)- 1 ,3-thiazole-5-carboxamide;
[(3R) - 1 -azabicyclo[2.2.2]ocl [-3-yl] ]-2 3-aminophenyl)- 1 ,3-thiazole-5-carboxamide;
[(3R) -l-azabicyclo[2.2.2]ocl :-3-yl] ]-2- 4-aminophenyl)- 1 ,3-thiazole-5-carboxamide;
[(3R) -l-azabicyclo[2.2.2]oc --3-yl] ]-2- 2-(methylamino)phenyl]- 1 ,3-thiazole-5- carboxamide; N-[(3R)- l-azabicyclo[2.2.2]oct-3-yl]-2-[3-(methylamino)phenyl]- 1 ,3- thiazole-5-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-[4- (methylamino)phenyl]-l,3-thiazole-5-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct- 3-yl]-2-[2-(acetylamino)phenyl]-l,3-thiazole-5-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-2-[3-(acetylamino)phenyl]-l,3-thiazole-5-carboxamide; N- [(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-2-[4-(acetylamino)phenyl]- 1 ,3-thiazole-5- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-(2- [(trifluoroacetyl)amino]phenyl)-l,3-thiazole-5-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-2-(3-[(trifluoiOacetyl)amino]phenyl)-l,3-thiazole-5- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]~2-(4-
[(trifluoroacetyl)amino]phenyl)-l,3-thiazole-5-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-2-(2-[(methylsulfonyl)amino]phenyl)-l,3-thiazole-5- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-(3- [(methylsulfonyl)amino]phenyl)-l,3-thiazole-5-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-2-(4-[(methylsulfonyl)amino]phenyl)- 1 ,3-thiazole-5- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-(3-hydroxyphenyl)-l,3- thiazole-5-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-2-(4-hydroxyphenyl)- l,3-thiazole-5-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-(2- methoxyphenyl)-l,3-thiazole-5-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2- (3-methoxyphenyl)-l,3-thiazole-5-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-2-(4-methoxyphenyl)-l,3-thiazole-5-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-2-[2-(trifluoromethoxy)phenyl]-l,3-thiazoIe-5- carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-2-[3-(trifluoromethoxy)phenyl]- l,3-thiazole-5-carboxamide; N-[(3R)-l-azabicycIo[2.2.2]oct-3-yl]-2-[4- (trifluoromethoxy)phenyl]- 1 ,3-thiazole-5-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-2-pyridin-2-yl-l,3-thiazole-5-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-2-pyridin-3-yl-l,3-thiazole-5-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-2-pyridin-4-yl-l,3-thiazole-5-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-2-(6-fluoropyridin-2-yl)-l,3-thiazole-5-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-(5-fluoropyridin-2-yl)-l,3-thiazole-5- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yI]-2-(4-fluoropyridin-2-yl)-l,3- thiazole-5-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-(3-fluoropyridin-2- yl)-l,3-thiazole-5-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-(2- fluoropyridin-2-yl)-l,3-thiazole-5-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-2-(6-fluoropyridin-3-yl)- 1 ,3-thiazole-5-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-2-(5-fluoropyridin-3-yl)-l,3-thiazole-5-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-(4-fluoropyridin-3-yl)-l,3-thiazole-5- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-(2-fluoropyridin-3-yl)-l,3- thiazole-5-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-2-(2-fluoropyridin-4- yl)-l,3-thiazole-5-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-2-(3- fluoropyridin-4-yl)- 1 ,3-thiazole-5-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(methylthio)-l,3-thiazole-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-chloro-l,3-thiazole-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-bromo-l,3-thiazole-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(phenylthio)-l,3-thiazole-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-[(2-fluorophenyl)thio]-l,3-thiazole-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[(3-fluorophenyl)thio]-l,3-thiazole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[(4-fluorophenyl)thio]-l,3- thiazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[(2- chlorophenyl)thio]-l,3-thiazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-[(3-chlorophenyl)thio]-l,3-thiazole-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-[(4-chlorophenyl)thio]-l,3-thiazole-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-phenoxy-l,3-thiazole-2-carboxamide; N-[(3R)- l-azabicyclo[2.2.2]oct-3-yl]-5-(2-fluorophenoxy)-l,3-thiazole-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-fluoiOphenoxy)-l,3-thiazole-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(4-fluorophenoxy)- 1 ,3-thiazole-2- cai-boxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-chlorophenoxy)-l,3- thiazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-chlorophenoxy)- l,3-thiazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- chlorophenoxy)-l,3-thiazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl)]- 5-thien-3-yl-l,3-thiazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- (2,4-difluorophenyl)-l,3-thiazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(3,5-difluorophenyl)-l,3-thiazole-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(2,4-dichlorophenyl)-l,3-thiazole-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,5-dichlorophenyl)-l,3-thiazole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-bromophenyl)-l,3-thiazole- 2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-bromophenyl)-l,3- thiazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-cyanophenyl)- l,3-thiazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- cyanoρhenyl)-l,3-thiazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- (4-cyanophenyl)-l,3-thiazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]- 5-(2-hydroxyphenyl)-l,3-thiazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(3-hydroxyphenyl)-l,3-thiazole-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(4-hydroxyphenyl)- 1 ,3-thiazole-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-nitrophenyl)-l,3-thiazole-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-nitrophenyl)-l,3-thiazole-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methylphenyl)-l,3-thiazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-methylphenyl)-l,3-thiazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-methylphenyl)-l,3-thiazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-aminophenyl)-l,3-thiazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-aminophenyl)-l,3-thiazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-aminophenyl)-l,3-thiazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[(2-(acetylamino)phenyl]-l,3-thiazole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[3-(acetylamino)phenyl]-l,3- thiazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[4-
(acetylamino)phenyl]-l,3-thiazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(ρyridin-2-yl)- 1 ,3-thiazole-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3- yl]-5-(pyridin-3-yl)-l,3-thiazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(pyridin-4-yl)-l,3-thiazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(3-fluoiOpyridin-2-yl)-l,3-thiazole-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(4-fluoropyridin-2-yl)-l,3-thiazole-2-carboxamide; N- [(3R)- l-azabicyclo[2.2.2]oct-3-yl]-5-(5-fluoropyridin-2-yl)- 1 ,3-thiazole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(6-fluoropyridin-2-yl)-l,3- thiazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-fluoropyridin-3- yl)-l,3-thiazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- fluoropyridin-3-yl)-l ,3-thiazole-2-carboxamide; N-[(3R)- l-azabicyclo[2.2.2]oct-3- yl]-5-(5-fluoropyridin-3-yl)-l,3-thiazole-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(6-fluoiOpyridin-3-yl)-l,3-thiazole-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-fluoropyridin-4-yl)-l,3-thiazole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[(2-methoxyphenyl)thio]-l,3- thiazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[(3- methoxyphenyl)thio]-l,3-thiazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-[(4-methoxyphenyl)thio]-l,3-thiazole-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-[(2-methylphenyl)thio]- 1 ,3-thiazole-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[(3-methylphenyl)thio]-l,3-thiazole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[(4-methylphenyl)thio]- 1 ,3- thiazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-([4- (acetylamino)phenyl]thio)-l ,3-thiazole-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-[(4-aminophenyl)thio]- 1 ,3-thiazole-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[(4-hydroxyphenyl)thio]-l,3-thiazole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methylphenoxy)-l,3- thiazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-methylphenoxy)- l,3-thiazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- methylphenoxy)-l,3-thiazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- (2-methoxyphenoxy)-l,3-thiazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(3-methoxyphenoxy)- 1 ,3-thiazole-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(4-methoxyphenoxy)- 1 ,3-thiazole-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-hydroxyphenoxy)-l,3-thiazple-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-aminophenoxy)-l,3- thiazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[4- (acetylamino)phenoxy]- 1 ,3-thiazole-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct- 3-yl]-5-(2-fluorophenyl)-4-methyl- 1 ,3-thiazole-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(3-fluorophenyl)-4-methyl- 1 ,3-thiazole-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(2-chlorophenyl)-4-methyl- 1 ,3-thiazole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-chlorophenyl)-4-methyl-l,3- thiazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methoxyphenyl)- 4-methyl-l,3-thiazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- methoxyphenyl)-4-methyl-l ,3-thiazole-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-4-methyl-5-thien-2-yl-l,3-thiazole-2-carboxamide,
N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-(2,3-difluoiOphenyl)-l,3- thiazole-5-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-(2,4- difluorophenyl)-l,3-thiazole-5-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-2-(2,5-difluorophenyl)-l,3-thiazole-5-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-(2,6-difluorophenyl)-l,3-thiazole-5- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-(3,4- difluorophenyl)-l,3-thiazole-5-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-2-(3,5-difluoiOphenyl)-l,3-thiazole-5-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-(2-chlorophenyl)-l,3-thiazole-5- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-(3-chlorophenyl)- 1 ,3-thiazole-5-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-(4- chlorophenyl)-l,3-thiazole-5-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-2-(2-bromophenyl)- 1 ,3-thiazole-5-carboxamide; N- [(2S,3R)-2-methyI-l-azabicyclo[2.2.2]oct-3-yl]-2-(3-bromophenyl)-l,3-thiazole-5- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-ylJ-2-(4-bromophenyl)- l,3-thiazole-5-caι-boxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-(2- cyanophenyl)-l,3-thiazole-5-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-2-(3-cyanophenyl)- 1 ,3-thiazole-5-carboxamide; N- [(2S,3R)-2-melhyl-l-azabicyclo[2.2.2]oct-3-yl]-2-(4-cyanophenyl)-l,3-thiazole-5- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-(2-nitrophenyl)- l,3-fhiazole-5-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-(3- nitrophenyl)-l,3-thiazole-5-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-2-(4-nitrophenyl)-l,3-thiazole-5-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-(2-methylρhenyl)-l,3-thiazole-5- carboxamide; N-[(2S,3R)-2-methyl- 1 -azabicyclo[2.2.2]oct-3-yl]-2-(3-methylphenyl)- 1 ,3-thiazole-5-carboxamide; N-[(2S,3R)-2-methyl- 1 -azabicyclo[2.2.2]oct-3-yl]-2-(2- aminophenyl)-l,3-thiazole-5-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-2-(3-aminophenyl)- 1 ,3-thiazole-5-caι-boxamide; N- [(2S,3R)-2-methyl- l-azabicyclo[2.2.2]oct-3-yl]-2-(4-aminophenyl)- 1 ,3-thiazole-5- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-[2- (methylamino)phenyl]-l,3-thiazole-5-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-2-[3-(methylamino)phenyl]-l,3-thiazole-5-carboxamide; N-[(2S,3R)-2-methyl- 1 -azabicyclo[2.2.2]oct-3-yl]-2-[4-(methylamino)phenyl]- 1 ,3- thiazole-5-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-[2- (acetylamino)phenyl]- 1 ,3-thiazole-5-carboxamide; N-[(2S ,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-2-[3-(acetylamino)phenyl]-l,3-thiazole-5-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-[4-(acetylamino)phenyl]-l,3- thiazole-5-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-(2- [(trifluoroacetyl)amino]phenyl)- 1 ,3-thiazole-5-carboxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-2-(3-[(trifluoroacetyl)amino]phenyl)-l,3-thiazole-5- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-(4- [(trifluoroacetyl)amino]phenyl)-l,3-thiazole-5-caι-boxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-2-(2-[(methylsulfonyl)amino]phenyl)-l,3-thiazole-5- carboxamide; N-[(2S,3R)-2-methyI-l-azabicyclo[2.2.2]oct-3-yl]-2-(3-
[(methylsulfonyl)amino]phenyl)-l,3-thiazole-5-carboxamide; N-[(2S,3R)-2-methyl- l-azabicyclo[2.2.2]oct-3-yl]-2-(4-[(methylsulfonyl)amino]phenyl)-l,3-thiazole-5- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-(3- hydroxyphenyl)-l,3-thiazole-5-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-2-(4-hydroxyphenyl)-l,3-thiazole-5-carboxamide; N-
[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-(2-methoxyphenyl)-l,3-thiazole-5- carboxamide; N-[(2S,3R)-2-methyl-l-azabiCyclo[2.2.2]oct-3-yl]-2-(3- methoxyphenyl)-l,3-thiazole-5-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-2-(4-methoxyphenyl)- 1 ,3-thiazole-5-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-[2-(trifluoromethoxy)phenyl]-l,3- thiazole-5-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-[3- (trifluoromethoxy)phenyl]-l,3-thiazole-5-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo [2.2.2] oct-3 -yl] -2- [4-(trifluoiOmethoxy)phenyl] -1,3 -thiazole-5- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-pyridin-2-yl-l,3- thiazole-5-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-pyridin- 3-yl-l,3-thiazole-5-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]- 2-pyridin-4-yl- 1 ,3-thiazole-5-carboxamide; N-[(2S ,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-2-(6-fluoropyridin-2-yl)- 1 ,3-thiazole-5-carboxamide; N- [(2S,3R)-2-methyl- l-azabicyclo[2.2.2]oct-3-yl]-2-(5-fluoropyridin-2-yl)- 1 ,3-thiazole- 5-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-(4- fluoropyridin-2-yl)- 1 ,3-thiazole-5-carboxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-2-(3-fluoropyridin-2-yl)-l,3-thiazole-5-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-(2-fluoiOpyridin-2-yl)-l,3-thiazole- 5-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-(6- fluoropyridin-3-yl)-l ,3-thiazole-5-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-2-(5-fluoropyridin-3-yl)-l,3-thiazole-5-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-(4-fIuoropyridin-3-yl)-l,3-thiazole- 5-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-(2- fluoiOpyridin-3-yl)-l,3-thiazole-5-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-2-(2-fluoropyridin-4-yl)- 1 ,3-thiazole-5-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-(3-fluoropyridin-4-yl)-l,3-thiazole- 5-carboxamide;
N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(methylthio)-l,3-thiazole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-chloro-l,3- thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-bromo- l,3-thiazole-2-carboxamide, N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5- (phenylthio)-l,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-[(2-fluorophenyl)thio]- 1 ,3-thiazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[(3-fluorophenyl)thio]-l,3-thiazole- 2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[(4- fluorophenyl)thio]-l,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-[(2-chlorophenyl)thio]-l,3-thiazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[(3-chloroρhenyl)thio]-l,3-thiazole- 2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[(4- chlorophenyl)thio]-l,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-phenoxy-l,3-thiazole-2-carboxamide; N-[(2S,3R)-2- methyl- l-azabicyclo[2.2.2]oct-3-yl]-5-(2-fluorophenoxy)-l,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-fluorophenoxy)-l,3-thiazole- 2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- fluorophenoxy)- 1 ,3-thiazole-2-carboxamide; N-[(2S ,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(2-chlorophenoxy)- 1 ,3-thiazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-chloroρhenoxy)-l,3-thiazole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- chlorophenoxy)-l,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-thien-3-yl- 1 ,3-thiazole-2-carboxamide; N-[(2S,3R)-2- methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2,4-difluorophenyl)-l,3-thiazole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,5- difluorophenyl)- 1 ,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl- 1- azabicyclo[2.2.2]oct-3-yl]-5-(2,4-dichloiOpheriyl)-l,3-thiazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,5-dichlorophenyl)-l,3-thiazole-2- carboxamide; N-[(2S,3R)-2-methyl- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(2-bromophenyl)- l,3-thiazole-2-caι-boxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- bromophenyl)-l ,3-thiazoIe-2-carboxamide; N-[(2S,3R)-2-methyl- 1- azabicyclo[2.2.2]oct-3-yl]-5-(2-cyanophenyl)-l,3-thiazole-2-caι-boxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-cyanophenyl)-l,3-thiazole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-cyanophenyl)- l,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- hydroxyphenyl)- 1 ,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl- 1- azabicyclo[2.2.2]oct-3-yl]-5-(3-hydroxyphenyl)- 1 ,3-thiazole-2-carboxamide; N- [(2S,3R)-2-methyl- l-azabicyclo[2.2.2]oct-3-yl]-5-(4-hydroxyphenyl)- 1 ,3-thiazole-2- carboxamide; N-[(2S,3R)-2-methyl- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(2-nitrophenyl)- l,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- nitrophenyl)-l,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-methylphenyl)- 1 ,3-thiazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-methylphenyl)-l,3-thiazole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-methylphenyl)- l,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- aminophenyl)- 1 ,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl- 1- azabicyclo[2.2.2]oct-3-yl]-5-(3-aminophenyl)-l,3-thiazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-aminophenyl)-l,3-thiazole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[2- (acetylamino)phenyl]- 1 ,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-[3-(acetylamino)phenyl]- 1 ,3-thiazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[4-(acetylamino)phenyl]-l,3- thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5- (pyridin-2-yl)- 1 ,3-thiazole-2-carboxamide; N- [(2S ,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(pyridin-3-yl)- 1 ,3-thiazole-2-carboxamide; N-[(2S,3R)- 2-methyl- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(pyridin-4-yl)- 1 ,3-thiazoIe-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-fluoropyridin-2-yl)-l,3- thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l -azabicy'clo[2.2.2]oct-3-yl]-5-(4- fluoropyridin-2-yl)-l,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(5-fluoropyridin-2-yl)- 1 ,3-thiazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(6-fluoropyridin-2-yl)-l,3-thiazole- 2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- fluoropyridin-3-yl)-l ,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(4-fluoropyridin-3-yl)- 1 ,3-thiazole-2-carboxamide; N- [(2S,3R)-2-methyl- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(5-fluoropyridin-3-yl)- 1 ,3-thiazole- 2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(6- fluoropyridin-3-yl)-l,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-fluoropyridin-4-yl)- 1 ,3-thiazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[(2-methoxyphenyl)thio]-l,3- thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[(3- methoxyphenyl)thio]-l,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-[(4-methoxyphenyl)thio]-l,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[(2-methylphenyl)thio]-l,3- thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[(3- methylphenyl)thio]-l,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-[(4-methylphenyl)thio]-l,3-thiazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-([4-(acetylamino)phenyl]thio)-l,3- thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[(4- aminophenyl)thio]-l ,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl- 1- azabicyclo[2.2.2]oct-3-yl]-5-[(4-hydroxyphenyl)thio]- 1 ,3-thiazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methylphenoxy)-l,3-thiazole-2- carboxamide; N-[(2S,3R)-2-methyl- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(3- methylphenoxy)-l,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(4-methylphenoxy)-l,3-thiazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methoxyphenoxy)-l,3-thiazole- 2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- methoxyphenoxy)-l,3-thiazole-2-caι-boxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(4-methoxyphenoxy)- 1 ,3-thiazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-hydroxyρhenoxy)-l,3-thiazole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- aminophenoxy)-l,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-[4-(acetylamino)phenoxy]-l,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-fluorophenyl)-4-methyl-l,3- thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- i fluorophenyl)-4-methyl-l,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-chlorophenyl)-4-methyl-l,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-chlorophenyl)-4-methyl-l,3- thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- methoxyphenyl)-4-methyl-l,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(3-methoxyphenyl)-4-methyl-l,3-thiazole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-4-methyl-5-thien-2- yl-l,3-thiazole-2-carboxamide, N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5- phenyl-l,3-thiazoIe-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3- yl]-5-ρhenyl-4-methyl-l ,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-fluorophenyl)-l,3-thiazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-fluorophenyl)-l,3-thiazole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-fluorophenyl)- l,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5- thien-2-yl-l ,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct- 3-yl]-5-(2-chlorophenyl)-l,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(3-chlorophenyl)-l,3-thiazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-chlorophenyl)-l,3-thiazole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-bromophenyl)- l,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- nitrophenyl)- 1 ,3-thiazole-2-caι-boxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(2-methoxyphenyl)- 1 ,3-thiazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-methoxyphenyl)-l,3-thiazole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- methoxyphenyl)-l,3-thiazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-2-(2-hydroxyphenyl)- 1 ,3-thiazole-5-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-(4-methylphenyl)-l,3-thiazole-5- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-phenyl-l,3- thiazole-5-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-(2- fluorophenyl)- l,3-thiazole-5-caιboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-2-(3-fluorophenyl)- 1 ,3-thiazole-5-carboxamide; N-
[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-2-(4-fluoroρhenyl)-l,3-thiazole-5- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-phenylsulfanyl-l,3-oxazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-fluorophenylsulfanyl)-l,3-oxazole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-fluorophenylsulfanyl)-l,3- oxazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- fluorophenylsulfanyl)-l,3-oxazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(3,4-difluorophenylsulfanyl)-l,3-oxazole-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(2,4-difluorophenylsulfanyl)-l,3-oxazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,5-difluorophenylsulfanyl)-l,3-oxazole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-chlorophenylsulfanyl)- 1 ,3- oxazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3~yl]-5-(3- chlorophenylsulfanyl)- 1 ,3-oxazole-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3- yl]-5-(4-chlorophenylsulfanyl)-l,3-oxazole-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(3,4-dichlorophenylsulfanyl)-l,3-oxazole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2,4-dichlorophenylsulfanyl)- 1 ,3-oxazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,5- dichlorophenylsulfanyl)-l,3-oxazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct- 3-yl]-5-(2-fluorophenyl)-l,3-oxazole-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(3-fluorophenyl)-l,3-oxazole-2-carboxamide; N-[(3R)- l-azabicyclo[2.2.2]oct-3-yl]-5-(3,4-difluorophenyl)-l ,3-oxazole-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2,4-difluorophenyl)-l,3-oxazole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,5-difluorophenyl)-l,3- oxazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-chlorophenyl)- l,3-oxazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,4- dichlorophenyl)-l,3-oxazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- (2,4-dichlorophenyl)-l,3-oxazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yI]-5-(3 ,5-dichlorophenyl)- 1 ,3-oxazole-2-carboxamide; N- [(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(2-bromophenyl)- 1 ,3-oxazole-2-carboxamide; N-[(3R)- l-azabicyclo[2.2.2]oct-3-yl]-5-(3-bromophenyl)-l,3-oxazole-2-carboxamide; N- [(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(2-cyanophenyl)- 1 ,3-oxazole-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-cyanophenyl)-l,3-oxazole-2-carboxamide; N- [(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(2-hydroxyphenyl)- 1 ,3-oxazole-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(3-hydroxyphenyl)- 1 ,3-oxazole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-hydroxyphenyl)-l,3- oxazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-nitrophenyl)-l,3- oxazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methylphenyl)- l,3-oxazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- methylphenyl)-l,3-oxazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- (4-methylphenyl)-l ,3-oxazole-2-carboxamide; N-[(3R)- l-azabicyclo[2.2.2]oct-3-yl]- 5-(2-methylaminophenyl)-l ,3-oxazole-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(3-methylaminophenyl)-l,3-oxazole-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-methylaminophenyl)-l,3-oxazole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-aminophenyl)-l,3-oxazole- 2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-aminophenyl)-l,3- oxazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-aminophenyl)- l,3-oxazole-2-caι-boxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[2- (acetylamino)phenyl]-l,3-oxazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-[3-(acetylamino)phenyl]-l ,3-oxazole-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]ocl-3-yl]-5-[4-(acetylamino)phenyl]-l,3-oxazole-2-carboxamide; N- [(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(pyridin-2-yl)- 1 ,3-oxazole-2-carboxamide; N- [(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(pyridin-3-yl)- 1 ,3-oxazole-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(pyridin-4-yl)-l,3-oxazole-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-fluoropyridin-2-yl)-l,3-oxazole-2- cai-boxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(4-fluoropyridin-2-yl)- 1 ,3- oxazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-fluoropyridin-2- yl)-l,3-oxazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(6- fluoiOpyridin-2-yl)-l ,3-oxazole-2-carboxamide; N-[(3R)- l-azabicyclo[2.2.2]oct-3- yl]-5-(2-fluoropyridin-3-yl)-l,3-oxazole-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(4-fluoropyridin-3-yl)- 1 ,3-oxazole-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-fluoropyridin-3-yl)-l,3-oxazole-2- carboxamide; N-[(3R)- l-azabicyclo[2.2.2]oct-3-yl]-5-(6-fluoropyridin-3-yl)-l ,3- oxazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-fluoiOpyridin-4- yl)-l,3-oxazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- fluoropyridin-3-yl)-l,3-oxazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-phenoxy-l ,3-oxazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- (2-fluorophenoxy)-l,3-oxazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]- 5-(3-fluoroρhenoxy)-l,3-oxazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(4-fluorophenoxy)-l,3-oxazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct- 3-yl]-5-(3,4-difluorophenoxy)-l,3-oxazole-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(2,4-difluorophenoxy)-l,3-oxazole-2-carboxamide; N- [(3R)-1 -azabicyclo[2.2.2]oct-3-yl]-5-(3,5-difluorophenoxy)-l ,3-oxazole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-chlorophenoxy)-l,3- oxazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-chlorophenoxy)- l,3-oxazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- chlorophenoxy)-l,3-oxazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- (3,4-dichlorophenoxy)-l,3-oxazole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct- 3-yl]-5-(2,4-dichIorophenoxy)-l,3-oxazole-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(3,5-dichlorophenoxy)-l,3-oxazole-2-carboxamide;
N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-phenylsulfanyl-l,3-oxazole-2- cai-boxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- fluorophenylsulfanyl)-l,3-oxazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(3-fluorophenylsulfanyl)- 1 ,3-oxazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-fluorophenylsulfanyl)-l,3- oxazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,4- difluoiOphenylsulfanyl)-l,3-oxazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2,4-difluorophenylsulfanyl)-l,3-oxazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,5-difluorophenylsulfanyl)-l,3- oxazole-2-carboxamide; N-[(2S,3R)-2-methyl- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(2- chlorophenylsulfanyl)-l,3-oxazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(3-chlorophenylsulfanyl)-l,3-oxazole-2-caι-boxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-chlorophenylsulfanyl)-l,3- oxazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,4- dichlorophenylsulfanyl)- 1 ,3-oxazole-2-carboxamide; N-[(2S ,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(2,4-dichlorophenylsulfanyl)-l,3-oxazole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,5- dichlorophenylsulfanyl)-l,3-oxazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-fluorophenyl)-l,3-oxazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-fluorophenyl)-l,3-oxazole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,4- difluorophenyl)-l,3-oxazolc-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2,4-difluorophenyl)-l,3-oxazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,5-difluorophenyl)-l,3-oxazole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-chlorophenyl)- l,3-oxazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5- (3,4-dichlorophenyl)-l,3-oxazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2,4-dichlorophenyl)- 1 ,3-oxazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,5-dichlorophenyl)-l,3-oxazole-2- carboxamide; N-[(2S,3R)-2-methyl- l-azabicyclo[2.2.2]oct-3-yl]-5-(2-bromophenyl)- l,3-oxazole-2-carboxamide; N-[(2S,3R)-2-methyI-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- bromophenyl)-l,3-oxazole-2-carboxamide; N-[(2S,3R)-2-melhyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-cyanophenyl)- 1 ,3-oxazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-cyanophenyl)-l,3-oxazole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- hydroxyphenyl)- 1 ,3-oxazole-2-caι-boxamide; N-[(2S,3R)-2-methyl- 1- azabicyclo[2.2.2]oct-3-yl]-5-(3-hydroxyphenyl)- 1 ,3-oxazole-2-caι-boxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-hydroxyphenyl)-l,3-oxazole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-nitrophenyl)- l,3-oxazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- methylphenyl)-l,3-oxazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(3-methylphenyl)- 1 ,3-oxazole-2-carboxamide; N- [(2S,3R)-2-methyl- l-azabicyclo[2.2.2]oct-3-yl]-5-(4-methylphenyl)- 1 ,3-oxazole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- methylaminophenyl)-l,3-oxazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(3-methylaminophenyl)-l,3-oxazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-methylaminophenyl)-l,3- oxazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- aminophenyl)-l,3-oxazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(3-aminophenyl)-l,3-oxazole-2-carboxamide; N-
[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-aminophenyl)-l,3-oxazole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[2- (acetylamino)phenyl]-l,3-oxazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-[3-(acetylamino)phenyl]-l,3-oxazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[4-(acetylamino)phenyl]-l,3- oxazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5- (pyridin-2-yl)-l,3-oxazole-2-caι-boxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(pyridin-3-yl)-l,3-oxazole-2-carboxamide; N-[(2S,3R)- 2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(pyridin-4-yl)-l,3-oxazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-fluoropyridin-2-yl)-l,3- oxazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- fluoiOpyridin-2-yl)-l,3-oxazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(5-fluoropyridin-2-yl)-l,3-oxazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(6-fluoropyridin-2-yl)-l,3-oxazole- 2-caι-boxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- fluoiOpyridin-3-yl)-l,3-oxazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(4-fluoropyridin-3-yl)-l,3-oxazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-fluoropyridin-3-yl)-l,3-oxazole- 2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(6- fluoropyridin-3-yl)-l,3-oxazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-fluoropyridin-4-yl)-l,3-oxazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-fluoroρyridin-3-yl)-l,3-oxazole- 2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-phenoxy-l,3- oxazole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2Joct-3-yl]-5-(2- fluorophenoxy)- 1 ,3-oxazole-2-carboxamide; N-[(2S ,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(3-fluorophenoxy)- 1 ,3-oxazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-fluorophenoxy)-l,3-oxazole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,4- difluorophenoxy)-l,3-oxazole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2,4-difluorophenoxy)-l,3-oxazole-2-carboxamide; N- [(2S,3R)-2-methyl- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(3,5-difluorophenoxy)- 1 ,3-oxazole- 2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- chlorophenoxy)- 1 ,3-oxazole-2-carboxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(3-chlorophenoxy)- 1 ,3-oxazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-chlorophenoxy)-l,3-oxazole-2- carboxamide; N-[(2S,3R)-2-methyl- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(3,4- dichlorophenoxy)- 1 ,3-oxazole-2-carboxamide; N-[(2S,3R)-2-methyl- 1- azabicyclo[2.2.2]oct-3-yl]-5-(2,4-dichlorophenoxy)-l,3-oxazole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,5-dichlorophenoxy)-l,3-oxazole- 2-carboxamide;
N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-bromo-l -methyl- lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[2-(methylthio)phenyl]-l-methyl-lH-pyrrole- 2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[4-(methyllhio)phenyl]-l- methyl-lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-phenyl- lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-fluorophenyl)- l-methyl-lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- fluorophenyl)-l -methyl- lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct- 3-yl]-5-(4-fluorophenyl)- 1 -methyl-1 H-pyrrole-2-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yI]-5-(2,3-difluorophenyl)-l-methyl-lH-pyrrole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2,4-difluorophenyl)-l-methyl- lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2,6- difluorophenyl)- 1 -methyl- lH-pyrrole-2-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(3,4-difluorophenyl)-l-methyl-lH-pyrrole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,5-difluorophenyl)-l-methyl- lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2,4,6- trifluorophenyl)- 1 -methyl- lH-pyrrole-2-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(2-chlorophenyl)- 1 -methyl- 1 H-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-chlorophenyl)-l-methyl-lH-pyrrole-2- cai-boxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-chlorophenyl)-l-methyl-lH- pyrrole-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(2,4-dichlorophenyl)- l-methyl-lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,4- dichlorophenyl)-l -methyl- lH-pyrrole-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(3,5-dichlorophenyl)-l-methyl-lH-pyrrole-2- carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(2-bromophenyl)-l -methyl- 1H- pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-bromophenyl)-l- methyl-lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- bromophenyl)- 1-methyl- 1 H-pyrrole-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct- 3-yl]-5-(2-hydroxyphenyl)-l -methyl- lH-pyrrole-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(3-hydroxyphenyl)-l-methyl-lH-pyriOle-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-hydroxyphenyl)-l-methyl-lH-pyrrole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methoxyphenyl)-l-methyl- lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- methoxyphenyl)- 1 -methyl- 1 H-pyrrole-2 -carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(4-methoxyphenyl)-l-methyl-lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methylphenyl)- 1-methyl- lH-pyrrole-2- carboxamide; N-[(3R)- l-azabicyclo[2.2.2]oct-3-yl]-5-(3-methylphenyl)-l-methyl- 1H- pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]ocl-3-yl]-5-(4-methylphenyl)-l- methyl- lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- methylaminophenyl)- 1 -methyl- 1 H-pyrrole-2-carboxamide; N- [(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(3-methylaminophenyl)-l-methyl-lH-pyrrole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-methylaminophenyl)-l- methyl-lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- nitrophenyl)- 1 -methyl- lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(3-nitrophenyl)-l-methyl-lH-pyrrole-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(4-nitiOphenyl)-l-methyl-lH-pyrrole-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-aminophenyl)-l-methyl-lH-pyrrole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-aminophenyl)-l-methyl-lH- pyrroIe-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-aminophenyl)-l- methyl-lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[2- (acetylamino)phenyl] - 1 -methyl- 1 H-pyrrole-2-carboxamide; N- [(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-[3-(acetylamino)phenyl]-l-methyl-lH-pyιτole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[4-(acetylamino)phenyl]-l- methyl-lH-pyrrole-2-caι-boxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(ρyrid-2- yl)-l -methyl- lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- (pyrid-3-yl)- 1 -methyl- 1 H-pyrrole-2-carboxamide; N-[(3R)- l-azabicyclo[2.2.2]oct-3- yl]-5-(pyridin-4-yl)-l-methyl-lH-pyrrole-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(3-fluoropyrid-2-yl)-l-methyl-lH-pyrrole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-fluoropyrid-2-yl)-l-methyl- lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-fluoroρyrid-2- yl)-l -methyl- lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(6- fluoropyrid-2-yl)- 1 -methyl- 1 H-pyrrole-2-carboxamide; N-[(3R)- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(2-fluoropyrid-3-yl)-l-methyl-lH-pynOle-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-fluoropyrid-3-yl)-l-methyl- lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-fluoropyrid-3- yl)-l -methyl- lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(6- fluoiOpyrid-3-yl)-l-methyl-lH-pyrrole-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(2-fluoropyrid-4-yl)-l-methyl-lH-pyrrole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-fluoiOpyrid-4-yl)-l-methyl- lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-cyanophenyl)- 1 -methyl- lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- cyanophenyl)-l -methyl- lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct- 3-yl]-5-(4-cyanophenyl)-l -methyl- lH-pyrrole-2-carboxamide; N-[(3 )-1- azabicyclo[2.2.2]oct-3-yl]-5-(2-fluoiOphenyl)-lH-pyrrole-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(3-fluorophenyl)- lH-pyrroIe-2-carboxamide; N-[(3R)- 1- azabicyclo[2.2.2]oct-3-yl]-5-(4-fluorophenyl)-lH-pyrrole-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(3,5-difluorophenyl)-lH-pyrrole-2-carboxamide; N-
[(3R)-l-azabicyclo[2.2.2]oct-3-yI]-5-(3,4-difluoiOphenyl)-iH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2,4-difluorophenyl)-lH-pyrrole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-chloiOphenyl)-lH-pyrrole-2- carboxamide; N-[(3R)-l-azabicycIo[2.2.2]oct-3-yI]-5-(3-chlorophenyI)-lH-pyrroIe-2- carboxamide; N-[(3R)- l-azabicyclo[2.2.2]oct-3-yl]-5-(4-chlorophenyl)-lH-pyrrole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,5-dichlorophenyl)-lH- pyrroIe-2-carboxamide; N-[(3R)-l-azabicycIo[2.2.2]oct-3-yl]-5-(3,4-dichIorophenyl)- lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2,4- dichlorophenyl)-lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- (2-bromophenyl)- lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- (3-bromophenyl)-lH-pyrrole-2-caι-boxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- (4-bromophenyl)-lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- (2-hydroxyphenyl)-lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]- 5-(3-hydroxyphenyl)-lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(4-hydroxyphenyl)- 1 H-pyrrole-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct- 3-yl]-5-(2-methoxyphenyl)-lH-pyrrole-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(3-methoxyphenyl)-lH-pyrrole-2-carboxamide; N-[(3R)- l-azabicyclo[2.2.2]oct-3-yl]-5-(4-methoxyphenyl)-lH-ρyrrole-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methylρhenyl)-lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yI]-5-(3-methylphenyl)-lH-pyrrole-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(4-methylphenyl)~ lH-pyrrole-2-caι-boxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methylaminoρhenyl)-lH-pyrrole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-methylaminophenyl)-lH- pyrrole-2-carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(4- methylaminophenyl)-lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(2-nitrophenyl)-lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(3-nitrophenyl)-lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(4-nitiOphenyl)-lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(2-aminophenyl)-lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(3-aminophenyl)-lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(4-aminophenyl)-lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-[2-(acetylamino)phenyI]-lH-pyrrole-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-[3-(acetylamino)phenyl]- lH-pyrrole-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-[4-(acetylamino)ρhenyl]-lH-pyrrole-2- carboxamide; N-[(3R)- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(pyrid-2-yl)- lH-pyrrole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(pyrid-3-yl)-lH-pyrrole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(pyrid-4-yl)-lH-pyrrole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-fluoropyrid-2-yl)-lH- pyrroIe-2-carboxamide; N-[(3R)- 1 -azabieycIo[2.2.2]oct-3-yl]-5-(4-fluoiOpyrid-2-yI)- lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(5-fluoropyrid-2- yl)-lH-ρyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(6- fluoropyrid-2-yl)-lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5- (2-fluoropyrid-3-yl)-lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3- yl]-5-(4-fluoiOpyrid-3-yl)-lH-pyrrole-2-carboxamide; N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]-5-(5-fluoiOpyrid-3-yl)-lH-pyrrole-2-carboxamide; N- [(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(6-fluoropyrid-3-yl)-lH-pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-fluoropyrid-4-yl)-lH-pyrrole-2- carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-fluoropyrid-4-yl)-lH- pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-cyanophenyl)-lH- pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-cyanophenyl)-lH- pyrrole-2-carboxamide; N-[(3R)-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-cyanophenyl)-lH- pyrrole-2-carboxamide;
N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-bromo-l-methyl-lH-pyrrole-2- carboxamide; N-[(2S,3R)-2-methyl- l-azabicyclo[2.2.2]oct-3-yl]-5-[2-
(methylthio)phenyl]-l-methyl-lH-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-[4-(methylthio)phenyl]-l-methyl-lH-pyrrole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-phenyl-lH- pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- fluorophenyl)- 1 -methyl- 1 H-pyrrole-2-carboxamide; N- [(2S ,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(3-fluorophenyl)- 1 -methyl- 1 H-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-fluorophenyl)-l-methyl-lH- pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2,3- difluorophenyl)-l -methyl- lH-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2,4-difluorophenyl)-l-methyl-lH-ρyrrole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2,6- difluorophenyl)- 1 -methyl- 1 H-pyrrole-2-carboxamide; N-[(2S ,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(3,4-difluorophenyl)-l-methyl-lH-ρyrrole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,5- difluorophenyl)- 1 -methyl- 1 H-pyrrole-2-carboxamide; N- [(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(2,4,6-trifluorophenyl)-l-methyl-lH-pyrrole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-chlorophenyl)- 1 -methyl- lH-ρyrrole-2-caι-boxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3- yl]-5-(3-chIoroρhenyl)- 1 -methyl- iH-pyrrole-2-carboxamide; N-[(2S ,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(4-chlorophenyl)-l-methyl-lH-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2,4-dichloroρhenyl)-l-methyl- lH-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,4- dichlorophenyl)- 1 -methyl- 1 H-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(3,5-dichlorophenyl)-l-methyl-lH-ρyrrole-2- carboxamide; N-[(2S,3R)-2-methyl- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(2-bromophenyl)- l-methyl-lH-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3- yl]-5-(3-bromophenyl)-l-methyl-lH-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(4-bromophenyl)-l-methyl-lH-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyI-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-hydroxyphenyl)-l-methyl-lH- pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- hydroxyphenyl)- 1 -methyl- lH-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(4-hydiOxyphenyl)-l-methyl-lH-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methoxyphenyl)-l-methyI-lH- pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- methoxyphenyl)- 1 -methyl- 1 H-pyrrole-2-carboxamide; N- [(2S ,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(4-methoxyphenyl)-l-methyl-lH-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methylphenyl)- 1-methyl- 1H- pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- methylphenyl)- 1 -methyl- 1 H-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl 1 - azabicyclo[2.2.2]oct-3-yl]-5-(4-methylphenyl)-l -methyl- lH-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-methyaminophenyl)-l-methyl- lH-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- methylaminophenyl)- 1 -methyl- 1 H-pyrrole-2-carboxamide; N- [(2S ,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(4-methylaminophenyl)-l-methy]-lH-pyrrole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-nitrophenyl)-l- methyl~lH-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3- yl]-5-(3-nitrophenyl)- 1 -methyl- 1 H-pyrrole-2-carboxamide; N-[(2S ,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(4-nitrophenyl)-l-methyl-lH-pyrrole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-aminophenyl)-l-methyl-lH- pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- aminophenyl)- 1 -methyl- 1 H-pyrrole-2-carboxamide; N-[(2S ,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(4-aminophenyl)-l-methyl-lH-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[2-(acetylamino)phenyl]-l- methyl-lH-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3- yl]-5-[3-(acetylamino)phenyl]-l-methyl-lH-pyrrole-2-caι-boxamide; N-[(2S,3R)-2- methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[4-(acetylamino)phenyl]-l-methyl-lH-pyrrole- 2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(pyrid-2-yl)-l- methyl- lH-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3- yl]-5-(pyrid-3-yl)-l-methyl-lH-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-pyridin-4-yl- 1 -methyl- 1 H-pyrrole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-fluoiOpyrid-2-yl)-l-methyl-lH- pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- fluoropyrid-2-yl)- 1-methyl- 1 H-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(5-fluoropyrid-2-yl)- 1 -methyl- 1 H-pyrrole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(6-fluoropyrid-2- yl)- 1-methyl- lH-pyrroIe-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-fluoropyrid-3-yl)- 1-methyl- lH-pyrrole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-fluoropyrid-3- yl)- 1 -methyl- 1 H-pyrrole-2-carboxamide; N-[(2S ,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(5-fluoropyrid-3-yl)-l-methyl-lH-pyπ-ole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(6-fluoropyrid-3- yl)- 1 -methyl- 1 H-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(2-fluoropyrid-4-yl)-l-methyl-lH-pyriOle-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-fluoroρyrid-4- yl)- 1 -methyl- 1 H-pyrroIe-2-carboxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(2-cyanophenyl)-l -methyl- lH-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-cyanophenyl)-l-methyl-lH- ρyrrole-2-carboxamide; N-[(2S,3R)-2-methyl- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(4- cyanophenyl)- 1 -methyl- 1 H-pyrrole-2-carboxamide; N-[(2S ,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(2-fluorophenyl)- 1 H-pyrrole-2-carboxamide; N- [(2S,3R)-2-methyl- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(3-fluorophenyl)- lH-pyrrole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-fluorophenyl)- lH-ρyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,5- difiuorophenyl)- 1 H-pyrrole-2-carboxamide; N-[(2S ,3R)-2-methyl- 1 - azabicyclo [2.2.2] oct-3-yl] -5-(3 ,4-difluorophenyl)- 1 H-ρyrrole-2-carboxamide ; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2,4-difluorophenyl)-lH-pyrrole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-chlorophenyl)- lH-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- chlorophenyl)- 1 H-pyrrole-2-carboxamide; N-[(2S ,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(4-chlorophenyl)-lH-pyrrole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,5-dichlorophenyl)-lH-pyrrole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3,4- dichlorophenyl)-lH-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2,4-dichlorophenyl)-lH-pyriOle-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-bromophenyl)-lH-pyriOle-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-bromophenyl)- lH-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- bromophenyl)-lH-pyrrole-2 -carboxamide; N-[(2S,3R)-2 -methyl- 1- azabicyclo[2.2.2]oct-3-yl]-5-(2-hydroxyphenyl)-lH-pynOle-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-hydiOxyρhenyl)-lH-pyrrole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- hydroxyphenyl)- 1 H-pyrrole-2-carboxamide; N-[(2S ,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(2-methoxyphenyl)-lH-pyrrole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-methoxyphenyl)-lH-pyrrole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4- methoxyphenyl)-lH-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(2-methylphenyl)-lH-pyrrole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-methylphenyl)-lH-pyrrole-2- carboxamide; N-[(2S,3R)-2-methyl- l-azabicyclo[2.2.2]oct-3-yl]-5-(4-methylphenyl)- lH-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2- methyaminophenyl)-lH-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(3-methylaminophenyl)-lH-pyrrole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-methylaminophenyl)-lH-pyrrole- 2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-nitrophenyl)- lH-pyrroIe-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3- nitrophenyl)-lH-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(4-nitiOphenyl)-lH-pyrrole-2-carboxamide; N-[(2S,3R)- 2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-aminophenyl)-lH-pyrrole-2-caι-boxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-aminophenyl)-lH-pyrrole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-aminophenyl)- lH-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[2- (acetylamino)phenyl]-lH-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-[3-(acetylamino)phenyl]-lH-pyrrole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-[4-(acetylamino)ρhenyl]-lH- pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(pyrid- 2-yl)-lH-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]- 5-(pyrid-3-yl)-lH-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicycIo[2.2.2]oct-3-yI]-5-(pyrid-4-yl)-lH-pyrroIe-2-carboxamide; N-[(2S,3R)-2- methyl- 1 -azabicyclo[2.2.2]oct-3-yl]-5-(3-fluoropyrid-2-yl)- lH-ρyrrole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-fluoropyrid-2- yl)-lH-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5- (5-fluoropyrid-2-yl)-lH-pyriOle-2-carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(6-fluoropyrid-2-yl)- 1 H-pyrrole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(2-fluoropyrid-3-yl)-lH-pyn-ole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4-fluoropyrid-3- yl)-lH-pyιτole-2-carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5- (5-fluoropyrid-3-yl)-lH-pyrrole-2~carboxamide; N-[(2S,3R)-2-methyl-l- azabicyclo[2.2.2]oct-3-yl]-5-(6-fluoropyrid-3-yl)-lH-pyrrole-2-carboxamide; N- [(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-y]]-5-(2-fluoiOpyrid-4-yl)-lH-ρyrrole-2- carboxamide; N-[(2S,3R)-2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(3-fluoι-opyrid-4- yl)- lH-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl- l-azabicyclo[2.2.2]oct-3-yl]-5- (2-cyanophenyl)- 1 H-pyrrole-2-carboxamide; N-[(2S,3R)-2-methyl- 1 - azabicyclo[2.2.2]oct-3-yl]-5-(3-cyanopheny])-lH-pyrrole-2 -carboxamide; N-[(2S,3R)- 2-methyl-l-azabicyclo[2.2.2]oct-3-yl]-5-(4~cyanophenyl)-lH-pyrrole-2-carboxamide; or pharmaceutically acceptable salts thereof.
20. A method for treating a disease or condition in a mammal, wherein the al nicotinic acetylcholine receptor is implicated comprising administering to a mammal a therapeutically effective amount of compound(s) according to claim 1.
21. The method according to claim 20, wherein the disease or condition is schizophrenia, or psychosis.
22. The method according to claim 21, wherein said compound(s) is(are) administered rectally, topically, orally, sublingually, or parenterally.
23. The method according to claim 21, wherein said compound(s) is(are) administered from about 0.001 to about 100 mg/kg of body weight of said mammal per day.
24. The method according to claim 21, wherein said compound(s) is(are) administered from about 0.1 to about 50 mg/kg of body weight of said mammal per • day.
25. A method for treating a disease or condition in a mammal, wherein the al nicotinic acetylcholine receptor is implicated comprising administering to a mammal a therapeutically effective amount of compound(s) according to claim 5.
26. The method according to claim 25, wherein the disease or condition is schizophrenia, or psychosis.
27. The method according to claim 26, wherein said compound(s) is(are) administered rectally, topically, orally, sublingually, or parenterally.
28. The method according to claim 26, wherein said compound(s) is(are) administered from about 0.001 to about 100 mg/kg of body weight of said mammal per day.
29. The method according to claim 26, wherein said compound(s) is(are) administered from about 0.1 to about 50 mg/kg of body weight of said mammal per day.
30. A method for treating a disease or condition in a mammal, wherein the al nicotinic acetylcholine receptor is implicated comprising administering to a mammal a therapeutically effective amount of compound(s) according to claim 6.
31. The method according to claim 30, wherein the disease or condition is schizophrenia, or psychosis.
32. The method according to claim 31 , wherein said compound(s) is(are) administered rectally, topically, orally, sublingually, or parenterally.
33. The method according to claim 31 , wherein said compound(s) is(are) administered from about 0.001 to about 100 mg/kg of body weight of said mammal per day.
34. The method according to claim 31 , wherein said compound(s) is(are) administered from about 0.1 to about 50 mg/kg of body weight of said mammal per day.
35. A method for treating a disease or condition in a mammal, wherein the al nicotinic acetylcholine receptor is implicated comprising administering to a mammal a therapeutically effective amount of compound(s) according to claim 10.
36. The method according to claim 35, wherein the disease or condition is schizophrenia, or psychosis.
37. The method according to claim 36, wherein said compound(s) is(are) administered rectally, topically, orally, sublingually, or parenterally.
38. The method according to claim 36, wherein said compound(s) is(are) administered from about 0.001 to about 100 mg/kg of body weight of said mammal
• per day.
39. The method according to claim 36, wherein said compound(s) is(are) administered from about 0.1 to about 50 mg/kg of body weight of said mammal per day.
40. A method for treating a disease or condition in a mammal, wherein the al nicotinic acetylcholine receptor is implicated comprising administering to a mammal a therapeutically effective amount of compound(s) according to claim 11.
41. The method according to claim 40, wherein the disease or condition is schizophrenia, or psychosis.
42. The method according to claim 41 , wherein said compound(s) is(are) administered rectally, topically, orally, sublingually, or parenterally.
43. The method according to claim 41, wherein said compound(s) is(are) administered from about 0.001 to about 100 mg/kg of body weight of said mammal per day.
44. The method according to claim 41 , wherein said compound(s) is(are) administered from about 0.1 to about 50 mg/kg of body weight of said mammal per day.
45. A method for treating a disease or condition in a mammal, wherein the 7 nicotinic acetylcholine receptor is implicated comprising administering to a mammal a therapeutically effective amount of compound(s) according to claim 12.
46. The method according to claim 45, wherein the disease or condition is schizophrenia, or psychosis.
47. The method according to claim 46, wherein said compound(s) is(are) administered rectally, topically, orally, sublingually, or parenterally.
48. The method according to claim 46, wherein said compound(s) is(are) administered from about 0.001 to about 100 mg/kg of body weight of said mammal per day.
49. The method according to claim 46, wherein said compound(s) is(are) administered from about 0.1 to about 50 mg/kg of body weight of said mammal per day.
50. A method for treating a disease or condition in a mammal, wherein the α7 nicotinic acetylcholine receptor is implicated comprising administering to a mammal a therapeutically effective amount of compound(s) according to claim 13.
51. The method according to claim 50, wherein the disease or condition is schizophrenia, or psychosis.
52. The method according to claim 51, wherein said compound(s) is(are) administered rectally, topically, orally, sublingually, or parenterally.
53. The method according to claim 51, wherein said compound(s) is(are) administered from about 0.001 to about 100 mg/kg of body weight of said mammal per day.
54. The method according to claim 51, wherein said compound(s) is(are) administered from about 0.1 to about 50 mg/kg of body weight of said mammal per day.
55. A method for treating a disease or condition in a mammal, wherein the α7 nicotinic acetylcholine receptor is implicated comprising administering to a mammal a therapeutically effective amount of compound(s) according to claim 14.
56. The method according to claim 55, wherein the disease or condition is schizophrenia, or psychosis.
57. The methqd according to claim 56, wherein said compound(s) is(are) administered rectally, topically, orally, sublingually, or parenterally.
58. The method according to claim 56, wherein said compound(s) is(are) administered from about 0.001 to about 100 mg/kg of body weight of said mammal per day.
59. The method according to claim 56, wherein said compound(s) is(are) administered from about 0.1 to about 50 mg/kg of body weight of said mammal per day.
60. A method for treating a disease or condition in a mammal, wherein the al nicotinic acetylcholine receptor is implicated comprising administering to a mammal a therapeutically effective amount of compound(s) according to claim 15.
61. The method according to claim 60, wherein the disease or condition is schizophrenia, or psychosis.
62. The method according to claim 61, wherein said compound(s) is(are) administered rectally, topically, orally, sublingually, or parenterally.
63. The method according to claim 61, wherein said compound(s) is(are) administered from about 0.001 to about 100 mg/kg of body weight of said mammal per day.
64. The method according to claim 61 , wherein said compound(s) is(are) administered from about 0.1 to about 50 mg/kg of body weight of said mammal per day.
65. A method for treating a disease or condition in a mammal, wherein the al nicotinic acetylcholine receptor is implicated comprising administering to a mammal a therapeutically effective amount of compound(s) according to claim 16.
66. The method according to claim 65, wherein the disease or condition is schizophrenia, or psychosis.
67. The method according to claim 66, wherein said compound(s) is(are) administered rectally, topically, orally, sublingually, or parenterally.
68. The method according to claim 66, wherein said compound(s) is(are) administered from about 0.001 to about 100 mg/kg of body weight of said mammal per day.
69. The method according to claim 66, wherein said compound(s) is(are) administered from about 0.1 to about 50 mg/kg of body weight of said mammal per day.
70. A method for treating a disease or condition in a mammal, wherein the al nicotinic acetylcholine receptor is implicated comprising administering to a mammal a therapeutically effective amount of compound(s) according to claim 17.
71. The method according to claim 70, wherein the disease or condition is schizophrenia, or psychosis.
72. The method according to claim 71, wherein said compound(s) is(are) administered rectally, topically, orally, sublingually, or parenterally.
73. The method according to claim 71, wherein said compound(s) is(are) administered from about 0.001 to about 100 mg/kg of body weight of said mammal per day.
74. The method according to claim 71, wherein said compound(s) is(are) administered from about 0.1 to about 50 mg/kg of body weight of said mammal per day.
75. A method for treating a disease or condition in a mammal, wherein the al nicotinic acetylcholine receptor is implicated comprising administering to a mammal a therapeutically effective amount of compound(s) according to claim 18.
76. The method according to claim 75, wherein the disease or condition is schizophrenia, or psychosis.
77. The method according to claim 76, wherein said compound(s) is(are) administered rectally, topically, orally, sublingually, or parenterally.
78. The method according to claim 76, wherein said compound(s) is(are) administered from about 0.001 to about 100 mg/kg of body weight of said mammal per day.
79. The method according to claim 76, wherein said compound(s) is(are) administered from about 0.1 to about 50 mg/kg of body weight of said mammal per day.
80. A method for treating a disease or condition in a mammal, wherein the al nicotinic acetylcholine receptor is implicated comprising administering to a mammal a therapeutically effective amount of compound(s) according to claim 19.
81. The method according to claim 80, wherein the disease or condition is schizophrenia, or psychosis.
82. The method according to claim 81 , wherein said compound(s) is(are) administered rectally, topically, orally, sublingually, or parenterally.
83. The method according to claim 81, wherein said compound(s) is(are) administered from about 0.001 to about 100 mg/kg of body weight of said mammal per day.
84. The method according to claim 81 , wherein said compound(s) is(are) administered from about 0.1 to about 50 mg/kg of body weight of said mammal per day.
85. A pharmaceutical composition comprising compound(s) according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
86. A pharmaceutical composition comprising compound(s) according to claim 5, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
87. A pharmaceutical composition comprising compound(s) according to claim 6, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
88. A pharmaceutical composition comprising compound(s) according to claim 10, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
89. A pharmaceutical composition comprising compound(s) according to claim
11, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable earner.
90. A pharmaceutical composition comprising compound(s) according to claim
12, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
91. A pharmaceutical composition comprising compound(s) according to claim
13, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
92. A pharmaceutical composition comprising compound(s) according to claim
14, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
93. A pharmaceutical composition comprising compound(s) according to claim 15, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
94. A pharmaceutical composition comprising compound(s) according to claim
16, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
95. A pharmaceutical composition comprising compound(s) according to claim
17, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
96. A pharmaceutical composition comprising compound(s) according to claim
18, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
97. A pharmaceutical composition comprising compound(s) according to claim
19, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
EP01961664A 2000-08-21 2001-08-17 Quinuclidine-substituted heteroaryl moieties for treatment of disease ( nicotinic acetylcholine receptor ligands ) Withdrawn EP1311505A2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22665200P 2000-08-21 2000-08-21
US226652P 2000-08-21
US28483201P 2001-04-19 2001-04-19
US284832P 2001-04-19
PCT/US2001/022597 WO2002016355A2 (en) 2000-08-21 2001-08-17 Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic) acetylcholine receptor ligands

Publications (1)

Publication Number Publication Date
EP1311505A2 true EP1311505A2 (en) 2003-05-21

Family

ID=26920741

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01961664A Withdrawn EP1311505A2 (en) 2000-08-21 2001-08-17 Quinuclidine-substituted heteroaryl moieties for treatment of disease ( nicotinic acetylcholine receptor ligands )

Country Status (5)

Country Link
EP (1) EP1311505A2 (en)
JP (1) JP2004506734A (en)
AU (1) AU2001282910A1 (en)
PE (1) PE20020505A1 (en)
WO (1) WO2002016355A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214686B2 (en) 1997-06-30 2007-05-08 Targacept, Inc. Pharmaceutical compositions and methods for effecting dopamine release
SE0000540D0 (en) 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
NZ554913A (en) 2001-12-14 2009-01-31 Targacept Inc Methods and compositions for the treatment of central nervous system disorders
DE10211415A1 (en) * 2002-03-15 2003-09-25 Bayer Ag New azabicycloalkyl carboxylic acid N-biarylamides, are alpha-7-nicotinic acetylcholine receptor ligands useful for improving attention, concentration, learning and/or memory performance
DE10211416A1 (en) * 2002-03-15 2003-09-25 Bayer Ag New azabicycloalkyl carboxylic acid N-arylamides, are alpha 7-nicotinic acetylcholine receptor ligands useful for improving attention, concentration, learning and/or memory performance
DE10234424A1 (en) * 2002-07-29 2004-02-12 Bayer Ag Benzothiophene, benzofuran and indoleureas
AU2003283648A1 (en) * 2002-12-06 2004-06-30 Pharmacia & Upjohn Company Llc Compounds as radioligands for the diagnosis of disease
KR20050092777A (en) * 2003-01-22 2005-09-22 파마시아 앤드 업존 캄파니 엘엘씨 Treatment of diseases with alpha-7 nach receptor full agonists
DE602004024565D1 (en) 2003-10-15 2010-01-21 Targacept Inc AZABICYCLIC COMPOUNDS FOR AFFILIATING PAIN AND TREATING DISEASES OF THE CENTRAL NERVOUS SYSTEM
SE0303076D0 (en) * 2003-11-19 2003-11-19 Astrazeneca Ab 5-substituted imidazoles
SE0303075D0 (en) * 2003-11-19 2003-11-19 Astrazeneca Ab 4-substituted imidazoles
JP2007515478A (en) * 2003-12-22 2007-06-14 アストラゼネカ・アクチエボラーグ Nicotinic acetylcholine receptor ligand
CN1914200A (en) * 2003-12-22 2007-02-14 阿斯利康(瑞典)有限公司 Nicotinic acetylcholine receptor ligands
US7514450B2 (en) 2004-05-19 2009-04-07 Neurosearch A/S Azabicyclic aryl derivatives
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
JP2009506037A (en) 2005-08-22 2009-02-12 ターガセプト，インコーポレイテッド Heteroaryl-substituted diazatricycloalkanes, methods for their preparation and methods for their use
SA08290475B1 (en) 2007-08-02 2013-06-22 Targacept Inc (2S,3R)-N-(2-((3-Pyridinyl)Methyl)-1-Azabicyclo[2.2.2]Oct-3-yl)Benzofuran-2-Carboxamide, Novel Salt forms, and Methods of Use Thereof
JP5718053B2 (en) 2007-08-27 2015-05-13 ヘリコン・セラピューティクス・インコーポレーテッド Therapeutic isoxazole compounds
DE602008005928D1 (en) 2007-10-01 2011-05-12 Comentis Inc 1H-INDOL-3-CARBOXYLIC ACID-CHINUCLIDIN-4-YLMETHYL ETER DERIVATIVES AS LIGANDS FOR THE NICOTINE ALPHA-7-ACETYLCHOLIN RECEPTOR FOR THE TREATMENT OF ALZHEIMER DISEASE
WO2009098282A1 (en) * 2008-02-06 2009-08-13 Novasaid Ab Low molecular weight 2,5-disubstituted thiophene derivatives and use thereof in therapy
RU2481123C2 (en) 2008-02-13 2013-05-10 Таргасепт, Инк. Combination of alpha 7 nicotinic receptor agonists and antipsychotic agents
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
AU2012221800B2 (en) * 2011-02-23 2016-10-27 Lupin Limited Heteroaryl derivatives as alpha7 nAChR modulators
ES2606043T3 (en) 2011-07-05 2017-03-17 Lupin Limited Biaryl derivatives as nAChR modulators
JPWO2013161871A1 (en) * 2012-04-25 2015-12-24 興和株式会社 Thiophene derivative having TLR inhibitory action
JPWO2014069554A1 (en) * 2012-10-31 2016-09-08 東レ株式会社 Quinuclidinamide derivative and its pharmaceutical use
AR101131A1 (en) 2014-07-11 2016-11-23 Comentis Inc QUINUCLIDINS FOR THE MODULATION OF ACTIVITY OF a7

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863919A (en) * 1988-02-01 1989-09-05 A. H. Robins Company, Incorporated Method of enhancing memory or correcting memory deficiency with arylamido(and arylthiomido)-azabicycloalkanes
IT1228288B (en) * 1989-01-09 1991-06-07 Zambon Spa COMPOUNDS WITH ANTI-SEROTONIN ACTIVITY
JPH04247081A (en) * 1991-02-01 1992-09-03 Takeda Chem Ind Ltd 5-membered heterocyclic acid amide
SE9600683D0 (en) * 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
AU744368B2 (en) * 1997-05-30 2002-02-21 Neurosearch A/S Spiro-quinuclidine derivatives, their preparation and use
SE9904176D0 (en) * 1999-11-18 1999-11-18 Astra Ab New use
SE0000540D0 (en) * 2000-02-18 2000-02-18 Astrazeneca Ab New compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0216355A2 *

Also Published As

Publication number Publication date
PE20020505A1 (en) 2002-06-12
WO2002016355A3 (en) 2002-07-18
JP2004506734A (en) 2004-03-04
WO2002016355A2 (en) 2002-02-28
AU2001282910A1 (en) 2002-03-04

Similar Documents

Publication Publication Date Title
US6599916B2 (en) Quinuclidine-substituted heteroaryl moieties for treatment of disease
US6492385B2 (en) Quinuclidine-substituted heteroaryl moieties for treatment of disease
US6500840B2 (en) Quinuclidine-substituted heteroaryl moieties for treatment of disease
EP1311505A2 (en) Quinuclidine-substituted heteroaryl moieties for treatment of disease ( nicotinic acetylcholine receptor ligands )
US6919359B2 (en) Azabicyclic-substituted-heteroaryl compounds for the treatment of disease
US6562816B2 (en) Substituted-heteroaryl-7-aza[2.2.1]bicycloheptanes for the treatment of disease
AU2004274492B2 (en) Substituted diazabicycloalkane derivatives as ligands at alpha 7 nicotinic acetylcholine receptors
JP2505875B2 (en) 5-membered ring system with azacyclic substituent bond
US7872010B2 (en) Substituted diazabicycloalkane derivatives having affinity for nicotinic acetylcholine receptors
US6486172B2 (en) Quinuclidine-substituted aryl compounds for treatment of disease
JP2004506735A (en) Quinuclidine-substituted aryl compounds for disease treatment
MXPA06010852A (en) Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof.
WO2002016356A2 (en) Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
CA2476624A1 (en) Azabicyclic compounds for the treatment of disease
JP4542891B2 (en) 2-heteroarylcarboxamides
MXPA04001695A (en) Substituted-heteroaryl-7-aza[2.2.1]bicycloheptanes for the treatment of disease.
AU2012202336B2 (en) Indazoles, Benzothiazoles, Benzoisothiazoles, Benzisoxazoles, and Preparation and Uses Thereof
KR20070085053A (en) Fused bicycloheterocycle substituted quinuclidine derivatives

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030307

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: CORBETT, JEFFREY, W.

Inventor name: JACOBSEN, ERIC, JON

Inventor name: BODNAR, ALICE, L.

Inventor name: PIOTROWSKI, DAVID, W.

Inventor name: GROPPI, VINCENT, E., JR.

Inventor name: ROGERS, BRUCE, N.

Inventor name: MYERS, JASON, K.

17Q First examination report despatched

Effective date: 20040115

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PHARMACIA & UPJOHN COMPANY LLC

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PHARMACIA & UPJOHN COMPANY LLC

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070228